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SUMMARY	  	  	  Neurogenin	   2	   (Ngn2)	   is	   a	   basic	   Helix-­‐Loop-­‐Helix	   (bHLH)	   transcription	   factor	   regulating	  differentiation	  and	  cell	  cycle	  exit	  in	  the	  developing	  brain.	  	  By	  transcriptional	  upregulation	  of	  a	  cascade	   of	   other	   bHLH	   factors,	   neural	   progenitor	   cells	   exit	   the	   cell	   cycle	   and	   differentiate	  towards	  a	  neuronal	   fate.	   	  Xenopus	   laevis	  Ngn2	  (xNgn2)	   is	  a	  short-­‐lived	  protein,	   targeted	   for	  degradation	  by	   the	  26S	  proteasome.	   	   I	   have	   investigated	   the	   stability	  of	  Ngn2	  mediated	  by	  post-­‐translational	  modifications	  and	  structural	  disorder.	  	  Firstly	  I	  will	  describe	  work	  focused	  on	  ubiquitylation	  of	  xNgn2,	  targeting	  it	   for	  proteasomal	  degradation.	   	   xNgn2	   is	   ubiquitylated	   on	   lysines,	   the	   recognized	   site	   of	   modification.	   I	   will	  discuss	  the	  role	  of	  lysines	  in	  ubiquitylation	  and	  stability	  of	  xNgn2.	  	  	  	  In	  addition	  to	  canonical	  ubiquitylation	  on	  lysines,	  I	  describe	  ubiquitylation	  of	  xNgn2	  on	  non-­‐canonical	   sites,	  namely	   its	  amino-­‐terminal	  amino	  group,	  and	  cysteine,	   serine	  and	   threonine	  residues.	   	   I	   show	   that	   the	   ubiquitylation	   of	   cysteines	   in	   particular	   exhibits	   cell	   cycle	  dependence	  and	   is	  also	  observed	   in	  mammalian	  cell	   lines,	   resulting	   in	   cell	   cycle-­‐dependent	  regulation	  of	  stability.	  	  I	  will	  then	  discuss	  whether	  phosphorylation,	  a	  regulator	  of	  xNgn2	  activity,	  also	  affects	  xNgn2	  stability.	  	  I	  will	  provide	  evidence	  of	  cell	  cycle-­‐dependent	  phosphorylation	  of	  cyclin	  dependent	  kinase	  (cdk)	  consensus	  sites	  affecting	  the	  stability	  of	  xNgn2.	  	  Finally	   I	   describe	   studies	   on	   the	   folding	   properties	   of	   Ngn2	   to	   assess	   their	   role	   in	   protein	  stability.	   	   xNgn2	  associates	  with	  DNA	  and	   its	  heterodimeric	  binding	  partner	  xE12	  and	  may	  interact	   directly	  with	   the	   cyclin-­‐dependent	   kinase	   inhibitor	   Xic1.	   	   I	  will	   discuss	   the	   role	   of	  these	   interaction	  partners	   in	  xNgn2	  stability.	   	  xNeuroD,	  a	  downstream	  target	  of	  xNgn2,	   is	  a	  related	   bHLH	   transcription	   factor	   which	   is	   stable.	   	   Here	   I	   describe	   domain	   swapping	  experiments	   between	   these	   two	   proteins	   highlighting	   regions	   conferring	   instability	   on	   the	  chimeric	  protein.	   	   Finally	   I	  will	   provide	  nuclear	  magnetic	   resonance	   (NMR)	  data	   looking	  at	  the	  effect	  of	  phosphorylation	  on	  protein	  structure	  in	  mouse	  Ngn2	  (mNgn2).	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ABBREVIATIONS	  	  	  AMP:	  	  adenosine	  monophosphate	  APC/C:	  	  Anaphase	  Promoting	  Complex/Cyclosome	  APF-­‐1:	  	  ATP-­‐dependent	  proteolysis	  factor	  1	  AR:	  	  androgen	  receptor	  ash:	  	  achaete-­‐scute	  homologue	  ATP:	  	  adenosine	  triphosphate	  bHLH:	  	  basic	  Helix-­‐Loop-­‐Helix	  BMP:	  	  Bone	  Morphogenic	  Protein	  °C:	  	  degrees	  centigrade	  Cdc20:	  	  cell	  division	  cycle	  protein	  20	  Cdh1:	  	  Cdc20-­‐homologue	  1	  Cdk:	  	  cyclin	  dependent	  kinase	  Cdki:	  	  cyclin	  dependent	  kinase	  inhibitor	  cDNA:	  	  complementary	  DNA	  Cip:	  	  cdk	  interacting	  protein	  	  CNS:	  	  central	  nervous	  system	  CBP:	  	  CREB	  (cAmp	  Response	  Element	  Binding	  Protein)-­‐Binding	  Protein	  DMSO:	  	  dimethyl	  sulfoxide	  DNA:	  	  Deoxyribonucleic	  Acid	  DUB:	  	  Deubiquitylating	  enzyme	  E2A:	  	  general	  class	  of	  gene	  products	  including	  E12	  and	  E47	  E12:	  	  E2A	  bHLH	  transcription	  factor	  E47:	  	  E2A	  bHLH	  transcription	  factor	  E1:	  	  Ub-­‐activating	  enzyme	  E2:	  	  Ub-­‐conjugating	  enzyme	  EDTA:	  	  Ethylenediaminetetraacetic	  acid	  Emi1:	  	  early	  mitotic	  inhibitor	  1	  EMSA:	  	  Electrophoretic	  Mobility	  Shift	  Assay	  ERAD:	  	  endoplasmic	  reticulum-­‐associated	  degradation	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FID:	  	  Free	  Induction	  Decay	  GABAergic:	  	  emitting/secreting	  γ-­‐aminobutyric	  acid	  GFP:	  	  Green	  Fluorescent	  Protein	  Gli:	  	  glioblastoma	  protein	  GO:	  	  gene	  ontology	  GSK3-­‐β:	  	  glycogen	  synthase	  kinase	  3	  beta	  HCV:	  	  Hepatitis	  C	  virus	  HECT:	  	  homologous	  to	  E6-­‐AP	  (E6-­‐associated	  protein)	  carboxy	  terminus	  Hes:	  	  Hairy	  enhancer	  of	  split	  HIV:	  	  Human	  Immunodeficiency	  Virus	  HPV:	  	  Human	  Papilloma	  Virus	  HSQC:	  	  heteronuclear	  single	  quantum	  coherence	  Id:	  	  Inhibitor	  of	  differentiation	  ID:	  	  Intrinsic	  Disorder	  IPTG:	  	  Isopropyl	  β-­‐D-­‐1-­‐thiogalactopyranoside	  ISH:	  	  in	  situ	  hybridisation	  IVT:	  	  in	  vitro	  translation	  IκB:	  nuclear	  factor	  of	  kappa	  light	  polypeptide	  gene	  enhancer	  in	  B-­‐cells	  inhibitor	  JAK-­‐STAT:	  	  janus	  kinase-­‐signal	  transducers	  kDa:	  	  kiloDalton	  Kip:	  	  Kinase	  inhibitory	  protein	  MAPK:	  	  mitogen-­‐activated	  protein	  kinase	  Mash1:	  	  Mus	  musculus	  achaete-­‐scute	  homologue	  1	  MBS:	  	  Modified	  Barth’s	  Saline	  Mdm2:	  	  murine	  double	  minute	  2	  protein	  MEM:	  	  Minimum	  Essential	  Media	  MG132:	  N-­‐carbobenzoxyl–Leu–Leu–Leucinal	  mins:	  	  minutes	  MMR:	  	  Marc’s	  modified	  Ringers	  MoRE:	  	  molecular	  recognition	  element	  mRNA:	  	  messenger	  Ribonucleic	  Acid	  Myf5:	  	  Myogenic	  factor	  5	  MyoD:	  	  Myogenic	  Differentiation	  factor	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NEM:	  	  N-­‐ethyl	  maleimide	  NeuroD:	  Neurogenic	  Differentiation	  factor	  NICD:	  	  Notch	  intracellular	  domain	  NMR:	  	  Nuclear	  Magnetic	  Resonance	  NS5A:	  	  non-­‐structured	  protein	  5A	  NT:	  	  N-­‐terminus	  Olig2:	  	  oligodendrocyte	  lineage	  2	  protein	  PBS:	  	  Phosphate	  Buffered	  Saline	  pI:	  	  Isoelectric	  point	  PNS:	  	  peripheral	  nervous	  system	  PTM:	  	  post-­‐translational	  modification	  qPCR:	  	  quantitative	  real-­‐tome	  Polymerase	  Chain	  Reaction	  Ras:	  	  rat	  sarcoma	  protein	  RING:	  	  Really	  Interesting	  New	  Gene	  SCF:	  	  Skp1-­‐Cullin1-­‐F-­‐box	  SDS-­‐LB:	  	  sodium	  dodecyl	  sulfate	  loading	  buffer	  SDS-­‐PAGE:	  	  sodium	  dodecyl	  sulfate	  polyacrylamide	  gel	  electrophoresis	  SEM:	  	  Standard	  Error	  of	  the	  Mean	  Sic1:	  Substrate/Subunit	  Inhibitor	  of	  Cyclin-­‐dependent	  protein	  kinase	  Skp1/Skp2:	  	  S-­‐phase	  kinase	  associated	  protein	  1/2	  SUMO:	  	  Small	  Ubl	  Modifier	  TAT:	  	  tyrosine	  amino-­‐transferase	  TCR:	  	  T-­‐Cell	  receptor	  TMSP:	  	  Trimethylsilyl	  propanoic	  acid	  Ub:	  	  ubiquitin	  Ubc:	  	  Ub-­‐conjugating	  enzyme	  Ubl:	  	  Ub-­‐like	  UFD:	  	  Ub	  fusion	  degradation	  UPS:	  	  Ub	  Proteasome	  System	  Xash1:	  	  Xenopus	  laevis	  achaete-­‐scute	  homologue	  1	  XB:	  	  extract	  buffer	  Xebf3:	  Xenopus	  laevis	  early	  B-­‐cell	  factor	  3	  Xic1:	  	  Xenopus	  laevis	  inhibitor	  of	  cyclin	  dependent	  kinases	  
	  xii	  
xMyT1:	  	  Xenopus	  laevis	  Myelin	  Transcription	  factor	  XPak3:	  	  Xenopus	  laevis	  p21-­‐activated	  kinase	  3	  
β-­‐TRCP:	  	  beta-­‐Transducin	  repeat	  containing	  protein	  
	  
	  
Neurogenin	  2	  proteins:	  	  Ngn2:	  	  neurogenin	  2	  xNgn3:	  	  Xenopus	  laevis	  neurogenin	  3	  mNgn2:	  	  Mus	  musculus	  neurogenin	  2	  xNgn2:	  	  Xenopus	  laevis	  neurogenin	  2	  	  
Ubiquitylation:	  	  Ac2	  prefix:	  	  N-­‐terminus	  mutated	  to	  upregulate	  cotranslational	  N-­‐terminal	  acetylation	  Ac3	  prefix:	  N-­‐terminus	  mutated	  to	  downregulate	  N-­‐terminal	  acetylation	  Ac2xNgn2KO:	  	  all	  amino-­‐based	  nucleophilic	  sites	  mutated	  or	  blocked	  Ac2xNgn2CO:	  	  N-­‐terminus	  targeted	  for	  acetylation,	  all	  cysteines	  mutated	  to	  alanines	  Ac2xNgn2KOCO:	  all	  amino-­‐	  and	  thiol-­‐based	  nucleophilic	  sites	  mutated	  or	  blocked	  	  C178AxNgn2:	  	  conserved	  cysteine	  178	  mutated	  to	  alanine	  C(169,178)AxNgn2:	  	  conserved	  cysteines	  169	  and	  178	  mutated	  to	  alanine	  	  KXXRxNgn2:	  	  lysine	  XX	  mutated	  to	  arginine	  RXXKxNgn2KO:	  	  lysine	  XX	  reintroduced,	  all	  other	  lysines	  mutated	  to	  arginines	  R(116,119)KxNgn2KO:	  	  bHLH	  lysines	  reintroduced	  to	  otherwise	  ‘lysineless’	  protein	  R(77,79,80)KxNgn2KO:	  	  KIKK	  lysines	  reintroduced	  to	  otherwise	  ‘lysineless’	  protein	  	  Ub-­‐xNgn2:	  	  Ub	  fused	  linearly	  to	  N-­‐terminus	  of	  xNgn2	  Ub-­‐9S-­‐AxNgn2:	  	  Ub	  fused	  linearly	  to	  N-­‐terminus,	  all	  SP	  serines	  mutated	  to	  alanines	  	  xNgn2KO:	  	  ‘lysineless’	  xNgn2;	  all	  lysines	  mutated	  to	  arginines	  xNgn2CO:	  	  ‘cysteineless’	  xNgn2;	  all	  cysteines	  mutated	  to	  alanines	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Phosphorylation:	  	  xS-­‐A1:	  	  xNgn2	  with	  most	  C-­‐terminal	  SP	  serine,	  184,	  mutated	  to	  alanine	  xS-­‐A2	  –	  xS-­‐A8:	  	  successive	  SP	  serines	  mutated	  to	  alanine	  from	  C-­‐terminus,	  until;	  xS-­‐A9:	  	  xNgn2,	  SP	  serines	  19,	  29,	  44,	  47,	  57,	  164,	  172,	  181	  and	  184	  mutated	  to	  alanine	  	  2S-­‐AxNgn2:	  	  GSK3-­‐β	  consensus	  site	  SP	  serines	  (181,	  184)	  mutated	  to	  alanine	  7S-­‐AxNgn2:	  	  all	  SP	  serines	  except	  GSK3-­‐β	  site	  serines	  (181,	  184)	  mutated	  to	  alanine	  	  8S-­‐AxNgn2SXX:	  	  all	  SP	  serines	  except	  serine	  XX	  mutated	  to	  alanine	  9S-­‐AxNgn2:	  all	  SP	  serines	  mutated	  to	  alanine	  –	  see	  xS-­‐A9	  9S-­‐AxNgn2KO:	  	  all	  SP	  serines	  mutated	  to	  alanine	  and	  all	  lysines	  mutated	  to	  arginine	  9S-­‐AT149AxNgn2KO:	  	  see	  9S-­‐AxNgn2KO,	  also	  T149	  mutated	  to	  alanine	  9S-­‐AT(118,149)AxNn2KO:	  	  see	  9S-­‐AxNgn2KO,	  also	  T118,	  T149	  mutated	  to	  alanine	  9S-­‐AAc2xNgn2KO:	  	  see	  9S-­‐AxNgn2KO,	  also	  upregulated	  for	  N-­‐terminal	  acetylation	  9S-­‐AT149AxNgn2:	  	  all	  SP	  and	  TP	  site	  serines/threonines	  mutated	  to	  alanine	  	  CT-­‐S-­‐AxNgn2:	  	  all	  SP	  site	  serines	  in	  C-­‐terminal	  domain	  mutated	  to	  alanine	  CT-­‐S-­‐AT49AxNgn2:	  	  all	  C-­‐terminal	  SP	  serines,	  and	  TP	  threonine,	  mutated	  to	  alanine	  NT-­‐S-­‐AxNgn2:	  	  all	  SP	  site	  serines	  in	  N-­‐terminal	  domain	  mutated	  to	  alanine	  NT-­‐S-­‐AT49AxNgn2:	  	  all	  N-­‐terminal	  SP	  serines,	  and	  TP	  threonine,	  mutated	  to	  alanine	  T149AxNgn2:	  	  TP	  site	  mutated	  to	  alanine	  	  
Domain	  swap	  chimeras:	  	  N-­‐Ngn/BC-­‐NeuroD:	  	  N-­‐terminal	  domain	  of	  xNgn2	  fused	  to	  bHLH	  and	  C-­‐terminal	  domains	  of	  xNeuroD	  NB-­‐Ngn/C-­‐NeuroD:	  N-­‐terminal	  and	  bHLH	  domains	  of	  xNgn2	  fused	  to	  C-­‐terminal	  domain	  of	  xNeuroD	  N-­‐NeuroD/BC-­‐Ngn:	  N-­‐terminal	  domain	  of	  xNeuroD	  fused	  to	  bHLH	  and	  C-­‐terminal	  domains	  of	  xNgn2	  NB-­‐NeuroD/C-­‐Ngn:	  N-­‐terminal	  and	  bHLH	  domains	  of	  xNeuroD	  fused	  to	  C-­‐terminal	  domain	  of	  xNgn2	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bHLH	  Proteins	  	  Basic	  Helix-­‐Loop-­‐Helix	  (bHLH)	  proteins	  are	  proteins	  of	  an	  ancient	  lineage	  (Rebeiz	  et	  al.,	  2005,	  Holland	  et	  al.,	  2000,	  Quan	  et	  al.,	  2004,	  Simionato	  et	  al.,	  2008)	  expressed	  in	  eukaryotes	  (Massari	  and	  Murre,	  2000).	  	  They	  consist	  of	  a	  DNA-­‐binding	  basic	  domain	  followed	  by	   two	  α-­‐helices	   separated	  by	  a	   loop	   (Murre	  et	   al.,	   1994).	   	  Tissue-­‐specific	  class	  II	  bHLH	  proteins	  bind	  as	  a	  heterodimer	  with	  the	  ubiquitously	  expressed	  class	  I	  bHLH	  E2A	  gene	  products,	  such	  as	  E12	  or	  E47,	  to	  a	  consensus	  pseudo-­‐palindromic	  E-­‐box	  DNA	  motif,	  CANNTG	  (where	  N	  is	  any	  nucleic	  acid)	  (Ma	  et	  al.,	  1994,	  Ellenberger	  et	  al.,	  1994,	  see	  Appendix	  1).	  	  	  	  bHLH	   proteins	   function	   as	   transcription	   factors	   (Massari	   and	   Murre,	   2000).	  	  Activation	   of	   transcription	   by	   bHLH	   proteins	   is	   involved	   in	   cell	   fate	   determination	  and	   differentiation.	   	   They	   have	   demonstrated	   roles	   in	   myogenesis	   (Yokoyama	   and	  Asahara,	   2011),	   haematopoiesis	   and	   heart	   development	   (Jones,	   2004),	   pancreatic	  development	   (Murtaugh	   and	  Melton,	   2003)	   and	   sex	  determination	   (Bhandari	   et	   al.,	  2011).	  	  I	  have	  investigated	  bHLH	  transcription	  factors	  involved	  in	  brain	  development	  by	  controlling	  the	  process	  of	  neurogenesis	  (Philpott,	  2010).	  	  
Neurogenesis	  	  bHLH	   proteins	   are	   of	   immense	   importance	   in	   nervous	   development	   (Ik	   Tsen	  Heng	  and	  Tan,	  2003,	  Kageyama	  and	  Nakanishi,	  1997,	  Ross	  et	  al.,	  2003,	  Talikka	  et	  al.,	  2002)	  and	   tumorigenesis.	   	   Much	   work	   on	   Drosophila	   atonal	   proteins	   (homologous	   to	  neurogenins)	   or	   achaete-­‐scute	   (relating	   to	   Xash/Mash	   in	   vertebrates)	   identifies	  functional	  roles	  that	  are	  conserved	  in	  vertebrates	  and,	  in	  particular,	  mammals	  (Farah	  et	   al.,	   2000,	   Garrell	   and	   Modolell,	   1990,	   Hassan	   and	   Bellen,	   2000,	   Hu	   et	   al.,	   2004,	  Korzh	  et	  al.,	   1998,	  Romani	  et	  al.,	  1989).	   	  bHLH	  proteins	  are	  heavily	   involved	   in	   the	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Figure 1.1: Pathways of Ngn2 action. 
The various inhibitors and transcriptional targets of Ngn2 promote both neuronal differentiation and 
lateral inhibition of neighbouring precursor cells.  Cyclin dependent kinase inhibitors (cdkis) relieve 
cyclin A2/cdk2 inhibition of Ngn2 allowing transcription of downstream targets such as NeuroD and 
MyT1 leading to neuronal differentiation.  Cdkis also stabilise Ngn2 against proteasomal 
degradation.  However the Notch ligand, Delta, is also transcribed, and binds to the Notch receptor 
of neighbouring cells.  The Notch intracellular domain (NICD) forms part of a transcriptional 
complex producing proteins such as Hairy enhancer of split (Hes) 1 and Hes5.  These 
transcriptional repressors prevent transcription of Ngn2 targets and the cell is held in a precursor 















transcription	   of	   the	   Notch	   ligand,	   Delta	   (see	   Figure	   1.1).	   	   Increasing	   levels	   of	  proneural	  proteins	  within	  a	  cell	  lead	  to	  increasing	  production	  of	  Delta,	  which	  induces	  Notch	  signalling	  in	  neighbouring	  cells.	  	  Activation	  of	  Notch,	  releasing	  the	  Notch	  intra-­‐cellular	  domain	  (NICD)	   into	   the	  cytoplasm,	   leads	  to	   transcriptional	  activation	  of	   the	  Hairy	   enhancer	   of	   split	   (Hes)	   proteins	  Hes1	   and	  Hes5.	   	   These	   proteins,	   also	   in	   the	  bHLH	   family,	   are	   repressors	   of	   transcription.	   	   Therefore	   Notch	   signalling	   leads	   to	  inhibition	  of	  the	  action	  of	  the	  proneural	  proteins	  in	  neighbouring	  cells	  and	  so	  leads	  to	  a	   network	   of	   lateral	   inhibition,	   where	   a	   differentiating	   neuronal	   cell	   maintains	  neighbouring	  cells	  in	  a	  precursor	  state	  (Chitnis	  and	  Kintner,	  1996).	  	  Many	  proteins	   interact	  with	  the	  bHLH	  pathway	   in	  neurogenesis.	   	  Glioblastoma	  (Gli)	  proteins	  affect	  neural	  plate	  development	  and	  are	  required	  for	  primary	  motor	  neuron,	  primary	   sensory	   neuron	   and	   primary	   interneuron	   production	   in	   Xenopus.	   	   These	  proteins	   are	   able	   to	   induce	   Ngn	   transcription	   and	   interact	   (albeit	   via	   an	   unknown	  mechanism)	   with	   the	   bHLH	   and	   Notch	   pathways	   (Nguyen	   et	   al.,	   2005).	  	  Transcriptional	   repressors	   can	   interact	   with	   bHLH	   proteins	   to	   regulate	  differentiation	  networks;	   for	   example	   the	  oligodendrocyte	   lineage	  2	   (Olig2)	  protein	  interacts	   with	   Ngn2	   to	   affect	   motor	   neuron	   subtype	   specification	   (Novitch	   et	   al.,	  2001).	  	  The	   role	   of	   the	   bHLH	   proteins	   in	   promoting	   neurogenesis	   whilst	   suppressing	  gliogenesis	  may	  also	  lead	  ultimately	  to	  control	  of	  cell	  fate	  in	  glial	  precursors.	   	  A	  role	  for	   the	   janus	   kinase-­‐signal	   transducers	   (JAK-­‐STAT)	   and	   mitogen-­‐activated	   protein	  kinase	   (MAPK)	  pathways	   in	   differentiation	   of	   astrocytes	   has	   been	   identified	   (Rajan	  and	  McKay,	  1998).	  	  A	  role	  for	  cytokines	  in	  promoting	  gliogenesis	  (Bonni	  et	  al.,	  1997)	  is	   linked	   to	   the	   action	   of	   proneural	   proteins	   indirectly.	   	   Neurogenesis	   precedes	  gliogenesis	  and	  neurons	  from	  the	  embryonic	  cortex	  (specified	  by	  proneural	  proteins	  as	  shown	  in	  (Ross	  et	  al.,	  2003))	  secrete	  cytokines	  that	  promote	  differentiation	  of	  glial	  precursors	  into	  astrocytes	  (Barnabe-­‐Heider	  et	  al.,	  2005).	  	  
	  5	  
Neurogenin	  	  Neurogenin	  was	  identified	  in	  the	  mid-­‐1990s	  from	  a	  cDNA	  library	  from	  rat	  dorsal	  root	  ganglia	   using	   consensus	   sequences	   from	   a	   particular	   protein	   fold	   family,	   the	   bHLH	  	  proteins	   (Ma	   et	   al.,	   1996).	   	   Xenopus	   laevis	   Ngn2	   (xNgn2,	   also	   known	   as	   X-­‐NGNR-­‐1	  (Nieber	   et	   al.,	   2009))	   was	   found	   to	   induce	   neurogenesis,	   the	   process	   of	   neuron	  formation	   from	  neural	  precursors	   (see	  Figure	  1.2).	   	   It	   activates	   the	   transcription	  of	  downstream	  targets	  such	  as	   the	  proneural	  bHLH	  protein	  xNeuroD	  (Ma	  et	  al.,	  1996)	  and	  the	  zinc-­‐finger	  protein	  xMyT1	  ((Bellefroid	  et	  al.,	  1996),	  see	  Figure	  1.1).	  	  Not	  long	  after,	   it	  was	   found	   in	  mouse	   that	  3	  distinct	  neurogenins	  were	  present:	  Ngn1;	  Ngn2	  and	   Ngn3,	   all	   with	   roles	   in	   determination	   of	   cell	   fate	   distinct	   from	   each	   other	  (Sommer	   et	   al.,	   1996)	   but	   acting	   upstream	   of	   NeuroD	   in	   determining	   the	   fate	   of	  progenitor	   cells	   as	   neural	   precursors.	   	   In	  Xenopus	   laevis,	   homologues	   to	   only	  Ngn2	  and	  Ngn3	  have	  been	  found	  but	  none	  for	  Ngn1.	  	  Ngn2	  acts	  as	  an	  activator	  of	  transcription	  for	  both	  itself	  and	  a	  cascade	  of	  other	  bHLH	  transcription	  factors	  (Mattar	  et	  al.,	  2004).	  	  The	  Ngn2/E12	  heterodimer	  bound	  to	  DNA	  recruits	   transcriptional	   coactivators	   such	   as	   p300/CBP	   (Koyano-­‐Nakagawa	   et	   al.,	  1999).	  	  The	  neuronal	  differentiation	  factor	  NeuroD,	  one	  of	  the	  transcriptional	  targets	  of	  the	  Ngn2/E12	  complex,	  can	  itself	  go	  on	  to	  associate	  with	  the	  p300/CBP	  coactivator	  in	   activation	   of	   transcription	   of	   markers	   of	   neuronal	   formation	   such	   as	   neural	   β-­‐tubulin;	  X-­‐MyT1;	  Xebf3;	   or	   the	  kinase	  XPak3	  which	  promotes	   cell	   cycle	  withdrawal	  (Seo	  et	  al.,	  2007,	  Souopgui	  et	  al.,	  2002).	  	  	  	  xNgn2	   is	   most	   closely	   related	   in	   sequence	   to	   mouse	   Ngn2	   (mNgn2).	   	   mNgn2	   is	  involved	  in	  formation	  of	  sensory	  neurons	  from	  the	  epibranchial	  placode	  (Fode	  et	  al.,	  1998).	  	  Both	  Ngn1	  and	  Ngn2	  are	  involved	  in	  neurogenesis	  in	  dorsal	  root	  ganglia	  (Ma	  et	   al.,	   1999).	   	   Ngn2	   acts	   to	   determine	   the	   fate	   of	   progenitor	   cells	   as	   neuronal	  precursors	  and	  also	  to	  repress	  glial	  cell	  fates	  using	  separate	  mechanisms	  (Korzh	  and	  Strahle,	  2002,	  Sun	  et	  al.,	  2001).	  	  Ngn2	  also	  induces	  exit	  from	  the	  cell	  cycle	  (Guillemot,	  2007),	  and	   if	   levels	  of	  Ngn2	  become	  too	  high	  can	  mediate	  early	  cell	  death	  of	  neural	  precursors	   as	   a	   self-­‐regulatory	   mechanism	   (Yeo	   and	   Gautier,	   2005).	   	   Ngn2	  demonstrates	   roles	   in	   reprogramming	   adult	   astroglial	   cells	   (Gross,	   2000)	   in	   the	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subventricular	   zone	   of	   the	   lateral	   ventricles	   (Rogelius	   et	   al.,	   2008)	   and	   the	  hippocampus	  (Ozen	  et	  al.,	  2007),	  and	  also	  a	  possible	  role	  in	  Alzheimer’s	  treatment	  by	  producing	   dopaminergic	   neuronal	   precursors	   (Kele	   et	   al.,	   2006,	   Thompson	   et	   al.,	  2006).	   	   Cell	   motility	   is	   also	   affected	   by	   Ngn2,	   which	   can	   control	   the	   growth	   and	  migration	  of	  neurons	  (Heng	  et	  al.,	  2008).	  
 The	  role	  of	  Ngn2	  in	  neurogenesis	  in	  the	  developing	  embryo	  has	  led	  to	  research	  into	  other	   settings	   for	   inducing	   neuronal	   differentiation.	   	   Differentiation	   of	   neural	   stem	  cells	  can	  be	   induced	  by	  transfection	  of	  Ngn2	  (Falk	  et	  al.,	  2002).	   	  Ngn2	  can	  suppress	  glial	   cell	   fates	   in	   neural	   stem	   cells	   to	   increase	   the	   chance	   of	   success	   of	   introducing	  such	  cells	   into	  damaged	  regions	  of	   the	  spinal	  chord	  to	  repair	  damage	  (Hofstetter	  et	  al.,	  2005).	  	  Likewise	  roles	  for	  proneural	  genes	  are	  emerging,	  such	  as	  in	  the	  context	  of	  Notch	   signalling	  maintaining	   neural	   stem	   cells	   in	   a	   progenitor	   state	   (Imayoshi	   and	  Kageyama,	  2011),	  which	  allow	  adult	  neurogenesis	  to	  take	  place.	  	  In	   summary,	  Ngn2	  acts	   to	  commit	  progenitor	  cells	   to	  a	  neuronal	   fate	  by	  exiting	   the	  cell	  cycle	  and	  directing	  subtype	  specification.	  	  It	  has	  further	  roles	  in	  other	  processes	  such	  as	  neuronal	  migration	  and	  neurite	  outgrowth	  (Hand	  2005).	  	  




Figure 1.2: Schematic of Ngn2 action with respect to cell fate. 
xNgn2, stabilised by Xic1, is expressed at the level of a neural progenitor cell.  xNgn2 activates 
transcription of xNeuroD at which point the cell becomes committed to a neuronal cell fate.  Further 
transcription of a cascade of bHLH factors and other factors results in primary neuron formation. 
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Ngn2,	   like	  Xic1,	   is	   controlled	  by	   lateral	   inhibition	   through	  Notch	   signalling	   (Chitnis	  and	   Kintner,	   1996,	   Chitnis,	   1999,	   Justice	   and	   Jan,	   2002,	   Vernon	   et	   al.,	   2006).	   	   This	  results	   in	   differentiation	   of	   primary	   neurons	   in	   the	   neural	   crest	   surrounded	   by	  inhibited	   cells	   that	  may	   be	   directed	   to	   gliogenesis	   as	   has	   been	   shown	   in	   transient	  Notch	  expression	  experiments	  ((Morrison	  et	  al.,	  2000),	  see	  Figure	  1.1).	  	  
	  
Neurogenins	  and	  structural	  considerations	  	  Whilst	   there	   is	   no	   published	   structural	   information	   for	   Ngn2,	   homologues	   such	   as	  MyoD	  and	  NeuroD	  bound	  to	  E47	  as	  a	  heterodimer	  to	  DNA	  do	  have	  crystal	  structures	  available	  (Longo	  et	  al.,	  2008,	  Ma	  et	  al.,	  1994,	  Wendt	  et	  al.,	  1998,	  see	  Appendix	  1).	  	  It	  is	  suggested	   that	   DNA	   binding	   is	   required	   for	   the	   protein	   to	   fold	   and	   also	   to	  heterodimerise	   through	   an	   unknown	   mechanism	   (Longo	   et	   al.,	   2008).	   	   However	  formation	  of	  the	  heterodimer	  before	  DNA-­‐binding	  cannot	  be	  precluded.	  	  There	  is	  also	  an	  NMR	  structure	  of	  the	  bHLH	  Ngn1	  homodimer	  bound	  to	  DNA	  (Aguado-­‐Llera	  et	  al.,	  2010).	   	   No	   evidence	   exists	   for	   homodimers	   of	   Ngn2	   binding	   DNA,	   whereas	   E2A	  homodimers	   can	   bind	   DNA,	   dependent	   on	   an	   intermolecular	   disulphide	   bond	  (Benezra,	   1994).	   	   The	   Ngn1	   homodimeric	   complex	   is	   described	   as	   “fuzzy”	   and	  remains	  highly	  dynamic	  even	  when	  bound	  to	  DNA	  (Aguado-­‐Llera	  et	  al.,	  2010).	  	  Ngn2	   binds	   as	   a	   heterodimer	   with	   E2A	   gene	   products.	   	   E2A	   proteins	   are	   also	  ubiquitylated	  and	  degraded,	  in	  a	  Notch-­‐dependent	  manner	  controlled	  by	  MAP	  kinase	  (Kho	   et	   al.,	   1997,	   Nie	   et	   al.,	   2003).	   	   Degradation	   of	   Inhibitor	   of	   differentiation	   (Id)	  proteins,	  which	  lack	  a	  basic	  domain	  and	  bind	  Ngn2	  to	  inhibit	  its	  transcription	  factor	  activity,	  is	  also	  ubiquitin-­‐dependent	  (Benezra	  et	  al.,	  1990,	  Berse	  et	  al.,	  2004).	  	  Mash	  is	  also	   degraded	   in	   a	   manner	   that	   is	   not	   only	   ubiquitin-­‐dependent,	   but	   occurs	   in	  response	  to	  Notch	  signalling	  (Sriuranpong	  et	  al.,	  2002).	  	  Ngn2	  is	  phosphorylated	  upon	  association	  with	  E12	  (Vosper	  et	  al.,	  2007).	   	  Mash	  also	  shows	   increased	   phosphorylation	   on	   heterodimerisation	   with	   E47	   (Vinals	   et	   al.,	  2004).	   	  Phosphorylation	  of	  Ngn2	   is	  also	   important	   in	  regulating	   its	  activity.	   	  Recent	  work	   has	   shown	   that	   phosphorylation	   on	   particular	   sites	   of	   Ngn2	   is	   required	   for	  specification	  of	  motor	  neurons	  (Ma	  et	  al.,	  2008).	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The	  Ubiquitin	  Proteasome	  System	  (UPS)	  	  Proteins	  are	  produced	  through	  transcription	  and	  translation	  of	  genes	  in	  the	  cell,	  from	  information	  encoded	  in	  DNA	  through	  RNA	  to	  protein.	  	  Proteins	  are	  also	  broken	  down	  to	   terminate	   their	   function	   and	   recycle	   their	   amino	   acid	   components	   for	   the	  production	  of	  other	  proteins.	   	  But	  how	  does	  the	  degradation	  machinery	  recognize	  a	  protein	  that	  must	  be	  degraded?	  	  One	  method	  of	  signalling	  proteins	  for	  destruction	  is	  through	   attachment	   of	   a	   protein	   modifier,	   ubiquitin	   (Ub),	   itself	   a	   7.6	   kDa	   protein	  molecule.	   	   The	   process	   of	   ubiquitylation	   can	   target	   the	   substrate	   protein	   for	  degradation	  by	  a	  cellular	  structure,	  the	  26S	  proteasome.	  	  
Discovery	  of	  ubiquitin	  	  Protein	  degradation	  may	  seem	  a	  necessary	  requirement	   to	  remove	  a	  protein	  signal.	  	  Otherwise	  a	  protein	  produced	  would	  need	   to	  be	  swamped	  by	  a	  different	  protein	   to	  cancel	  its	  effects,	  and	  in	  turn	  this	  protein	  by	  another.	  	  This	  might	  lead	  to	  a	  frightening	  mass	  of	  protein	  before	  barely	  a	  few	  cell	  divisions	  in	  a	  developing	  embryo	  in	  a	  logical	  thought	   experiment,	   but	   in	   the	   early	   studies	   of	   protein	   metabolism	   this	   was	   not	  appreciated.	   	   The	   concept	   of	   protein	   catabolism	   had	   surprisingly	   controversial	  beginnings.	  	  A	  long	  established	  view	  that	  cellular	  proteins,	  once	  produced,	  are	  stable	  (Folin,	  1905)	  was	  only	  challenged	  by	  work	  using	   isotopically	   labelled	   leucine	   fed	  to	  rats	   (Schoenheimer	   et	   al.,	   1939).	   	   Rather	   than	   passing	   straight	   through	   the	   rats,	   a	  large	  proportion	  of	  the	  label	  was	  incorporated	  into	  their	  tissue,	  suggesting	  that	  some	  form	  of	  protein	  turnover,	  replacing	  “endogenous”	  protein	  with	  labelled	  protein,	  was	  occurring.	   	   This	   led	   to	   Schoenheimer’s	   proposal	   that	   protein	   levels	   were	   held	   in	   a	  dynamic	  state	  (Schoenheimer,	  1942).	  	  This	   rebellion	   from	   textbook-­‐enshrined	   dogma	   was	   rebuffed	   by	   none	   other	   than	  Jacob	  Monod	  (Hogness	  et	  al.,	  1955),	  whose	  authority	   in	   the	  scientific	  establishment	  was	  so	  great	  as	   to	  suppress	   this	  concept	  until	   sufficient	  experimental	  evidence	  was	  produced	  to	  support	  Schoenheimer’s	  theory.	  	  Protein	  catabolism	  became	  an	  accepted	  process	  in	  the	  metabolism	  of	  cellular	  proteins	  (Schimke	  and	  Doyle,	  1970).	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Cells	  contain	  a	  variety	  of	  proteolytic	  enzymes,	  such	  as	  the	  serine	  proteases,	  which	  can	  cleave	  polypeptide	   chains	   (Rawlings	   and	  Barrett,	   1994).	   	  However	   observations	   on	  the	   ATP-­‐dependence	   of	   the	   rapidly	   degraded	   tyrosine	   amino-­‐transferase	   (TAT)	  protein	  (Hershko	  and	  Tomkins,	  1971)	  suggested	  another	  component	  of	  degradation	  machinery	  was	  present	   in	  cells.	   	  Fractionation	  of	  a	  reticulocyte	   lysate	  system	  led	   to	  identification	   of	   a	   small	   protein,	   ATP-­‐dependent	   proteolysis	   factor	   1	   (APF-­‐1)	  (Ciechanover	   et	   al.,	   1978),	   later	   identified	   as	   the	   ubiquitous	   (throughout	   all	  eukaryotic	  cells)	  protein	  ubiquitin	  (Ub,	  (Wilkinson	  et	  al.,	  1980)).	  	  	  	  This	  Ub,	  covalently	  linked	  to	  proteins,	  was	  suggested	  to	  target	  proteins	  for	  degradation	  by	  a	  specific	  ATP-­‐dependent	  protease	   (Hershko	  et	  al.,	  1980).	   	  This	  process	  of	  discovery	   (discussed	   in	  more	   detail	   in	   (Mayer,	   2005))	   carried	   on	   with	   identification	   of	   the	   particular	  ubiquitylation	  machinery	  that	  comprises	  the	  Ub	  proteasome	  system	  (UPS,	  reviewed	  in	  (Glickman	  and	  Ciechanover,	  2002,	  Hershko	  and	  Ciechanover,	  1998,	  Pickart,	  2001b,	  Pickart,	  2001a,	  Weissman,	  2001)).	  
	  
Roles	  of	  ubiquitylation	  	  Ubiquitylation	  and	  modification	  by	  the	  related	  ubiquitin-­‐like	  (Ubl)	  modifiers	  can	  have	  a	  variety	  of	  signalling	  effects	  on	  proteins	  (reviewed	  in	  (Kerscher	  et	  al.,	  2006)).	  	  These	  moieties	  are	  covalently	  linked	  to	  their	  substrates.	  	  Ubiquitylation	   itself	   has	   roles	   in	   an	   array	   of	   cellular	   processes.	   	   DNA	   repair	   and	  histone	  modification	   (Pickart,	  2002),	   receptor	  endocytosis	   (Hicke	  and	  Dunn,	  2003),	  endocytic	   sorting	   (Katzmann	  et	   al.,	   2002)	  and	   inflammatory	   responses	   (Deng	  et	   al.,	  2000)	  can	  all	  be	  mediated	  by	  ubiquitylation.	  	  However	   the	   role	   for	   which	   Ub	   was	   originally	   discovered	   is	   protein	   degradation	  (Ciechanover,	  1994).	   	  This	  has	  proven	  to	  provide	  control	   in	  cell	  signalling	  (Haglund	  and	   Dikic,	   2005)	   and	   to	   provide	   control	   in	   the	   cell	   cycle	   and	   differentiation	   (see	  below),	   for	   example	   in	   differentiation	   of	   mammalian	   stem	   and	   progenitor	   cells	  (Naujokat	  and	  Saric,	  2007).	   	  Spatio-­‐temporal	  regulation	  of	  ubiquitylation	  within	  the	  cell	   is	   organized	   to	   allow	   a	   dynamic	   signalling	   network	   (Grabbe	   et	   al.,	   2011).	  	  Therefore	   ubiquitylation	   of	   proteins	   can	   be	   controlled	   by	   the	   cell	   to	   allow	   a	   fluid	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response	  to	  changing	  conditions.	  	  Ubls	  such	  as	  the	  small	  Ub-­‐like	  modifier,	  or	  SUMO	  (Johnson,	  2004)	  are	  involved	  not	  in	  targeting	   for	   proteasomal	   degradation,	   but	   in	   localisation	   or	   activation	   of	   proteins.	  	  For	  example,	  SUMOylation	  induces	  localisation	  of	  proteins	  to	  nuclear	  pore	  complexes	  or	  promyelocytic	   leukemia	  (PML)	  nuclear	  bodies	  (Zhong	  et	  al.,	  2000).	   	  On	  the	  other	  hand,	   these	   Ubl	   modifiers	   can	   indirectly	   affect	   the	   stability	   of	   proteins	   against	  proteasomal	   degradation.	   	   Neddylation	   (modification	   by	   a	   Nedd8	   Ubl	   modifier)	   of	  cullins	   is	   required	   for	   activation	   of	   Skp1-­‐Cullin1-­‐F-­‐box	   (SCF,	   see	   below)	   complexes	  (Wu	  et	   al.,	   2005).	   	   Therefore	   activation	  of	   an	   enzyme	   complex,	  which	  ubiquitylates	  proteins	  to	  target	  for	  destruction	  itself,	  requires	  Ub-­‐like	  modification.	  	  Likewise	  the	  ubiquitylation	  machinery	  can	  be	  utilized	  to	  the	  detriment	  of	  a	  host	  cell	  by	   a	   virus,	   such	   as	   in	   HIV	   budding	   (Pornillos	   et	   al.,	   2002).	   	   Malfunctions	   in	   the	  ubiquitylation	  machinery	   also	   have	   implications	   in	   cancer,	   Parkinson’s	  Disease	   and	  Alzheimer’s	  (Kerscher	  et	  al.,	  2006).	  	  
The	  Ub-­Proteasome	  System	  (UPS)	  	  The	   process	   of	   ubiquitylation	   is	   illustrated	   in	   Figure	   1.3.	   It	   begins	   with	   the	  adenylation	  of	   the	  C-­‐terminus	  of	  Ub	  by	  the	  Ub-­‐activating	  (E1)	  enzyme	  using	  energy	  from	  the	  hydrolysis	  of	  ATP	  (Hershko	  et	  al.,	  1981).	  	  This	  modification	  activates	  the	  Ub	  moiety	   energetically	   throughout	   the	   ubiquitylation	   cascade	   for	   eventual	   transfer	   to	  the	  substrate	  protein.	  	  Ub	  is	  then	  covalently	  fused	  via	  a	  thioester	  linkage	  to	  a	  cysteine	  residue	   in	   the	   E1	   by	   attack	   of	   the	   cysteine	   at	   the	   C-­‐terminus	   of	   Ub,	   releasing	   AMP	  (Ciechanover	   et	   al.,	   1981).	   	   The	   E1	   cannot	   just	   take	   Ub	   straight	   to	   the	   substrate	  (though	   such	   a	   concept	   is	   possible	   such	   as	   in	   non-­‐ribosomal	   polypeptide	   synthesis	  (Cane	  and	  Walsh,	  1999)).	   	  Ub	  is	  shuttled	  onto	  a	  cysteine	  residue	  of	  another	  enzyme,	  the	  Ub-­‐conjugating	   (E2)	   enzyme	   (Hershko	  et	   al.,	   1983),	   of	  which	   there	   are	   a	   larger	  number	  (~50)	  (Wu	  et	  al.,	  2003).	   	  This	  E2	  can	  then	  pass	  on	  the	  Ub	  moiety	   in	  one	  of	  two	  ways,	  in	  concert	  with	  an	  Ub	  (E3)	  ligase	  (of	  which	  there	  are	  several	  hundred	  kinds	  described	   below).	   	   Specificity	   increases	   through	   the	   ubiquitylation	   cascade	   from	   a	  single	  Ub-­‐specific	  E1,	  to	  a	  larger	  number	  of	  E2s	  and	  then	  to	  hundreds	  of	  E3s	  (Semple,	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2003).	   	   The	   E2	   binds	   to	   the	   E3	   ligase	   which	   itself	   binds	   the	   substrate	   protein	  (Hershko	  et	  al.,	  1986).	   	  The	  E3	  ligase	  confers	  specificity	  for	  the	  substrate	  protein	  on	  the	  ubiquitylation	  process	  (Hershko,	  1988).	  	  
 The	   E2	   may	   pass	   Ub	   directly	   onto	   the	   substrate	   protein	   using	   the	   E3	   ligase	   as	   a	  scaffold,	  such	  as	  with	  the	  SCF	  complexes	  (Jackson	  et	  al.,	  2000);	  or	  the	  E2	  passes	  Ub	  to	  a	   cysteine	   residue	   of	   a	   HECT	   (Homologous	   to	   the	   E6-­‐AP	   Carboxyl	   Terminus)	   E3	  ligase,	  which	   then	   passes	   Ub	   to	   the	   substrate	   protein	   (Huibregtse	   et	   al.,	   1995).	   	   In	  either	  case,	  Ub	  is	  passed	  onto	  the	  substrate	  protein,	  canonically	  onto	  a	  lysine	  residue	  to	   form	   an	   isopeptide	   bond.	   	   The	   cycle	   can	   then	   be	   repeated	   to	   add	   further	   Ub	  moieties	  to	  the	  Ub	  already	  attached	  to	  the	  protein.	  	  	  E4	  ligases	  also	  exist,	  which	  add	  a	  polyUb	  chain	  to	  a	  monoubiquitylated	  site:	  p300	  can	  carry	  out	  this	  function	  on	  a	  site	  monoubiquitylated	  by	  Mdm2	  on	  p53	  (Grossman	  et	  al.,	  2003).	   	  Proteins	  with	  a	  K48-­‐linked	   polyUb	   moiety	   containing	   at	   least	   4	   Ub	   subunits	   are	   targeted	   to	   the	   26S	  proteasome	   (Thrower	   et	   al.,	   2000),	   a	   multimeric	   complex	   consisting	   of	   α	   and	   β	  barrels	   in	   the	  20S	  complex,	   capped	  by	  "lids"	  of	  19S	  proteasome	  complexes	   (Pickart	  and	  Cohen,	  2004).	  	  Using	  energy	  from	  ATP	  hydrolysis,	  proteins	  are	  unfolded	  from	  an	  unfolding	   initiation	   site	   (Prakash	   et	   al.,	   2004)	   and	   fed	   through	   the	   narrow	   channel	  formed	  by	  the	  26S	  proteasome,	  where	  the	  substrate	  is	  cleaved	  into	  small	  peptides.	  	  
 
E3	  ligases	  






Figure 1.3: The Ubiquitin Proteasome System (UPS). 
Ub is activated by an Ub-activating (E1) enzyme using energy from ATP hydrolysis and passed to 
an Ub-conjugating (E2) enzyme.  Ub can then be passed to a substrate protein, specified by the 
particular E3 ligase that binds both the substrate and the E2.  Many E3 ligases act as a scaffold to 
pass Ub from the E2 directly to the substrate protein whilst homologous to E6-AP carboxy-terminus 
(HECT) E3 ligases form a covalent bond with Ub themselves.  The Ub moiety, covalently bound to 
the substrate protein, is then itself ubiquitylated by either successive rounds of ubiquitylation or by 
addition of a pre-assembled polyUb chain by the action of an E4 ligase.  Once sufficiently 
ubiquitylated, the substrate is targeted to the 26S proteasome.  The Ubs are cleaved from the 
protein by the action of de-ubiquitylating enzymes (DUBs) whilst the protein itself is, using energy 
from ATP hydrolysis and binding of ATP to the 26S proteasome, unfolded and cleaved into small 
peptides. 
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Really	   Interesting	  New	  Gene	   (RING)	  E3	   ligases	   are	   the	   largest	   family	   of	  Ub	   ligases.	  	  They	  are	  assembled	  into	  a	  scaffold	  based	  on	  Cullin	  proteins	  and	  the	  most	  common	  are	  the	  S-­‐phase	  kinase	  associated	  protein	  (Skp)	  1-­‐Cullin-­‐F-­‐box	  (SCF)	  complexes	  (Jackson	  et	  al.,	  2000).	  	  This	  multi-­‐protein	  scaffold	  binds	  a	  particular	  F-­‐box	  protein	  to	  generate	  the	  substrate	  specificity	  required	  of	  an	  E3	  ligase	  (Petroski	  and	  Deshaies,	  2005).	  	  SCF	  E3	   ligases	  have	  a	  wide	   range	  of	   roles,	  not	   least	   in	   cell	   fate	  determination	   in	  a	  wide	  range	  of	  organisms	  mediated	  over	  a	  variety	  of	  tissue	  types	  (Hindley	  et	  al.,	  2011).	  	  Homologous	   to	   E6-­‐AP	   Carboxy-­‐Terminus	   (HECT)	   E3	   ligases	   share	   homologous	   C-­‐terminal	   domains	   that	   are	   involved	   in	   ubiquitylation,	  whilst	   substrate	   specificity	   is	  achieved	  with	   a	   diverse	   range	   of	   N-­‐termini.	   	   These	   ligases	   differ	   from	   all	   other	   E3	  ligases	  in	  forming	  a	  covalent	  bond	  with	  the	  Ub	  moiety	  when	  picking	  it	  up	  from	  the	  E2	  before	   passing	   it	   onto	   a	   substrate	   protein	   (Huibregtse	   et	   al.,	   1995).	   	   E6-­‐AP	   itself	   is	  produced	   by	   human	   papilloma	   virus	   and	   is	   able	   to	   target	   p53	   for	   degradation	  (Scheffner	  et	  al.,	  1993)	  thus	  promoting	  tumour	  formation	  in	  infected	  lesions.	  	  The	  Anaphase	  Promoting	  Complex/Cyclosome	  (APC/C)	  is	  a	  multisubunit	  E3	  Ub	  ligase	  (Sudakin	   et	   al.,	   1995,	   King	   et	   al.,	   1995).	   	   It	   is	   activated	   through	   the	   binding	   of	   Cell	  Division	  Cycle	  (Cdc)	  20	  in	  the	  metaphase-­‐anaphase	  transition	  and	  Cdc20-­‐homologue	  (Cdh)	   1	   in	   late	  mitosis-­‐G1,	   releasing	   early	  mitotic	   inhibitor	   (Emi)	   1	   (Visintin	   et	   al.,	  1997).	  	  It	  remains	  active	  through	  to	  S	  phase.	  	  Cdh1	  and	  Cdc20	  are	  only	  active	  during	  late-­‐M/G1/early-­‐S	   and	   early-­‐M	   phases	   of	   the	   cell	   cycle,	   respectively.	   	   Through	   this	  temporal	   control	   of	   the	   co-­‐activators,	   the	   APC/C	   is	   able	   to	   control	   various	  checkpoints	   to	   prevent	   early	   or	   incorrect	   cell	   cycle	   progression	   (Manchado	   et	   al.,	  2010,	  Peters,	  2006,	  van	  Leuken	  et	  al.,	  2008).	  	  Mitotic	   cyclins	   are	   targeted	   as	   well	   as	   the	   complexes	   keeping	   sister	   chromatids	  together;	  the	  protein	  securin	  is	  cleaved	  by	  the	  APC/C	  allowing	  chromatid	  separation	  and	   the	   irreversible	   onset	   of	   anaphase	   (Zou	   et	   al.,	   1999).	   	   It	   also	   participates	   in	  targeting	  Skp2	  (S-­‐phase	  kinase-­‐associated	  protein	  2)	  degradation	  to	  prevent	  early	  S	  phase	  entry	  (Bashir	  et	  al.,	  2004).	  	  	  The	  APC/C	   responds	   to	  DNA	  damage	   (Bassermann	   et	   al.,	   2008,	   Coster	   et	   al.,	   2007,	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Townsend	   et	   al.,	   2009,	   Li	   and	   Zhang,	   2009),	   and	   is	   implicated	   in	   tumorigenesis	  (Garcia-­‐Higuera	   et	   al.,	   2008).	   	   Cell	   cycle-­‐independent	   functions	   have	   also	   been	  established,	  particularly	   in	   the	  patterning	  and	  development	  of	  post-­‐mitotic	  neurons	  (Manchado	  et	  al.,	  2010).	  	  In	  addition,	  enzymes	  that	  can	  place	  pre-­‐assembled	  polyUb	  chains	  onto	  ubiquitylated	  substrates	   have	   been	  discovered	   and	   are	   termed	  E4	   ligases	   (Koegl	   et	   al.,	   1999).	   	   A	  good	  example	   is	   seen	   in	   the	  monoubiquitylation	  of	  p53	  by	  Mdm2	  (Lai	  et	  al.,	  2001),	  followed	   by	   addition	   of	   a	   K48-­‐linked	   polyUb	   chain	   by	   E4	   ligase	   activity	   of	   p300	  (Grossman	  et	  al.,	  2003).	  	  	  
Modes	  of	  ubiquitylation	  	  Ubiquitylation	  of	  a	  substrate	  protein	  is	  followed	  by	  ubiquitylation	  of	  the	  Ub	  itself	  on	  an	   internal	   lysine	   residue	   to	   build	   up	   a	   polyUb	   chain.	   	   The	   particular	   lysine	  ubiquitylated	   is	   regulated	   by	   the	   E2	   (David	   et	   al.,	   2010)	   and	   various	   linkages	   of	  polyUb	  chains	  may	  confer	  various	  properties.	  	  For	  example,	  K48-­‐linked	  chains	  target	  for	  proteasomal	  degradation	  (Thrower	  et	  al.,	  2000);	  but	  K11-­‐linked	  chains	  can	  do	  so	  also	  (Song	  and	  Rape,	  2011).	  	  Various	  other	  linked	  chains	  exist	  with	  various	  functions	  suggested	   (Pickart	   and	   Fushman,	   2004).	   	   Many	   other	   possibilities	   of	   homologous,	  heterologous	  and	  branched	  Ub	  chains	  are	  possible	  and	  the	  functions	  of	  these	  are	  yet	  to	  be	  elucidated.	  	  
26	  S	  proteasome	  	  The	  structure	  of	  the	  26S	  proteasome	  is	  complex	  and	  reviewed	  in	  (Coux	  et	  al.,	  1996).	  	  Basically	   the	   proteasome	   consists	   of	   a	   barrel-­‐shaped	   core	   20S	   particle	   flanked	   at	  either	  or	  both	  ends	  by	  a	  19S	  regulatory	  particle	  (Schrader	  et	  al.,	  2009).	  	  Proteins	   are	   targeted	   for	   the	   proteasome	   once	   a	   polyUb	   chain	   of	   at	   least	   4	   Ubs	   is	  covalently	  attached	  (Thrower	  et	  al.,	  2000).	  	  The	  26S	  proteasome	  binds	  polyUb	  chains	  through	  the	  19S	  lid	  component,	  which	  also	  contains	  an	  ATPase	  activity	  (Glickman	  et	  al.,	  1998).	  	  This	  regulatory	  particle	  unfolds	  proteins	  to	  allow	  them	  to	  feed	  through	  the	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narrow	  channel	  at	  the	  centre	  of	  the	  20S	  particle	  where	  proteolysis	  occurs	  (Braun	  et	  al.,	  1999).	  	  There	  is	  an	  interdependence	  between	  ubiquitylation	  sites	  and	  unfoldable	  regions	  of	  a	  protein	  to	  allow	  it	  to	  be	  unfolded	  (Prakash	  et	  al.,	  2004)	  and	  it	  may	  be	  that	  Ub	  itself	  can	  aid	  in	  this	  unfolding	  (Hagai	  and	  Levy,	  2010).	  	  At	   the	   lid	  of	   the	  proteasome,	  and	   indeed	   throughout	  all	   stages	  of	   the	  ubiquitylation	  process,	  de-­‐ubiquitylating	  enzymes	   (DUBs	   (Wilkinson,	  1997))	   such	  as	  Rpn11	  act	   to	  cleave	  Ub	  itself	  from	  the	  substrate	  (Verma	  et	  al.,	  2002).	  	  This	  adds	  reversibility	  to	  the	  polyubiquitylation	   pathway	   and	   prevents	   Ub	   itself	   from	   being	   cleaved	   by	   the	  proteasome.	   	   PolyUb	   chains	   are	   cleaved	   from	   the	   substrate	   at	   the	   surface	   of	   the	  proteasome	   to	   liberate	   free	   Ub.	   	   PolyUb	   chain	   ‘trimming’,	   releasing	   individual	   Ub	  units	  from	  a	  polyUb	  chain,	  assists	  proteasomal	  degradation	  and	  may	  facilitate	  loading	  of	  polyubiquitylated	  substrates	  at	  the	  proteasome	  (Zhang	  et	  al.,	  2011).	  
	  
Ubiquitylation	  and	  the	  cell	  cycle	  	  Ubiquitylation	  and	  proteasomal	  degradation	  of	  proteins	   is	   important	   in	  modulating	  the	   cell	   cycle	   and	   particularly	   in	   targeting	   cyclins	   for	   degradation	   (reviewed	   in	  (Hershko	   and	   Ciechanover,	   1998)).	   	   The	   role	   of	   ubiquitylation	   in	   the	   cell	   cycle	   is	  demonstrated	  early	  on	  as	  even	  E2	  enzymes	  can	  exhibit	  specific	  cell	  cycle	  roles.	   	  The	  E2	  enzyme	  Ubc3/Cdc34	  is	  particularly	  active	  in	  the	  G1	  to	  S-­‐phase	  transition	  (Mathias	  et	  al.,	  1996).	  	  E2-­‐C	  is	  also	  involved	  in	  cell	  cycle	  regulation	  by	  ubiquitylation	  of	  cyclin	  B	  in	   concert	  with	   the	   APC/C	   (Hershko	   et	   al.,	   1994).	  Mitotic	   cyclin	   ubiquitylation	   can	  also	  be	  performed	  by	  Ubc11/Ubc4	  (Yu	  et	  al.,	  1996).	  	  Cyclin	  B	  is	  a	  mitotic	  cyclin	  which	  combines	  with	  the	  cyclin	  dependent	  kinase	  cdk1	  to	  promote	  entry	  of	  the	  cell	  cycle	  into	  mitosis	  (Evans	  et	  al.,	  1983).	  	  Cyclin	  B	  degradation	  is	  mediated	  by	  the	  UPS	  (Hershko	  et	  al.,	  1991)	  in	  Xenopus	  laevis	  egg	  extracts	  (Glotzer	  et	  al.,	  1991)	  and	  by	  interaction	  with	  Hip2	  (Bae	  et	  al.,	  2010).	  	  The	  degradation	  of	  cyclin	  B	   is	   regulated	   in	   a	   cell	   cycle-­‐dependent	  manner	   by	   the	   reversible	   phosphorylation	  and	   hence	   activation	   of	   the	  APC/C	   (Lahav-­‐Baratz	   et	   al.,	   1995).	   	   The	   degradation	   of	  cyclin	   B	   is	   absolutely	   required	   for	   processes	   allowing	   progression	   of	   the	   cell	   cycle	  past	   mitosis,	   such	   as	   reformation	   of	   the	   nuclear	   envelope	   and	   chromosome	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decondensation	  (Murray,	  1989).	  	  G1-­‐phase	   cyclins	   are	   also	   targeted	   for	   UPS-­‐mediated	   degradation,	   but	   with	   a	  requirement	  for	  a	  priming	  phosphorylation,	  as	  observed	  for	  cyclin	  E	  (Won	  and	  Reed,	  1996,	  Clurman	  et	  al.,	  1996)	  and	  cyclin	  D1(Diehl	  et	  al.,	  1997).	  
	  
Canonical	  ubiquitylation	  	  Canonical	  ubiquitylation	  sites	  are	  described	  as	  lysine	  residues	  in	  the	  definition	  of	  the	  UPS	  given	  above	  (Freiman	  and	  Tjian,	  2003).	  	  	  Unlike	   many	   post-­‐translational	   modifications	   (PTMs)	   and	   even	   Ub-­‐like	   modifiers	  such	  as	  SUMO,	  there	  is	  no	  known	  consensus	  site	  for	  identifying	  a	  ubiquitylation	  site	  (Peng	   et	   al.,	   2003).	   	   There	   are	   examples	   of	   protein	   ubiquitylation	   occurring	   on	  specified	   lysines,	   such	  as	   lysines	  21	  and	  22	   in	   IκBα	  (Baldi	  et	  al.,	  1996).	   	  Conversely	  there	   are	   proteins	  where	   ubiquitylation	   can	   occur	   on	   any	   lysine,	   for	   example	   c-­‐Jun	  (Treier	  et	  al.,	  1994)	  and	  cyclin	  B	  (King	  et	  al.,	  1996).	  	  From	  the	  canonical	  description	  of	  ubiquitylation	  (Freiman	  and	  Tjian,	  2003),	  removal	  of	   all	   lysine	   residues	   in	   a	   protein	   should	   completely	   stabilise	   against	   Ub-­‐mediated	  proteasomal	   degradation.	   	   Indeed	   there	   are	   examples	   of	   proteins	   that	   appear	  completely	  stabilised	  by	  removal	  of	  lysines,	  most	  commonly	  by	  mutation	  of	  lysines	  to	  arginines	   or	   even	   by	   chemical	   modification	   of	   lysines	   (Hershko	   et	   al.,	   1986).	   	   But	  many	  investigators	  observed	  that	  proteins	  were	  still	  being	  polyubiquitylated	  and	  that	  these	   polyUb	   chains	   could	   still	   target	   the	   substrate	   protein	   for	   proteasomal	  degradation.	  	  Where	  could	  this	  ubiquitylation	  be	  occurring?	  	  
N-­terminal	  ubiquitylation	  	  Lysine	  residues	  form	  a	  covalent	  linkage	  to	  Ub	  by	  formation	  of	  an	  isopeptide	  bond	  to	  the	  carboxy	  terminus	  of	  Ub,	  activated	  by	  the	  enzyme	  cascade	  in	  Figure	  1.3,	  using	  the	  amino	  group.	  	  But	  all	  proteins	  contain	  another	  amino	  group.	  	  Polypeptides	  consist	  of	  a	  backbone	   created	   by	   peptide	   bond	   formation	   between	   amino	   acid	   residues.	   	   In	   a	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linear	   chain	   there	   is	   therefore	   a	   free	   amino	   group	   (at	   the	   N-­‐terminus)	   and	   a	   free	  carboxylate	   group	   (at	   the	   C-­‐terminus).	   	   	   	   Theoretically,	   the	   N-­‐terminus	   could	   be	  modified	  by	  Ub	  in	  the	  same	  way	  as	  lysines.	  	  	  The	  xNgn2	  homologue	  in	  myogenesis,	  MyoD,	  is	  also	  a	  short-­‐lived	  protein	  (Thayer	  et	  al.,	  1989,	  Abu	  Hatoum	  et	  al.,	  1998)	  and	  is	  partially	  stabilised	  by	  mutation	  of	  all	  lysine	  residues	   to	   arginine	   residues	   (Breitschopf	   et	   al.,	   1998).	   	  Most	   lysines	   are	   in	   the	  N-­‐terminal	  region	  of	  the	  protein	  and	  the	  stability	  is	  not	  affected	  by	  one	  individual	  lysine	  residue	  alone.	   	  Also	  no	   lysosomal	  degradation	  was	  observed	   for	  MyoD.	   	  Blocking	  of	  amino	   groups	   from	   ubiquitylation	   by	   reductive	  methylation,	   and	   of	   the	   N-­‐terminal	  amino	  group	  of	   the	  peptide	  backbone	   specifically	  by	   carbamylation	   (Hershko	  et	   al.,	  1984),	  illustrated	  that	  not	  only	  did	  blocking	  the	  N-­‐terminal	  amino	  group	  stabilise	  the	  protein,	  but	  that	   lysines	  were	  unable	  to	  be	  ubiquitylated.	   	  N-­‐terminal	  ubiquitylation	  may	  be	  required	  as	  a	  ‘priming’	  ubiquitylation	  (Breitschopf	  et	  al.,	  1998).	  	  	  There	   are	   naturally	   occurring	   lysineless	   proteins	   where	   this	   non-­‐canonical	  ubiquitylation	   (i.e.	   ubiquitylation	   on	   sites	   other	   than	   lysine	   amino	   groups)	   in	   fact	  must	  be	  essential	  for	  UPS-­‐mediated	  degradation	  to	  occur,	  such	  as	  p16INK4a	  and	  HPV-­‐58	  E7	  (Ben-­‐Saadon	  et	  al.,	  2004).	  	  Moreover,	  the	  Ub	  fusion	  degradation	  (UFD)	  pathway	  targets	  proteins	  for	  degradation	  where	  Ub	  is	  fused	  linearly	  via	  its	  C-­‐terminus	  to	  the	  N-­‐terminus	  of	  a	  protein	  (Johnson	  et	  al.,	  1995).	  	  Here	   we	   differentiate	   ubiquitylation	   of	   the	   N-­‐terminal	   amino	   group	   itself	   from	  ubiquitylation	   by	   the	   ‘N-­‐end	   rule’	   ((Wang	   et	   al.,	   2008),	   reviewed	   in	   (Varshavsky,	  2011)).	   	   A	   destabilizing	   N-­‐terminal	   residue	   in	   a	   protein	   can	   act	   as	   a	   degron	   to	  facilitate	  ubiquitylation	  and	  proteasomal	  degradation.	  	  However	  the	  Ub	  moiety	  in	  this	  case	   is	   fused	   to	   an	   internal	   lysine	   residue	   and	   not	   to	   the	   N-­‐terminal	   amino	   group.	  	  Therefore	  the	  N-­‐terminus	  acts	  as	  a	  signal	  but	  not	  as	  an	  acceptor	  for	  ubiquitylation.	  	  The	   N-­‐terminal	   residue	   of	   MyoD	   is	   not	   converted	   into	   a	   lysine	   (as	   occurs	   with	  conversion	   of	   some	   acidic	   residues	   to	   arginine	   to	   target	   for	   ubiquitylation	   (Ferber	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and	  Ciechanover,	  1987)).	  	  The	  effects	  of	  the	  N-­‐end	  rule	  were	  also	  dismissed	  as	  N-­‐end	  rule	  inhibitors	  had	  no	  effect	  on	  the	  stability	  of	  MyoD	  (Breitschopf	  et	  al.,	  1998).	  	  Fusion	  of	  a	  Myc-­‐tag	  to	  the	  N-­‐terminus	  did	  stabilise	  MyoD	  (Breitschopf	  et	  al.,	  1998)	  but	  there	  was	  no	  C-­‐terminal	  fusion	  as	  a	  control.	  	  	  	  This	  N-­‐terminal	  ubiquitylation	  is	  apparent	  in	  a	  number	  of	  proteins	  (Breitschopf	  et	  al.,	  1998,	  Chen	  et	  al.,	  2004,	  Ciechanover	  and	  Ben-­‐Saadon,	  2004,	  Kuo	  et	  al.,	  2004,	  Mayer,	  2005,	  Sadeh	  et	  al.,	  2008).	   	  Recent	  evidence	  has	  shown	  a	  role	   in	  cell	  cycle-­‐regulating	  proteins	   such	   as	   cyclin	  G1	   (Li	   et	   al.,	   2009).	   	   There	   are	  many	  ways	   in	  which	   the	  N-­‐terminus	  can	  affect	  protein	  stability	  including	  N-­‐terminal	  ubiquitylation,	  providing	  E3	  ligase	  binding	  sites	  and	  N-­‐terminal	  co-­‐translational	  acetylation	  (Meinnel	  et	  al.,	  2005,	  Meinnel	  et	  al.,	  2006).	  	  N-­‐terminal	  co-­‐translational	  acetylation	  is	  suggested	  to	  occur	  in	  75%	  of	  eukaryotic	  proteins	  (Polevoda	  and	  Sherman,	  2003a)	  although	  investigation	  of	  N-­‐terminal	   processing	   disputes	   this	   and	   places	   the	   figure	   at	   30%	   (Meinnel	   et	   al.,	  2005).	   	   However	   studies	   had	   been	   made	   of	   protein	   degradation	   in	   N-­‐terminally	  acetylated	   proteins	   (Polevoda	   and	   Sherman,	   2002)	   and	   the	   process	   of	   N-­‐terminal	  acetylation	   is	   well	   characterised,	   including	   N-­‐terminal	   consensus	   sites	   for	   the	  regulation	   of	   acetylation	   (Bradshaw	   et	   al.,	   1998,	   Polevoda	   and	   Sherman,	   2002,	  Polevoda	  and	  Sherman,	  2003b,	  Polevoda	  and	  Sherman,	  2003a,	  Utsumi	  et	  al.,	  2001).	  	  Acetylation	   is	   irreversible	   and	   so	   acetylation	   and	   ubiquitylation	   are	   mutually	  exclusive	  reactions.	  	  Therefore	  N-­‐terminal	  mutations	  can	  be	  introduced	  to	  alter	  the	  N-­‐terminal	  sequence	  and	  either	  up-­‐	  or	  down-­‐regulate	  co-­‐translational	  acetylation.	  	  	  How	   then	   to	   investigate	  N-­‐terminal	   ubiquitylation?	   	  Deletion	  of	   a	   portion	  of	   the	  N-­‐terminus	  -­‐	  say	  the	  first	  20	  residues	  –	  might	  be	  used	  to	  demonstrate	  the	  importance	  of	  the	  N-­‐terminus	   in	  targeting	  the	  substrate	   for	  polyubiquitylation.	   	  However	  this	  may	  not	  allow	  distinction	  of	  N-­‐terminal	  ubiquitylation	  from	  ubiquitylation	  targeted	  by	  the	  N-­‐End	  Rule	   (Varshavsky,	   1997)	   -­‐	   both	  may	   require	   a	   particular	   sequence	   at	   the	  N-­‐terminus	  to	  target	  for	  ubiquitylation	  but	  the	  modification	  will	  occur	  at	  different	  sites	  in	   the	   two	  processes.	   	  The	  most	  obvious	  caveat	   is	   that	   there	   is	  always	  a	   free	  amino	  group	  at	   the	  N-­‐terminus	  of	  a	   truncated	  protein.	   	  Therefore	  blocking	  the	  N-­‐terminus	  more	  directly	  is	  necessary.	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A	  common	  strategy	  is	  to	  add	  a	  bulky	  tag	  to	  the	  N-­‐terminus	  of	  the	  protein	  (Trausch-­‐Azar	   et	   al.,	   2010)	   under	   the	   rationale	   that	   such	   a	   group	   will	   physically	   block	   the	  normal	  N-­‐terminal	   site	   from	  being	   ubiquitylated.	   	   In	  many	   cases	   this	   does	   seem	   to	  work,	   but	   there	   are	   many	   factors	   to	   consider	   under	   such	   an	   experimental	   design.	  	  Firstly,	   there	   is	   some	  debate	   as	   to	  what	  defines	   a	   "bulky"	   tag	   ((Trausch-­‐Azar	   et	   al.,	  2010)	  and	  personal	  communication,	  Alan	  Schwartz).	  	  Is	  an	  HA	  tag	  sufficient?	  	  Or	  is	  a	  tag	  on	  the	  order	  of	  GFP	  required	  to	  block	  the	  site	  sufficiently?	  	  Secondly,	  once	  a	  tag	  is	  established	  as	  suitable	  and	  stabilises	  the	  protein	  when	  fused	  to	  the	  N-­‐terminus,	  it	  is	  important	  to	  also	  check	  as	  a	  control	  that	  fusion	  of	  the	  same	  tag	  to	  the	  C-­‐terminus	  does	  not	  also	  stabilise	  the	  protein	  and	  this	  is	  often	  not	  checked	  (Vosper	  et	  al.,	  2009).	  	  In	  the	  case	  of	  intrinsically	  disordered	  proteins	  it	  may	  well	  be	  the	  case	  that	  a	  tag,	  particularly	  a	   folded	   tag	   such	   as	   GFP,	   may	   stabilise	   the	   protein	   through	   blockage	   of	   unfolding	  initiation	  sites	  also	  required	  for	  proteasomal	  degradation	  (Prakash	  et	  al.,	  2004).	  	  This	  is	  indeed	  the	  case	  with	  the	  disordered	  protein	  Ngn2	  (Supplementary	  data	  in	  (Vosper	  et	   al.,	   2009)).	   	  Work	   in	  our	   lab	  making	   fusion	  proteins	  with	  N-­‐	  and	  C-­‐terminal	   tags	  proved	   that	   use	   of	   bulky	   tags	   was	   an	   unreliable	   method	   for	   studying	   protein	  degradation	  at	   the	  N-­‐terminus	  as	   tags	  at	  either	  end	  of	   the	  protein	  stabilised	  xNgn2,	  possibly	   due	   to	   steric	   or	   unfolding	   issues,	   rather	   than	   simply	   blocking	   N-­‐terminal	  ubiquitylation	  (Vosper	  et	  al.,	  2009).	  	  N-­‐terminal	  fusion	  of	  GFP	  stabilises	  xNgn2,	  but	  so	  does	   the	   C-­‐terminal	   fusion,	   rendering	   discussion	   of	   N-­‐terminal	   ubiquitylation	  unreliable	  using	  these	  results.	  	  	  	  A	   third	   approach	   could	   be	   using	   chemical	   methods	   to	   block	   the	   N-­‐terminus.	   	   This	  includes	   reductive	  methylation	  with	   sodium	   cyanoborohydride,	   guanidination	  with	  O-­‐methylisourea	  or	  carbamylation	  (Breitschopf	  et	  al.,	  1998).	  	  Due	  to	  the	  similarity	  in	  functionality,	  blocking	  of	  all	  lysine	  residue	  side-­‐chains	  will	  occur	  simultaneously	  with	  methylation.	   	   However	   guanidination	   is	   specific	   to	   lysine	   residues	   whilst	  carbamylation	   is	   specific	   to	   the	  N-­‐terminal	   amino	   group	   only.	   	   I	   opted	   for	   a	   fourth	  method	  to	  specifically	  block	  the	  N-­‐terminus	  alone.	  	  	  Particular	  amino	  acid	  residues	  at	  the	  N-­‐terminus	  can	  up-­‐	  or	  down-­‐regulate	   the	  process	  of	  co-­‐translational	  N-­‐terminal	  acetylation	   (Bradshaw	   et	   al.,	   1998,	   Polevoda	   and	   Sherman,	   2000,	   Polevoda	   and	  Sherman,	   2003b,	   Polevoda	   and	   Sherman,	   2003a)	   which	   is	   a	   mutually	   exclusive	  reaction	   to	   N-­‐terminal	   ubiquitylation	   preventing	   further	   modification	   of	   the	   N-­‐
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terminus.	  	  The	  effect	  of	  N-­‐terminal	  acetylation	  on	  protein	  stability	  can	  be	  checked	  by	  blocking	  acetylation	  using	  the	  Palmiter	  method	  (Palmiter,	  1977).	  	  
Non-­canonical	  ubiquitylation	  sites	  	  By	   whatever	   means	   available,	   a	   wide	   range	   of	   substrates	   for	   N-­‐terminal	  ubiquitylation	   have	   been	   identified	   (Ciechanover	   and	   Ben-­‐Saadon,	   2004).	   	   An	  additional	   site	   for	   ubiquitylation	   to	   the	   established	   lysines,	   the	   N-­‐terminus	   still	  resembles	   them	  chemically.	   	  But	   it	   is	  possible	   to	  generalise	   the	  mechanism	   further.	  	  Lysines	  are	  able	  to	  form	  isopeptide	  bonds	  due	  to	  the	  presence	  of	  a	  nitrogen	  atom	  that	  can	  attack	  the	  thioester	  linkage	  between	  the	  Ub	  and	  E2	  enzyme.	  	  In	  this	  manner	  the	  nitrogen	  is	  acting	  as	  a	  nucleophile,	  attracted	  to	  electropositive	  centres	  by	  virtue	  of	  its	  lone	  pair	   of	   electrons	   that	   can	   attack	   the	   thioester	   linkage	   at	   the	   electron-­‐deficient	  carbonyl	   carbon,	  which	  acts	   therefore	  as	  an	  electrophile.	   	  There	  are	  however	  other	  examples	  of	  nucleophilic	  groups	  in	  proteins:	  I	  have	  already	  discussed	  the	  N-­‐terminal	  amino	  group,	  but	  what	  about	  other	  nucleophiles	  aside	   from	  nitrogen?	   	   In	   fact	   there	  are	   several	   amino	   acid	   residues	   with	   the	   potential	   to	   attack	   electron-­‐deficient	  carbonyl	  carbons	  as	  nucleophiles.	   	  Serines,	  threonines	  and	  tyrosines	  are	  all	  residues	  containing	   electron-­‐rich	  oxygen	  atoms	   capable	  of	   forming	  hydroxyester	  bonds;	   and	  cysteine	   residues	   have	   the	   potential	   to	   act	   as	   nucleophiles	   using	   lone	   pairs	   of	  electrons	  on	  sulfur.	  	  	  Two	  key	  questions	  must	  be	  asked	  with	  respect	  to	  non-­‐canonical	  ubiquitylation:	  does	  it	  actually	  occur;	  and	  is	  it	  physiologically	  relevant?	  	  
Ub-­thioester	  linkages	  
	  Non-­‐canonical	  ubiquitylation	  is	  also	  beginning	  to	  appear	  in	  the	  literature,	  describing	  ubiquitylation	  on	  nucleophilic	  residues	  such	  as	  cysteine	  for	  peroxisomal	  degradation	  (Carvalho	  et	  al.,	  2007,	  Grou	  et	  al.,	  2008,	  Kragt	  et	  al.,	  2005,	  Leon	  and	  Subramani,	  2007,	  Williams	  et	  al.,	  2007)	  and	  by	  viral	  E3	  ligases	  (Cadwell	  and	  Coscoy,	  2005,	  Cadwell	  and	  Coscoy,	  2008).	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That	   cysteine	   residues	   might	   undergo	  modification	   by	   ubiquitylation	  may	   seem	   at	  first	  counterintuitive	  -­‐	  after	  all,	  thioester	  linkages	  (in	  a	  manner	  similar	  to	  disulphide	  bonds)	  can	  be	  broken	  under	  reducing	  conditions	  and	  the	  intracellular	  environment	  is	  often	  simply	  referred	  to	  as	  a	  "reducing"	  environment.	   	  However,	  as	  described	  above	  and	  in	  Figure	  1.3,	  at	  each	  stage	  of	  the	  ubiquitylation	  process	  before	  loading	  Ub	  onto	  the	   substrate,	   the	   E1/2/3	   enzymes	   are	   all	   able	   to	   carry	   Ub	   on	   a	   thioester	   linkage.	  	  Indeed	  it	  is	  this	  activated	  linkage	  that	  allows	  facile	  attack	  of	  the	  substrate	  nucleophile.	  	  The	   stability	   of	   these	   intermediates	   was	   recently	   discussed	   and	   found	   to	   be	  intrinsically	  highly	  stable	  (Song	  et	  al.,	  2009).	  	  A	  role	  for	  cysteine	  ubiquitylation	  was	  first	  identified	  in	  the	  peroxisomal	  import	  factor	  Pxp5	   to	   give	   a	   signalling	   role	   (Carvalho	   et	   al.,	   2007,	   Grou	   et	   al.,	   2008,	   Kragt	   et	   al.,	  2005,	  Leon	  and	  Subramani,	  2007,	  Williams	  et	  al.,	  2007).	   	  Whilst	  signalling	  might	  be	  considered	   a	   transient	   process	   in	  which	   a	  weak	   thioester	   linkage	   to	   ubiquitylation	  might	   provide	   for	   a	   more	   dynamic	   system,	   it	   might	   seem	   unlikely	   that	   thioester	  linkages	   could	   be	  maintained	   long	   enough	   to	   allow	  development	   of	   a	   polyUb	   chain	  (canonically,	  a	  K48-­‐linked	  Ub	  tetramer	  or	  longer)	  then	  targeting	  for	  degradation.	  	  The	  first	   evidence	   that	   this	   polyubiquitylation	   can	   occur,	   however,	   came	   from	   viral	   E3	  ligase	  systems	  (Cadwell	  and	  Coscoy,	  2005,	  Cadwell	  and	  Coscoy,	  2008).	  	  The	   caveat	   with	   this	   work	   is	   that	   viral	   systems	   may	   exhibit	   completely	   different	  behaviour	   to	   cellular	   systems	   in	  general.	   	  My	  work	   focuses	  on	  using	   the	  vertebrate	  system	  Xenopus	  laevis	  and	  the	  mammalian	  P19	  embryonal	  carcinoma	  cell	  line.	  	  
Ub-­ester	  linkages	  	  My	  work	  in	  xNgn2	  suggests	  a	  role	  for	  serines	  and	  threonines	  in	  ubiquitylation	  in	  vitro	  in	  Xenopus	  laevis	  extracts	  and	  P19	  cell	  lines	  (McDowell	  et	  al.,	  2010).	  	  Evidence	  for	  this	  had	  previously	  been	  suggested	   in	  the	  apoptotic	  protein	  Bid	  (Tait	  et	  al.,	  2007)	  albeit	  with	  the	  caveat	  that	  structural	  properties	  such	  as	  folding	  stability	  could	  not	  be	  ruled	  out	  as	  targeting	  Bid	  for	  degradation.	  	  The	   strongest	   evidence	   for	   Ub-­‐ester	   linkages	   comes	   from	   research	   into	   the	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endoplasmic	   reticulum-­‐associated	   degradation	   (ERAD)	   pathway.	   	   Serines	   and	  threonines	   are	   sufficient	   for	   ubiquitylation	   of	   major	   histocompatibility	   complex	   I	  heavy	  chain	  by	  the	  viral	  E3	  ligase	  mK3	  targeting	  for	  ERAD	  (Wang	  et	  al.,	  2007).	  	  In	  this	  case	  lysines	  are	  also	  present	  in	  the	  cytoplasmic	  tail	  of	  the	  heavy	  chain.	  	  	  	  However	  an	  absolute	  requirement	  for	  a	  serine	  residue	  in	  targeting	  a	  protein	  for	  ERAD	  was	   demonstrated	   in	   TCRα.	   	   The	   cytoplasmic	   tail	   of	   TCRα	   consists	   of	   the	   residues	  RLWSS	  and	   is	  not	  only	  ubiquitylated	  and	  degraded	  but	  replacement	  of	  serines	  with	  alanines	   reduces	   this	   ubiquitylation	   whilst	   mutation	   of	   serines	   to	   cysteines,	  threonines	  or	  lysines	  maintains	  ubiquitylation	  and	  degradation	  (Ishikura	  et	  al.,	  2010).	  	  	  	  Whilst	   containing	   a	   similar	   nucleophilic	   hydroxyl	   group	   to	   serines	   and	   threonines,	  tyrosines	  consist	  of	  a	  phenolic	  group,	  which	  may	  be	   less	   reactive	   than	   the	  aliphatic	  serine	  and	  threonine	  residues.	  	  The	  presence	  of	  an	  aromatic	  ring	  in	  this	  residue	  may	  result	  in	  delocalisation	  of	  electron	  density	  around	  the	  aromatic	  system	  resulting	  in	  a	  less	   reactive	   lone	   pair	   of	   electrons	   on	   the	   hydroxyl	   group.	   	   No	   direct	   evidence	   for	  tyrosines	   as	   non-­‐canonical	   sites	   of	   ubiquitylation	   has	   been	   demonstrated.	   	   Indeed,	  when	   replacing	   serines	   with	   tyrosines	   in	   the	   cytoplasmic	   tail	   of	   TCRα,	   no	  ubiquitylation	  was	  observed	  (Juan	  Bonifacino,	  personal	   communication)	   in	  contrast	  to	  replacing	  serines	  with	  threonines	  (Ishikura	  et	  al.,	  2010).	  
	  
bHLH	  protein	  degradation	  	  Transcription	  factors	  tend	  to	  be	  highly	  unstable	  proteins	  (examples	  in	  (Hershko	  and	  Ciechanover,	   1998))	   allowing	   highly	   dynamic	   protein	   levels,	   easily	   adjusted	   in	  response	  to	  intrinsic	  and	  extrinsic	  cell	  factors.	  	  The	   role	   of	   the	   UPS	   in	   myogenesis	   has	   been	   extensively	   researched	   in	   the	   bHLH	  protein	   MyoD	   (Breitschopf	   et	   al.,	   1998)	   as	   discussed	   above.	   	   Myogenin,	   the	  downstream	   target	   of	   MyoD,	   is	   destabilized	   as	   a	   result	   of	   the	   action	   of	   Bone	  Morphogenic	  Protein	  (BMP)	  signalling	  through	  the	  Id	  proteins	  (Vinals	  et	  al.,	  2004).	  	  Id	  proteins,	  which	  contain	  the	  Helix-­‐Loop-­‐Helix	  motif	  but	  lack	  the	  basic	  domain	  and	  so	  prevent	  DNA	  binding,	  are	  themselves	  degraded	  by	  the	  proteasome	  (Bounpheng	  et	  al.,	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1999).	  	  However	  the	  role	  of	   the	  UPS	  in	  proneural	  protein	  regulation	  has	  only	  recently	  been	  investigated.	   	  The	  bHLH	  proneural	  protein	  and	  achaete-­‐scute	  homologue,	  Mash1,	   is	  destabilized	   indirectly	   by	   BMP	   signalling	   (Shou	   et	   al.,	   1999).	   	   This	   is	   through	  UPS-­‐mediated	  degradation	  (Vinals	  et	  al.,	  2004).	  	  Previous	  to	  work	  contained	  in	  this	  thesis,	  xNgn2	   was	   found	   to	   be	   degraded	   by	   the	   UPS	   with	   a	   short	   half-­‐life	   (Vosper	   et	   al.,	  2007).	  	  Interestingly	  the	  bHLH	  protein	  and	  downstream	  target	  of	  xNgn2,	  xNeuroD,	  is	  stable	  under	  the	  same	  conditions	  in	  Xenopus	  laevis	  egg	  extract	  (Vosper	  et	  al.,	  2007).	  	  However	  outside	  of	  unpublished	  data	  on	  the	  non-­‐canonical	  ubiquitylation	  of	  xNgn2	  in	  
Xenopus	   laevis	   egg	   extract	   systems	   (Vosper,	   2008),	   and	   a	   yeast	   two-­‐hybrid	   screen	  suggesting	   possible	   E3	   ligases	   for	   xNgn2	   (Gabriel	   Markson	   and	   Anna	   Philpott,	  unpublished	   data),	   the	   mechanism	   of	   bHLH	   proneural	   protein	   degradation	   was	  largely	   unexplored.	   	   The	   differences	   in	   xNgn2	   and	   xNeuroD	   stability	   illustrate	  different	   degradation	   behaviour	   within	   the	   same	   family	   of	   proteins.	   	   The	   UPS-­‐mediated	   degradation	   of	   bHLH	   proteins	   cannot	   therefore	   be	   generalized	   and	  warrants	  further	  investigation.	  	  
Phosphorylation	  and	  Stability	  	  Protein	  phosphorylation	  is	  a	  PTM	  that	  places	  a	  phosphate	  group	  upon	  a	  protein	  to	  act	  as	   a	   signal	   for	   a	   range	   of	   processes	   (Tarrant	   and	   Cole,	   2009).	   	   The	   role	   of	  phosphorylation	  in	  the	  cell	  cycle	  is	  evident	  from	  the	  importance	  of	  kinases,	  enzymes	  that	  place	  phosphate	  moieties	  on	  proteins	  (Schafer,	  1998).	  	  Phosphorylation	  has	  been	  implicated	  in	  targeting	  proteins	  for	  degradation	  (Thien	  and	  Langdon,	  2001,	   Jimenez	  et	   al.,	   1999).	   Phosphorylation	   even	   affects	   the	   ubiquitylation	   process	   itself,	   for	  example	   by	   modulating	   the	   E2	   activity	   of	   Cdc34	   through	   allosteric	   effects	   on	   the	  catalytic	  site	  by	  phosphorylation	  in	  a	  particular	  region	  (Papaleo	  et	  al.,	  2011).	  	  Transcription	   factor	   activity	   is	   tightly	   regulated	   and	   control	   can	  be	   achieved	   at	   the	  level	   of	   phosphorylation	   (Tootle	   and	   Rebay,	   2005).	   	   The	   role	   of	   Xic1,	   a	   cdki,	   in	  stabilising	   xNgn2	   led	   to	   interest	   in	   the	   phosphorylation	   of	   xNgn2	   as	   a	   means	   of	  regulating	   stability	   (Vernon	   et	   al.,	   2003).	   	   Similarly	   p27Kip1	   stabilises	  mNgn2	   in	   the	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mouse	   cortex	   (Nguyen	   et	   al.,	   2006).	   	   xNgn2	   has	   clearly	   been	   shown	   to	   be	  phosphorylated	   in	  a	  manner	  affecting	   its	   function	   (on	  Y241	   in	  mNgn2,	   (Hand	  et	  al.,	  2005)	  and	  in	  motor	  neuron	  specification,	  (Ma	  et	  al.,	  2008))	  and	  its	  stability	  (on	  T118	  in	  xNgn2,	  (Vosper	  et	  al.,	  2007)).	  	  The	  phosphorylation	  state	  of	  the	  transcription	  factor	  Olig2	   whilst	   bound	   to	   promoter	   regions	   of	   DNA	   regulates	   proliferation	   of	   neural	  progenitors	  (Sun	  et	  al.,	  2011)	  and	  the	  same	  may	  be	  the	  case	  for	  xNgn2.	  	  There	   is	   a	   clear	   link	   between	   the	   signalling	   roles	   of	   phosphorylation	   and	  ubiquitylation	  for	  proteasomal	  degradation	  (Hunter,	  2007).	   	  Targeting	  of	  substrates	  for	  degradation	  by	   the	  SCF	  complex	   (Skp-­‐Cullin-­‐F-­‐box)	   requires	  phosphorylation	  of	  conditional	   ‘phosphodegron’	   sites	   (Willems	   et	   al.,	   2004).	   	   This	   phosphorylation	   is	  required	  for	  the	  production	  of	  substrate-­‐E3	  ligase	  interactions	  (Mayer,	  2005).	  	  Indeed	  phosphorylation,	   without	   ubiquitylation,	   can	   be	   sufficient	   to	   target	   proteins	   for	  proteasomal	   degradation	   (Machiya	   et	   al.,	   2010).	   	   Skp2	   substrates	   require	  phosphorylation	  at	  an	  (S/T)P	  minimal	  motif	  (Bornstein	  et	  al.,	  2003).	  	  Also	  the	  GSK3-­‐β	  consensus	   phosphorylation	   site	   in	   IκB	   targets	   for	   ubiquitylation	   and	   degradation	  (Winston	   et	   al.,	   1999)	   and	   likewise	   for	   β-­‐TRCP-­‐mediated	   degradation	   there	   are	  consensus	  SP	  phosphorylation	  sites	   in	  Sic1	  that	  have	  been	   investigated	  (Nash	  et	  al.,	  2001).	  	  The	  stability	  of	  many	  bHLH	  proteins	  such	  as	  MyoD	  is	  regulated	  by	  phosphorylation	  events	  (Kitzmann	  et	  al.,	  1999).	  	  In	  the	  case	  of	  MyoD	  degradation	  can	  be	  regulated	  by	  phosphorylation	  events	  on	  cdk	  consensus	  sites	  (Song	  et	  al.,	  1998).	  	  	  Phosphorylation	  regulates	  transcriptional	  activation	  in	  another	  bHLH	  protein,	  Twist	  (Lu	   et	   al.,	   2011).	   	   However	   phosphorylation	   by	  MAPK	   also	   stabilises	   Twist	   against	  UPS-­‐mediated	   degradation.	   	   Activation	   of	   the	   Ras	   signalling	   pathway	   results	   in	  elevated	  levels	  of	  Twist,	  leading	  to	  transition	  in	  breast	  cancer	  cells	  from	  epithelial	  to	  mesenchymal	  and	  promoting	  metastasis	  (Hong	  et	  al.,	  2011).	  	  Ubiquitylation,	  even	   if	  assisted	  by	  phosphorylation,	   is	  not	  enough	  to	  target	  proteins	  for	  proteasomal	  degradation;	  an	  unfolding	  initiation	  site	  is	  also	  required	  (Prakash	  et	  al.,	  2004).	  	  This	  unfolding	  may	  be	  facilitated	  by	  structural	  disorder	  in	  proteins.	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Intrinsic	  Disorder	  (ID)	  	  
What	  is	  ID?	  	  Proteins	  carry	  out	  various	  roles	  in	  the	  cell	  as	  a	  function	  of	  their	  structure.	  	  Enzymes	  require	   specific	   active	   sites	   to	   carry	   out	   catalysis	   and	   structural	   proteins	   require	  particular	   conformations	   to	   achieve	  mechanical	   strength.	   	   However	   the	   problem	  of	  how	   a	   protein	   actually	   achieves	   its	   structure	   was	   posed	   in	   the	   protein	   folding	  paradox.	  	  	  How	  can	  a	  protein	  molecule,	  with	  all	  the	  possible	  conformations	  available	  to	  it	  through	  all	  possible	  angles	  of	  rotation	  around	  interatomic	  bonds,	  ever	  achieve	  a	  required	  structure?	   	  A	  random	  distribution	  gives	   the	  time	  taken	  to	   find	  a	  particular	  conformation	  as	  longer	  than	  the	  lifetime	  of	  the	  universe	  (Levinthal,	  1969).	  	  	  	  The	  solution	  lies	  in	  challenging	  the	  assumption	  that	  a	  protein	  arrives	  at	  a	  functional	  structure	  by	  random	  chance.	  	  The	  overall	  thermodynamic	  stability	  of	  the	  molecule	  as	  the	   sum	   of	   hydrophobic	   interactions,	   electrostatics	   and	   Van	   der	   Waal’s	   forces	   is	  important.	   	   The	   formation	   of	   local	   interactions,	   such	   as	   hydrophobic	   interactions	  (Dyson	   et	   al.,	   2006)	   leading	   towards	   the	   final	   structure	   down	   a	   “folding	   funnel”	  energy	   landscape	   can	   contribute	   to	   allow	   a	   protein	   to	   find	   its	   structure	   in	  microseconds	  (reviewed	  in	  (Dill	  et	  al.,	  2008)).	  	  However	   it	   has	   become	   apparent	   that	   many	   functional	   proteins	   are,	   in	   fact,	   not	  natively	  folded	  at	  all	  times	  in	  the	  cell	  (Dyson	  and	  Wright,	  2006).	  	  Disorder	  in	  proteins	  arising	  from	  amino	  acid	  residue	  position	  variation	  leads	  to	  loss	  of	  electron	  density	  in	  X-­‐ray	   crystallography	   (Bloomer	   et	   al.,	   1978).	   	   Highly	   dynamic	   protein	   regions	   are	  observable	   from	   nuclear	   magnetic	   resonance	   (NMR)	   experiments,	   such	   as	   the	  functional	   tail	   of	   histone	   H5	   (Aviles	   et	   al.,	   1978)	   and	   even	   proteins	   that	   appear	  entirely	  disordered	  throughout	  their	   full	   length	  are	  common	  such	  as	  p21Waf1/Cip1/Sdi1	  (Kriwacki	   et	   al.,	   1996).	   	   Proteins	   that	   are	   natively	   unfolded	   and	   lacking	   regular	  structure	  are	  termed	  intrinsically	  disordered	  (ID)	  proteins	  (Dunker	  et	  al.,	  2001).	  	  ID	   proteins	   show	   a	   lack	   of	   hydrophobicity	   (Gast	   et	   al.,	   1995)	   and	   extreme	   pI	  (isoelectric	   point)	   values	   at	   neutral	   pH	   due	   to	   a	   large	   net	   charge	   from	   a	   high	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prevalence	   of	   charged	   residues	   (see	   Table	   1	   in	   (Weinreb	   et	   al.,	   1996)).	   	   In	   a	  comparison	  of	  ID	  protein	  databases,	  it	  was	  found	  that	  the	  amino	  acid	  residues	  W,	  F,	  Y,	  I,	  L,	  V,	  C	  and	  N,	  I,	  L	  and	  V	  were	  under-­‐represented	  in	  ID	  proteins	  whilst	  A,	  G,	  P,	  R,	  Q,	  S,	  E	  and	  K	  were	  abundant	  (H,	  M,	  T	  and	  D	  showed	  no	  deviation	  from	  random	  prevalence	  either	  way)	  (Dunker	  et	  al.,	  2001).	  	  Length-­‐dependent	  prediction	  of	  disorder	  (Peng	  et	  al.,	   2005)	   shows	   a	   propensity	   for	   G	   and	  D	   in	   short	   ID	   segments	   and	  K,	   E,	   and	  P	   in	  longer	  sections,	  while	  there	  was	  a	  reduction	  in	  I,	  V	  and	  L	  in	  short	  segments	  and	  G	  and	  N	  in	  the	  longer.	  	  	  	  It	  has	  also	  been	  suggested	  that	  there	  is	  an	  increased	  rate	  of	  evolution	  in	  ID	  segments	  and	  proteins	  (Brown	  et	  al.,	  2002).	  	  Therefore	  it	  may	  be	  that	  in	  these	  regions	  there	  is	  a	  lack	   of	   function	   allowing	   unconstrained	   mutation;	   or	   perhaps	   the	   function	   of	   the	  protein	  is	  disorder	  itself	  and	  so	  a	  lack	  of	  evolutionary	  constraint	  on	  specific	  sequence	  allows	  a	  larger	  amount	  of	  variability.	  	  This	  also	  suggests	  that	  the	  behaviour	  of	  related	  proteins	  within	  families	  of	  similar	  folds	  may	  actually	  be	  quite	  different.	  	  
Roles	  of	  ID	  proteins	  	  The	  investigation	  of	  ID	  proteins	  has	  advanced	  significantly	  in	  the	  last	  decade	  fuelled	  in	   part	   by	   the	   discovery	   that	   they	   are	   actually	   more	   common	   in	   eukaryotes	   than	  archaea	   or	   eubacteria,	   and	   by	   the	   large	   variety	   of	   cellular	   processes	   affected	   by	  unfolded	  proteins	  (Dunker	  et	  al.,	  2008a).	  	  	  An	   investigation	   of	   the	   gene	   ontology	   (GO)	   terms	   associated	   with	   ID	   proteins	  highlights	  a	  significant	  number	  of	  proteins	  are	  involved	  in	  DNA-­‐binding,	  transcription	  activation	  and	  acting	  as	  transcription	  factors	  (Ward	  et	  al.,	  2004).	  	  Predicting	  function	  of	   disordered	   proteins	   is	   difficult	   (Dunker	   et	   al.,	   2008b)	   due	   to	   the	   low	   sequence	  homology	  between	  possibly	  related	  proteins	  as	  a	  result	  of	  higher	   levels	  of	  mutation	  and	  lower	  sequence	  conservation	  in	  disordered	  regions	  of	  related	  proteins	  (Brown	  et	  al.,	   2002).	   	   Most	   function	   is	   assigned	   to	   ID	   proteins	   by	   individual	   study	   and	   in	  particular	   a	   role	   in	   cell	   cycle	   regulation	   has	   been	   highlighted	   by	   study	   of	   the	   ID	  proteins	  p21	  and	  p27,	  which	  are	  cdk	  inhibitors	  (reviewed	  in	  (Galea	  et	  al.,	  2008)).	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Many	  proteins	  appear	  to	   fold	  or	  have	  folding	  stabilised	  upon	  association	  with	  other	  binding	   factors	  ((Uversky	  et	  al.,	  2000,	  Sugase	  et	  al.,	  2007),	  reviewed	  in	  (Wright	  and	  Dyson,	   2009)).	   	   Particular	  motifs	   for	   recognising	   and	   binding	   interacting	   partners,	  molecular	   recognition	   elements	   (MoREs),	   are	   proposed	   that	   become	   ordered	   upon	  binding	  (Oldfield	  et	  al.,	  2005).	  	  Furthermore,	  entire	  proteins	  may	  become	  folded	  upon	  binding,	   but	   may	   still	   be	   highly	   dynamic,	   forming	   “fuzzy	   complexes”	   (Tompa	   and	  Fuxreiter,	  2008).	  	  Indeed,	  this	  is	  suggested	  to	  be	  the	  case	  for	  Ngn1,	  which	  overlaps	  in	  function	  with	  Ngn2	  in	  neural	  development	  (Aguado-­‐Llera	  et	  al.,	  2010).	  	  Protein-­‐protein	   and	   protein-­‐nucleic	   acid	   binding	   interactions	   appear	   to	   be	   an	  important	   role	   for	   intrinsic	  disorder	  and	   thermodynamically	   this	   gives	   flexibility	   to	  signalling	   processes	   and	   assembly	   of	   complexes	   in	   the	   cell.	   	   The	   free	   energy	   of	  binding	   is	   counteracted	   by	   the	   free	   energy	   required	   to	   fold	   the	   structure	   and	   so	  overall	   there	   is	  a	  small	   free	  energy	  change.	   	  Whilst	  this	  allows	  only	  a	   low	  affinity	  of	  binding,	  there	  is	  therefore	  high	  specificity	  achieved	  by	  requiring	  the	  correct	  binding	  interactions	  and	  easy	  reversibility	  is	  obtained	  (Dunker	  et	  al.,	  2002).	  	  So	  small	  are	  the	  energy	  differences	  involved,	  perhaps	  it	  could	  allow	  minor	  changes	  to	  the	  structure	  of	  a	  protein,	  say	  by	  PTM,	  to	  alter	  the	  formation	  of	  multi-­‐factor	  complexes	  dramatically.	  	  For	  example,	  this	  may	  allow	  tweaking	  of	  transcription	  dynamics	  to	  form	  slow	  or	  fast	  promoter	   complexes	   (Hager	   et	   al.,	   2009,	  Michel,	   2009),	   particularly	   as	   ID	   proteins	  exhibit	   less	   transcriptional	   noise	   than	   structured	   proteins	   and	   so	   appear	   to	   be	  regulated	  at	  the	  point	  of	  destruction	  (Gsponer	  et	  al.,	  2008).	  
	  
ID	  protein	  stability	  and	  phosphorylation	  	  The	  presence	  of	  disordered	  regions	  in	  proteins	  allows	  access	  to	  sites	  for	  PTM,	  such	  as	  ubiquitylation	  and	  phosphorylation	  (Gsponer	  et	  al.,	  2008).	   	  Regulation	  of	  PTMs	  and	  blocking	  them	  by	  interaction	  with	  cofactors	  can	  regulate	  protein	  stability	  (Dunker	  et	  al.,	  2001,	  Grimmler	  et	  al.,	  2007,	  Kriwacki	  et	  al.,	  1996,	  Wu	  et	  al.,	  2007).	  	  The	  mRNAs	  of	  ID	  proteins	  and	  the	  proteins	  themselves	  are	  unstable,	  and	  the	  level	  of	  formation	   of	   protein	   product	   is	   lower	   when	   compared	   with	   structured	   proteins	  (Gsponer	   et	   al.,	   2008).	   	   Proteases	   may	   be	   able	   to	   break	   down	   ID	   proteins	   but	   a	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comparison	  of	  the	  literature	  suggests	  that	  this	  is	  not	  always	  the	  case.	  	  The	  activity	  of	  proteases	  can	  be	  prevented	  by	  their	  sequestration;	  by	  regulation	  of	  protease	  activity	  by	   the	   cell;	   or	   by	   preventing	   protease	   association	   with	   the	   protein	   by	   lacking	  targeting	  residues,	  or	  blocking	  off	  sites	  sterically.	  	  Protease	  sites	  could	  also	  be	  blocked	  by	  association	  with	  cofactors	  (all	  reviewed	  in	  (Dunker	  et	  al.,	  2002)).	   	  Ubiquitylation	  sites	  often	  contain	  charged	  residues	  and	  fewer	  hydrophobic	  residues.	  	  It	  is	  suggested	  that	  this	  could	  facilitate	  contact	  with	  an	  E2	  (Cai	  et	  al.,	  2011).	  	  As	  mentioned	  above,	  ID	  proteins	   are	   more	   charged	   and	   less	   hydrophobic	   than	   more	   structured	   proteins	  (Dunker	  et	  al.,	  2001).	  	  Indeed	  association	  of	  a	  disordered	  region	  with	  another	  cofactor	  can	  prevent	  ubiquitylation	  such	  as	  in	  the	  case	  of	  β-­‐catenin,	  which	  has	  PEST	  sequences	  targeting	   for	   ubiquitylation	   towards	   UPS-­‐mediated	   degradation.	   	   However,	   on	  association	   with	   E-­‐cadherin,	   this	   ubiquitylation	   is	   sterically	   blocked	   (Huber	   et	   al.,	  2001).	   	   It	   is	   suggested	   that	   a	  way	   of	   differentiating	   ID	   proteins	   and	   linker	   regions	  from	  misfolded	  proteins	  is	  the	  lack	  of	  hydrophobic	  residues	  exposed	  thus	  suggesting	  a	  way	   of	   allowing	   disorder	   to	   fulfil	   a	   function	  without	   being	   degraded	   (Dyson	   and	  Wright,	  2005b).	  	  There	   is	   a	   large	   correlation	   between	   amino	   acid	   composition	   of	   ID	   proteins	   and	  phosphorylation	  sites	  suggesting	  phosphorylation	  is	  promoted	  in	  disordered	  regions	  (Iakoucheva	  et	  al.,	  2004).	  	  Further,	  ID	  proteins	  are	  targeted	  by	  twice	  as	  many	  kinases	  as	   structured	   proteins	   (Gsponer	   et	   al.,	   2008).	   	   Many	   of	   those	   kinases	   whose	  substrates	  are	  mainly	  unstructured	  proteins	  also	  tend	  to	  be	  regulated	  in	  a	  cell	  cycle-­‐dependent	  manner	  (Gsponer	  et	  al.,	  2008).	  	  This	  phosphorylation	  can	  regulate	  protein	  stability,	  as	  observed	  for	  p27	  (Chu	  et	  al.,	  2007).	  	  ID	  proteins	  may	  be	  particularly	  susceptible	  to	  proteasomal	  degradation	  by	  providing	  easily	   unfolded	   regions	   of	   a	   protein.	   	   An	   unfolding	   initiation	   site	   is	   required	   for	  proteasomal	  degradation	   (Prakash	  et	   al.,	   2004).	   	   In	   fact	  proteins	  with	  unstructured	  regions	  can	  be	  degraded	  by	  the	  UPS	  without	  PTM	  if	  they	  associate	  with	  ubiquitylated	  proteins	  (Prakash	  et	  al.,	  2009).	  	  Ub-­‐independent	  proteasomal	  degradation	  is	  arguably	  demonstrated	  in	  a	  growing	  number	  of	  proteins	  (Jariel-­‐Encontre	  et	  al.,	  2008)	  such	  as	  in	  virus-­‐induced	  tumours	  (Hwang	  et	  al.,	  2011).	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NMR	  studies	  of	  ID	  proteins	  	  NMR	   spectroscopy	   allows	   us	   to	   investigate	   materials	   with	   atomic	   resolution.	   	   The	  technique	   relies	   on	   the	   properties	   of	   certain	   ‘spin-­‐active’	   nuclei	   when	   placed	   in	   a	  magnetic	   field.	   	   The	   basic	   principle	   is	   to	   perturb	   the	   equilibrium	   of	   spin-­‐states	   of	  these	   nuclei	   by	   irradiating	   the	   molecule	   sample	   with	   a	   broad	   band	   of	   radio	  frequencies	  and	  to	  measure	  a	  free	  induction	  decay	  (FID)	  as	  the	  spins	  collapse	  back	  to	  equilibrium	  by	  a	  process	  called	  relaxation.	  	  Return	  to	  equilibrium	  is	  associated	  with	  a	  specific	  frequency	  for	  each	  nucleus	  or	  spin.	  	  In	  a	  macroscopic	  description,	  this	  can	  be	  viewed	   as	   a	   decrease	   of	   the	   signal	   in	   the	   xy	   plane	   whilst	   the	   net	   magnetisation	  increases	  back	  along	  the	  z-­‐axis	  parallel	  to	  the	  static	  magnetic	  field.	   	  To	  translate	  the	  time	  domain	  into	  a	  frequency	  domain	  the	  FID	  is	  Fourier	  transformed.	  	  The	  frequency	  of	  each	  individual	  nucleus	   is	  expressed	  as	  chemical	  shift	   in	  parts	  per	  million	  of	   the	  static	   field	   relative	   to	  a	   reference	  molecule	  within	   the	  sample	  so	   that	  measurements	  can	  be	  compared	  independently	  of	  the	  field	  of	  the	  spectrometer	  (e.g.	  600	  MHz	  or	  900	  MHz).	   	  The	  resonance	  of	  each	   individual	  nucleus	   is	  affected	  by	  the	  environment	  of	  the	  atom	  and	  therefore	  by	  the	  amino	  acid	  residue	  sequence,	  spatially	  close	   residues	   in	   a	   3D	   structure	   or	   even	   the	   conformation	   of	   the	   residue	   itself	   (for	  example	  in	  an	  α-­‐helix	  or	  β-­‐sheet).	  	  Protein	  NMR	  can	  be	  carried	  out	  using	  various	  spin-­‐active	  nuclei.	  	  1H	  or	  proton	  NMR	  is	  possible	  for	  all	  proteins	  as	  the	  1H	  isotope	  has	  100%	  natural	  abundance.	  	  13C	  and	  15N	  isotopes	  are	  spin	  active	  but	  have	  a	   low	  natural	  abundance	  and	  so	  proteins	  must	  be	  artificially	  enriched	  in	  these	  nuclei.	  	  	  Studying	   large	   folded	   proteins	   is	   difficult	   using	   NMR	   because	   their	   nuclei	   are	  associated	  with	   a	   fast	   relaxation	   time	  due	   to	   the	  dynamic	  properties	   of	   these	   large	  objects.	   	   Large	  proteins	  do	  not	   reorient	   themselves	   rapidly	   enough	   in	   the	  magnetic	  field	   (corresponding	   to	  a	   large	   correlation	   time	  τC),	   creating	   local	   fluctuation	  of	   the	  magnetic	  field	  and	  faster	  relaxation.	  	  As	  a	  consequence,	  the	  resonances	  are	  broadened	  sometimes	   even	   beyond	   detection.	   	   ID	   proteins	   have	   in	   contrast	   fast	   molecular	  dynamics	   that	   allow	   a	   good	   averaging	   of	   the	   magnetic	   field	   during	   the	   data	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acquisition.	   	   They	   have	   longer	   relaxation	   times	   compared	   to	   folded	   proteins	   of	   the	  same	   size,	   and	   narrow	   resonances	   that	   allow	   good	   detection	   and	   resolution	  (Cavanagh	  et	  al.,	  2006).	  	  NMR	  can	  be	  carried	  out	  in	  proteins	  in	  one	  dimension	  by	  investigating	  a	  single	  species	  of	   spin-­‐active	   isotope	   (e.g.	   1H	   only)	   or	   by	   combining	   the	   spectra	   by	   heteronuclear	  single	   quantum	   coherence	   (HSQC)	   of	   two	   isotopes	   (e.g.	   2D	   1H-­‐15N	   HSQC)	   or	   even	  three	  (3D	  1H-­‐15N-­‐13C	  HSQC)	  (Bhavesh	  et	  al.,	  2001).	   	  1D	  proton	  NMR	  of	  proteins	  is	  of	  limited	   use	   due	   to	   the	   number	   of	   nuclei	   present	   that	   will	   result	   in	   a	   spectrum	   of	  severely	   overlapped	   signals.	   	   Use	   of	   multiple	   dimensions	   will	   thus	   spread	   these	  signals	  in	  addition	  to	  giving	  information	  on	  several	  nuclei.	  	  The	  2D	  1H-­‐15N	  HSQC	  acts	  as	   a	   “fingerprint”	   of	   the	   protein	   as	   it	  will	   give	   a	   point	   for	   each	   amino	   acid	   residue	  (except	  proline,	  which	   lacks	   a	  proton	  and	   so	   is	  not	   seen	  by	  2D	   1H-­‐15N	  HSQC).	   	   In	   a	  HNCACB	   experiment,	   the	   additional	   13C	   dimension	   will	   allow	   identification	   of	   the	  amino	  acid	  residue	  associated	  with	  each	  1H-­‐15N	  correlation	  in	  the	  HSQC	  (CA	  and	  CB	  of	  residue	  i)	  and	  also	  connect	  it	  to	  its	  preceding	  residue	  in	  the	  sequence	  (CA	  and	  CB	  of	  residue	  i-­‐1).	  	  NMR	   can	   thus	   be	   used	   to	   study	   ID	   proteins	   (Dyson	   and	  Wright,	   2005a,	   Dyson	   and	  Wright,	   2004).	   	   Although	   these	  proteins	   do	  not	   have	   a	   3D	   structure,	   they	   can	  have	  local	  transient	  secondary	  structures	  and	  preferred	  topologies	  that	  will	  influence	  their	  function,	   for	   example	   their	   interaction	   with	   other	   protein	   partners	   or	   their	  aggregation	  propensity.	  	  The	  transient	  secondary	  structure	  could	  be	  associated	  with	  a	  molecular	  recognition	  element	  (MoRE),	  but	  this	  is	  not	  always	  the	  case	  (Marsh	  et	  al.,	  2010).	  	  NMR	   is	   a	   technique	   that	   will	   allow	   the	   characterisation	   of	   these	   very	   dynamic	  features.	   	   Specific	   examples	   of	   ID	   proteins	   studied	   by	   NMR	   include	   CREB,	   to	  investigate	   “fly-­‐casting”	   using	   disordered	   regions	   to	   find	   binding	   partners	   and	  stabilise	   folding	   intermediates	   (Sugase	   et	   al.,	   2007).	   	   Studies	   have	   also	   identified	  natively	   unfolded	   domains	   in	   non-­‐structured	   protein	   5A	   (NS5A)	   from	   hepatitis	   C	  virus	  (HCV)	  (Hanoulle	  et	  al.,	  2009)	  and	  NMR	  has	  been	  used	  towards	  an	  investigation	  of	  the	  Tau	  protein	  associated	  with	  Alzheimer’s	  disease	  (Verdegem,	  2009).	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Xenopus	  laevis	  	  To	  study	  proneural	  protein	  structure	  and	  how	  this	  relates	  to	  function	  it	  is	  important	  to	   use	   a	   system	   where	   biochemical	   analysis	   can	   be	   easily	   translated	   into	  investigations	  of	  functionality.	  	  
Xenopus	   laevis	   have	   had	   a	   large	   contribution	   to	   research	   in	   developmental	   biology	  and	  other	  areas	  (Callery,	  2006).	   	  Xenopus	  laevis	  represents	  a	  model	  organism	  that	  is	  very	   easy	   to	   work	   with:	   producing	   large	   volumes	   of	   large	   (therefore	   easily	  microinjected)	  eggs	  useful	  for	  both	  in	  vivo	  studies	  and	  in	  vitro	  assays.	  	  	  
Xenopus	   eggs	   and	   embryos	   can	   also	   be	   manipulated	   to	   make	   cytoplasmic	   extract	  systems	   (Murray,	   1991)	   that	   can	   carry	   out	   various	   cellular	   processes	   such	   as	  ubiquitylation	  and	  phosphorylation.	  	  Ubiquitylation	  processes	  are	  highly	  conserved	  in	  eukaryotes	  –	  Ub	  itself	  is	  conserved	  from	   yeast	   to	   humans	   –	   and	   so	   Xenopus	   laevis	   can	   be	   used	   to	   investigate	  ubiquitylation	  processes	   relevant	   to	  other	  organisms.	   	  Much	  work	  has	  been	  carried	  out	  on	  ubiquitylation	  processes	   in	  Xenopus	   laevis	  such	  as	   investigation	  of	  β-­‐catenin	  stability	   (Salic	   et	   al.,	   2000)	   and	   investigation	   of	   the	   anaphase-­‐promoting	   complex	  (APC)	  (Kimata	  et	  al.,	  2008,	  Yamano	  et	  al.,	  2004).	  	  	  	  The	   uses	   of	   Xenopus	   in	   biophysical	   and	   protein	   structural	   methods	   are	   also	   being	  explored,	   for	   example	   allowing	   in-­‐cell	   NMR	   of	   proteins	   (Selenko	   et	   al.,	   2008)	   and	  investigation	  of	  brain	  tissue	  using	  mass	  spectrometry	  (Serrano	  et	  al.,	  2010).	  	  
Xenopus	   embryos	  are	   easily	  manipulated	  and	   can	  be	  used	   to	   investigate	   the	   role	  of	  protein	  produced	  from	  microinjected	  mRNA,	  for	  example	  using	   in	  situ	  hybridisation	  to	  look	  for	  particular	  cell	  types.	  	  Xenopus	  laevis	  embryos	  have	  an	  added	  advantage	  in	  that	   the	   bilateral	   symmetry	   of	   the	   embryo	   is	   fixed	   at	   the	   first	   cleavage	   after	  fertilisation.	   	   Cells	   do	   not	   mix	   between	   the	   left	   and	   right	   sides.	   	   Therefore	  microinjection	  of	  mRNA	  into	  one	  of	  these	  two	  cells	  allows	  a	  comparison	  between	  the	  injected	  and	  uninjected	  sides	  of	  the	  embryo	  (Sive	  et	  al.,	  2000).	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  As	   a	   vertebrate	   organism	   Xenopus	   laevis	   allows	   study	   of	   developmental	   processes	  relevant	   to	   humans	   and	   has	   great	   promise	   for	  work	   in	   the	   future	   (Beck	   and	   Slack,	  2001).	  	  
Aims	  	  Controlling	   the	   level	   of	   a	   transcription	   factor	   in	   the	   cell	   is	   crucial	   to	  mediating	   its	  function.	  	  The	  transcription	  factor	  xNgn2	  plays	  an	  important	  role	  in	  neurogenesis	  by	  determining	  cell	  fate	  and	  causing	  cell	  cycle	  exit.	  	  Work	  in	  this	  dissertation	  investigates	  the	  regulation	  of	  stability	  of	  bHLH	  proteins	  and	  in	  particular	  the	  Xenopus	  laevis	  transcription	  factor	  Ngn2.	  	  The	  role	  of	  PTMs	  (such	  as	  ubiquitylation	   and	   phosphorylation),	   protein	   folding	   and	   intrinsic	   disorder	   are	  explored.	   	   The	   techniques	   used	   to	   carry	   out	   this	   work	   are	   described	   in	   detail	   in	  Chapter	  2.	  	  Chapter	   3	   details	   the	   role	   of	   ubiquitylation	   on	   lysine	   residues	   in	   regulating	   the	  stability	  of	  xNgn2.	   	   I	  aim	  to	  present	  detailed	  evidence	  of	  ubiquitylation	  of	  xNgn2	  on	  lysine	   residues	   that	   affects	   xNgn2	   stability.	   	   The	   relationship	   between	   stability	   and	  activity	  will	   be	   investigated	   in	   vitro	   and	   in	   vivo	   using	   Xenopus	   laevis	   extracts	   and	  embryo	  microinjection.	  	  Chapter	  4	  then	  describes	  the	  role	  of	  other	  potential	  sites	  of	  ubiquitylation,	  such	  as	  the	  N-­‐terminus,	   and	  nucleophilic	   residues	   such	  as	   cysteines,	   serines	  and	   threonines,	  on	  regulating	  xNgn2	  stability.	  	  I	  aim	  to	  investigate	  the	  possible	  physiological	  relevance	  of	  non-­‐canonical	  ubiquitylation	  in	  both	  Xenopus	  extract	  systems	  and	  the	  P19	  embryonal	  carcinoma	  cell	  line.	  	  Chapters	  4	  and	  5	  will	  highlight	  the	  importance	  of	  ubiquitylation	  on	  various	  sites	  in	  xNgn2,	  which	  occurs	  in	  a	  cell	  cycle-­‐dependent	  manner	  and	  is	  also	  observed	  in	  cell	  lines.	  	  	  	  Chapter	   5	   introduces	   protein	   phosphorylation	   on	   cdk	   consensus	   sites	   and	   the	   role	  that	  this	  has	  in	  relation	  to	  xNgn2	  stability	  in	  vitro	  and	  activity	  in	  vivo.	   	  I	  aim	  to	  show	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the	   relationship	   between	   phosphorylation,	   ubiquitylation,	   and	   the	   role	   of	   xNgn2	   at	  the	  promoter	  of	  downstream	  transcriptional	  targets.	  	  Chapter	   6	   investigates	   the	   role	   of	   protein	   folding	   in	   stability,	   through	   experiments	  looking	  at	  binding	  of	  cofactors	  to	  xNgn2,	  to	  assess	  how	  stability	  of	  the	  active	  complex	  of	  xNgn2	  is	  regulated.	  	  Using	  chimeric	  proteins	  of	  xNgn2	  and	  xNeuroD,	  I	  will	  attempt	  to	  identify	  whether	  bHLH	  proteins	  contain	  regions	  which	  affect	  stability	  and	  possibly	  regulate	  degradation.	  	  	  Finally,	  Chapter	  7	  will	  describe	  work	  carried	  out	   in	  collaboration	  with	  Guy	  Lippens	  and	  Isabelle	  Landrieu	  at	  the	  Université	  de	  Sciences	  et	  Technologies	  Lille,	  using	  NMR	  to	  study	  intrinsically	  disordered	  regions	  of	  mouse	  Ngn2.	  	  I	  will	  then	  provide	  evidence	  for	  phosphorylation	  of	  mNgn2	  by	  cyclin	  dependent	  kinases	  and	  how	  this	  affects	  the	  structure	  of	  the	  intrinsically	  disordered	  protein.	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CHAPTER	  2	  
Materials	  &	  Methods	  
 
	  
Plasmids	  	  Plasmids	   used	  were	   pCS2	   vectors	   containing	   the	   gene	   of	   interest,	   which	   had	   been	  kindly	  prepared	   for	   the	   lab	  previously	  by	   Ian	  Horan,	  Catherine	  Wilson,	  Helen	  Wise,	  Jonathan	  Vosper,	  Ali	  Jones	  or	  were	  prepared	  by	  myself	  as	  described	  in	  the	  text.	  	  
In	  Vitro	  Transcription/Translation	  
	  
In	  vitro	  transcription	  and	  translation	  of	  radiolabelled	  proteins	  was	  carried	  out	  using	  the	  Promega	  SP6	  (or	  in	  the	  case	  of	  MyoD	  KO,	  T7)	  TNT	  Master	  Mix	  Kit.	  	  Aliquots	  of	  the	  reticulocyte	   lysate	   were	   defrosted	   from	   -­‐80	   °C	   by	   hand	   and	   to	   this	   1/10	   35S-­‐methionine	   (Perkin	   Elmer)	   and	   1/10	   250	   ng	   µl-­‐1	   plasmid	   solution	   (in	   H2O)	   were	  added.	  	  IVTs	  were	  then	  incubated	  at	  30	  °C	  for	  2	  hours.	  	  IVTs	  were	  stored	  at	  -­‐20	  °C.	  	  
In	  Vitro	  Fertilisation	  &	  Embryo	  Handling	  (Sive	  et	  al.,	  2000)	  	  
	  Female	  wild	  type	  Xenopus	  laevis	  had	  been	  previously	  primed	  a	  week	  before	  required	  by	   injection	   of	   Pregnant	  Mare	   Serum	   Gonadotropin	   (PMSG)	   and	   ovulation	   induced	  the	  day	  before	  required	  using	  Human	  Chorionic	  Gonadotropin	  (HCG).	  	  Eggs	  were	  laid	  in	  Egg-­‐Laying	  Solution	  (ELS:	  110	  mM	  NaCl;	  2	  mM	  KCl;	  0.5	  mM	  Na2HPO4;	  15	  mM	  Tris-­‐base;	  2	  mM	  NaHCO3;	  1	  mM	  MgSO4.7H2O;	  pH	  to	  7.6	  with	  glacial	  acetic	  acid)	  and	  were	  harvested	  and	  washed	  thoroughly	  with	  1	  x	  Modified	  Barth’s	  Saline	  (MBS;	  from	  10	  x	  stock:	  88	  mM	  NaCl;	  1	  mM	  KCl;	  0.7	  mM	  CaCl2;	  1	  mM	  MgSO4;	  5	  mM	  HEPES	  pH	  7.8;	  2.5	  mM	  NaHCO3).	  	  Eggs	  were	  placed	  in	  Petri	  dishes	  and	  excess	  buffer	  carefully	  removed.	  	  A	  small	  section	  of	  wild	  type	  testis	  was	  then	  mashed	  in	  200	  µl	  of	  0.1	  x	  MBS	  for	  each	  Petri	  dish	  of	  eggs	  and	  spread	  over	  the	  eggs	  to	  fertilise	  in	  vitro.	   	  After	  10	  minutes	  the	  eggs	  were	   flushed	  with	  0.1	  x	  MBS.	   	  Eggs	  were	  then	  separated	   into	   further	  dishes	  to	  reduce	  crowding	  and	  incubated	  at	  14	  °C	  overnight.	  	  The	  dishes	  were	  drained	  of	  buffer	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and	  2	  %	  cysteine	  solution	   (pH	  7.7-­‐7.9	  using	  10	  M	  NaOH)	  was	  added	   for	  5	  minutes.	  	  Embryos	  were	  washed	   thoroughly	   in	   0.1	   x	  MBS,	   dead	   embryos	  were	   removed	   into	  100%	  ethanol	  and	  embryos	  were	  incubated	  at	  either	  room	  temperature	  (~20	  °C)	  or	  14	  °C	  until	  they	  had	  passed	  Stage	  15	  (Nieuwkoop	  and	  Faber,	  1994).	  	  
Interphase	  Extracts	  (Murray,	  1991)	  	  Eggs	  from	  wild	  type	  Xenopus	  laevis	  were	  harvested	  and	  washed	  thoroughly	  with	  1	  x	  MBS.	   	  Abnormal/dead	  eggs	  were	  removed.	   	  2	  %	  cysteine	  solution	  (pH	  7.7-­‐7.9	  using	  10	  M	  NaOH)	  was	  added	  for	  10	  minutes.	  	  Eggs	  were	  washed	  thoroughly	  with	  2	  x	  MMR	  (200	  mM	  NaCl;	  4	  mM	  KCl;	  2	  mM	  MgCl2;	  4	  mM	  CaCl2;	  0.2	  mM	  EDTA;	  10	  mM	  HEPES	  pH	  7.8	  with	  NaOH),	   then	  activated	   in	  2	  x	  MMR	  supplemented	  with	  0.5	  µg	  ml-­‐1	  A23187	  calcium	   ionophore	   (Sigma).	   	   Once	   activation	   was	   observed	   through	   contraction	   of	  pigment	  in	  the	  animal	  hemisphere,	  eggs	  were	  washed	  again	  in	  2	  x	  MMR	  then	  washed	  in	  chilled	  XB	  (extract	  buffer:	  100	  mM	  KCl;	  1	  mM	  MgCl2;	  0.1	  mM	  CaCl2;	  50	  mM	  sucrose;	  10	   mM	   HEPES	   (pH	   7.7	   using	   10	   M	   KOH)	   in	   H2O).	   	   Eggs	   were	   pipetted	   into	  microcentrifuge	  tubes	  in	  a	  minimal	  amount	  of	  buffer	  using	  a	  plastic	  pipette	  and	  2	  µl	  10	  mg	  ml-­‐1	  Cytochalasin	  B.	  	  Tubes	  were	  spun	  1	  krpm	  for	  1	  minute	  at	  4	  °C	  and	  excess	  buffer	  was	  removed	  using	  a	  chilled	  glass	  pipette.	  	  Tubes	  were	  then	  spun	  at	  13.2	  krpm	  for	  5	  minutes	  at	  4	  °C	  and	  the	  cytoplasmic	  layer	  (sandwiched	  between	  the	  lipid	  layer	  and	  pelleted	  pigment)	  was	  removed	  into	  a	  new	  tube	  and	  the	  process	  repeated	  until	  a	  straw-­‐coloured	  cytoplasmic	  extract	  was	  obtained.	  	  When	  freezing	  extract	  for	  storage	  at	  -­‐80	  °C,	  extract	  was	  supplemented	  with	  2	  %	  v/v	  glycerol,	   then	   frozen	   as	   16.5	   µl	   beads	   in	   liquid	   nitrogen	   and	   stored	   at	   -­‐80	   °C.	  	  Previously	  frozen	  extracts	  are	  used	  in	  Figures:	  3.10,	  4.5	  ,	  4.8,	  6.6,	  6.11	  and	  6.15.	  	  
High-­Speed	  Interphase	  Extracts	  	  Interphase	  egg	  extract	  was	  spun	  further	  at	  55	  krpm	  at	  4	  °C	  for	  40	  minutes	  and	  then	  used	  as	  described	  for	  degradation	  assays	  below.	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Mitotic	  Extracts (Murray,	  1991)	  	  Eggs	   from	   wild	   type	   Xenopus	   laevis	   were	   prepared	   and	   used	   to	   make	   extract	   as	  described	   for	   interphase	   extracts	   above.	   	   However	   before	   use	   in	   assays,	   the	  cytoplasmic	   layer	   was	   supplemented	   with	   5	   µg	   of	   recombinant	   Cyclin	   B	   ∆90	  (previously	  purified	  by	  Jonathan	  Vosper)	  per	  100	  µl	  extract.	  	  Extracts	  were	  incubated	  for	  20	  minutes	  at	  room	  temperature	  (~20	  °C).	  	  
Neurula	  Extracts	  	  Neurula	   stage	   embryos	   (Nieuwkoop	   and	   Faber,	   1994)	  were	   prepared	   as	   described	  above	  and	  washed	  in	  2	  x	  MMR	  then	  washed	  in	  chilled	  XB	  (extract	  buffer:	  100	  mM	  KCl;	  1	  mM	  MgCl2;	  0.1	  mM	  CaCl2;	  50	  mM	  sucrose;	  10	  mM	  HEPES	  (pH	  7.7	  using	  10	  M	  KOH)	  in	  H2O).	  	  Embryos	  were	  pipetted	  into	  2	  ml	  microcentrifuge	  tubes	  in	  minimal	  amount	  of	  buffer	  using	  a	  plastic	  pipette	  and	  2	  µl	  10	  mg	  ml-­‐1	  Cytochalasin	  B.	  	  Tubes	  were	  spun	  0.8	  krpm	   for	  1	  minute	   at	  4	   °C	  and	  excess	  buffer	  was	   removed	  using	  a	   chilled	  glass	  pipette.	  	  Tubes	  were	  then	  spun	  at	  13.2	  krpm	  for	  5	  minutes	  at	  4	  °C	  and	  the	  cytoplasmic	  layer	  (sandwiched	  between	  the	  lipid	  layer	  and	  pelleted	  pigment)	  was	  removed	  into	  a	  new	   tube	   and	   the	   process	   repeated	   until	   a	   grey-­‐coloured	   cytoplasmic	   extract	   was	  obtained.	  	  Extracts	  could	  be	  frozen	  as	  described	  above	  and	  previously	  frozen	  neurula	  extracts	  were	  used	  in	  Figures:	  3.8,	  3.9	  and	  4.15.	  	  






Figure 2.1: Degradation assays. 
For interphase extracts, a)  Xenopus laevis eggs are harvested and treated with calcium ionophore 
to mimic fertilization, resulting in b) the animal hemispheres (pigmented) being presented dorsally 
and contracting.  c) Eggs are packed into Eppendorf tubes and spun at high speed to separate out 
layers of lipids (shown in green), cytoplasm (yellow) and pigment (black).  d) The cytoplasmic layer 
is removed, supplemented with ATP and Ub and e) IVT radiolabelled protein is added.  The sample 
is incubated at 21 °C and at particular timepoints f) aliquots of the degradation reaction are 
removed into quenching sodium dodecyl sulfate loading buffer (SDS-LB) which are then g) 
separated on a gel by sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE). 
	  39	  
removed	   and	   added	   to	   15µl	   of	   SDS	   gel-­‐loading	   buffer	   supplemented	   with	   β-­‐mercaptoethanol	   then	   run	   out	   by	   SDS-­‐PAGE.	   	   Gels	   were	   dried	   and	   placed	   with	   a	  phosphoscreen	   (Molecular	   Dynamics)	   and	   levels	   of	   protein	   sample	   quantified	   by	  phosphoimaging	   (FLA-­‐5000	   Fluoro	   Image	   Analyzer	   (Fujifilm)	   with	   Image	   Reader	  software;	  quantification	  with	  Image	  Gauge	  Software	  (Fuji	  Film	  Science	  lab)).	  	  Protein	  half-­‐lives	   were	   determined	   by	   using	   first-­‐order	   kinetic	   analysis	   (see	   below).	  	  Qualitative	   analysis	   was	   carried	   out	   by	   autoradiography.	   Degradation	   assays	   were	  carried	  out	  in	  triplicate	  in	  fresh	  extract	  unless	  otherwise	  stated.	  	  
ATP-­depletion	  Degradation	  Assays	  	  8	  µl	  of	   in	  vitro	   translated	  35S-­‐methione-­‐labelled	  protein	  was	  combined	  with	  40	  µl	  of	  high	   speed	   interphase-­‐activated	   egg	   extract,	   cleared	   of	   ribosomes	   by	   spinning	   at	  107,400	   x	   g	   for	   40	   min,	   supplemented	   with	   200	   µg/ml	   cycloheximide,	   10	   µg/ml	  leupeptin,	  pepstatin,	  and	  chymostatin,	  1.5	  mg/ml	  Ub,	  and	  2	  µl	  of	  Energy	  Regeneration	  mix	   (20	   µl	   of	   100	   mM	   EGTA;	   20	   µl	   of	   1	   M	   MgCl2;	   150	   µl	   of	   1	   M	   phosphocreatine	  (Sigma);	   200	  µl	   of	   100	  mM	  adenosine	  5'-­‐triphosphate	   (GE	  Healthcare))	   or	  0.8	  µl	   of	  1600	   units/ml	   hexokinase	   with	   0.8	   µl	   of	   1	   M	   glucose.	   Samples	   were	   used	   as	   in	   a	  normal	  degradation	  assay,	  described	  above.	  	  
Acetylation-­blocking	  Degradation	  Assays	  (Palmiter,	  1977)	  	  	  240	  µl	   of	   SP6	   TNT	  Master	  Mix	  was	   defrosted	   and	   120	  µl	   taken	   for	   acetyl-­‐blocking	  whilst	  the	  other	  120	  µl	  was	  taken	  for	  controls.	  	  To	  each	  120	  µl	  set,	  10.08	  µl	  of	  citrate	  synthase	   from	   porcine	   heart	   was	   added	   (Sigma;	   59.3	   µl	   of	   suspension	   spun	   in	  ultracentrifuge	   at	   50,000	   x	   g	   for	   5	   minutes.	   	   Supernatant	   removed	   and	   citrate	  synthase	  resuspended	  in	  500	  µl	  H2O).	   	  6.9	  µl	  of	  reticulocyte	  lysate	  was	  added	  to	  the	  control	  set,	  whereas	  6.9	  µl	  of	  oxaloacetic	  acid	  (500	  µl	  of	  500	  mM	  stock	  added	  to	  12	  ml	  H2O	   and	  10	  M	  KOH	  added	   til	   pH	  7.5)	  was	   added	   to	   the	   acetyl-­‐block	   set.	   	   Both	   sets	  were	   then	   incubated	   at	   25	   °C	   for	   7	  minutes.	   	   3.24	  µl	   of	   reticulocyte	   lysate	   (for	   the	  control	   set)	   or	   of	   50	  mM	  De-­‐sulfo	  CoA	   lithium	  salt	   solution	  was	   added	  and	   treated	  reticulocyte	   lysates	   aliquoted	   into	   23.37	  µl	   samples.	   	   To	   these,	   2	  µl	   35S-­‐methionine	  and	  2	  µl	  250	  ng	  µl-­‐1	  plasmid	  solution	  were	  added	  and	  incubated	  at	  30	  °C	  for	  2	  hours.	  	  
	  40	  
IVTs	  were	  passed	   through	  Zeba	  Microspin	   columns	  before	  being	  used	   as	  described	  for	  degradation	  assays	  above.	  	  
Alkylating	  Agent	  Degradation	  Assays:	  NEM	  
	  24	  µl	  IVT	  radio-­‐labelled	  proteins	  were	  prepared	  as	  described	  above	  and	  either	  1.2	  µl	  H2O	  (for	  control)	  or	  1.2	  µl	  100	  mM	  NEM	  (N-­‐ethylmaleimide)	  added.	   	  Samples	  were	  then	  incubated	  at	  20	  °C	  for	  40	  minutes	  and	  passed	  through	  Zeba	  MicroSpin	  columns	  before	  being	  used	  as	  described	  for	  degradation	  assays	  above.	  	  






Figure 2.2: Ubiquitylation assays. 
For interphase extracts, a)  Xenopus laevis eggs are harvested and treated with calcium ionophore 
to mimic fertilization, resulting in b) the animal hemispheres (pigmented) being presented dorsally 
and contracting.  c) Eggs are packed into Eppendorf tubes and spun at high speed to separate out 
layers of lipids (shown in green), cytoplasm (yellow) and pigment (black).  d) The cytoplasmic layer 
is removed, supplemented with ATP, MG132 and Ub (either untagged or his-tagged) and e) IVT 
radiolabelled protein is added.  The sample is incubated at 20 °C for 90 minutes and f) nickel 
chelating beads are added and incubated for a further 75 minutes with rolling.  Samples are then 
treated with eluting sodium dodecyl sulfate loading buffer (SDS-LB) and are g) separated on a gel 
by sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE). 	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Vosper	   buffer	   was	   prepared	   containing:	   8.5	   M	   urea;	   0.1	   M	   Tris	   pH	   7.4;	   20	   mM	  imidazole;	  6	  mM	  NaCl;	  1	  %	  Nonidet	  P40	  (v/v)	  (Sigma).	   	  A	  sample	  of	  this	  buffer	  was	  supplemented	  with	  10	  µg	  ml-­‐1	  LPC	  and	  250	  µl	  added	  to	  each	  sample	  at	  the	  end	  of	  the	  90	  minute	  incubation	  (or	  variable	  time	  of	  incubation	  if	  undertaking	  a	  ubiquitylation	  timecourse).	   	   30	   µl	   Ni-­‐NTA	   agarose	   bead	   slurry	   from	   Qiagen	   was	   added	   to	   each	  sample	  and	  all	  samples	  rotated	  for	  75	  minutes	  at	  14	  rpm	  at	  room	  temperature	  (~20	  °C).	  	  All	  samples	  were	  then	  spun	  down	  at	  0.8	  rcf	  for	  30	  seconds,	  most	  of	  the	  supernatant	  removed	   and	  discarded	   and	  400	  µl	   Vosper	   buffer	   (supplemented	  with	   LPC)	   added.	  	  Samples	  were	  mixed	  by	  gentle	  inversion,	  spun	  down	  and	  the	  process	  repeated	  to	  give	  a	  total	  of	  3	  washes	  in	  Vosper	  buffer	  supplemented	  with	  LPC	  and	  one	  wash	  in	  Vosper	  buffer	  alone.	  	  After	  the	  final	  wash	  all	  supernatant	  was	  removed	  to	  leave	  15	  µl	  of	  bead	  slurry.	  	  To	  the	  reducing	  samples,	  15	  µl	  reducing	  2	  x	  SDS	  PAGE	  buffer	  (1000	  µl	  2	  x	  SDS	  PAGE	  buffer	  pH	  10	  +	  100	  µl	  β-­‐mercaptoethanol	  +	  100	  mM	  imidazole)	  was	  added.	  	  To	  the	  non-­‐reducing	  samples,	  15	  µl	  non-­‐reducing	  2	  x	  SDS	  PAGE	  buffer	  (1000	  µl	  2	  x	  SDS	  PAGE	  buffer	  +	  100	  µl	  H2O	  +	  100	  mM	  imidazole)	  was	  added.	  	  All	  samples	  were	  gently	  mixed	  and	  rocked	  at	  room	  temperature	  (~20	  °C)	  for	  20	  minutes.	   	  Reducing	  samples	  were	  boiled	  at	  98	  °C	  for	  5	  minutes	  whilst	  non-­‐reducing	  samples	  were	   incubated	  on	  ice	  for	  5	  minutes.	   	  Samples	  were	  stored	  at	  -­‐20	  °C	  until	  run	  out	  using	  SDS-­‐PAGE	  and	  analysed	  by	  autoradiography.	  	  
Electrophoretic	  Mobility	  Shift	  Assay	  (EMSA)	  
	  DNA-­‐binding	  activity	  of	  xNgn2	  proteins	  was	  assayed	  by	  EMSA	  using	  32P-­‐labelled	  DNA	  probe	  comprising	  the	  E1	  E-­‐box	  domain	  of	  the	  NeuroD	  promoter	  (Huang	  et	  al	  2000).	  	  The	   probe	   incorporated	   the	   forward	   primer	   5’-­‐GGACCGGGAAGACCATATGGCGCATGCCGGG-­‐3’	   and	   the	   reverse	   primer	   3’-­‐CCTGGCCTTCTGGTATACCGCGTACGGCCC-­‐5’,	  with	  the	  E-­‐box	  domain	  emboldened.	  	  10	  
µM	  of	   the	   complementary	  oligonucleotides	  were	   annealed	   in	   annealing	  buffer	   (100	  mM	  NaCl,	  10	  mM	  Tris-­‐HCl)	  at	  95	  °	  C	  and	  gradually	  cooled	  at	  room	  temperature	  (~20	  °C).	   	   5’	   overhangs	   in	   the	   resulting	  DNA	  were	   filled	   in	   using	  Klenow	   fragment	   from	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DNA	  polymerase	  (NEB).	  	  Probe-­‐labelling	  reactions	  were	  prepared	  in	  a	  20	  µl	  reaction	  with	  5	  pmol	  dsDNA,	  2mM	  each	  of	  dGTP,	  dATP,	  dTTP,	  10	  pmol	   32P-­‐dCTP	  and	  0.5	  µl	  Klenow	  fragment.	   	  The	  mixture	  was	  incubated	  at	  room	  temperature	  (~20	  °C)	  for	  20	  minutes,	   supplemented	   with	   2	   mM	   non-­‐radiolabelled	   dCTP	   and	   incubated	   for	   a	  further	  10	  minutes.	  	  The	  reaction	  was	  diluted	  to	  50	  µl	  in	  STE	  buffer	  (100	  mM	  NaCl,	  10	  mM	  Tris,	  1	  mM	  EDTA)	  and	  the	  Klenow	  heat-­‐inactivated	  at	  65	  °C	  for	  10	  minutes.	  	  The	  reaction	   was	   passed	   through	   an	   Amersham	   ProbeQuant	   G-­‐50	   microcolumn	   by	  centrifugation	   at	   3	   krpm	   for	   1	   minute.	   	   32P-­‐labelled	   E1	   probe	   was	   diluted	   1:2	   in	  binding	  buffer	  (20	  mM	  Tris-­‐HCl	  pH	  7.4,	  2	  mM	  MgCl2,	  50	  mM	  KCl,	  1	  mM	  EDTA,	  10	  %	  glycerol,	  1	  mM	  DTT).	  	  Non-­‐radiolabelled	  IVT	  proteins	  were	  prepared	  (see	  above)	  and	  proteins	  (e.g.	  xNgn2	  and	   E12)	   combined	   1:1	   by	   volume	   in	   Xenopus	   extract	   supplemented	   with	   20	   µM	  MG132	  or	  XB	  buffer	   for	  20	  minutes	   at	   room	   temperature	   (~20	   °C).	   	   Probe-­‐binding	  was	  carried	  out	  using	  4	  µl	  IVT	  protein	  incubated	  in	  XB	  or	  extract;	  0.2	  mg	  ml-­‐1	  poly(dI-­‐dC)	   and	   1	  µl	   E1	   probe	   in	   a	   final	   volume	   of	   10	  µl.	   	   Samples	  were	   incubated	   for	   20	  minutes	   at	   room	   temperature	   (~20	   °C).	   	   Samples	   were	   run	   out	   on	   5	   %	   non-­‐denaturing	  PAGE	  in	  0.25	  x	  TBE	  (Tris/Borate/EDTA)	  buffer.	   	  Gels	  were	  visualised	  by	  autoradiography.	  	  
mRNA	  Synthesis	  	  15	  µg	  template	  DNA	  was	  linearised	  using	  NotI	  restriction	  enzyme	  (NEB).	   	  Reactions	  were	  cleaned	  with	  addition	  of	  150	  µg	  µl-­‐1	  proteinase	  K	   (Roche)	  and	  0.5	  %	  SDS	  and	  incubation	  at	  50	  °C	  for	  1	  hour,	  followed	  by	  phenol/chloroform	  extraction.	  	  DNA	  was	  precipitated	   overnight	   at	   -­‐20	   °C	   with	   2.5	   volumes	   of	   absolute	   ethanol	   and	   0.25	  volumes	   7.5	  M	   ammonium	   acetate.	   	   Precipitated	   samples	  were	   spun	   down	   at	   13.2	  krpm	  4	   °C	   for	   at	   least	   45	  minutes,	  washed	  with	   70	  %	   ethanol	   and	   spun	   again	   and	  dried.	  	  Pellets	  were	  resuspended	  in	  10	  µl	  H2O	  (ultra-­‐pure).	  	  1	  µg	   linearised	  DNA	  was	  used	   in	   a	   transcription	   reaction	  with	   transcription	  buffer,	  ribonucleotide	  mix	  and	  enzyme	  mix	  (all	  reagents	  supplied	  by	  Ambion)	   incubated	  at	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37	   °C	   for	   2	   hours.	   	   Samples	  were	  DNase	   (Ambion)	   treated	   for	   15	  minutes	   at	   37	   °C	  before	   addition	   of	   ammonium	   acetate	   stop	   solution	   (Ambion)	   and	   nuclease	   free	  water.	  	  RNA	  was	  phenol/chloroform	  extracted	  and	  precipitated	  in	  an	  equal	  volume	  of	  ice-­‐cold	   isopropanol.	   	   Reactions	  were	   spun	  down	   at	   13.2	   krpm	  4	   °C	   for	   at	   least	   45	  minutes,	  washed	  with	  70	  %	  ethanol	  and	  spun	  again	  and	  resuspended	  in	  100	  µl	  RNase	  free	  water.	   	  RNA	  was	  precipitated	  overnight	  at	   -­‐20	   °C	  with	  2.5	  volumes	  of	  absolute	  ethanol	  and	  0.25	  volumes	  7.5	  M	  ammonium	  acetate.	  	  Precipitated	  samples	  were	  spun	  down	  at	  13.2	  krpm	  4	  °C	  for	  at	  least	  45	  minutes,	  washed	  with	  70	  %	  ethanol	  and	  spun	  again	  and	  dried.	  	  Pellets	  were	  resuspended	  in	  10	  µl	  H2O	  (ultra-­‐pure).	  	  Concentration	  was	   determined	   using	   the	   Nanodrop	   ND-­‐1000	   spectrophotometer	   and	   RNA	   was	  stored	  at	  –	  80	  °C	  in	  0.5	  µg	  µl-­‐1	  aliquots.	  
	  
Xenopus	  laevis	  Embryo	  Microinjection	  (see	  Figure	  2.3)	  
	  
Xenopus	   laevis	   eggs	   were	   collected,	   washed	   3	   times	   in	   MBS	   and	   fertilized	   in	   vitro.	  	  Fertilised	   embryos	   were	   treated	   with	   2	   %	   (w/v)	   L-­‐cysteine	   solution	   (pH	   7.8)	   to	  remove	  the	  jelly	  coat.	   	  Embryos	  were	  transferred	  to	  agarose	  dishes	  containing	  0.1	  x	  MBS	  with	   4	  %	   Ficoll	   solution	   and	   50	  µg	  ml-­‐1	   gentamycin.	   	   Embryos	  were	   injected	  using	   a	   Harvard	   Apparatus	   Medical	   Systems	   Picoinjector.	   	   10	   nl	   RNA	   solution	  (concentrations	  are	  specified	  in	  the	  text)	  was	  injected	  at	  the	  one	  cell	  stage	  in	  embryos	  destined	   for	   quantitative	   PCR	   experiments	   and	   in	   one	   of	   two	   cells	   at	   the	   two-­‐cell	  stage	  in	  embryos	  used	  for	  in	  situ	  hybridization.	  	  Embryos	  were	  cultured	  at	  14	  °C.	  
	  
In	  situ	  Hybridization	  (ISH)	  







Figure 2.3: Xenopus laevis embryo microinjection. 
A) Eggs are fertilized in vitro and injected in one cell at the two-cell stage (for ISH) with the mRNA 
of interest and mRNA for β-galactosidase.  Embryos are cultured, fixed and stained using X-gal to 
highlight the injected side of the embryo before in situ hybridisation (ISH) is carried out probing for 
a marker of interest, for example neural β-tubulin.  B) Representative embryos used for scoring ISH 
embryos for ectopic neurogenesis at the level of neural β-tubulin induction.  C) Representative 
embryos used for scoring ISH embryos for ectopic neurogenesis at the level of NeuroD induction. 	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solution	  (0.02	  %	  Dicoll,	  0.02	  %	  polyvinylpyrrolidine,	  0.02	  %	  BSA	   fraction	  V),	  1	  mM	  EDTA,	  0.1	  %	  Tween,	  0.1	  %	  CHAPS,	  100	  µg	  ml-­‐1	  heparin,	  1	  mg	  ml-­‐1	  torula	  RNA).	  	  Embryos	  destined	  for	  ISH	  were	  coinjected	  with	  500	  pg	  β-­‐galactosidase	  (β-­‐gal)	  mRNA	  as	  well	  as	  the	  mRNA	  of	  interest.	  	  Embryos	  were	  first	  fixed	  in	  MEMFA	  (100	  mM	  MOPS,	  2	  mM	  EGTA,	  1	  mM	  MgSO4,	  10	  %	  formaldehyde)	  for	  1	  hour	  at	  room	  temperature	  (~20	  °C)	  then	  washed	  with	  PBS.	  	  Embryos	  were	  then	  incubated	  in	  PBS	  supplemented	  with	  2	  mM	  MgCl2	  for	  15	  minutes	  at	  room	  temperature	  (~20	  °C).	  	  Embryos	  were	  stained	  by	  incubation	  with	  X-­‐Gal	  mixer	  (5.35	  mM	  K3Fe(CN)6,	  5.35	  mM	  K4Fe(CN)6.3H2O,	  1.2	  mM	  MgCl2,	  0.01	  %	  sodium	  deoxycholate,	  0.02	  %	  Igepal	  in	  PBS)	  supplemented	  with	  1	  mg	  ml-­‐1	   X-­‐Gal	   at	   37	   °C	   until	   stained.	   	   Embryos	  were	   dehydrated	   in	  methanol	   at	   -­‐20	   °C	  overnight.	  	  ISH	  was	  carried	  out	  using	  a	  BioLane	  HTI	   in	   situ	   robot	   (Holle	  and	  Hunter)	   following	  programmes	  outlined	  in	  Tables	  2.1	  and	  2.2	  below.	  
	  
Table	  2.1	  In	  situ	  hybridisation	  Day	  1	  programme	  	  





(°C)	  75	  %	  methanol	   1	   10	   22	  50	  %	  methanol	   1	   5	   22	  25	  %	  methanol	   1	   5	   22	  PBS	  +	  0.1	  %	  Tween	   4	   5	   22	  0.5	  µg	  µl-­‐1	  proteinase	  K	  in	  PBST	   1	   5	   22	  0.1	  M	  triethanolamine	   1	   5	   22	  0.5	  %	  (v/v)	  acetic	  anhydride	  in	  0.1	  M	  TEA	   1	   10	   22	  PBS	  +	  0.1	  %	  Tween	   2	   5	   22	  4	  %	  formaldehyde	  in	  PBS	  +	  0.1	  %	  Tween	   1	   20	   22	  PBS	  +	  0.1	  %	  Tween	   6	   5	   22	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Table	  2.2	  In	  situ	  hybridisation	  Day	  2	  programme	  	  





(°C)	  2	  x	  SSC	  (0.3	  M	  NaCl,	  30	  mM	  sodium	  citrate)	   1	   5	   60	  2	  x	  SSC	   3	   20	   60	  2	  x	  SSC	   1	   10	   60	  0.2	  x	  SSC	   2	   20	   60	  MAB	  (0.1	  M	  maleic	  acid,	  0.15	  M	  NaCl,	  pH	  7.5)	   2	   5	   22	  Blocking	  buffer	  (2	  %	  blocking	  reagent	  (Roche)	  in	  MAB,	  20	  %	  heat	  inactivated	  lamb	  serum)	  
1	   60	   22	  
1:5000	  Anti-­‐Digoxigenin	  ALP	  antibody	  in	  blocking	  buffer	   1	   240	   22	  MAB	   3	   5	   22	  MAB	   4	   150	   4	  	  On	  Day	  1	  embryos	  are	  rehydrated	  and	  washed	  and	  permeabilised	  with	  proteinase	  K.	  	  Negatively	   charged	   proteins	   are	   neutralized	   by	   acetic	   anhydride	   buffered	   by	  triethanolamine.	  	  Embryos	  are	  re-­‐fixed	  in	  formaldehyde	  and	  washed.	  	  Embryos	  were	  then	  incubated	  for	  2	  hours	  at	  60	  °C	  in	  hybridisation	  buffer	  and	  incubated	  overnight	  at	  60	   °C	   with	   rocking	   in	   hybridisation	   buffer	   supplemented	   with	   2	   ng	   	   µl-­‐1	   of	   the	  appropriate	  digoxigenin-­‐labelled	  ISH	  probe.	  	  On	  Day	  2	  embryos	  were	  washed	  to	  remove	  excess	  probe	  and	  incubated	  with	  blocking	  buffer	   before	   incubation	   with	   alkaline	   phosphatase-­‐conjugated	   anti-­‐digoxigenin	  antibody	  (Roche).	  	  Embryos	  were	  washed	  twice	  in	  NTMT	  buffer	  (100	  mM	  Tris	  pH	  9.5,	  100	  mM	  NaCl,	  50	  mM	  MgCl2,	  0.1	  %	  Tween)	  for	  10	  minutes	  at	  room	  temperature	  (~20	  °C)	   with	   rocking.	   	   Embryos	   were	   treated	   with	   BM	   Purple	   alkaline	   phosphatase	  substrate	   (Roche)	   supplemented	  with	   2	  mM	   levamisole	   at	   room	   temperature	   (~20	  °C)	   with	   rocking	   until	   purple	   staining	   of	   all	   probe-­‐interacting	   antibodies	   was	  observed.	   	   Staining	   was	   stopped	   by	   addition	   of	   methanol	   for	   30	   minutes	   at	   room	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temperature	  (~20	  °C)	  and	  embryos	  were	  fixed	  in	  MEMFA.	  	  Bleaching	  was	  carried	  out	  in	  a	  solution	  of	  3	  %	  H2O2,	  5	  %	  formamide,	  1	  x	  SSC	  in	  a	  light	  box	  at	  room	  temperature	  (~20	   °C)	  until	  bleaching	  was	  complete.	   	  Embryos	  were	  photographed	  using	  a	  Leica	  MZ	  FLIII	  dissection	  microscope	  equipped	  with	  a	  Hamamatsu	  camera	  and	  then	  stored	  in	  MEMFA.	   	   Images	  were	  processed	  using	  Openlab	  software	  and	  minimal	  editing	   to	  arrange	  embryo	  orientation	  in	  Adobe	  Photoshop.	  	  Scoring	  of	  ISH	  embryos	  was	  carried	  out	  by	  comparison	  to	  the	  representative	  embryo	  scales	  depicted	  in	  Figure	  2.3.	  
	  
Molecular	  Cloning	  	  
	  Subcloning	   by	   PCR,	   restriction	   digest	   and	   ligation	   was	   carried	   out	   by	   standard	  procedures	  as	  described	  in	  Molecular	  Cloning	  (Sambrook	  et	  al.,	  1989).	  	  
	  
Quantitative	  Reverse	  Transcriptase	  PCR	  (qRT-­PCR)	  Assays	  
	  Embryos	  microinjected	  with	  mRNA	  in	  one	  cell	  at	  the	  one-­‐cell	  stage	  were	  harvested	  at	  Stage	  15	  (Nieuwkoop	  and	  Faber,	  1994)	  and	  lysed	  in	  350	  µl	  Buffer	  RLT	  supplemented	  with	  1	  %	  (v/v)	  β-­‐mercaptoethanol	  (Qiagen	  RNeasy	  Mini	  Kit).	  	  Lysates	  were	  spun	  for	  1	  minute	   13.2krpm	  4	   °C	   and	   the	   supernatant	   collected	   and	  mixed	  with	   350	  µl	   70	  %	  ethanol.	   	  RNA	  was	  purified	  using	   the	  Qiagen	  RNeasy	  Mini	  kit	   into	  50	  µl	  RNase-­‐free	  H2O.	   	   RNA	  was	   treated	  with	   1	  µl	   DNase	   I	   Turbo	   and	   5	  µl	   DNase	   I	   digestion	   buffer	  (Qiagen)	   for	   1	   hour	   at	   37	   °C.	   	   Digestion	   was	   terminated	   by	   addition	   of	   DNase	  inactivation	   solution	   and	   the	   sample	   spun	   for	   2	   minutes	   at	   13.2	   krpm.	   	   The	  supernatant	  was	  collected	  and	  RNA	  concentration	  determined	  by	  the	  Nanodrop	  ND-­‐1000	  spectrophotometer.	  	  	  	  RNA	  samples	  were	   then	  used	   for	   cDNA	  synthesis	  by	   combining	  0.5	  µg	  µl-­‐1	  oligo	  dT	  primer,	  10	  mM	  dNTP	  mix	  and	  2	  µg	  RNA	  in	  a	  total	  volume	  of	  13	  µl	  in	  RNase-­‐free	  H2O.	  	  RNA	  was	  denatured	  by	  heating	  to	  65	  °C	  for	  5	  minutes	  followed	  by	  rapid	  chilling	  on	  ice	  for	  1	  minute.	   	  The	   reaction	  mixtures	  were	   supplemented	  with	  4	  µl	   5	   x	  First-­‐strand	  buffer,	   1	   µl	   RNase	   OUT	   RNase	   inhibitor,	   1	   µl	   0.1	   M	   DTT	   and	   1	   µl	   Superscript	   III.	  	  Reactions	   were	   incubated	   for	   30	   minutes	   at	   50	   °C	   and	   the	   enzyme	   was	   heat-­‐
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inactivated	  at	  70	  °C	  for	  15	  minutes	  before	  cooling	  on	  ice.	  	  RNA	  was	  eliminated	  with	  1	  
µl	  RNase	  H	  for	  20	  minutes	  at	  37	  °C.	  	  1	  µl	  cDNA	  sample	  was	  diluted	  to	  5	  µl	  in	  H2O	  and	  added	  to	  15	  µl	  1.5	  x	  SybrGreen	  supplemented	  with	  0.5	  µl	  of	  each	  primer	  required	  for	  qPCR	  (provided	  by	  Fahad	  Ali).	  	  Samples	  were	  then	  read	  by	  Rotorgene.	  
	  
Mus	  musculus	   P19	  Embryonal	   Carcinoma	  Cell	   culture	   (Rudnicki	   and	  McBurney,	  1987)	  
	  P19	  embryonal	  carcinoma	  cells	  were	  maintained	  in	  cell	  culture	  at	  37	  °C	  in	  α-­‐modified	  Minimum	   Essential	   Medium	   (Invitrogen)	   supplemented	   with	   7.5	   %	   Bovine	   Calf	  Serum	   (Invitrogen);	   2.5	   %	   Foetal	   Bovine	   Serum	   (Invitrogen);	   100mM	   Glutamax	  (Invitrogen)	   and	   100	   units	   penicillin	  with	   100	  µg	   streptomycin	   (Invitrogen).	   	   Cells	  were	  split	  every	  2	  days	  using	  trypsin	  (Invitrogen).	  
	  
Mus	  musculus	  P19	  Degradation	  Assays	  
	  P19	   embryonal	   carcinoma	   cells	   were	   plated	   onto	   polylysine-­‐coated	   plates	   at	   a	  concentration	  of	  400,000	  cells	  per	  well	  and	  incubated	  in	  α-­‐MEM	  (Minimum	  Essential	  Media)	  37	  °C.	  	  Media	  was	  removed	  after	  24	  hours	  and	  replaced	  with	  antibiotic-­‐free	  α-­‐MEM	   and	   incubated	   for	   2	   hours	   at	   37	   °C.	   5	   µg	   DNA	   with	   250	   µl	   OPTIMEM	  (Invitrogen)	  per	  well	  was	  incubated	  with	  15	  µl	  lipofectamine	  (Invitrogen)	  and	  250	  µl	  OPTIMEM	  per	  well	  for	  20	  minutes	  and	  500	  µl	  added	  to	  each	  well	  of	  P19	  cells	  in	  2	  ml	  medium.	   	   Cells	  were	   transfected	   overnight	   at	   37	   °C.	   	  Where	  mentioned	   in	   the	   text,	  cells	   were	   treated	   with	   20	   µM	   MG132	   (N-­‐carbobenzoxyl–Leu–Leu–Leucinal,	  Calbiochem)	  or	  an	  equal	  volume	  of	  DMSO	  as	  a	  control.	  	  At	  the	  start	  of	  the	  assay,	  100	  
µg	   ml-­‐1	   cycloheximide	   was	   added	   to	   each	   well	   and	   at	   each	   timepoint	   media	   was	  removed	   from	  the	  well,	   cells	  washed	   in	  warmed	  1	  x	  PBS,	  50	  µl	   lysis	  buffer	   (50	  mM	  Tris	   pH	   7.5;	   150	  mM	  NaCl;	   1	  %	   IgePal	   (Sigma);	   protease	   inhibitors	   (Sigma);	   1	  µM	  pepstatin)	   added	   and	   cells	   scraped,	   placed	   on	   ice,	   then	   stored	   -­‐20	   °C.	   	   Cells	   were	  sonicated	  in	  a	  sonicating	  water	  bath	  and	  centrifuged	  13.2	  krpm	  4	  °C	  10	  minutes.	  	  The	  supernatant	   was	   removed	   and	   protein	   levels	   quantified	   by	   BCA	   Protein	   Assay	  (Pierce).	   	   20	  µg	  protein	  was	  added	   to	  SDS	  gel-­‐loading	  buffer	   supplemented	  with	  β-­‐
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mercaptoethanol	   then	   run	   out	   by	   SDS-­‐PAGE	   and	   transferred	   to	   nitrocellulose	  membrane	  by	  Western	  Blot	  (BIORAD)	  at	  100	  V	  for	  1	  hour.	  	  Membranes	  were	  blocked	  in	  5	  %	   (w/v)	   skimmed	  milk	   in	  PBST	   (1	  x	  PBS;	  0.1	  %	  Tween)	  at	   room	   temperature	  (~20	  °C)	  for	  1	  hour.	  	  Primary	  antibody	  incubations	  in	  2	  %	  milk	  PBST	  were	  performed	  at	  4	  °C	  overnight.	  	  Secondary	  antibody	  incubations	  were	  performed	  in	  2	  %	  milk	  PBST	  at	   room	   temperature	   (~20	   °C)	   for	   1	   hour.	   	   Immunodetection	  was	  performed	  using	  ECL	  Plus	  Western	  Blotting	  Reagent	  (GE	  Healthcare).	   	  Proteins	  were	  quantified	  using	  ImageJ	  (http://rsbweb.nih.gov/ij/)	  (Abramoff	  et	  al.,	  2004)	  software.	  	  
Mus	  musculus	  P19	  IP-­re-­IP	  	  P19	   embryonal	   carcinoma	   cells	   were	   plated	   onto	   polylysine-­‐coated	   plates	   at	   a	  concentration	  of	  400,000	  cells	  per	  well	  and	   incubated	   in	  α-­‐MEM	  37	  °C.	   	  Media	  was	  removed	  after	  24	  hours	  and	  replaced	  with	  antibiotic-­‐free	  α-­‐MEM	  and	  incubated	  for	  2	  hours	  at	  37	  °C.	  5	  µg	  DNA	  with	  250	  µl	  OPTIMEM	  (Invitrogen)	  per	  well	  was	  incubated	  with	  15	  µl	   lipofectamine	  (Invitrogen)	  and	  250	  µl	  OPTIMEM	  per	  well	   for	  20	  minutes	  and	  500	  µl	  added	  to	  each	  well	  of	  P19	  cells	   in	  2	  ml	  medium.	   	  Cells	  were	   transfected	  overnight	   at	   37	   °C.	   	   After	   24	   hours,	   cells	   were	   treated	   with	   20	   µM	   MG132	   (N-­‐carbobenzoxyl–Leu–Leu–Leucinal,	  Calbiochem).	   	  Media	  was	   removed	   from	   the	  well,	  cells	  washed	  in	  warmed	  1	  x	  PBS,	  50	  µl	  lysis	  buffer	  (50	  mM	  Tris	  pH	  7.5;	  150	  mM	  NaCl;	  1	   %	   IgePal	   (Sigma);	   protease	   inhibitors	   (Sigma);	   1	   µM	   pepstatin)	   added	   and	   cells	  scraped,	  placed	  on	  ice,	  then	  stored	  -­‐20	  °C.	  	  Cells	  were	  sonicated	  in	  a	  sonicating	  water	  bath	  and	  centrifuged	  13.2	  krpm	  4	  °C	  10	  minutes.	  	  The	  supernatant	  was	  removed	  and	  protein	   levels	  quantified	  by	  BCA	  Protein	  Assay	  (Pierce).	   	  1.2	  mg	  protein	  was	  pulled	  down	  with	  α-­‐HA	  (Roche)	  or	  α-­‐FLAG	  (Sigma)	  antibody	  and	  rolled	  at	  4	  °C	  overnight.	  	  Sepharose	   beads	   (G	   sepharose	   for	   HA	   immunoprecipitation,	   A	   sepharose	   for	   FLAG	  (GE	   Healthcare))	   were	   added	   and	   samples	   rolled	   at	   4	   °C	   overnight	   for	   2-­‐4	   hours.	  	  Proteins	  were	  eluted	  using	  0.1	  M	  glycine	  pH	  2.4	  at	  room	  temperature	  (~20	  °C)	  for	  10	  minutes.	  	  SDS	  LB	  was	  added	  to	  1/5	  of	  the	  sample	  and	  frozen.	  	  2/5	  of	  the	  sample	  were	  treated	  with	  1	  %	  SDS	  at	  70	  °C	  for	  20	  minutes	  and	  the	  remaining	  2/5	  were	  kept	  on	  ice	  for	  20	  minutes.	  	  Both	  samples	  were	  divided	  into	  FLAG	  IP	  and	  HA	  IP	  samples	  and	  the	  IP	   procedure	   described	   above	   repeated.	   	   Proteins	   were	   eluted	   in	   SDS	   LB	   and	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separated	   by	   SDS-­‐PAGE.	   	   Primary	   antibody	   incubations	   in	   2	   %	   milk	   PBST	   were	  performed	  at	  4	  °C	  overnight.	  	  Secondary	  antibody	  incubations	  were	  performed	  in	  2	  %	  milk	   PBST	   at	   room	   temperature	   (~20	   °C)	   for	   1	   hour.	   	   Immunodetection	   was	  performed	  using	  ECL	  Plus	  Western	  Blotting	  Reagent	  (GE	  Healthcare).	  	  Proteins	  were	  quantified	  using	  ImageJ	  (http://rsbweb.nih.gov/ij/)	  (Abramoff	  et	  al.,	  2004)	  software.	  	  
Protein	  NMR	  	  Protein	  purification	  using	  GST-­‐tagged	  mNgn2	  or	  His-­‐tagged	  mNgn2	  was	  carried	  out	  as	  discussed	   in	  Chapter	  7.	   	  Proteins	  were	  expressed	   in	  BL21	  cells	   transformed	  with	  ampicillin	  resistant	  plasmids	  and	  grown	  in	  M9-­‐based	  semi-­‐rich	  medium	  (M9	  medium	  (50	   mM	   Na2HPO4,	   15	   mM	   KH2PO4,	   8.5	   mM	   NaCl)	   supplemented	   with	   MEM,	   1mM	  MgSO4,	   100	   µM	   CaCl2,	   1	   g	   l-­‐1	   15N-­‐NH4Cl,	   2	   g	   l-­‐1	   13C6-­‐D-­‐glucose	   (when	   13C	   labelling	  required,	  otherwise	  4	  g	   l-­‐1	  unlabelled	  glucose	  (Sigma)	  used),	  0.7	  g	   l-­‐1	   Isogro	  13C,	   15N	  powder	  growth	  medium	  (Sigma),	  100	  µg	  ml-­‐1	  ampicillin)	  at	  37	  °C	  to	  an	  OD600	  of	  0.6.	  	  Protein	  expression	  was	  induced	  with	  0.4	  mM	  IPTG	  at	  20	  °C	  overnight.	  	  Harvested	  cells	  were	   lysed	  using	   lysozyme	  and	  sonication.	   	  GST-­‐tagged	  proteins	  were	  purified	  on	  a	  glutathione-­‐bead	   containing	   column	   (Amersham)	   using	   an	  AKTA	   FPLC	   purifier	   (GE	  Healthcare).	   	   GST-­‐tagged	  proteins	  were	   eluted	  by	   cleavage	   of	   the	  GST	   tag	   from	   the	  protein	  using	  PreScission	  Protease	  (GE	  Healthcare)	  overnight	  at	  4	  °C	  and	  elution	  in	  1	  x	  PBS	  +	  2	  mM	  EDTA.	  	  mNgn2	  was	  phosphorylated	  using	  CyclinA3/Cdk2	  protein	  (supplied	  by	  Lippens	   lab)	  in	  5	  mM	  ATP,	  12.5	  mM	  MgCl2,	  50	  mM	  HEPES	  pH	  8.0,	  55	  mM	  NaCl,	  5	  mM	  DTT,	  at	  30	  °C	  before	  passing	  through	  a	  Zeba	  spin	  column.	  	  For	  NMR,	  protein	  samples	  were	  placed	  into	  buffer	  containing	  50	  mM	  Tris	  25	  mM	  NaCl	  2.5	   mM	   EDTA	   2	   mM	   DTT	   using	   Zeba	   Spin	   columns.	   	   0.625	  %	   (v/v)	   trimethylsilyl	  propanoic	  acid	  and	  5	  %	  (v/v)	  D2O	  were	  added.	  	  NMR	  measurements	  were	  performed	  at	  293	  K	  on	  a	  Bruker	  Avance	  600	  MHz	  spectrometer	  using	  TMSP	  as	  a	  reference.	  
	  52	  
Calculating	  Half-­Lives	  	  Half-­‐lives	  were	  calculated	  according	  to	  first-­‐order	  rate	  kinetics:	  	  If	  we	  define	  [N]	  as	  the	  amount	  of	  neurogenin	  (xNgn2)	  present	  in	  the	  sample,	  we	  can	  describe	  the	  rate	  of	  neurogenin	  degradation	  in	  vitro,	  assuming	  first	  order	  kinetics,	  as:	  	  Where	  a	  decrease	  in	  neurogenin	  level	  is	  described	  by	  virtue	  of	  the	  negative	  rate	  law.	  Rearranging:	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Therefore	  plotting	   ln[N]	  against	  t	  should	  give	  a	  straight-­‐line	  plot	  of	  gradient	  K	  from	  which	  we	  are	  able	  to	  calculate	  half-­‐life	  values.	  	  
Error	  Analysis	  	  Half-­‐lives	  were	  calculated	  relative	  to	  the	  wild	  type	  xNgn2	  control	  and	  averaged	  over	  all	  experiments.	  	  The	  standard	  deviation	  of	  the	  mean	  was	  found	  using:	  	  
From	  this,	  the	  standard	  error	  of	  the	  mean	  was	  calculated:	  	  Where	  n	  is	  the	  number	  of	  samples	  used	  to	  calculate	  the	  average	  (typically	  n	  =	  3).	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Canonical	  Ubiquitylation	  of	  xNgn2	  
	  
	  
INTRODUCTION	  	  xNgn2	  undergoes	  Ub-­‐mediated	  proteolysis	  (Vosper	  et	  al.,	  2007)	  and	  I	  am	  seeking	  to	  establish	  how	  xNgn2	  activity	  and	  stability	  may	  be	  regulated	  and	  linked	  to	  control	  cell	  cycle	  progression	  and	  proliferation.	  The	  canonical	  description	  of	  ubiquitylation	  given	  in	   the	   literature	   describes	   transfer	   of	   Ub	   from	   a	   thiol	   linkage	   on	   the	   E2	   Ub-­‐conjugating	  enzyme	  to	  an	   internal	   lysine	  residue	  on	   the	  substrate	  protein	  (Freiman	  and	  Tjian,	  2003),	  forming	  an	  isopeptide	  linkage.	  	  	  	  MyoD,	  the	  myogenic	  homologue	  of	  xNgn2,	  is	  ubiquitylated	  particularly	  on	  lysine	  133.	  	  Mutation	  of	   lysine	  133	   to	  arginine	  both	   stabilises	   the	  protein	  and	   raises	   its	   activity	  (Batonnet	  et	  al.,	  2004).	  	  Much	  work	  has	  been	  carried	  out	  on	  the	  degradation	  of	  MyoD	  (Abu	   Hatoum	   et	   al.,	   1998,	   Breitschopf	   et	   al.,	   1998,	   Thayer	   et	   al.,	   1989),	   other	  myogenic	  bHLH	  proteins	  such	  as	  Myf5	  (Lindon	  et	  al.,	  2000)	  and	  their	  heterodimeric	  binding	  partners,	   the	  E2A	  proteins	  (Kho	  et	  al.,	  1997).	   	  However,	   relatively	   little	  has	  been	   established	   about	   the	   degradation	   of	   proneural	   proteins	   outside	   of	   Mash1	  (Vinals	  et	  al.,	  2004).	  	  	  	  Neurogenin	  contains	  8	  lysine	  residues:	  K5,	  K70,	  K77,	  K79	  and	  K80	  in	  the	  N-­‐terminal	  (NT)	  region;	  K85	  in	  the	  basic	  region;	  K116	  in	  the	  loop	  and	  K119	  on	  the	  NT	  cap	  of	  the	  2nd	  helix	  of	  the	  bHLH	  motif.	   	  The	  role	  of	  the	  Ub	  proteasome	  system	  (UPS)	  in	  xNgn2	  degradation	  has	  been	  shown	  (Vosper	  et	  al.,	  2007)	  and	  highlighted	  in	  relation	  to	  PTMs	  and	  stabilising	   factors	  of	  xNgn2	  (Hand	  et	  al.,	  2005,	  Nguyen	  et	  al.,	  2006,	  Vernon	  and	  Philpott,	   2003b).	   	  My	   aims	   in	   this	   chapter	   are	   to	   establish	   the	   role	   that	   conserved	  lysines,	   especially	   within	   structured	   regions	   of	   xNgn2	   protein,	   may	   have	   in	   Ub-­‐mediated	  proteolysis	  of	  xNgn2,	  and	  the	  effect	  that	  this	  may	  have	  on	  xNgn2	  activity.	  	  I	  will	   be	   using	   Xenopus	   laevis	   extract	   systems	   as	   a	   convenient	   method	   for	   assaying	  xNgn2	   degradation	   as	   it	   contains	   all	   components	   of	   the	   proteasomal	   degradation	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bHLH	   proteins	   undergo	   lysine-­dependent	   degradation	   by	   the	   UPS	   in	  Xenopus	  
laevis	  	  To	   test	   for	   an	   appropriate	   assay	   system	   to	   investigate	   xNgn2	   UPS-­‐mediated	  degradation,	  Xenopus	  laevis	  interphase	  activated	  egg	  extract	  was	  supplemented	  with	  









Figure 3.1: xNgn2 degradation in Xenopus laevis interphase activated egg extract is 
inhibited by the proteasome inhibitor MG132. 
Xenopus laevis interphase activated egg extracts were supplemented with 35S-labelled xNgn2 in 
the presence or absence of the proteasome inhibitor MG132.  Samples were taken at the 
timepoints indicated and subjected to 15 % SDS-PAGE.  Gels were analysed by autoradiography 
(A) and quantitative phosphorimaging analysis (B).  (C) Half-lives in the presence or absence of 
MG132 were calculated using first-order rate kinetics, and errors calculated using the Standard 
Error of the Mean (SEM). 
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To	  find	  the	  stability	  of	  xNgn3	  in	  vitro,	  Xenopus	  laevis	  interphase	  activated	  egg	  extract	  was	   supplemented	   with	   IVT	   35S-­‐methionine	   radiolabelled	   xNgn3	   protein	   and	  incubated	  at	  21°C.	  	  Aliquots	  of	  the	  degradation	  reaction	  were	  removed	  at	  increasing	  timepoints	  into	  quenching	  SDS-­‐LB	  and	  separated	  by	  15	  %	  SDS-­‐PAGE.	  	  Half-­‐lives	  were	  then	  calculated	  from	  three	  repeat	  experiments	  using	  first-­‐order	  rate	  kinetics	  (Figure	  3.2).	  	  	  	  xNgn3	  protein	  is	  slightly	  larger	  than	  xNgn2	  (Figure	  3.2,	  A,	  B)	  and	  has	  a	  shorter	  half-­‐life	  than	  that	  typically	  exhibited	  by	  xNgn2	  (12.9	  +/-­‐	  1.0	  mins	  (Figure	  3.2,	  D)	  and	  22.9	  +/-­‐	  1.0	  mins	  (Figure	  3.1,	  C),	  respectively).	   	  Therefore	  both	  neurogenins	  identified	  in	  
Xenopus	  are	  unstable	  in	  Xenopus	  extract.	  	  Neurogenins	   regulate	  neurogenesis	   and	  other	   bHLH	  proteins	   regulate	   different	   cell	  specification	  pathways	  such	  as	  MyoD,	  the	  Ngn2	  homologue	  in	  myogenesis	  (Walsh	  and	  Perlman,	  1997).	   	  The	  stability	  of	  MyoD	  has	  been	  extensively	  studied	   in	   the	  work	  of	  the	  Ciechanover	  group	  and	  others	  (Abu	  Hatoum	  et	  al.,	  1998,	  Breitschopf	  et	  al.,	  1998,	  Thayer	  et	  al.,	  1989)	  with	  particular	  reference	  to	  the	  Mus	  musculus	  protein,	  mMyoD.	  	  	  	  To	   compare	   stability	   of	   the	   similarly	   structured	   xMyoD	   and	   xNgn2,	   Xenopus	   laevis	  interphase	   activated	   egg	   extract	   was	   supplemented	   with	   IVT	   35S-­‐methionine	  radiolabelled	   xNgn2	   or	   xMyoD	   protein	   and	   incubated	   at	   21°C.	   	   Aliquots	   of	   the	  degradation	  reaction	  were	  removed	  at	  increasing	  timepoints	  into	  quenching	  SDS-­‐LB	  and	  separated	  by	  15	  %	  SDS-­‐PAGE.	  	  Half-­‐lives	  were	  then	  calculated	  from	  three	  repeat	  experiments	  using	  first-­‐order	  rate	  kinetics	  (Figure	  3.4,	  A).	  	  	  	  xMyoD	  is	  unstable	  with	  a	  half-­‐life	  of	  33.7	  +/-­‐	  1.5	  mins.	   	  xNgn2	  has	  a	  half-­‐life	  here	  of	  24.5	  +/-­‐	  3.4	  mins	  (Figure	  3.4,	  A).	   	  Therefore	   the	  similarly	  structured	  proteins	  show	  similar	  rates	  of	  degradation	  in	  interphase	  extract.	  	  Lysine	  residues	  are	  the	  canonical	  sites	  of	  ubiquitylation	  in	  a	  protein	  targeted	  for	  UPS-­‐mediated	   degradation	   (Mayer,	   2005).	   	   Ubiquitylation	   can	   therefore	   be	   blocked	   by	  site-­‐directed	  mutagenesis	   of	   lysines	   to	   arginines.	   	   This	   semi-­‐conservative	  mutation	  maintains	  the	  alkyl	  chain	  and	  basic	  charge	  within	  the	  protein	  but	  removes	  the	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Figure 3.2: xNgn3 is degraded in Xenopus laevis interphase activated egg extract. 
(A) ClustalW2 analysis was carried out to align xNgn2 and xNgn3 sequences.  Exact matches are 
denoted by * and decreasingly similar properties by : and . with no symbol present for no similarity.  
– highlights a gap in the sequence alignment.  The disordered N-terminal domain is bordered in 
blue; the bHLH domain in red; and the disordered C-terminal domain in green.  (B,C) Xenopus 
laevis interphase activated egg extracts were supplemented with 35S-labelled xNgn3.  Samples 
were taken at the timepoints indicated and subjected to 15 % SDS-PAGE.  Gels were analysed by 
autoradiography (B) and quantitative phosphorimaging analysis (C).  (D) The half-life for protein 
degradation was calculated using first-order rate kinetics, and errors calculated using the Standard 
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Figure 3.3: Positions of lysine residues in xNgn2. 
Schematic of lysine positions and lysines modelled onto a structure of a proneural bHLH 
heterodimer complexed to DNA. The disordered N-terminal domain is bordered in blue; the bHLH 















Figure 3.4: MyoD is degraded in Xenopus laevis interphase activated egg extract. 
Xenopus laevis interphase activated egg extracts were supplemented with 35S-radiolabelled xNgn2 
or (A) xMyoD, (B) xNgn2KO or (C) mMyoDKO.  Samples were taken at the timepoints indicated 
and subjected to 15 % SDS-PAGE.  Gels were analysed by quantitative phosphorimaging analysis.  
The half-life for protein degradation was calculated using first-order rate kinetics, and errors 
calculated using the Standard Error of the Mean (SEM). 
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much	  more	  stable	   than	  xNgn2.	   	  Mutation	  of	   canonical	  ubiquitylation	  sites	   stabilises	  bHLH	  proteins.	  
	  
No	  individual	  lysine	  alone	  targets	  xNgn2	  for	  Ub-­mediated	  proteolysis	  	  Mutating	   all	   lysines	   to	   arginines	   stabilises	   xNgn2	   and	   mMyoD.	   	   Like	   xNgn2,	   most	  lysines	  in	  mMyoD	  are	  in	  the	  N-­‐terminal	  region	  of	  the	  protein	  and	  no	  single	  lysine	  is	  responsible	  for	  mMyoD	  instability	  (Breitschopf	  et	  al.,	  1998).	   	   I	   investigated	  whether	  any	  individual	  lysine	  is	  required	  to	  target	  xNgn2	  for	  proteasomal	  degradation.	   	  Site-­‐directed	   mutagenesis	   was	   carried	   out	   by	   Kate	   Wilson	   of	   individual	   lysines	   to	  arginines,	   generating	   mutants	   K5RxNgn2,	   K70RxNgn2,	   K77RxNgn2,	   K79TRxNgn2,	  K80RxNgn2,	   K85RxNgn2,	   K116RxNgn2	   and	   K119RxNgn2	   (see	   Figure	   3.3	   for	   a	  schematic	  of	  lysine	  positions).	  	  	  	  To	   compare	   the	   stability	   of	   individual	   lysine	   mutants	   of	   xNgn2,	   Xenopus	   laevis	  interphase	   activated	   egg	   extract	   was	   supplemented	   with	   IVT	   35S-­‐methionine	  radiolabelled	  xNgn2,	  xNgn2KO	  or	   individual	   lysine	  mutant	  protein	  and	   incubated	  at	  21°C.	   	   Aliquots	   of	   the	   degradation	   reaction	  were	   removed	   at	   increasing	   timepoints	  into	   quenching	   SDS-­‐LB	   and	   separated	   by	   15	   %	   SDS-­‐PAGE.	   	   Half-­‐lives	   were	   then	  calculated	  using	   first-­‐order	   rate	  kinetics.	  The	  average	   ratio	  of	  protein	   stability	  with	  respect	  to	  wild	  type	  was	  also	  calculated.	  	  Experiments	  were	  carried	  out	  once	  by	  Kate	  Wilson	  and	  twice	  by	  myself	  to	  generate	  a	  triplicate	  data	  set	  (Figure	  3.5).	  	  	  	  Mutation	  of	  all	   lysines	  in	  xNgn2	  to	  generate	  xNgn2KO	  results	  in	  a	  1.56	  +/-­‐	  0.14	  fold	  stabilisation	  over	  wild	  type	  (Figure	  3.5,	  A).	  	  No	  individual	  lysine	  mutation	  results	  in	  a	  change	   in	   half-­‐life	   compared	   to	   wild	   type	   (Figure	   3.5,	   B).	   	   No	   individual	   lysine	   to	  arginine	  mutant	  of	  xNgn2	  stabilises	  xNgn2	  protein.	  	  Therefore	  no	  individual	  lysine	  on	  its	  own	  targets	  xNgn2	  for	  efficient	  Ub-­‐mediated	  proteasomal	  degradation.	  	  
Conserved	  lysines	  play	  a	  role	  in	  Ub-­mediated	  proteolysis	  of	  xNgn2	  	  As	  no	  single	  lysine	  is	  essential	  for	  xNgn2	  targeting	  to	  the	  proteasome,	  related	  bHLH	  proteins	  were	  compared	  to	  identify	  clusters	  of	  conserved	  lysines	  which	  may	  be	  	  
	  63	  




Figure 3.5: No individual lysine mutant alone stabilises xNgn2 against proteasomal 
degradation. 
Xenopus laevis interphase activated egg extracts were supplemented with 35S-labelled xNgn2, 
xNgn2KO or individual lysine to arginine mutants as indicated.  Samples were taken at 0, 15, 30, 
45, 60, 90 and 120 mins and subjected to 15 % SDS-PAGE.  Gels were analysed by quantitative 
phosphorimaging analysis.  The half-life for protein degradation was calculated using first-order 
rate kinetics.  Each half-life within an experiment was normalised to xNgn2 within the experiment 
and the ratios of stability compared to xNgn2 averaged over the 3 experiments.  Errors were 
calculated using the Standard Error of the Mean (SEM).  One of the 3 data sets used above was 
generated by Kate Wilson. 	  
	  64	  




Figure 3.6: bHLH proneural protein sequence alignment. 
ClustalW2 analysis was carried out to align neurogenin and NeuroD sequences from Xenopus 
laevis (x), Mus musculus (m) and Homo sapiens (h).  Exact matches are denoted by * and 
decreasingly similar properties by : and . with no symbol present for no similarity.  – highlights a 
gap in the sequence alignment.  The disordered N-terminal domain is bordered in blue; the bHLH 






Figure 3.6: bHLH proneural protein sequence alignment, continued. 
ClustalW2 analysis was carried out to align neurogenin and NeuroD sequences from Xenopus 
laevis (x), Mus musculus (m) and Homo sapiens (h).  Exact matches are denoted by * and 
decreasingly similar properties by : and . with no symbol present for no similarity.  – highlights a 
gap in the sequence alignment.  The disordered C-terminal domain is bordered in green.  
	  67	  
To	   investigate	   their	  stability,	   35S-­‐radiolabelled	   IVT	  proteins	  of	   these	  xNgn2	  mutants	  were	   added	   to	   Xenopus	   laevis	   interphase	   activated	   egg	   extract	   (Figure	   3.7,	   A)	   and	  




Figure 3.7: Conserved KIKK lysines affect stability of xNgn2. 
Xenopus laevis (A) interphase activated egg or (B) neurula embryo extracts were supplemented 
with 35S-labelled xNgn2, xNgn2KO, xNgn2 mutations of lysine to arginines or xNgn2KO mutations 
of arginines back to lysines as indicated.  Samples were taken at 0, 15, 30, 45, 60, 75, 90 and 120 
mins and subjected to 15 % SDS-PAGE.  The half-life for protein degradation was calculated using 
first-order rate kinetics (C).  Each half-life within an experiment was normalised to xNgn2 within the 
experiment and the ratios of stability compared to xNgn2 averaged.  Errors were calculated using 
the Standard Error of the Mean (SEM).  Experiments in interphase were carried out in triplicate; 
experiments in neurula were carried out in duplicate. 
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These	  experiments	  were	  also	  carried	  out	  in	  neurula	  extract.	  	  In	  neurula	  the	  half-­‐life	  of	  xNgn2	  is	  29.3	  +/-­‐	  2.5	  mins	  compared	  to	  xNgn2KO	  at	  106	  +/-­‐	  11	  mins	  (Figure	  3.7,	  B	  and	  C).	  	  Therefore	  xNgn2KO	  appears	  stabilised	  to	  a	  greater	  extent	  in	  neurula	  than	  in	  interphase,	  where	  it	  has	  a	  half-­‐life	  of	  49.8	  +/-­‐	  0.8	  mins	  (Figure	  3.7,	  C).	  	  Firstly	   the	   individual	   mutations	   of	   lysine	   to	   arginine	   in	   xNgn2	   were	   compared	   in	  neurula	  extract.	  	  K77RxNgn2	  in	  neurula	  has	  a	  half-­‐life	  of	  34.3	  +/-­‐	  12.7	  mins,	  similar	  to	  xNgn2	  whereas	  K79RxNgn2	   and	  K80RxNgn2	   exhibit	   half-­‐lives	   of	   46.1	   +/-­‐	   1.4	  mins	  and	   49.2	   +/-­‐	   11	   mins	   respectively	   which	   are	   significantly	   longer	   than	   xNgn2.	  	  Therefore	  mutation	   of	   lysines	   79	   and	   80	   alone	   has	   a	   stabilising	   effect	   on	   xNgn2	   in	  neurula.	  	  The	  mutants	  of	   lysineless	  xNgn2,	  reintroducing	   lysines	  to	  the	  KIKK	  motif,	  were	  also	  compared.	  	  R79KxNgn2KO,	  R(79,80)KxNgn2KO	  and	  R(77,79,80)KxNgn2KO	  have	  half-­‐lives	  of	  49.8	  +/-­‐	  9.0	  mins,	  50.8	  +/-­‐	  1.3	  mins	  and	  46.4	  +/-­‐	  1.1	  mins	  respectively.	  	  These	  are	   significantly	   shorter	   than	   the	   half-­‐life	   of	   xNgn2KO	   at	   106	   +/-­‐	   11	   mins,	   but	  significantly	   longer	   than	   the	  half-­‐life	   for	  xNgn2	  at	  29.3	  +/-­‐	  2.5	  mins	   (Figure	  3.7,	  C).	  	  This	   suggests	   that	   any	   lysine	   is	   sufficient	   for	   ubiquitylation	   targeting	   xNgn2	   for	  proteasomal	  degradation,	  but	  degradation	  does	  not	  reach	  the	  same	  level	  of	  efficiency	  as	  when	  all	  lysines	  are	  present.	  	  In	  both	  extracts,	  the	  presence	  of	  any	  lysines	  at	  all	  is	  destabilizing.	  	  In	  neurula	  embryo	  extract,	   there	  appears	  to	  be	  a	  small	  yet	  significant	  stabilisation	  relative	  to	  wild	  type	  xNgn2	  on	  removal	  of	  lysines	  79	  and	  80	  –	  but	  not	  77	  –	  and	  the	  individual	  lysine	  knock-­‐ins	  of	  the	  KIKK	  motif	  in	  an	  otherwise	  lysineless	  background	  are	  destabilised	  relative	  to	  xNgn2KO,	  but	  not	  entirely	  to	  the	  level	  of	  xNgn2.	  	  These	  lysines	  are	  ubiquitylated	  in	  neurula	  extract	  but	  cannot	  completely	  destabilise	  the	  otherwise	  lysineless	  xNgn2.	  	  It	  is	  possible	  that	  xNgn2	  may	  be	  able	  to	  bind	  to	  DNA	  in	  these	  extracts,	  which	  is	  present	  at	  much	  higher	  levels	  than	  in	  interphase	  extract.	  	  Binding	  cofactors	  such	  as	  DNA	  may	  stabilise	  the	  folded	  structure	  of	  xNgn2	  and	  protect	  certain	  sites	  from	  ubiquitylation.	  	  Lysine	   85,	   in	   the	   basic	   domain,	   and	   lysines	   116	   and	   119	   in	   the	   Helix-­‐Loop-­‐Helix	  domain	  are	  also	  conserved	  lysine	  residues	  (Figure	  3.6).	  	  The	  single	  knock-­‐out	  of	  K85	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in	  wild	  type	  (K85RxNgn2)	  and	  knock-­‐in	  of	  K85	  into	  the	  otherwise	  lysineless	  protein	  (R85KxNgn2KO)	  were	  used	  to	  investigate	  the	  role	  of	  this	  lysine	  in	  the	  basic	  domain,	  which	   binds	   DNA	   at	   the	   E-­‐box	   consensus	   sequence	   of	   target	   gene	   promoters	  (Bertrand	   et	   al.,	   2002).	   	   The	   role	   of	   lysine	   ubiquitylation	   in	   the	   Helix-­‐Loop-­‐Helix	  domain	   was	   assessed	   by	   using	   lysine	   to	   arginine	   mutants,	   K116RxNgn2	   and	  K119RxNgn2,	   as	   well	   as	   mutants	   reintroducing	   HLH	   lysines	   to	   lysineless	   xNgn2,	  R116KxNgn2KO,	   R119KxNgn2KO	   and	   the	   double	   mutant,	   R(116,119)KxNgn2KO,	  restoring	  HLH	  lysines	  in	  an	  otherwise	  lysine-­‐less	  background.	   	  Lysines	  116	  and	  119	  are	  predicted	  to	  have	  direct	  contact	  with	  the	  DNA	  bound	  by	  the	  active	  xNgn2/xE12	  heterodimer	  (Bertrand	  et	  al.,	  2002).	  	  	  	  To	  assess	  stability	  of	  these	  lysine	  mutants	  degradation	  assays	  in	  both	  Xenopus	  laevis	  fresh	  interphase	  activated	  egg	  (Figure	  3.8,	  A)	  and	  previously	  frozen	  neurula	  embryo	  (Figure	  3.8,	  B)	  extracts	  were	  carried	  out.	  Aliquots	  of	   the	  degradation	  reaction	  were	  removed	  at	  increasing	  timepoints	  into	  quenching	  SDS-­‐LB	  and	  separated	  by	  15	  %	  SDS-­‐PAGE.	   	   Half-­‐lives	   were	   then	   calculated	   from	   three	   repeat	   experiments	   using	   first-­‐order	  rate	  kinetics	  (Figure	  3.8,	  C).	  	  In	  interphase,	  xNgn2	  has	  a	  half-­‐life	  of	  30.3	  +/-­‐	  2.2	  mins,	  K85RxNgn2	  has	  a	  half-­‐life	  of	  29.2	   +/-­‐	   0.5	   mins	   and	   R85KxNgn2KO	   exhibits	   a	   half-­‐life	   of	   31.6	   +/-­‐	   1.4	   mins.	  	  However	   xNgn2KO	   is	   degraded	  more	   slowly	   than	   these	   proteins	  with	   a	   half-­‐life	   of	  49.8	  +/-­‐	  0.8	  mins	  (Figure	  3.8,	  C).	   	  In	  interphase,	  lysine	  85	  shows	  no	  effect	  on	  xNgn2	  stability	  (Figure	  3.8,	  A).	  	  Mutation	  of	  this	  lysine	  to	  arginine	  in	  xNgn2	  does	  not	  stabilise	  the	  protein	  suggesting	  it	   is	  not	  required	  for	  xNgn2	  proteasomal	  degradation.	   	  When	  lysine	  85	  is	  the	  only	   lysine	  reintroduced	  into	  xNgn2KO,	   it	   is	  sufficient	  to	  allow	  UPS-­‐mediated	  degradation	  as	  the	  stability	  returns	  to	  wild	  type	  levels	  once	  more.	  	  In	  another	   interphase	  experiment,	  xNgn2	   is	  again	   less	  stable	   than	  xNgn2KO	  (with	  a	  half-­‐life	  of	  25.8	  +/-­‐	  5.3	  mins	  compared	  to	  43.4	  +/-­‐	  2.3	  mins	  (Figure	  3.8,C)).	  	  The	  half-­‐lives	   of	   the	   HLH	   lysine	   mutants	   R116KxNgn2KO,	   R119KxNgn2KO	   and	  R(116,119)KxNgn2KO	   (32.8	   +/-­‐	   3.2	  mins,	   37.3	   +/-­‐	   3.0	  mins	   and	   33.0	   +/-­‐	   5.2	  mins	  respectively)	   lie	   between	   the	   values	   of	   the	  wild	   type	   or	   lysineless	   proteins	   (Figure	  3.8,	  C).	  	  The	  presence	  of	  either	  lysine	  in	  xNgn2KO	  results	  in	  a	  protein	  intermediate	  in	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Figure 3.8: bHLH lysines affect stability of xNgn2. 
Xenopus laevis (A) interphase activated egg or (B) neurula embryo extracts were supplemented 
with 35S-labelled xNgn2, xNgn2KO, xNgn2 mutations of lysine to arginines or xNgn2KO mutations 
of arginines back to lysines as indicated.  Samples were taken at 0, 15, 30, 45, 60, 75, 90 and 120 
mins and subjected to 15 % SDS-PAGE. The half-life for protein degradation was calculated using 
first-order rate kinetics (C).  Each half-life within an experiment was normalised to xNgn2 within the 
experiment and the ratios of stability compared to xNgn2 averaged (A), (B).  Errors were calculated 



































































































































































































































Figure 3.9: bHLH lysines affect stability of xNgn2 in neurula. 
Xenopus laevis neurula embryo extracts, either A) previously frozen or (B) fresh, were 
supplemented with 35S-labelled xNgn2, xNgn2KO, xNgn2 mutations of lysine to arginines or 
xNgn2KO mutations of arginines back to lysines as indicated.  Samples were taken at 0, 15, 30, 
45, 60, 75, 90 and 120 mins and subjected to 15 % SDS-PAGE. Each half-life within an experiment 
was normalised to xNgn2 within the experiment and the ratios of stability compared to xNgn2 
averaged.  Errors were calculated using the Standard Error of the Mean (SEM).  The frozen extract 




hint	   at	   a	  possible	   subtle	  difference	  between	   the	   ability	   of	  K116	  and	  K119	   to	   target	  xNgn2	  for	  degradation	  (Figure	  3.9,	  B).	  This	  would	  suggest	  K116	  is	  a	  preferential	  site	  for	   modification	   by	   ubiquitylation	   compared	   to	   K119.	   	   However	   this	   apparent	  difference	  is	  not	  significant	  using	  the	  Standard	  Error	  of	  the	  Mean	  (SEM).	  
	  











Figure 3.10: bHLH lysines do not restore DNA-binding in Electrophoretic Mobility Shift 
Assay (EMSA). 
IVT xNgn2, xNgn2KO, xNgn2KO mutations of arginines back to lysines as indicated and 9S-
AxNgn2, which contains no serine-proline motifs but only alanine-proline, were incubated in extract 
buffer (XB) or Xenopus laevis activated interphase or mitotic extracts, with 32P-labelled E-box DNA 
probe.  Samples were separated by SDS-PAGE and analysed by autoradiography.  ‘*’ denotes 
position of heterodimer bound to DNA probe.  n = 1. 
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xNgn2KO	   is	   less	   active	   in	   vivo	   than	   xNgn2	   but	   is	   not	   a	   dominant	   negative	  
repressor	  	  xNgn2	   is	   stabilised	   when	   all	   lysines	   are	   mutated	   to	   arginines	   to	   form	   xNgn2KO	  (Figure	  3.4)	  but	  these	  mutations	  reduce	  binding	  to	  DNA	  in	  EMSA	  (Figure	  3.10).	  	  These	  results	   suggest	   that	   the	  protein	  may	  be	  more	   stable	  but	  binds	   to	  promoter	   regions	  less	  tightly.	  	  Hence,	  it	  is	  hard	  to	  predict	  its	  effect	  on	  xNgn2	  activity	  in	  vivo.	  	  To	  test	  this,	  xNgn2	  or	  xNgn2KO	  mRNA	  was	  injected	  into	  Xenopus	  laevis	  embryos	  (with	  GFP	  as	  an	  injection	  control)	  to	  assess	  in	  vivo	  activity	  by	  in	  situ	  hybridization	  (ISH).	  	  mRNA	  was	  injected	   into	   stage	   2	   Xenopus	   laevis	   embryos,	   which	   were	   allowed	   to	   develop	   and	  were	   fixed	   at	   stage	   15	   (Nieuwkoop	   and	   Faber,	   1994).	   	   Ectopic	   neurogenesis	   was	  assessed	  using	  levels	  of	  neural	  β-­‐tubulin	  expression	  revealed	  by	  ISH	  and	  comparing	  this	  expression	  in	  the	  injected	  side	  of	  the	  embryo	  to	  the	  uninjected	  side	  (Figure	  3.11,	  scale	  of	  neurogenesis	  defined	  in	  Figure	  2.3).	  	  	  	  Compared	  to	  the	  control	  GFP	  injection,	  injection	  of	  xNgn2	  leads	  to	  extensive	  ectopic	  neurogenesis	   as	   assessed	   by	   levels	   of	   neural	   β-­‐tubulin	   expression	   (Figure	   3.11).	  	  xNgn2KO	  mRNA	  microinjection	   also	   results	   in	   ectopic	  neurogenesis,	   but	   it	   shows	  a	  reduced	   activity	   compared	   to	   xNgn2.	   	   Therefore	   increased	   stability,	   by	   loss	   of	  canonical	  ubiquitylation	  sites,	  does	  not	  translate	  directly	  into	  increased	  activity.	  	  This	  may	  be	  because	  lysine	  mutation	  reduces	  the	  ability	  of	  xNgn2	  to	  bind	  DNA.	  	  Inhibitor	  of	  differentiation	  (Id)	  proteins	  prevent	  transcription	  factor	  activity	  of	  bHLH	  heterodimeric	   complexes	   (Sun	   and	   Baltimore,	   1991).	   	   They	   bind	   E2A	   proteins	   but	  lack	  basic	  domains	  and	  so	  are	  unable	  to	  bind	  DNA.	  	  It	  is	  possible	  that	  xNgn2KO	  may	  be	   able	   to	   act	   as	   a	   dominant	   negative	   repressor	   of	   xNgn2	   neurogenic	   activity	   by	  preventing	   DNA	   binding	   by	   the	   heterodimer	   in	   an	   analogous	   fashion.	   	   To	   check	  whether	   this	   is	   the	   case,	   xNgn2	   and	   xNgn2KO	  mRNA	  were	   coinjected	   into	  Xenopus	  













Figure 3.11: xNgn2KO has reduced activity in vivo compared to xNgn2 with respect to 
neural β-tubulin induction. 
20 pg GFP, xNgn2 or xNgn2KO mRNA were coinjected with 500 pg β-galactosidase mRNA into 1 
cell of Stage 2 embryos and allowed to develop to stage 15.  Embryos were then fixed and in situ 
hybridization (ISH) performed for neural β-tubulin.  Embryos were scored according to the extent of 











































	  	  	  	  	  
	  	  	  
 
 
Figure 3.12: xNgn2KO does not act as a dominant negative inhibitor of neurogenesis. 
GFP, xNgn2 or xNgn2KO mRNA were coinjected with 500 pg β-galactosidase mRNA into 1 cell of 
Stage 2 embryos at the levels indicated and allowed to develop to stage 15.  Embryos were then 
fixed and in situ hybridization (ISH) performed for neural β-tubulin.  Embryos were scored 





























































































ISH	   and	   comparing	   this	   expression	   in	   the	   injected	   side	   of	   the	   embryo	   to	   the	  uninjected	  side	  (Figure	  3.12).	  	  	  	  xNgn2KO	  induces	  less	  ectopic	  neurogenesis	  than	  xNgn2	  (as	  in	  Figure	  3.11)	  but	  this	  is	  less	  obvious	  when	  higher	   concentrations	  of	   xNgn2KO	  are	   injected	   (see	  Figure	  3.11,	  75	   pg).	   	   Co-­‐injection	   of	   xNgn2	   and	   xNgn2KO	   together	   induce	   greater	   neurogenesis	  than	   xNgn2	   alone	   (Figure	   3.12).	   	   Therefore	   the	   xNgn2KO	  mutant	   is	   not	   acting	   as	   a	  dominant	  negative	  inhibitor	  of	  neurogenesis.	  	  Mutation	   of	   lysines	   of	   xNgn2	   reduces	   its	   ability	   to	   induce	   ectopic	   neurogenesis	   as	  assayed	   by	   neural	   β-­‐tubulin	   expression	   (Figure	   3.11)	   but	   to	   see	   if	   any	   effects	   are	  observed	  on	  a	  direct	  target	  of	  xNgn2,	  xNeuroD	  expression	  was	  investigated.	  	  20	  pg	  of	  xNgn2	  or	   xNgn2KO	  were	   injected	   into	   stage	   2	  Xenopus	   laevis	   embryos	   and	   fixed	   at	  stage	   15	   (Nieuwkoop	   and	   Faber,	   1994).	   	   ISH	   for	   xNeuroD	  was	   performed	   and	   the	  extent	   of	   ectopic	   xNeuroD	   expression	   scored	   (Figure	   3.13,	   scoring	   scale	   defined	   in	  Figure	  2.3).	  	  	  	  xNgn2KO	   induces	   less	   xNeuroD	   expression	   than	   xNgn2	   (Figure	   3.13).	   	   Therefore	  xNgn2KO	  acts	  as	  a	   less	  active	   form	  of	  xNgn2	   from	  the	  very	  earliest	  points	  at	  which	  xNgn2	  exerts	  its	  activity.	  	  
DISCUSSION	  	  The	  aim	  of	  the	  experiments	  presented	  in	  this	  chapter	  was	  firstly	  to	  establish	  the	  role	  of	  proteasomal	  degradation	  in	  xNgn2	  instability	  and	  secondly	  to	  determine	  whether	  specific	   residues	   were	   responsible	   for	   directing	   Ub-­‐mediated	   proteolysis.	   	   In	  particular	  I	  investigated	  the	  lysine	  residues	  of	  xNgn2,	  which	  are	  characterised	  in	  the	  literature	   as	   canonical	   sites	   of	   substrate	   protein	   ubiquitylation	   targeting	   for	   UPS-­‐mediated	  degradation.	  	  
Xenopus	   laevis	   extract	   systems	   provide	   a	   convenient	   assay	   system	   for	   analysis	   of	  proteasomal	   degradation	   of	   proteins.	   	   xNgn2	   (Figure	   3.1),	   xNgn3	   (Figure	   3.2)	   and	  xMyoD	  (Figure	  3.4,	  A)	  are	  degraded	  in	  Xenopus	  laevis	  extract	  and	  in	  a	  proteasome-­‐	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Figure 3.13: xNgn2KO induces lower levels of xNeuroD than xNgn2. 
20 pg xNgn2 or xNgn2KO mRNA were coinjected with 500 pg β-galactosidase mRNA into 1 cell of 
Stage 2 embryos (Nieuwkoop and Faber, 1994) and allowed to develop to stage 15.  Embryos 
were then fixed and in situ hybridization (ISH) performed for xNeuroD.  Embryos were scored 









































dependent	   manner	   (Figure	   3.1).	   	   These	   results	   demonstrate	   that	   the	   use	   of	  radiolabelled	   IVT	   proteins	   in	   extract	   systems	   allows	   a	   quick	   assay	   to	   investigate	  stability,	   with	   robust	   reproducible	   results,	   and	   that	   bHLH	   proteins	   can	   be	   rapidly	  degraded	  in	  extract.	  	  Canonical	  ubiquitylation	  is	  regarded	  as	  a	  transfer	  of	  Ub	  from	  a	  thiol	  linkage	  on	  the	  E2	  Ub-­‐conjugating	  enzyme	  to	  an	  internal	  lysine	  residue	  on	  the	  substrate	  protein,	  forming	  an	  isopeptide	  linkage	  (Mayer,	  2005).	  In	  some	  proteins	  there	  are	  specific	  lysines	  that	  target	  for	  Ub-­‐mediated	  proteolysis	  (Baldi	  et	  al.,	  1996)	  whilst	  in	  other	  proteins	  several	  or	  any	  lysines	  are	  used	  for	  ubiquitylation	  (King	  et	  al.,	  1996).	  	  xNgn2	  contains	  8	  lysine	  residues	  (Figure	  3.3).	  	  Figure	  3.5	  shows	  that	  mutation	  of	  any	  single	  lysine	  has	  no	  appreciable	  effect	  on	  the	  rate	  of	  xNgn2	  degradation.	  	  Therefore	  no	  individual	  lysine	  residue	  is	  essential	  for	  Ub-­‐mediated	  targeting	  of	  xNgn2	  for	  UPS-­‐mediated	  degradation.	  	  However	  mutation	  of	  all	  8	   lysines	   simultaneously	   results	   in	   marked	   stabilisation	   of	   xNgn2	   indicating	  redundancy	  in	  sites	  of	  ubiquitylation.	  	  Possibly	   there	   is	   non-­‐selective	   ubiquitylation	   of	   any	   lysine	   residue	   in	   the	   protein,	  which	  can	  then	  target	  for	  proteasomal	  degradation	  as	  has	  been	  described	  for	  cyclin	  B	  degradation	   by	   APC/CCdc20	   (King	   et	   al.,	   1996).	   	   It	   is	   possible	   that	   ubiquitylation	  usually	   occurs	   on	   a	   particular	   lysine	   residue,	   but	   once	   that	   lysine	   is	   mutated	   the	  ubiquitylation	  process	  can	  be	  easily	  switched	  to	  another	  lysine	  residue.	   	   It	  may	  also	  be	   the	   case	   that	   modification	   of	   more	   than	   one	   lysine	   is	   important	   in	   regulating	  stability.	  	  This	  was	  the	  rationale	  behind	  adding	  back	  individual	  lysines	  in	  a	  lysineless	  background	  as	  discussed	  below.	  	  	  	  When	  all	  the	  lysines	  are	  mutated	  to	  arginines	  in	  xNgn2KO	  we	  see	  an	  increase	  in	  the	  half-­‐life	  of	  the	  protein	  and	  so	  we	  can	  postulate	  that	  mutating	  all	  the	  lysines	  stabilises	  xNgn2.	   	   However,	   this	   increased	   half-­‐life	   is	   still	   only	   around	   40	   minutes	  (approximately	   double	   that	   of	   the	   wild	   type	   protein)	   and	   so	   xNgn2KO	   is	   still	   an	  unstable	  protein.	  	  Work	  by	  Jonathan	  Vosper	  suggested	  a	  role	  for	  other	  non-­‐canonical	  sites	   of	   ubiquitylation	   and	   this	   is	   work	   discussed	   both	   in	   the	   next	   chapter	   and	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(Vosper,	   2008,	   Vosper	   et	   al.,	   2009).	   	   The	   degradation	   assays	   for	   single	   lysine	   to	  arginine	  mutants	  of	  xNgn2	  (Figure	  3.5)	  were	  carried	  out	  in	  Xenopus	  laevis	  interphase	  activated	  egg	  extract.	  	  Later	  experiments	  with	  single	  lysine	  to	  arginine	  xNgn2	  mutants	  in	  neurula	  embryo	  extract	  hint	  at	  a	  difference	   in	  stabilisation	   in	   this	  extract	  system	  and	   so	   a	   systematic	   analysis	   of	   all	   xNgn2	   lysine	   to	   arginine	   mutants	   in	   neurula	  embryo	  extracts	  would	  be	  desirable.	  	  Lysines	  in	  xNgn2	  conserved	  amongst	  related	  bHLH	  proteins	  –	  namely	  77,	  79	  and	  80	  (the	  KIKK	  motif)	  and	  the	  bHLH	  lysines	  85,	  116	  and	  119	  –	  were	  assessed	  for	  their	  role	  in	  xNgn2	  stability	  in	  interphase	  and	  neurula	  extract	  degradation	  assays	  (Figures	  3.7,	  3.8	  and	  3.9).	  	  The	  lysine	  77,	  79,	  80	  ‘KIKK’	  motif,	  and	  K85,	  destabilise	  xNgn2KO	  to	  the	  level	   of	   xNgn2.	   	  However,	   in	  both	   interphase	   and	  neurula	   extracts,	   lysines	  116	  and	  119	  alone	  are	  not	  sufficient	  to	  target	  for	  destruction	  at	  the	  same	  rate	  as	  the	  wild	  type	  protein.	   	   Restoration	   of	   lysines	   in	   the	   ‘KIKK’	   motif	   does	   target	   xNgn2	   for	   efficient	  degradation	  whereas	  K116	  and	  K119	  do	  not.	  	  	  The	  ‘KIKK’	  lysines	  are	  not	  implicated	  in	  DNA	  binding.	  	  Lysine	  85,	  in	  the	  basic	  domain,	  is	   directly	   implicated	   in	   DNA	   binding,	   whilst	   lysines	   116	   and	   119	   are	   proposed	   to	  contact	  DNA	  in	  the	  E-­‐box	  (Bertrand	  et	  al.,	  2002).	  	  This	  might	  explain	  the	  difference	  in	  stability	  in	  neurula	  extract,	  which	  has	  a	  higher	  DNA	  content	  than	  egg	  extract.	  	  Binding	  of	   xNgn2	   to	   DNA	   may	   preclude	   ubiquitylation	   of	   lysines	   85,	   116	   and	   119	   thus	  stabilising	   xNgn2	   (Figure	   3.9).	   	   However	   lysines	   116	   and	   119	   destabilise	   xNgn2KO	  less	  than	  reintroduction	  of	  other	  lysine	  residues	  (Figure	  3.8)	  and	  this	  may	  be	  due	  to	  their	   location	   in	   the	  HLH	  domain,	   the	  only	  putative	  structured	  region	   in	   the	   largely	  unstructured	  bHLH	  proteins	   (McEwan	  et	  al.,	  1996).	   	  Whilst	  xNgn2	   is	  most	   likely	  an	  intrinsically	   disordered,	   natively	   unfolded	   protein	   (Aguado-­‐Llera	   et	   al.,	   2010),	   the	  HLH	   lysines	  may	  still	  be	  unavailable	   for	  ubiquitylation	  by	  being	  present	   in	  a	  region	  that	   tends	   towards	   lower	   disorder.	   	   The	   lysine-­‐rich	   N-­‐terminus	   is	   predicted	   to	   be	  highly	   disordered	   and	   so	   may	   provide	   more	   available	   sites	   for	   canonical	  ubiquitylation.	   	   However	  my	   results	   suggest	   that	   degradation	   of	   xNgn2	   can	   still	   be	  mediated	  by	   the	  HLH	   lysines	  and	  most	   likely	  by	  polyubiquitylation.	   	  This	  might	  not	  have	  been	  expected	  of	   lysine	  residues	   in	  the	  only	  region	  of	  the	  protein	  that	   forms	  a	  structured	  motif,	  but	  is	  perhaps	  unsurprising	  in	  such	  a	  highly	  disordered	  protein.	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In	   Figure	   3.10,	   EMSA	   shows	   that	   whilst	   wild	   type	   xNgn2	   can	   bind	   DNA	   in	   the	  presence	   of	   xE12	   in	   interphase,	   the	   9S-­‐AxNgn2	   phosphomutant	   can	   bind	   in	   both	  interphase	  and	  mitosis.	   	  However	  the	  lysineless	  xNgn2KO	  is	  reduced	  in	  its	  ability	  to	  bind	   DNA,	   and	   reintroducing	   lysines	   116	   or	   119	   to	   xNgn2KO	   does	   not	   increase	  binding	  in	  interphase	  and	  mitotic	  extract.	   	  This	  result	  could	  suggest	  that	  each	  lysine	  on	   its	   own	   is	   not	   sufficient	   to	   support	   binding	   so	   perhaps	   investigation	   of	  R(116,119)KxNgn2KO	   –	   the	   double	   knock-­‐in	   of	   the	   HLH	   lysines	   –	   would	   show	  whether	  both	  are	  required.	  	  However	  efficient	  DNA	  binding	  may	  require	  the	  action	  of	  K85,	  or	  all	  3	  lysines	  in	  the	  bHLH	  domain,	  or	  even	  others	  besides.	  	  	  The	   EMSA	   result	   also	   seems	   to	   contradict	   Figure	   5	   of	   (Vosper	   et	   al.,	   2009),	  where	  xNgn2KO	   and	   indeed	   all	   mutant	   forms	   of	   xNgn2	   appear	   to	   bind	   to	   DNA	   in	   the	  presence	   of	   xE12	   in	   EMSA	   with	   similar	   affinities.	   	   However	   in	   those	   particular	  experiments,	   no	   Xenopus	   laevis	   extract	   incubation	   was	   used,	   only	   IVT	   protein	   and	  radiolabelled	   DNA	   probe	   in	   extract	   buffer	   (XB	   buffer)	   with	   large	   volumes	   of	   IVT	  protein	   (Christopher	   Hindley,	   personal	   communication).	   	   Therefore	   under	   those	  conditions	  it	  may	  be	  that	  binding	  is	  still	  possible,	  whereas	  the	  conditions	  I	  have	  used	  are	  different.	  	  For	  example,	  it	  is	  possible	  that	  lysines	  are	  already	  ubiquitylated	  when	  extract	  is	  used	  and	  therefore	  unable	  to	  bind	  DNA.	  	  The	  appearance	  of	  binding	  in	  the	  absence	  of	  extract,	  but	  no	  binding	  with	   incubation	   in	  extract,	  could	  suggest	  extract-­‐dependent	   PTM	   –	   for	   example,	   ubiquitylation	   or	   phosphorylation	   –	   which	   impairs	  binding.	  	  In	  theory,	  xNgn2KO	  should	  still	  bind	  DNA	  as	  all	  lysines	  have	  been	  replaced	  with	   arginines,	   which	   whilst	   lacking	   the	   nucleophilic	   amine	   group	   required	   for	  ubiquitylation	  still	  maintain	  the	  positive	  charge	  that	  would	  be	  required	  for	  a	  strong	  DNA-­‐binding	  interaction.	  	  Finally	  it	  should	  be	  noted	  that	  this	  EMSA	  result	  is	  preliminary	  as	  it	  has	  been	  carried	  out	  only	  once	  and	  so	  whilst	  being	  indicative	  of	  the	  binding	  affinity	  of	  the	  HLH	  lysine	  mutant	  proteins,	  should	  not	  be	  taken	  as	  a	  conclusive	  result.	  	  As	  discussed,	  work	  by	  Christopher	  Hindley	  in	  EMSA	  has	  shown	  that	  xNgn2KO	  can	  still	  potentially	  bind	  to	  an	  E-­‐box	  oligonucleotide	  (Vosper	  et	  al.,	  2009).	  	  Therefore	  it	  might	  be	  assumed	  that	  the	  lysineless	  protein	  is	  active	  in	  vivo.	  	  However,	  work	  carried	  out	  by	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Helen	  Wise	   in	  mRNA	  microinjections	  of	  Xenopus	   laevis	  embryos	  has	  suggested	  that	  xNgn2KO	   is	   significantly	   impaired	   in	   its	   ability	   to	   induce	   primary	   neurons	   as	  compared	   to	   the	   wild	   type	   protein	   (Helen	   Wise,	   unpublished	   data).	   	   My	   own	  injections	  of	  xNgn2KO	  would	  suggest	  that	  xNgn2KO	  is	  less	  active	  than	  xNgn2	  but	  not	  inactive	  (Figures	  3.11,	  3.12,	  3.13).	   	  However	  I	  am	  typically	  injecting	  higher	  amounts	  of	  xNgn2KO	  mRNA	  (≥	  20	  pg)	  than	  Helen	  Wise	  (10	  pg),	  which	  result	  in	  greater	  activity	  of	   xNgn2KO.	   	   Nevertheless,	   xNgn2KO	   shows	   comparatively	   less	   activity	   than	   wild	  type	   xNgn2.	   	   It	   is	   possible	   that	   lysine	   residues,	   aside	   from	   acting	   as	   sites	   of	  ubiquitylation	   targeting	   for	  proteasomal	  degradation,	   are	   also	   acting	   at	   the	   level	   of	  transcription	   factor	   activity	   in	   xNgn2	   in	   a	   structural	  manner	   not	   related	   to	   protein	  stability.	  Otherwise	  we	  would	  hypothesise	   that	  a	  more	  stable	   form	  of	  xNgn2	  would	  also	  be	  more	  active.	  	  xNgn2KO	  is	  less	  active	  than	  xNgn2	  at	  inducing	  	  neural	  β-­‐tubulin	  expression	   (Figure	   3.11)	   and	   at	   inducing	   its	   downstream	   target	   xNeuroD	   (Figure	  3.13)	   therefore	  xNgn2KO	  is	   less	  active	  as	  a	   transcription	   factor.	   	  xNgn2KO	  does	  not	  appear	   to	   act	   as	   a	   dominant	   negative	   repressor	   of	   xNgn2	   activity	   by	   sequestering	  xE12	  without	  binding	  DNA,	  as	  xNgn2	  can	  still	  promote	  ectopic	  neurogenesis	  even	  in	  the	  presence	  of	  xNgn2KO	  (Figure	  3.12).	  	  	  	  My	  data	  indicate	  that	  ubiquitylation	  can	  occur	  on	  most	  or	  all	  lysines	  to	  target	  xNgn2	  for	   destruction.	   	   Firstly,	   although	   reintroduction	   of	   ubiquitylation	   sites	   seems	   the	  most	   likely	   cause	  of	   instability,	   other	   factors	   such	  as	  effects	  on	   the	   structure	  of	   the	  protein	  cannot	  be	  ruled	  out.	  	  Mass	  spectrometry	  could	  be	  used	  to	  definitively	  identify	  ubiquitylation	  at	  these	  sites.	  	  Also,	  it	  is	  thus	  far	  not	  clear	  whether	  these	  are	  consensus	  sites	   for	   ubiquitylation	   or	  whether	   the	   ubiquitylation	  machinery	   is	   so	   promiscuous	  that	  any	  lysine	  is	  suitable	  for	  targeting	  for	  degradation.	  	  Certainly	  mutating	  individual	  lysines	   to	   arginines	   showed	   no	   individual	   lysine	   is	   essential	   to	   target	   xNgn2	   for	  degradation	  (Figure	  3.5).	  	  xNgn2KO	  is	  still	  unstable,	  with	  a	  half-­‐life	  of	  only	  47.8	  +/-­‐	  7.9	  mins	  (Figure	  3.4,	  B)	  and	  work	  by	   Jonathan	  Vosper	  established	   that	  ubiquitylation	  of	   xNgn2	   still	   occurs	  even	  when	  all	   lysines	   are	  mutated	   (Vosper	  et	   al.,	   2009).	   	  Therefore	   the	  next	   step	  was	   to	  investigate	  where	  else	  ubiquitylation	  targeting	  xNgn2	  for	  degradation	  was	  occurring.	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CHAPTER	  4	  
Non-­Canonical	  Ubiquitylation	  of	  xNgn2	  
	  
	  
INTRODUCTION	  	  The	   ubiquitylation	   of	   proteins	   canonically	   takes	   place	   on	   internal	   lysine	   residues.	  	  However	  for	  an	  increasing	  number	  of	  proteins,	  ubiquitylation	  on	  other	  sites	  has	  been	  demonstrated.	   	   Modification	   of	   the	   N-­‐terminus	   by	   polyubiquitylation	   to	   target	   for	  proteasomal	   degradation	   has	   been	   described	   and	   even	   proteins	   with	   all	   lysines	  mutated	   to	   arginines	   are	   ubiquitylated	   and	   degraded	   (Ben-­‐Saadon	   et	   al.,	   2004,	  Breitschopf	   et	   al.,	   1998).	   	   Where	   ubiquitylation	   is	   still	   required	   for	   proteasomal	  degradation,	   N-­‐terminal	   ubiquitylation	   can	   be	   invoked.	   	   There	   are	   also	   naturally	  occurring	   lysineless	   proteins	   where	   N-­‐terminal	   ubiquitylation	   has	   been	   suggested	  (Ben-­‐Saadon	   et	   al.,	   2004).	   	   Ubiquitylation	   on	   the	   N-­‐terminal	   amine	   group	   is	  chemically	  identical	  to	  lysine	  ubiquitylation	  (Figure	  4.1,	  A).	  	  In	   fact,	  Aaron	  Ciechanover	  makes	  the	  point	  himself	   that	  many	  proteins	  are	  wrongly	  assumed	  to	  be	  ubiquitylated	  only	  on	  lysines.	  	  The	  evidence	  for	  lysine	  ubiquitylation	  is	  often	   indirect	  evidence	  based	  on	  mutational	  analyses.	   	  Chromatographic	   techniques	  or	  mass	   spectroscopy	   are	   suggested	   to	   be	   the	   only	  methods	   of	   directly	   identifying	  ubiquitylation	  sites	  (Chapter	  2	  in	  (Mayer,	  2005)).	  	  xNgn2	   protein	   stability	   increases	   when	   lysine	   residues,	   the	   canonical	   sites	   of	  ubiquitylation,	  are	  no	  longer	  available.	  	  However	  xNgn2KO,	  the	  form	  of	  xNgn2	  with	  all	  lysines	  mutated	  to	  arginines,	  is	  still	  an	  unstable	  protein.	  	  Moreover	  ubiquitylation	  of	  xNgn2	   could	   still	   be	   observed	   by	   Jonathan	  Vosper	   (Vosper	   et	   al.,	   2009)	   and	   I	   have	  demonstrated	   that	   no	   particular	   lysine	   residue	   shows	   particular	   prominence	   as	   a	  regulator	   of	   xNgn2	   stability,	   as	   is	   often	   observed	   in	   proteins	   demonstrating	   N-­‐terminal	  ubiquitylation.	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xNgn2	  N-­terminal	  ubiquitylation	  is	  blocked	  by	  co-­translational	  acetylation	  	  Acetylation	  and	  ubiquitylation	  on	  specific	   residues	  are	  mutually	  exclusive	   reactions	  in	  the	  cell	  (Polevoda	  and	  Sherman,	  2000,	  Polevoda	  and	  Sherman,	  2002)	  (Figure	  4.2).	  	  To	   assess	   whether	   N-­‐terminal	   ubiquitylation	   in	   xNgn2	   is	   possible,	   a	   series	   of	   N-­‐terminal	  cotranslational	  acetylation	  mutants	  was	  constructed.	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Figure 4.1: Nucleophilic sites of ubiquitylation. 
Proteins contain many nucleophilic sites capable of attacking an E2-Ub thioester linkage and 
becoming ubiquitylated.  The best-described sites are (A) the amine-containing internal lysine 
residues and the free amine of the N-terminus of the polypeptide backbone.  However (B) cysteine 
thiols and (C) hydroxyls on serines, threonines and tyrosines could also potentially be ubiquitylated 
by an identical mechanism. 
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Figure 4.2: N-terminal acetylation and ubiquitylation are mutually exclusive reactions. 
The N-terminal amine group of polypeptides can potentially either be (A) ubiquitylated or (B) 
acetylated. 
	  89	  
N-­‐terminal	  consensus	  sequences	  can	  target	  a	  protein	  for	  co-­‐translational	  acetylation	  with	  high	  probability	  (Polevoda	  and	  Sherman,	  2003b,	  Polevoda	  and	  Sherman,	  2003a)	  and	   so	   constructs	   were	   designed	   by	   Jonathan	   Vosper	   and	   Ian	   Horan	   to	   both	  potentiate	  and	  inhibit	  co-­‐translational	  acetylation;	  Ac1xNgn2	  (mutation	  of	  N-­‐terminal	  sequence	   from	   MVLL	   to	   MSES);	   Ac2xNgn2	   (mutation	   of	   MVLL	   to	   MAES)	   and	  Ac3xNgn2	  (mutation	  of	  MVLL	  to	  MPLL).	  	  Ac1xNgn2	  and	  Ac2xNgn2	  are	  both	  predicted	  to	  be	  acetylated	  whilst	   co-­‐translational	   acetylation	   should	  be	  blocked	   in	  Ac3xNgn2.	  	  The	   effect	   of	   the	  Ac3	  mutation	   cannot	   necessarily	   be	   predicted.	   	   The	  presence	   of	   a	  proline	   at	   the	  N-­‐terminus	   of	   β-­‐galactosidase	   stabilises	   the	   protein	   (Bachmair	   et	   al.,	  1986)	   whereas	   addition	   of	   a	   non-­‐cleavable	   Ub	   moiety	   to	   the	   N-­‐terminus	   is	  destabilizing	  (Johnson	  et	  al.,	  1992).	  	  	  Work	  on	  the	  stability	  of	  acetylation	  mutants	  has	  been	  carried	  out	  previously,	  showing	  that	  blocking	  the	  N-­‐terminus	  by	  co-­‐translational	  acetylation	  stabilises	  xNgn2	  and	  that	  an	   acetylated	   form	   of	   xNgn2	   with	   all	   lysines	   mutated	   to	   arginines	   shows	   an	   even	  greater	   increase	   in	   stability	   (Vosper	   et	   al.,	   2009).	   	   To	   investigate	   whether	   co-­‐translational	  acetylation	  is	  being	  regulated	  as	  predicted	  in	  the	  acetylation	  constructs,	  I	  blocked	  protein	  acetylation	  during	   in	  vitro	   translation	  and	  performed	  degradation	  assays	  using	  Xenopus	  laevis	  interphase	  activated	  egg	  extracts.	  	  Acetylation	   was	   blocked	   according	   to	   the	   method	   of	   Palmiter	   (Palmiter,	   1977).	  	  Addition	   of	   citrate	   synthase	   and	   oxaloacetate	   depletes	   the	   acetyl	   CoA	   within	   the	  reticulocyte	  lysate	  and	  metabolises	  it	  to	  citrate.	  	  Therefore	  there	  is	  no	  available	  Acetyl	  CoA	  for	  protein	  acetylation.	  	  This	  treated	  reticulocyte	  lysate	  was	  then	  used	  for	  in	  vitro	  translation	  followed	  by	  degradation	  assays.	  	  Acetylation	  blocking	  experiments	  were	  carried	  out	  using	   lysineless	   forms	  of	  xNgn2.	  	  In	  xNgn2KO	  all	  lysines	  are	  mutated	  to	  arginines,	  thereby	  removing	  the	  possibility	  of	  ubiquitylation	  on	   lysines.	   	   In	  Ac2xNgn2KO,	   the	  N-­‐terminus	  of	   the	   lysineless	  protein	  has	   been	   mutated	   to	   the	   co-­‐translational	   acetylation	   consensus	   sequence;	   and	   in	  Ac3xNgn2KO,	   the	   N-­‐terminus	   of	   the	   lysineless	   protein	   has	   been	   mutated	   to	   a	  sequence	   associated	   with	   repression	   of	   co-­‐translational	   acetylation.	   	   Radiolabelled	  proteins	   were	   translated	   in	   vitro	   in	   reticulocyte	   lysate	   depleted	   of	   Acetyl	   CoA	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(Palmiter,	   1977)	   and	   added	   to	   Xenopus	   laevis	   interphase	   activated	   egg	   extracts.	  	  Aliquots	   of	   the	   degradation	   reaction	   were	   removed	   at	   increasing	   timepoints	   into	  quenching	   SDS-­‐LB	   and	   separated	   by	   15	   %	   SDS-­‐PAGE.	   	   Half-­‐lives	   for	   the	   rates	   of	  degradation	  were	  then	  calculated	  using	  first-­‐order	  rate	  kinetics	  (Figure	  4.3).	  	  	  xNgn2KO	  has	  a	  half-­‐life	  of	  60.9	  +/-­‐	  15.7	  mins	  in	  acetylation	  blocking	  conditions	  and	  a	  half-­‐life	   of	   67.8	   +/-­‐	   19.2	  mins	  without	   acetylation	  blocking.	   	   Ac3xNgn2KO	  has	  half-­‐lives	  of	  53.7	  +/-­‐	  11.4	  mins	  and	  41.2	  +/-­‐	  6.6	  mins	   in	  the	  same	  respective	  conditions.	  	  Therefore	  these	  proteins	  show	  similar	  half-­‐lives	  to	  one	  another	  and	  no	  stabilisation	  when	  cotranslational	  acetylation	  is	  blocked.	  	  Ac2xNgn2KO	  is	  more	  stable	  than	  xNgn2KO	  or	  Ac3xNgn2KO	  in	  the	  control	  experiment	  (91.4	   +/-­‐	   10.1	   mins	   compared	   to	   67.8	   +/-­‐	   19.2	   mins	   and	   41.2	   +/-­‐	   6.6	   mins	  respectively)	   but	   when	   acetylation	   is	   blocked,	   Ac2xNgn2KO,	   xNgn2KO	   and	  Ac3xNgn2KO	   all	   have	   similar	   half-­‐lives	   (42.5	   +/-­‐	   5.9	  mins,	   60.9	   +/-­‐	   15.7	  mins	   and	  53.7	   +/-­‐	   11.4	   mins	   respectively,	   Figure	   4.3,	   B).	   	   Hence	   blocking	   acetylation	  destabilises	  Ac2xNgn2KO	  to	  the	  level	  of	  xNgn2KO,	  which	  has	  a	  wild	  type	  N-­‐terminal	  sequence.	  	  It	   is	   predicted	   that	   the	  wild	   type	   and	  Ac3	  N-­‐termini	   of	   xNgn2	  are	  not	  normally	   co-­‐translationally	   acetylated,	   but	   the	   Ac2	   protein	   is	   (Vosper	   et	   al.,	   2009).	   	   Under	  conditions	   allowing	   protein	   acetylation,	   Ac2xNgn2KO	   is	   acetylated,	   blocking	  ubiquitylation,	   conferring	   stability	   on	   the	   protein.	   	   xNgn2KO	   and	   Ac3xNgn2KO	   are	  not	  acetylated	  and	  therefore	  can	  be	  N-­‐terminally	  ubiquitylated	  and	  degraded.	  	  When	  co-­‐translation	  acetylation	  is	  blocked,	  Ac2xNgn2KO	  can	  be	  N-­‐terminally	  ubiquitylated	  again,	   leading	   to	   decreasing	   stability.	   	   The	   Ac2	   mutants	   are	   therefore	   correctly	  targeted	   for	   N-­‐terminal	   acetylation	   and	   the	   N-­‐terminus	   of	   xNgn2KO	   acts	   as	   a	   site	  targeting	  for	  proteasomal	  degradation.	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Figure 4.3: xNgn2 N-terminal ubiquitylation and acetylation are mutually exclusive. 
Xenopus laevis interphase activated egg extracts were supplemented with 35S-labelled xNgn2KO, 
Ac2xNgn2KO or Ac3xNgn2KO in the presence or absence of citrate synthase and oxaloacetate, 
which depletes the reticulocyte lysate of acetyl CoA.  Samples were taken at the timepoints 
indicated and subjected to 15 % SDS-PAGE.  Gels were analysed by autoradiography and 
quantitative phosphorimaging analysis, plotting readings at each timepoint as a log of the reading 
as a percentage of the reading at 0 mins (A).  (B) Half-lives in the presence or absence of 
acetylation-blocking conditions were calculated using first-order rate kinetics, and errors calculated 
using the Standard Error of the Mean (SEM). 
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Figure 4.4: ATP-depletion stabilises xNgn2 and Ac2xNgn2KO. 
High-speed Xenopus laevis interphase activated egg extracts were supplemented with 35S-labelled 
xNgn2 or Ac2xNgn2KO in the presence of either energy regeneration (ER) mix or 1.3 units 
hexokinase with 0.8 µmoles glucose, to deplete the extract of ATP.  Samples were taken at the 
timepoints indicated and subjected to 15 % SDS-PAGE.  Gels were analysed by autoradiography 
(A) and quantitative phosphorimaging analysis, plotting readings at each timepoint as a log of the 
reading as a percentage of the reading at 0 mins (B).  (C) Half-lives in the presence or absence of 
acetylation-blocking conditions were calculated using first-order rate kinetics, and errors calculated 
using the Standard Error of the Mean (SEM). 
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Figure 4.5: Reducing agent dependence of xNgn2, mMyoD and mMyoDKO ubiquitylation. 
Xenopus laevis interphase activated egg extracts were supplemented with 35S-radiolabelled xNgn2 
(A), mMyoD or mMyoDKO (B) in the presence of MG132 and either His6-ubiquitin (His) or 
untagged ubiquitin as a control for background binding (Reg).  Samples were isolated in either high 
pH 10 % β-mercaptoethanol reducing loading buffer (R) or non-reducing loading buffer (N).  
Sample of in vitro translated (IVT) radiolabelled protein were run out with samples on 12 % SDS-
PAGE.  Lanes are numbered 1-14 as described in text.  Arrows highlight the position of bands 
representing unmodified protein. 
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The	   reducing	   agent	   dependence	   of	   xNgn2	   and	   xNgn2KO	   was	   demonstrated	   by	  Jonathan	   Vosper	   (Vosper	   et	   al.,	   2009).	   	   To	   investigate	   whether	   other	   proteins	  undergo	  reducing	  agent-­‐dependent	  ubiquitylation,	  a	  ubiquitylation	  assay	  was	  carried	  out	  with	  the	  related	  bHLH	  proteins	  mMyoD	  and	  mMyoDKO	  (Figure	  4.5,	  B).	  	  	  Unmodified	  mMyoD	  is	  released	  under	  reducing	  conditions	  (Figure	  4.5,	  B,	  comparing	  lanes	  3	  and	  5,	  highlighted	  by	  arrow).	  	  This	  band	  does	  not	  appear	  under	  non-­‐reducing	  	  conditions	  (Figure	  4.5,	  B,	  comparing	  lanes	  5	  and	  6).	   	  This	  indicates	  ubiquitylation	  of	  mMyoD	  via	  labile	  linkages	  to	  non-­‐canonical	  sites.	  	  	  	  This	  effect	   is	  present	  also	  in	  mMyoDKO,	  but	  to	  a	  much	  more	  obvious	  extent	  (Figure	  4.5,	   B,	   lane	   11	   compared	   to	   lanes	   9	   and	   12	   and	   highlighted	   by	   arrow),	   even	  accounting	  for	  a	   low	  level	  of	  background	  binding	  of	  protein	  (Figure	  4.5,	  B,	   lane	  13).	  	  Therefore	  non-­‐canonical	  ubiquitylation	  also	  occurs	  in	  the	  lysineless	  form	  mMyoDKO	  where	  the	  only	  non-­‐labile	  linkage	  site	  remaining	  is	  the	  N-­‐terminal	  amino	  group.	  	  Non-­‐canonical	  ubiquitylation	   is	  evident	   in	  both	  xNgn2	  (Figure	  4.5,	  A,	   (Vosper	  et	  al.,	  2009))	  and	  mMyoD	  (Figure	  4.5,	  B)	  and	  their	  lysineless	  forms.	  	  I	  wished	  to	  investigate	  which	  particular	  non-­‐canonical	  sites	  may	  be	  targeting	  for	  proteasomal	  degradation	  in	  xNgn2.	  	  
Cysteines	  are	  ubiquitylation	  sites	  in	  xNgn2	  	  xNgn2	   and	  mMyoD	   can	   be	   ubiquitylated	   in	   the	   absence	   of	   canonical	   ubiquitylation	  sites.	   	   Other	   nucleophilic	   residues,	   such	   as	   cysteines,	   could	   form	   labile	   thioester	  bonds	   with	   the	   C-­‐terminus	   of	   Ub	   (Figure	   4.1,	   B).	   	   Some	   examples	   of	   cysteine	  ubiquitylation	  have	  been	  described	  in	  peroxisomal	  degradation	  and	  in	  viral	  systems	  (Cadwell	  and	  Coscoy,	  2005,	  Cadwell	  and	  Coscoy,	  2008,	  Carvalho	  et	  al.,	  2007,	  Grou	  et	  al.,	   2008,	   Kragt	   et	   al.,	   2005,	   Leon	   and	   Subramani,	   2007,	   Williams	   et	   al.,	   2007).	  	  Suggestions	  of	  ubiquitylation	  on	  serine	  and	  threonine	  have	  also	  been	  made	  (Ishikura	  et	   al.,	   2010,	   Tait	   et	   al.,	   2007,	   Wang	   et	   al.,	   2007).	   	   However	   ubiquitylation	  simultaneously	  on	  canonical	  and	  non-­‐canonical	  sites	  has	  not	  been	  demonstrated	  to	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Figure 4.6: Cysteine residues in xNgn2. 
Schematic of cysteine positions and cysteines modelled onto a structure of a proneural bHLH 
heterodimer complexed to DNA. The disordered N-terminal domain is bordered in blue; the bHLH 
domain in red; and the disordered C-terminal domain in green. 
	  98	  
target	  proteins	  for	  proteasomal	  degradation.	   	  xNgn2	  has	  7	  cysteine	  residues	  (Figure	  4.6).	  	  	  	  A	  mutant	  of	  xNgn2	  with	  cysteines	  mutated	   to	  alanines	  was	  created	  by	  site-­‐directed	  mutagenesis	  to	  produce	  xNgn2CO,	  to	   investigate	  any	  effect	  of	   loss	  of	  cysteines	   from	  xNgn2	  on	  stability.	  	  35S-­‐radiolabelled	  IVT	  xNgn2	  or	  xNgn2	  mutants	  lacking	  canonical	  or	   non-­‐canonical	   putative	   ubiquitylation	   sites	   were	   added	   to	   Xenopus	   laevis	  interphase	  activated	  egg	  extract	  and	  incubated	  at	  21	  °C.	  	  Aliquots	  of	  the	  degradation	  reaction	   were	   removed	   at	   increasing	   timepoints	   into	   quenching	   SDS-­‐LB	   and	  separated	   by	   15	   %	   SDS-­‐PAGE.	   	   Half-­‐lives	   for	   the	   rates	   of	   degradation	   were	   then	  calculated	  using	  first-­‐order	  rate	  kinetics	  (Figure	  4.7).	  	  xNgn2CO	  exhibits	  a	  half-­‐life	  of	  33.3	  +/-­‐	  2.1	  mins	  compared	  to	  the	  stability	  of	  xNgn2	  (21.5	   +/-­‐	   0.2	   mins).	   	   However	   the	   stabilisation	   is	   much	   less	   than	   the	   stabilisation	  provided	   by	   blocking	   off	   internal	   lysines	   (xNgn2KO,	   60.2	   +/-­‐	   1.4	   mins),	   the	   N-­‐terminus	  (Ac2xNgn2,	  52.4	  +/-­‐	  6.3	  mins),	  or	  all	  canonical	  sites	  (Ac2xNgn2KO,	  138	  +/-­‐	  20	  mins)	   from	  ubiquitylation.	   	  xNgn2CO	  is	  significantly	  more	  stable	  than	  xNgn2	  but	  much	  less	  stable	  than	  xNgn2KO	  or	  Ac2xNgn2.	   	  This	  indicates	  cysteines	  do	  target	  for	  UPS-­‐mediated	  degradation	  but	  not	  as	  efficiently	  as	  canonical	  ubiquitylation	  sites.	  	  To	   confirm	   that	   all	   these	  mutants	   are	   being	   degraded	   by	   Ub-­‐mediated	   proteolysis,	  ubiquitylation	   assays	   were	   carried	   out	   in	   Xenopus	   laevis	   interphase	   activated	   egg	  extract.	   	  35S-­‐radiolabelled	  IVT	  xNgn2,	  Ac2xNgn2KO,	  Ac2xNgn2CO	  or	  Ac2xNgn2KOCO	  were	   added	   to	   Xenopus	   laevis	   interphase	   activated	   egg	   extract	   supplemented	   with	  MG132	  to	  prevent	  proteasomal	  degradation,	  and	  either	  His6-­‐Ub	  (Sigma)	  or	  untagged	  Ub	   (Sigma).	   	   An	   IVT	   reaction	   using	   empty	   pCS2+	   vector	   (as	   a	   control)	   was	   also	  included.	   This	   reaction	   was	   incubated	   at	   20	   °C	   for	   90	   mins.	   	   Samples	   were	   then	  incubated	  with	  denaturing	  Vosper	  buffer	  (containing	  8.5	  M	  urea)	  and	  nickel-­‐chelating	  agarose	   beads	   (Ni-­‐NTA,	   Invitrogen)	   to	   purify	   his-­‐tagged	   protein.	   	   Samples	   were	  eluted	  in	  a	  high	  pH	  reducing	  (R)	  SDS-­‐LB,	  or	  in	  a	  non-­‐reducing	  (N)	  SDS-­‐LB	  and	  run	  out	  on	  12	  %	  SDS-­‐PAGE	  (Figure	  4.8,	  A).	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Figure 4.7: Comparison of stability of canonical and non-canonical xNgn2 ubiquitylation site 
mutants in Xenopus interphase egg extract. 
Xenopus interphase extracts were supplemented with 35S-labelled xNgn2, xNgn2CO, xNgn2KO, 
Ac2xNgn2, Ac3xNgn2 or Ac2xNgn2KO.  Samples were taken at the timepoints indicated and 
subjected to 15 % SDS-PAGE.  Gels were analysed by autoradiography (A).  (B) Half-lives were 
normalised to xNgn2 stability in each experiment and the average ratio of stability of each protein 
with respect to wild type plotted.  (C) Half-lives were calculated using first-order rate kinetics, and 
errors calculated using the Standard Error of the Mean (SEM). 
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In	  Figure	  4.8,	  A,	  all	  xNgn2	  proteins	  are	  ubiquitylated.	  	  For	  xNgn2	  (Figure	  4.8,	  A,	  lanes	  5	   and	  6),	   Ac2xNgn2KO	   (Figure	  4.8,	  A,	   lanes	   9	   and	  10),	  Ac2xNgn2CO	   (Figure	  4.8,	  A,	  lanes	   13	   and	   14)	   and	   Ac2xNgn2KOCO	   (Figure	   4.8,	   A,	   lanes	   17	   and	   18)	   there	   are	  polyubiquitylation	   ladders	   that	   show	   a	   dependence	   on	   high	   pH	   and	   reducing	  conditions,	  displaying	  a	  band	  at	   the	  mass	  of	  unmodified	  protein	  under	  reducing	  (R)	  conditions	  (Figure	  4.8,	  A,	  lanes	  5,	  9,	  13	  and	  17).	  	  The	  labile	  linkages	  that	  are	  broken	  to	  release	  unmodified	  protein	  are	  produced	  even	  in	  wild	  type	  xNgn2	  (Figure	  4.8,	  A,	  lane	  5),	  where	  canonical	  sites	  of	  ubiquitylation	  are	  present.	   	   In	   Ac2xNgn2CO	   (Figure	   4.8,	   A,	   lane	   13)	  whilst	   there	   is	   some	   unmodified	  protein	   liberated	   under	   reducing	   conditions,	   there	   are	   still	   lysines	   present	   in	   the	  protein	   that	   can	   be	   ubiquitylated.	   	   Comparing	   xNgn2	   (lanes	   5	   and	   6)	   with	  Ac2xNgn2CO	  (lanes	  13	  and	  14)	  it	  is	  clear	  that	  mutation	  of	  cysteines	  to	  alanines	  leads	  to	  formation	  of	  clearer,	  tighter	  bands	  on	  the	  gel.	  	  Ac2xNgn2KO	  demonstrates	  the	  most	  dramatic	   collapse	  of	   the	  polyubiquitylation	   ladder	   (lane	  10)	   to	  an	  unmodified	  band	  (lane	  9)	  as	  only	  non-­‐canonical,	  non-­‐amine	  nucleophiles	  remain	  in	  the	  protein.	  	  When	  cysteines	  are	  mutated	  as	  well	  as	  the	  N-­‐terminus	  and	  the	  lysines,	   in	  Ac2xNgn2KOCO,	  ubiquitylation	   still	   persists	   (lanes	   17	   and	   18).	   	   Therefore	   ester	   linkages	   through	  hydroxyl-­‐containing	  amino	  acid	  residues,	  for	  example	  serine	  and	  threonine,	  are	  also	  formed	  in	  the	  ubiquitylation	  assay	  and	  broken	  in	  reducing	  conditions.	  	  There	  is	  a	  single	  band	  apparent	  in	  the	  untagged	  Ub	  gel	  under	  reducing	  (R)	  conditions	  (Figure	   4.8,	   A	   lanes	   7	   and	   11	   particularly,	   also	   lanes	   15	   and	   19).	   	   This	   suggests	  insufficient	   washing	   of	   the	   nickel	   beads	   resulting	   in	   a	   high	   level	   of	   background	  binding	  especially	  for	  xNgn2	  and	  Ac2xNgn2KO.	  	  	  To	   assess	   whether	   ubiquitylation	   on	   reducing-­‐agent/high	   pH/high	   temperature	  dependent	  sites	   is	  specific	   to	  bHLH	  proteins,	  ubiquitylation	  assays	  were	  carried	  out	  with	  the	  important	  anaphase	  promoting	  complex/cyclosome	  (APC/C)	  substrate	  Mes1	  (Kimata	  et	  al.,	  2008,	  Yamano	  et	  al.,	  2004)	  and	  its	   lysineless	  mutant	  Mes1KO	  (Figure	  4.8,	   B).	   	   35S-­‐radiolabelled	   IVT	   Mes1	   or	   Mes1KO	   were	   added	   to	   Xenopus	   laevis	  interphase	  activated	  egg	  extract	  supplemented	  with	  MG132	  to	  prevent	  proteasomal	  degradation,	  and	  either	  His6-­‐Ub	  (Sigma)	  or	  untagged	  Ub	  (Sigma).	  	  This	  reaction	  was	  	  
	  101	  
Figure 4.8: Ubiquitylation assays highlighting cysteine ubiquitylation in Xenopus extract. 
Xenopus laevis interphase extracts were supplemented with (A) 35S-radiolabelled xNgn2, 
Ac2xNgn2KO, Ac2xNgn2CO, Ac2xNgn2KOCO or pCS2+ and (B) the yeast protein Mes1 or its 
lysineless form Mes1KO.  Either His6-Ub (His) or untagged Ub (Reg) were added.  Samples were 
isolated in either reducing SDS-LB (R) or non-reducing SDS-LB (N) and run on 12 % SDS-PAGE.	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incubated	  at	  20	  °C	  for	  90	  mins.	  	  Samples	  were	  then	  incubated	  with	  denaturing	  Vosper	  buffer	   (containing	   8.5	   M	   urea)	   and	   nickel-­‐chelating	   agarose	   beads	   (Ni-­‐NTA,	  Invitrogen)	  to	  purify	  his-­‐tagged	  protein.	  	  Samples	  were	  eluted	  in	  a	  high	  pH	  reducing	  (R)	  SDS-­‐LB,	  or	  in	  a	  non-­‐reducing	  (N)	  SDS-­‐LB	  and	  run	  out	  on	  12	  %	  SDS-­‐PAGE	  (Figure	  4.8,	  B).	  	  Mes1	   is	   polyubiquitylated	   as	   demonstrated	   by	   the	   polyubiquitylation	   ladder	  produced	   in	   reducing	   (R)	   and	   non-­‐reducing	   (N)	   conditions	   (Figure	   4.8,	   B,	   lanes	   23	  and	  24).	   	  However	  neither	  sample	  exhibits	  a	  strong	  band	  running	  at	  the	  level	  of	  the	  IVT	  proteins	  in	  lanes	  21	  and	  22.	  	  Therefore	  there	  is	  not	  a	  reducing	  agent	  dependence	  in	  Mes1	  ubiquitylation.	  	  In	  Mes1KO,	  the	  reducing	  conditions	  produce	  a	  band	  running	  at	   the	   level	   of	   the	   unmodified	   IVT	   protein	   (lane	   29	   compared	   to	   lanes	   27	   and	   28).	  	  There	   is	   no	   evidence	   of	   a	   polyubiquitylation	   ladder	   in	   lanes	   29	   and	   30.	   	   Therefore	  Mes1KO	   is	   not	   highly	   ubiquitylated	   but	   the	   appearance	   of	   an	   unmodified	   protein	  band	   liberated	   in	  reducing	  conditions	  suggests	   that,	   in	   the	  absence	  of	   lysines,	   some	  ubiquitylation	  is	  possible	  on	  non-­‐canonical	  sites,	  using	  labile	  linkages.	  	  The	   behaviour	   of	   Mes1	   ubiquitylation	   is	   very	   different	   to	   xNgn2	   and	   xMyoD.	  	  Therefore	  non-­‐canonical	  ubiquitylation	   is	  specific	   to	   the	  particular	  proteins	  present	  in	  Xenopus	  extract	  and	  not	  the	  extract	  itself.	  	  As	  this	  ubiquitylation	  occurs	  on	  xNgn2	  I	  wished	  to	  investigate	  particular	  non-­‐canonical	  sites	  of	  ubiquitylation	  further.	  	  There	   are	   2	   cysteine	   residues	   conserved	   in	   the	   sequence	   of	   Homo	   sapiens,	   Mus	  
musculus	  and	  Xenopus	  laevis	  Ngn2	  proteins,	  cysteines	  169	  and	  178,	  highlighted	  in	  the	  ClustalW2	  analysis	   in	  Figure	  4.9.	   	  To	  assess	  whether	  these	  conserved	  cysteines	  may	  be	   important	   ubiquitylation	   sites,	   Christopher	   Hindley	   performed	   site-­‐directed	  mutagenesis	   to	   create	   mutants	   of	   cysteine	   residues	   in	   xNgn2	   to	   alanine,	   creating	  C178AxNgn2	   and	   C(169,178)AxNgn2,	   which	   were	   then	   assessed	   by	   degradation	  assay.	   	   	   35S-­‐radiolabelled	   IVT	   xNgn2	   or	   xNgn2	   cysteine	   mutants	   were	   added	   to	  
Xenopus	   laevis	   interphase	  activated	  egg	  extract	   and	   incubated	  at	  21	   °C.	   	  Aliquots	  of	  the	   degradation	   reaction	   were	   removed	   at	   increasing	   timepoints	   into	   SDS-­‐LB	   and	  separated	   by	   15	   %	   SDS-­‐PAGE.	   	   Half-­‐lives	   for	   the	   rates	   of	   degradation	   were	   then	  calculated	  using	  first-­‐order	  rate	  kinetics	  (Figure	  4.10).	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Figure 4.9: Alignment highlighting conserved cysteines in xNgn2.	  
Cysteines 169 and 178 are conserved cysteines in Ngn2 across species, shown in boxes above. 
ClustalW2 analysis was carried out to align neurogenin and NeuroD sequences from Xenopus 
laevis (x), Mus musculus (m) and Homo sapiens (h).  Exact matches are denoted by * and 
decreasingly similar properties by : and . with no symbol present for no similarity.  – highlights a 
gap in the sequence alignment.  The disordered C-terminal domain is bordered in green. 
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Figure 4.10: The role of conserved cysteines in stability in Xenopus interphase egg extract. 
Xenopus laevis interphase extracts were supplemented with 35S-labelled xNgn2, xNgn2 
C178AxNgn2 or C(169,178)AxNgn2 and incubated at 21 °C.  Samples were taken at 0, 15, 30, 60, 
90, 120, 180 mins and subjected to 15 % SDS-PAGE. (A) Half-lives were normalised to xNgn2 
stability in each experiment and the average ratio of stability of each protein with respect to wild 
type plotted.  (B) Half-lives were calculated using first-order rate kinetics, and errors calculated 
using the Standard Error of the Mean (SEM). 
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The	  half-­‐life	   for	   the	   single	   cysteine	   to	   alanine	  mutant,	   C178AxNgn2,	   is	   23.3	   +/-­‐	   0.9	  mins	   compared	   to	   the	   average	  wild	   type	   value	   of	   30.5	   +/-­‐	   2.5	  mins.	   	   Loss	   of	   both	  conserved	   cysteine	   residues,	   in	   C(169,178)AxNgn2,	   results	   in	   a	   half-­‐life	   for	  degradation	  of	  39.5	  +/-­‐	  6.7	  mins.	  	  	  	  The	  value	  for	  wild	  type	  is	  larger	  than	  usually	  observed,	  most	  likely	  due	  to	  the	  use	  of	  frozen	  egg	  extract,	  and	  so	  I	  conclude	  that	  loss	  of	  C178	  does	  not	  increase	  xNgn2	  half-­‐life.	  	  However	  loss	  of	  both	  cysteines	  can	  inhibit	  xNgn2	  proteasomal	  degradation.	  	  To	  investigate	  the	  effect	  on	  stability	  of	  inhibiting	  cysteine	  ubiquitylation	  by	  methods	  other	  than	  mutation,	  alkylation	  experiments	  on	  xNgn2	  cysteine	  mutants	  were	  carried	  out	  using	  N-­‐ethyl	  maleimide	  (NEM),	  which	  selectively	  reacts	  with	  cysteines	  to	  block	  their	  nucleophilic	  potential.	  	  As	  this	  alkylation	  also	  inhibits	  the	  action	  of	  Ub-­‐activating	  (E1),	  Ub-­‐conjugating	   (E2)	   and	  de-­‐ubiquitylating	   (DUB)	   enzymes,	   IVT	  proteins	  were	  purified	   away	   from	   NEM	   after	   treatment.	   	   35S-­‐radiolabelled	   IVT	   xNgn2,	   xNgn2CO,	  Ac2xNgn2KO	  or	  Ac2xNgn2KOCO,	  treated	  with	  NEM	  (or	  with	  buffer	  alone	  as	  a	  control)	  were	  added	  to	  Xenopus	  laevis	  interphase	  activated	  egg	  extract	  and	  incubated	  at	  21	  °C.	  	  Aliquots	  of	  the	  degradation	  reaction	  were	  removed	  at	  increasing	  timepoints	  into	  SDS-­‐LB	   and	   separated	  by	  15	  %	  SDS-­‐PAGE.	   	  Half-­‐lives	   for	   the	   rates	   of	   degradation	  were	  then	  calculated	  using	  first-­‐order	  rate	  kinetics	  (Figure	  4.11).	  	  The	  half-­‐life	  of	   xNgn2	   treated	  with	  buffer	  alone	   is	  37.5	  +/-­‐	  2.7	  mins	  and	  with	  NEM	  treatment	  is	  32.3	  +/-­‐	  4.2	  mins.	  	  This	  suggests	  that	  NEM	  has	  no	  effect	  in	  the	  wild	  type	  protein	   and	   therefore	   that	   modifying	   cysteines	   has	   no	   effect	   on	   the	   rate	   of	  degradation.	  	  xNgn2CO	  has	  a	  half-­‐life	  of	  57	  +/-­‐	  12.4	  mins	  in	  buffer	  alone	  which	  increases	  to	  86.7	  +/-­‐	  26.9	  mins	  in	  NEM.	  	  As	  cysteines	  are	  modified	  by	  NEM	  no	  effect	  would	  be	  expected	  on	  NEM	  treatment.	  	  xNgn2CO	  is	  not	  significantly	  stabilised	  by	  NEM	  treatment.	  	  The	  same	  applies	   to	  Ac2xNgn2KOCO	  which	  has	   half-­‐lives	   of	   131	  +/-­‐	   73	  mins	   and	  125	  +/-­‐	   46	  mins	  with	  and	  without	  NEM	  treatment	  respectively.	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Figure 4.11: NEM treatment modifies cysteines to affect stability. 
Xenopus laevis interphase activated egg extracts were supplemented with 35S-labelled xNgn2, 
xNgn2CO, Ac2xNgn2KO and Ac2xNgn2KOCO IVT proteins which had been pre-treated with N-
ethyl maleimide (NEM), and incubated at 21 °C.  Samples were taken at 0, 15, 30, 60, 90, 120, 180 
mins and subjected to 15 % SDS-PAGE.  (A) Gels were analysed by quantitative phosphorimaging 
analysis and levels of protein plotted against time.  (B) Half-lives in the presence or absence of 
NEM were calculated using first-order rate kinetics, and errors calculated using the Standard Error 
of the Mean (SEM). 
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Ac2xNgn2KO	  stability	  is	  affected	  by	  NEM	  treatment,	  which	  increases	  the	  protein	  half-­‐life	  from	  124	  +/-­‐	  22	  mins	  to	  a	  half-­‐life	  greater	  than	  the	  length	  of	  the	  timecourse	  (294	  mins,	   but	   this	   cannot	   be	   stated	   with	   confidence	   as	   it	   exceeds	   the	   length	   of	   the	  timecourse).	  	  Thus,	  cysteines	  do	  not	  appear	  to	  target	  wild	  type	  xNgn2	  for	  degradation	  in	  interphase	  but	  are	   sufficient	   to	   target	   for	  proteasomal	  degradation	   in	   the	  absence	  of	   canonical	  and	  amino-­‐based	  sites	  of	  ubiquitylation.	  	  IVT	   radiolabelled	   proteins	   were	   purified	   by	   small-­‐scale	   purification	   columns	   to	  isolate	   the	   proteins	   from	   NEM	   before	   being	   added	   to	   extract	   and	   this	   may	   have	  affected	   the	   half-­‐lives,	   as	   they	   differ	   from	   expected	   levels	   in	   extract	   as	   shown	   in	  preceding	  figures.	  	  
Cysteine	  residues	  regulate	  stability	  in	  a	  cell	  cycle-­dependent	  manner	  	  Cysteine	   residues	  demonstrate	  a	   role	   in	  xNgn2	  Ub-­‐mediated	  proteolysis	   in	  Xenopus	  
laevis	   interphase	   extract.	   	   To	   examine	   whether	   this	   was	   the	   case	   in	   other	  developmental	  settings,	  other	  extracts	  were	  employed	  to	  investigate	  the	  possible	  role	  of	  cysteines	  in	  regulating	  xNgn2	  stability.	  	  	  
	  




Figure 4.12: Mutation of cysteines is sufficient to stabilise xNgn2 in Xenopus mitotic egg 
extract. 
Xenopus laevis mitotic activated egg extracts were supplemented with 35S-labelled xNgn2, 
xNgn2CO, xNgn2KO or Ac2xNgn2KO IVT proteins and incubated at 21 °C.  Samples were taken 
at the timepoints indicated and subjected to 15 % SDS-PAGE.  Gels were analysed by 
autoradiography (A) and quantitative phosphorimaging analysis (B) and average ratios of half-lives 
normalised to wild type stability in each experiment calculated.  (C) Half-lives were calculated using 
first-order rate kinetics and errors calculated using the Standard Error of the Mean (SEM).  n = 4  	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lives,	  of	  35.6	  +/-­‐	  2.7	  mins	  and	  38.3	  +/-­‐	  5.4	  mins	  respectively	  (Figure	  4.12,	  C)	  giving	  similar	   average	   ratios	   of	   stabilisation	   (Figure	   4.12,	   C).	   	   Therefore	   cysteines	   and	  lysines	  are	  similarly	  important	  for	  targeting	  xNgn2	  for	  degradation	  in	  mitosis.	  	  Cysteine	  residues	  affect	  Ub-­‐mediated	  proteolysis	  of	  xNgn2	  in	  a	  cell-­‐cycle	  dependent	  manner.	   	   I	   went	   on	   to	   investigate	   Ub-­‐mediated	   proteolysis	   of	   xNgn2	   in	   neurula	  embryo	   extracts,	   made	   at	   the	   developmental	   stage	   at	   which	   xNgn2	   is	   usually	  expressed.	  	  	  To	  test	  the	  role	  of	  cysteines	  in	  regulating	  xNgn2	  stability	  in	  neurula	  stage	  extract,	  35S-­‐radiolabelled	  IVT	  xNgn2,	  xNgn2CO,	  xNgn2KO,	  Ac2xNgn2,	  Ac3xNgn2	  or	  Ac2xNgn2KO	  were	   added	   to	   Xenopus	   laevis	   neurula	   embryo	   extract	   and	   incubated	   at	   21	   °C.	  	  Aliquots	  of	  the	  degradation	  reaction	  were	  removed	  at	  increasing	  timepoints	  into	  SDS-­‐LB	   and	   separated	  by	  15	  %	  SDS-­‐PAGE.	   	  Half-­‐lives	   for	   the	   rates	   of	   degradation	  were	  then	  calculated	  using	  first-­‐order	  rate	  kinetics	  (Figure	  4.13).	  	  xNgn2CO	  has	  an	  average	  half-­‐life	  of	  125	  +/-­‐	  62	  mins	  in	  neurula	  extract	  (Figure	  4.13,	  C)	  where	  xNgn2KO	  has	  a	  half-­‐life	  of	  107	  +/-­‐	  29	  mins	  and	  Ac2xNgn2	  has	  a	  half-­‐life	  of	  89.4	   +/-­‐	   17.2	  mins.	   	  Mutation	   of	   cysteines,	   lysines	   or	   the	  N-­‐terminus	   has	   a	   similar	  effect	  on	  protein	  stability.	  	  To	   take	   this	   analysis	   further	   35S-­‐radiolabelled	   xNgn2,	   Ac2xNgn2KO	   or	  Ac2xNgn2KOCO	  were	  added	  to	  Xenopus	  laevis	  neurula	  embryo	  extract	  and	  subjected	  to	  degradation	   assay	   (Figure	  4.14).	   	   This	  was	   to	   investigate	  whether	  non-­‐canonical	  ubiquitylation	  could	  direct	  proteolysis	  in	  the	  absence	  of	  canonical	  ubiquitylation	  sites	  in	  neurula	  extracts.	  	  	  	  In	  this	  experiment,	  xNgn2	  demonstrated	  an	  average	  half-­‐life	  for	  degradation	  of	  42.8	  +/-­‐	   2.4	   mins,	   and	   Ac2xNgn2KO	   a	   half-­‐life	   of	   112	   +/-­‐	   7	   mins.	   	   The	   half-­‐life	   for	  degradation	   of	   Ac2xNgn2KOCO,	   however,	   was	   extended	   beyond	   the	   length	   of	   the	  degradation	   assay	   timecourse	   of	   240	   mins.	   	   Therefore	   I	   can	   conclude	   that	  ubiquitylation	   on	   cysteines	   can	   direct	   proteolysis	   in	   the	   absence	   of	   canonical	  ubiquitylation,	  in	  neurula	  stage	  extracts.	  
	  110	  
	  
Figure 4.13: xNgn2 cysteine mutants affect stability in Xenopus neurula embryo extract. 
Xenopus laevis neurula extracts were supplemented with 35S-labelled xNgn2, xNgn2CO, 
xNgn2KO, Ac2xNgn2, Ac3xNgn2 or Ac2xNgn2KO IVT proteins.  Samples were taken at the 
timepoints indicated and subjected to 15 % SDS-PAGE.  Gels were analysed by autoradiography 
(A) and average ratios of half-lives normalised to wild type stability in each experiment calculated 
(B).  (C) Half-lives were calculated using first-order rate kinetics and errors calculated using the 




Figure 4.14: Loss of non-canonical ubiquitylation sites further stabilises xNgn2 lacking 
canonical sites of ubiquitylation in Xenopus neurula extract. 
Xenopus laevis neurula embryo extracts were supplemented with 35S-labelled xNgn2, 
Ac2xNgn2KO or Ac2xNgn2KOCO IVT proteins and incubated at 21 °C.  Samples were taken at the 
timepoints indicated and subjected to 15 % SDS-PAGE.  Gels were analysed by autoradiography 
(A) and quantitative phosphorimaging analysis and average ratios of half-lives normalised to wild 
type stability in each experiment calculated (B).  (C) Half-lives were calculated using first-order rate 
kinetics and errors calculated using the Standard Error of the Mean (SEM). 
	  112	  
To	   observe	   whether	   xNgn2	   is	   still	   modified	   by	   ubiquitylation	   after	   mutation	   of	  lysines,	   cysteines	   and	   the	   N-­‐terminus,	   ubiquitylation	   assays	  were	   carried	   out.	   	   35S-­‐radiolabelled	   IVT	   xNgn2,	   Ac2xNgn2KO,	   or	   Ac2xNgn2KOCO	  were	   added	   to	   Xenopus	  
laevis	   neurula	   embryo	   extract	   supplemented	   with	   MG132	   to	   prevent	   proteasomal	  degradation	  and	  His6-­‐Ub	  (Sigma).	  This	  reaction	  was	  incubated	  at	  20	  °C	  for	  90	  mins.	  	  Samples	  were	  then	  incubated	  with	  denaturing	  Vosper	  buffer	  (containing	  8.5	  M	  urea)	  and	  nickel-­‐chelating	  agarose	  beads	  (Ni-­‐NTA,	  Invitrogen)	  to	  purify	  his-­‐tagged	  protein.	  	  Samples	  were	  eluted	  in	  a	  high	  pH	  reducing	  (R)	  SDS-­‐LB,	  or	  in	  a	  non-­‐reducing	  (N)	  SDS-­‐LB	  and	  run	  out	  on	  12	  %	  SDS-­‐PAGE	  (Figure	  4.15).	  	  xNgn2	   is	   released	   from	   Ub	   in	   reducing	   conditions,	   demonstrating	   non-­‐canonical	  ubiquitylation	  via	  thioester	  and	  ester	  linkages	  (Figure	  4.15,	  marked	  by	  arrow,	  lane	  1).	  	  This	  is	  due	  to	  ubiquitylated	  xNgn2	  being	  pulled	  down	  by	  nickel	  beads,	  but	  under	  the	  high	   temperature,	   high	   pH	   and	   reducing	   conditions	   of	   the	   gel	   loading	   buffer,	   labile	  thioester	   and	   ester	   linkages	   are	   broken	   and	   xNgn2	   is	   liberated.	   	   This	   band	   is	   not	  present	  under	  non-­‐reducing	  conditions	  (Figure	  4.15,	  lane	  2).	  	  The	  effect	  is	  greater	  in	  Ac2xNgn2KO	  where	   higher	  molecular	  weight	   forms	   are	   lost	   in	   reducing	   conditions	  (Figure	   4.15,	   lane	   3)	   compared	   to	   non-­‐reducing	   conditions	   (Figure	   4.15,	   lane	   4)	   to	  release	   unmodified	   protein.	   	   Ac2xNgn2KOCO	   is	   not	   only	   still	   ubiquitylated	   in	   non-­‐reducing	  conditions	  (Figure	  4.15,	  lane	  6)	  but	  under	  reducing	  conditions	  (Figure	  4.15,	  lane	   5)	   unmodified	   xNgn2	   is	   released.	   	   Therefore	   non-­‐canonical	   sites	   are	  ubiquitylated	  not	  only	  in	  Ac2xNgn2KO,	  where	  no	  canonical	  sites	  are	  present,	  but	  also	  in	  Ac2xNgn2KOCO,	  where	  there	  are	  also	  no	  cysteines	  present.	  	  Therefore	  this	  means	  that	   further	   non-­‐canonical	   ubiquitylation	   must	   be	   occurring,	   using	   the	   hydroxyl	  groups	  on	  residues	  such	  as	  serine	  and	  threonine	  to	  form	  ester	  linkages	  with	  Ub.	  	  
xNgn2	  is	  degraded	  in	  P19	  cells	  by	  the	  proteasome	  and	  using	  non-­canonical	  sites	  
of	  ubiquitylation	  	  So	  far	  evidence	  from	  Xenopus	  laevis	  extract	  systems	  has	  been	  presented	  in	  discussion	  of	  serines	  and	  threonines	  as	  well	  as	  cysteines	   in	  ubiquitylation	  of	  xNgn2	  (Vosper	  et	  al.,	   2007,	   Vosper	   et	   al.,	   2009).	   	   The	   Xenopus	   laevis	   extract	   system	   is	   a	   simple	   and	  robust	  means	  of	  assaying	  processes	  such	  as	  protein	  ubiquitylation.	  	  However	  it	  is	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Figure 4.15: Ubiquitylation of non-canonical sites in xNgn2 in Xenopus neurula extract. 
Xenopus laevis neurula embryo extracts were supplemented with 35S-radiolabelled xNgn2, 
Ac2xNgn2KO or Ac2xNgn2KOCO with His6-ubiquitin.  Samples were isolated in either high pH 10 
% β-mercaptoethanol reducing loading buffer (R) or non-reducing loading buffer (N).  Sample of in 
vitro translated (IVT) radiolabelled protein were run out with samples on 12 % SDS-PAGE.  Lanes 
are numbered 1-6 as described in text. 
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possible	  that	  ubiquitylation	  in	  a	  non-­‐canonical	  fashion,	  despite	  showing	  cell	  cycle	  and	  developmental	   dependence,	   may	   be	   specific	   to	   this	   in	   vitro	   system.	   	   Therefore	   I	  decided	   to	   determine	   whether	   ubiquitylation	   occurs	   on	   non-­‐canonical	   residues	   in	  cultured	  cells,	  using	  the	  Mus	  musculus	  P19	  embryonal	  carcinoma	  cell	  line	  (McBurney	  and	  Rogers,	  1982).	   	  The	  P19	  cell	   line	   in	  particular	  was	  employed	  as	   these	   cells	   are	  capable	   of	   differentiating	   into	   neurons	   and	   so	   provide	   a	   physiologically	   relevant	  system	  with	  which	  to	  work	  (Jones-­‐Villeneuve	  et	  al.,	  1982,	  McBurney	  et	  al.,	  1982).	  	  To	  establish	  whether	  xNgn2	  is	  degraded	  by	  the	  proteasome	  in	  P19	  cells,	  and	  whether	  such	  degradation	  may	  be	  affected	  by	  loss	  of	  canonical	  sites	  of	  ubiquitylation,	  xNgn2	  and	   Ac2xNgn2KO	   (both	   triply	   HA-­‐tagged	   on	   the	   C-­‐terminus)	  were	   transfected	   into	  P19	   cells	   overnight.	   	   Cells	   were	   then	   treated	   with	   20	  µM	   cycloheximide	   to	   inhibit	  further	  protein	  translation	  and	  20	  µM	  MG132	  as	  a	  proteasome	  inhibitor	  (or	  an	  equal	  volume	  of	  DMSO	  as	  a	   control).	   	  Then	  at	   certain	   timepoints	   cells	  were	   removed	  and	  lysed	   and	  proteins	   separated	  by	  15	  %	  SDS-­‐PAGE,	   before	  Western	  blotting	  using	  α-­‐HA-­‐HRP	  antibody	   (Roche).	   	  The	  half-­‐lives	   for	  xNgn2	  proteasomal	  degradation	  were	  calculated	  by	  reading	  protein	  levels	  from	  autoradiography	  using	  ImageJ	  (Abramoff	  et	  al.,	  2004)	  software	  and	  using	  first-­‐order	  kinetics	  (Figure	  4.16).	  	  xNgn2	  has	  a	  half-­‐life	  of	  13.1	  +/-­‐	  1.8	  mins	  in	  P19	  cells	  (Figure	  4.16,	  C).	  	  However	  upon	  treatment	  with	   the	  proteasome	   inhibitor	  MG132	  xNgn2	   is	  stabilised	  (Figure	  4.16,	  A	  and	  B)	  to	  a	  half-­‐life	  of	  200	  +/-­‐	  118	  mins	  (Figure	  4.16,	  C).	  	  Ac2xNgn2KO	  has	  a	  half-­‐life	  of	  177	  +/-­‐	  72	  mins	   (Figure	  4.16,	  C)	   and	   so	   is	   stabilised	   compared	   to	   xNgn2	   in	  P19	  cells.	   	   However	   on	   treatment	   with	   MG132,	   Ac2xNgn2KO	   is	   stabilised	   beyond	   the	  length	   of	   the	   240	   min	   timecourse	   (Figure	   4.16).	   	   Therefore	   in	   P19	   cells	   xNgn2	   is	  proteasomally	  degraded,	  while	   loss	  of	   canonical	  ubiquitylation	  sites	   leads	   to	  partial	  stabilisation.	  	  However	  Ac2xNgn2KO	  is	  still	  degraded	  by	  the	  proteasome	  in	  P19	  cells.	  	  I	  have	  shown	  that	  mutation	  of	  xNgn2	  to	  remove	  canonical	  sites	  of	  ubiquitylation	  can	  stabilise	   xNgn2	   in	   Xenopus	   laevis	   interphase	   activated	   egg	   extract	   and	   neurula	  embryo	  degradation	  assays	  (Figures	  4.7	  and	  4.13,	  respectively).	  	  Repeating	  this	  in	  the	  P19	  cell	   line,	  xNgn2,	  xNgn2KO,	  Ac2xNgn2	  and	  Ac2xNgn2KO	  (all	  triply	  HA-­‐tagged	  on	  the	  C-­‐terminus)	  were	  transfected	  into	  P19	  cells	  overnight.	  	  Cells	  were	  then	  treated	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Figure 4.16: xNgn2 lacking canonical sites of ubiquitylation is still degraded in a 
proteasome-dependent manner. 
P19 embryonal carcinoma cells were transfected with 5 µg xNgn2 or Ac2xNgn2KO DNA.  20 µM 
cycloheximide was added after either 20 µM MG132 or an equal volume of DMSO as a control and 
cells removed onto ice and lysed at the timepoints indicated in lysis buffer.  Samples were 
separated by 15 % SDS-PAGE and Western blotting was undertaken using α-HA and α -tubulin 
antibodies.  Half-lives were calculated by measuring exposures on film (A) using ImageJ software 
to determine protein quantity at each timepoint (B) and half-lives were calculated using first-order 
rate kinetics (C).  Errors were calculated as the standard error of the mean (SEM).  All xNgn2 
proteins were triply HA tagged on the C-terminus. 
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with	   20	   µM	   cycloheximide	   to	   inhibit	   further	   protein	   translation.	   	   Then	   at	   certain	  timepoints	  cells	  were	  removed	  and	  lysed	  and	  proteins	  separated	  by	  15	  %	  SDS-­‐PAGE,	  before	  Western	   blotting	   using	  α-­‐HA-­‐HRP	   antibody	   (Roche).	   	   xNgn2	   half-­‐lives	  were	  calculated	  by	  reading	  protein	  levels	  after	  densitometry	  using	  ImageJ	  (Abramoff	  et	  al.,	  2004)	  software	  and	  using	  first-­‐order	  kinetics	  (Figure	  4.17).	  	  xNgn2	  has	  a	  half-­‐life	  of	  9.93	  +/-­‐	  2.74	  mins	  (Figure	  4.17,	  C).	  	  xNgn2KO	  and	  Ac2xNgn2	  have	   half-­‐lives	   of	   25.6	   +/-­‐	   7.5	  mins	   and	   38.3	   +/-­‐	   26.0	  mins	   respectively.	   	   However	  greatest	   stabilisation	  was	   achieved	  by	  mutating	   all	   canonical	   ubiquitylation	   sites	   in	  Ac2xNgn2KO,	   resulting	   in	   a	   half-­‐life	   of	   209	   +/-­‐	   23	   mins.	   	   Therefore	   mutation	   of	  canonical	   ubiquitylation	   sites	   stabilises	   xNgn2	   against	   proteasomal	   degradation	   in	  P19	  cells.	  	  To	   investigate	   the	   role	   of	   non-­‐canonical	   sites	   and	   in	  particular	   cysteine	   residues	   in	  regulating	   xNgn2	   stability,	   xNgn2	   and	   xNgn2CO	   (both	   triply	   HA-­‐tagged	   on	   the	   C-­‐terminus)	  were	  transfected	  into	  P19	  cells	  overnight.	  	  Cells	  were	  then	  treated	  with	  20	  
µM	  cycloheximide	   to	   inhibit	   further	  protein	   translation.	   	  Then	  at	  certain	   timepoints	  cells	   were	   removed	   and	   lysed	   and	   proteins	   separated	   by	   15	   %	   SDS-­‐PAGE,	   before	  Western	   blotting	   using	  α-­‐HA-­‐HRP	   antibody	   (Roche).	   	   The	   half-­‐lives	   of	   xNgn2	  were	  calculated	  by	  reading	  protein	  levels	  after	  densitometry	  using	  ImageJ	  (Abramoff	  et	  al.,	  2004)	  software	  and	  using	  first-­‐order	  kinetics	  (Figure	  4.18).	  	  In	  P19	  cells,	  xNgn2	  has	  a	  half-­‐life	  of	  9.93	  +/-­‐	  2.74	  mins,	  whereas	  xNgn2CO	  was	  more	  stable	  with	  a	  half-­‐life	  of	  39.2	  +/-­‐	  19.4	  mins	  (Figure	  4.18,	  C).	  	  In	  Xenopus	  laevis	  mitotic	  activated	   egg	   extracts	   (Figure	   4.12)	   and	   neurula	   embryo	   extracts	   (Figure	   4.13),	  mutation	   of	   cysteines	   to	   alanines	   in	   xNgn2	   can	   be	   sufficient	   to	   stabilise	   xNgn2.	  	  Therefore	   cysteines	   can	   also	   target	   xNgn2	   for	   proteasomal	   degradation	   in	   this	  physiologically	  relevant	  setting	  in	  P19	  cells.	  	  Having	   investigated	   the	   half-­‐life	   of	   various	   xNgn2	  mutants	   in	   P19	   cell	   degradation	  assays,	   I	  wished	   to	   investigate	  whether	  ubiquitylation	  of	   xNgn2	   could	  be	  observed,	  and	   also	   whether	   ubiquitylation	   also	   occurred	   on	   serines	   and	   threonines	   in	  Ac2xNgn2KOCO.	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Figure 4.17: Removing canonical sites stabilises xNgn2 in P19 cells. 
P19 cells were transfected with 5 µg xNgn2, xNgn2KO, Ac2xNgn2 or Ac2xNgn2KO DNA.  20 µM 
cycloheximide was added and cells lysed at the timepoints indicated.  Samples were separated by 
15 % SDS-PAGE and Western blotting was undertaken using α-HA and α -tubulin antibodies.  
Half-lives were calculated by measuring exposures on film (A) and stability was plotted as the 
average of the stabilisation relative to wild type xNgn2 in each experiment (B).  (C) Half-lives were 




Figure 4.18: Mutation of cysteines is sufficient to stabilise xNgn2 in P19 cells. 
P19 embryonal carcinoma cells were transfected with 5 µg xNgn2 or xNgn2CO DNA.  20 µM 
cycloheximide was added and cells removed onto ice and lysed at the timepoints indicated in lysis 
buffer.  Samples were separated by 15 % SDS-PAGE and Western blotting was undertaken using 
α-HA and α -tubulin antibodies.  Half-lives were calculated by measuring exposures on film (A) and 
stability was plotted as the average of the stabilisation relative to wild type xNgn2 in each 
experiment (B).  (C) Half-lives were calculated using first-order rate kinetics.  Errors were 
calculated as the standard error of the mean (SEM).  All xNgn2 proteins were triply HA tagged on 
the C-terminus. 
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Figure 4.19: IP-re-IP of xNgn2 and Ub in P19 cells. 
P19 cells were transfected with HA-tagged xNgn2 or Ac2xNgn2KOCO and FLAG-tagged ubiquitin. 
Cells were lysed and samples were pulled down using either α-HA antibody (1st pulldown HA) or α-
FLAG antibody (1st pulldown FLAG). Samples were then pulled down again using either α-HA 
antibody (2nd pulldown HA) or α-FLAG antibody (2nd pulldown FLAG).  Samples were treated either 
with reducing buffer (+) or non-reducing buffer (-) before being separated by 15 % SDS-PAGE.  
Western blotting was undertaken using α-HA (A) and α-FLAG (B) antibodies. 
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For	  this,	  an	  immunoprecipitation	  re-­‐immunoprecipitation	  (IP-­‐re-­‐IP)	  was	  carried	  out.	  	  xNgn2	  or	  Ac2xNgn2KOCO	  DNA	  (triply	  HA-­‐tagged	  on	  the	  C-­‐terminus)	  was	  transfected	  into	  P19	  cells	  with	  FLAG-­‐tagged	  Ub	  DNA	  and	  stored	  at	  37	  °C	  overnight.	   	  Cells	  were	  treated	  with	  MG132	  for	  one	  hour	  before	  being	  collected	  onto	  ice	  and	  lysed.	  	  Samples	  were	   then	   either	   incubated	  with	   agarose	   beads	   coated	  with	  α-­‐HA	   antibody	   to	   pull	  down	  xNgn2	  proteins,	  or	  α-­‐FLAG	  antibody	  to	  pull	  down	  ubiquitylated	  proteins.	  	  	  	  These	   samples	   were	   eluted,	   divided	   into	   HA	   and	   FLAG	   samples,	   and	   the	  immunoprecipitation	   repeated	   again	   using	   either	   agarose	   beads	   coated	   with	  α-­‐HA	  antibody	   to	   pull	   down	   xNgn2	   proteins,	   or	   α-­‐FLAG	   antibody	   to	   pull	   down	  ubiquitylated	  proteins.	  	  	  	  After	   this	   second	  pulldown,	   samples	  were	  washed	   and	   eluted	   in	   either	   reducing	  or	  non-­‐reducing	   buffer.	   	   All	   samples	   were	   heated	   before	   12	  %	   SDS-­‐PAGE	   separation.	  	  Samples	  were	  subjected	  to	  Western	  Blotting	  using	  α-­‐HA-­‐HRP	  antibody	  (Figure	  4.19,	  A)	   or	  α-­‐FLAG	   antibody	   followed	  by	  α-­‐rabbit-­‐HRP	   secondary	   antibody	   (Figure	   4.19,	  B).	  	  First	  pulldown	  –	  blotting	  for	  HA	  (Figure	  4.19,	  A,	  lanes	  1-­‐4):	  	  At	  the	  first	  pulldown	  and	  blotting	  for	  HA-­‐tagged	  protein,	  pulling	  down	  xNgn2	  with	  α-­‐HA	  beads	  produces	  an	  ubiquitylation	  ladder	  (Figure	  4.19,	  A,	  lane	  1)	  whereas	  pulling	  down	   Ac2xNgn2KOCO	   results	   in	   a	   single	   band	   with	   the	   mobility	   of	   the	   wild	   type	  protein	  (Figure	  4.19,	  A,	  lane	  3).	  	  	  	  Likewise	   in	   FLAG	   pulldown,	   ubiquitylated	   HA-­‐tagged	   proteins	   are	   present	   in	   the	  xNgn2	   sample	   (Figure	   4.19,	   A,	   lane	   2)	   but	   only	   a	   single	   band	   appears	   for	  Ac2xNgn2KOCO	  (Figure	  4.19,	  A,	  lane	  4).	  	  	  	  In	  these	  particular	  samples	  we	  should	  only	  be	  observing	  HA-­‐tagged	  proteins	  so	  this	  suggests	   that	   we	   are	   able	   to	   pull	   down	   ubiquitylated	   xNgn2,	   but	   only	   unmodified	  Ac2xNgn2KOCO	  is	  observed	  as	  expected,	  as	  any	  linkages	  to	  Ac2xNgn2KOCO	  are	  labile	  and	   therefore	   linkages	   to	  Ub	  are	  broken	  under	  SDS-­‐PAGE	  conditions	  and	  a	  band	  at	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the	  level	  of	  unmodified	  xNgn2	  is	  observed.	  	  This	  is	  as	  we	  would	  expect,	  for	  only	  labile	  non-­‐canonical	  ubiquitylation	  linkages	  are	  available	  in	  Ac2xNgn2KOCO.	  	  	  	  First	  pulldown	  –	  blotting	  for	  FLAG	  (Figure	  4.19,	  B,	  lanes	  21-­‐24):	  	  With	   the	   first	  pulldown	  with	  FLAG	  all	   that	   is	   observed	   is	  polyubiquitylated	  protein	  (Figure	   4.19,	   B,	   lanes	   22	   and	   24)	   whereas	   pulldown	   with	   HA	   does	   not	   seem	   to	  produce	   any	   visible	   bands	   even	   at	   high	   exposure	   of	   film	   to	   ECL-­‐treated	  membrane	  (Figure	  4.19,	  B,	  lanes	  21	  and	  23).	  	  Second	  pulldown	  –	  blotting	  for	  HA	  (lanes	  5-­‐20):	  	  When	  a	  second	  pulldown	  is	  performed	  and	  blotted	  using	  α-­‐HA,	  for	  xNgn2	  pulldown	  1st	  with	   FLAG	   and	  2nd	  with	  HA	  or	   FLAG	   there	   are	   no	   visible	   bands	   (Figure	   4.19,	  A,	  lanes	   9-­‐12).	   	   However	   as	   this	   occurs	   for	   all	   samples	   in	   this	   set	   this	   suggests	   that	  perhaps	  sample	  was	  lost	  between	  the	  1st	  and	  2nd	  pulldowns.	  	  	  	  Pulling	   down	   xNgn2	   protein	  with	  HA	   pulldown	   1st	   and	   then	  HA	   again	   2nd	   shows	   a	  clear	   band	   running	   at	   the	   level	   of	   unmodified	   protein	   in	   reducing	   conditions	   (+)	  (Figure	   4.19,	   A,	   lane	   5)	   and	   non-­‐reducing	   conditions	   (-­‐)	   (Figure	   4.19,	   A,	   lane	   7)	  suggesting	  a	  substantial	  amount	  of	  unmodified	  protein	  is	  present.	  	  	  	  However	  when	  compared	  to	  Ac2xNgn2KOCO	  (Figure	  4.19,	  A,	  lanes	  6	  and	  8),	  there	  is	  greater	   evidence	   for	   a	   ladder	   of	   polyubiquitylated	   protein	   in	   xNgn2	   in	   these	   lanes	  which	  does	  not	  appear	  to	  be	  present	  in	  Ac2xNgn2KOCO,	  with	  a	  more	  obvious	  ladder	  in	   the	  xNgn2	   lane	   treated	  with	  non-­‐reducing	   (-­‐)	   conditions	   (Figure	  4.19,	  A,	   lane	  8).	  	  This	   suggests	   that	   polyubiquitylated	   protein	   is	   pulled	   down	   but	   that	  polyubiquitylation	  occurs	   at	  non-­‐canonical	   sites,	  which	  are	  disrupted	  when	  heating	  xNgn2	  samples	  but	  especially	  Ac2xNgn2KOCO.	  	  There	  is	  also	  a	  strong	  reducing	  agent	  dependence	  on	  xNgn2	  protein	  pulled	  down	  with	  HA	   beads	   1st	   and	   then	   FLAG	   beads	   2nd	   (Figure	   4.19,	   A,	   lanes	   6	   and	   8),	   which	   is	  repeated	   in	   Ac2xNgn2KOCO	   (Figure	   4.19,	   A,	   lane	   14	   and	   16).	   	   When	   reducing	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conditions	  are	  used	  (+)	  no	  band	  appears	  (Figure	  4.19,	  A,	   lanes	  6	  and	  14),	  but	  when	  non-­‐reducing	  conditions	  are	  used	  (-­‐),	  there	  is	  a	  strong	  ladder	  in	  xNgn2	  (Figure	  4.19,	  A,	  lane	  8),	  but	  a	  single	  band	  again	  in	  Ac2xNgn2KOCO	  (Figure	  4.19,	  A,	  lane	  16).	  	  	  	  Under	   these	  conditions	  we	  expect	   to	  see	  xNgn2	  protein	   that	  has	  been	  pulled	  down,	  then	  only	   polyubiquitylated	   xNgn2	   should	   be	   selected	   in	   the	   second	  pulldown,	   and	  then	   using	   reducing	   or	   non-­‐reducing	   conditions	   the	   samples	   are	   separated	   and	  blotted	  against	  α-­‐HA-­‐HRP	  to	  look	  for	  xNgn2.	  	  In	  Ac2xNgn2KOCO,	  this	  pattern	  is	  again	  observed	  when	   instead	  we	   pull	   down	   ubiquitylated	   protein	  with	  α-­‐FLAG	   and	   then	  pull	   down	   with	   α-­‐FLAG	   beads	   again	   and	   treat	   with	   either	   reducing	   (+)	   or	   non-­‐reducing	  (-­‐)	  conditions	  (Figure	  4.19,	  A,	  lanes	  18	  and	  20).	  	  Reducing	  conditions	  appear	  to	  result	  in	  loss	  of	  samples	  where	  ubiquitylated	  protein	  is	  pulled	  down	  in	  the	  second	  pulldown.	  	  Second	  pulldown	  –	  blotting	  for	  FLAG	  (Figure	  4.19,	  B,	  lanes	  25-­‐40):	  	  Repeating	   these	   pulldowns	   but	   blotting	   for	   FLAG-­‐tagged	   protein	   (Figure	   4.19,	   B)	  seems	  to	  show	  that	  the	  2nd	  pulldown	  using	  HA	  beads	  (Figure	  4.19,	  B,	  lanes	  25,	  27,	  29,	  31,	  33,	  35,	  37	  and	  39)	  results	  in	  either	  severe	  reduction	  or	  loss	  of	  signal.	  	  Conversely	  when	  the	  2nd	  pulldown	  is	  carried	  out	  using	  α-­‐FLAG	  (Figure	  4.19,	  B,	  lanes	  26,	  28,	  30,	  32,	   34,	   36,	   38	   and	   40)	   there	   is	   only	   a	   single	   clear	   band	   present.	   	   This	   band	   also	  migrates	  more	   slowly	   than	  xNgn2	  protein	   and	   so	   this	  may	   represent	   a	  background	  band,	  as	  it	  is	  present	  whether	  the	  first	  pulldown	  is	  selecting	  for	  FLAG-­‐	  or	  HA-­‐tags,	  and	  it	  is	  present	  in	  both	  xNgn2	  and	  Ac2xNgn2KOCO	  samples.	  	  
DISCUSSION	  	  If	  a	  variety	  of	  different	  sites	  in	  a	  protein	  could	  target	  for	  UPS-­‐mediated	  degradation,	  it	  	  could	  provide	  a	  highly	  dynamic	  system	  for	  swift	  ubiquitylation	  and	  deubiquitylation	  events.	  	  This	  may	  be	  required	  in	  maintaining	  short-­‐lived	  proteins	  in	  a	  dynamic	  range	  that	   is	   rapidly	   altered	   in	   response	   to	   changing	   environmental	   and	   developmental	  cues.	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The	   role	   of	   xNgn2	   N-­‐terminal	   ubiquitylation	   is	   clearly	   established	   and	   N-­‐terminal	  ubiquitylation	   can	   be	   blocked	   through	   the	   mutually	   exclusive	   process	   of	   co-­‐translational	  N-­‐terminal	  acetylation	   in	  preference	  to	  using	  bulky	  tags	  (Vosper	  et	  al.,	  2009).	   	  Addition	  of	   citrate	   synthase	  and	  oxaloacetate	  depletes	   the	   reserve	  of	   acetyl	  CoA	   in	   extract	   systems	   and	   therefore	   co-­‐translational	   acetylation	   cannot	   occur.	  	  Figure	  4.3	  clearly	  illustrates	  that	  upregulation	  of	  acetylation	  can	  be	  blocked	  to	  again	  free	  the	  N-­‐terminus	  for	  ubiquitylation	  in	  Ac2xNgn2KO,	  whilst	  preventing	  N-­‐terminal	  acetylation	  has	  no	  effect	  on	  wild	  type	  xNgn2.	  	  This	  demonstrates	  that	  the	  N-­‐terminus	  acts	  as	  an	  important	  ubiquitylation	  site	  targeting	  xNgn2	  for	  proteasomal	  degradation.	  	  xNgn2	  is	  degraded	  by	  the	  proteasome	  using	  canonical	  sites	  of	  ubiquitylation	  (Vosper	  et	   al.,	   2007).	   	   I	   wanted	   to	   confirm	   that	   non-­‐canonical	   ubiquitylation	   can	   target	   for	  proteasome-­‐mediated	  destruction.	  	  Figure	   4.4	   shows	   clearly	   that	   xNgn2	   degradation	   is	   ATP-­‐dependent	   and	   that	  interestingly	   the	   mutant	   form	   of	   xNgn2	   with	   no	   canonical	   sites	   of	   ubiquitylation	  available,	   Ac2xNgn2KO,	   also	   shows	  ATP-­‐dependent	   degradation.	   	   This	  may	   suggest	  that	   ubiquitylation	   on	   non-­‐canonical	   sites	   can	   target	   for	   proteasome-­‐mediated	  destruction.	  	  However	  this	  experiment	  does	  not	  clarify	  whether	  Ac2xNgn2KO	  may	  be	  targeted	  for	  degradation	   in	   an	  Ub-­‐independent	  manner.	   	   It	   could	   be	   the	   case,	   for	   example,	   that	  xNgn2	   can	   also	   be	   targeted	   for	   proteasomal	   degradation	   by	   unfolding	   properties	  alone	  (Prakash	  et	  al.,	  2004).	  	  	  xNgn2	   is	   ubiquitylated	   on	   non-­‐canonical	   sites.	   	   This	   may	   be	   a	   more	   widespread	  phenomenon	  but	  we	  have	  not	  looked	  for	  it	  before.	  	  Reducing	  agents	  are	  usually	  used	  in	   running	   SDS-­‐PAGE	   as	   part	   of	   a	   standard	   protocol.	   	   Bands	   at	   the	   level	   of	   native	  protein	   that	   would	   be	   released	   from	   polyUb	   chains	   anchored	   via	   thioester	   and	  possibly	   ester	   bonds	   may	   be	   mistaken	   for	   background	   non-­‐specific	   binding	   in	   a	  ubiquitylation	  assay,	  if	  proper	  controls	  are	  not	  used.	  	  Assays	  in	  Xenopus	  laevis	  are	  also	  much	  more	  sensitive	  than	  those	  used	  so	  far	  in	  tissue	  culture.	  	  	  	  
	  124	  
MyoD	   is	   a	   basic	   helix-­‐loop-­‐helix	   protein	   involved	   in	  myogenesis,	   playing	   the	   same	  role	  as	  xNgn2	  does	   in	  neurogenesis.	   	  MyoD	   is	  known	  to	  be	  ubiquitylated	  on	   lysines	  and	  the	  N-­‐terminus	  in	  a	  similar	  manner	  to	  xNgn2	  (Breitschopf	  et	  al.,	  1998)	  therefore	  I	  wanted	  to	  investigate	  if	  MyoD	  is	  also	  non-­‐canonically	  ubiquitylated.	  	  An	  ubiquitylation	  assay	  was	  performed	  for	  wild	  type	  MyoD	  and	  a	  mutant	  form	  with	  all	   lysines	  mutated	   to	   arginines.	   	  Ub	   is	   covalently	   attached	   to	   lysines	   and	   to	   the	  N-­‐terminus.	   	   Therefore	   pulling	   out	   his-­‐Ub-­‐linked	   proteins	   should	   result	   in	   a	   ladder	  running	   at	   least	   8	   kDa	   higher	   than	   the	   unconjugated	   protein.	   	   However,	   if	  ubiquitylation	  occurs	  via	  labile	  linkages,	  chemical	  conditions	  that	  disrupt	  this	  linkage	  such	  as	   reducing	  agents	  and	  high	  pH	  will	   result	   in	  a	   release	  of	  unconjugated	  MyoD	  from	  the	  his-­‐Ub	  chain.	  The	  results	  of	  the	  ubiquitylation	  assay	  in	  Figure	  4.5	  show	  that	  non-­‐canonical	   ubiquitylation	   is	   also	   present	   in	   wild	   type	   MyoD,	   as	   well	   as	   the	  lysineless	  form.	  	  Polyubiquitylated	  forms	  of	  the	  proteins	  are	  clearly	  seen	  in	  the	  form	  of	   ladders	   spaced	   about	   8kDa	   apart	   in	   both	   reducing	   and	   non-­‐reducing	   conditions.	  	  Therefore	  other	  bHLH	  proteins	  are	  capable	  of	  being	  modified	  by	  Ub	  on	  non-­‐canonical	  sites.	  	  Having	  established	  that	  xNgn2	  and	  MyoD	  are	  ubiquitylated	  on	  non-­‐canonical	  sites	   I	  then	   wished	   to	   see	   if	   this	   ubiquitylation	   could	   target	   xNgn2	   for	   proteasomal	  degradation.	   	  There	  are	  7	  cysteines	   to	  which	  Ub	  could	  potentially	  be	  attached	  via	  a	  thioester	   bond	   (see	   Figure	   4.6).	   	   In	   an	   interphase	   degradation	   assay,	   mutation	   of	  cysteines	   to	   alanines	   has	   a	   slight	   stabilising	   effect	   on	   xNgn2	   (Figure	   4.7)	   and	   in	  interphase	   extract,	   non-­‐canonical	   sites	   are	   clearly	   ubiquitylated	   (Figure	   4.8)	   in	  xNgn2.	  	  This	  also	  occurs	  in	  Ac2xNgn2KO	  where	  only	  non-­‐canonical	  sites	  are	  available	  and	  also	  in	  Ac2xNgn2KOCO,	  where	  only	  hydroxyl-­‐bearing	  residues	  are	  present.	  	  The	  ubiquitylation	  assays	  in	  Figure	  4.8,	  A	  do	  exhibit	  a	  large	  amount	  of	  background	  in	  the	  untagged	   Ub	   control	   samples,	   with	   bands	   running	   at	   the	   level	   of	   unconjugated	  protein,	  which	  is	  most	  likely	  due	  to	  insufficient	  washing.	  	  However	  I	  am	  confident	  of	  the	  results	  in	  the	  his-­‐Ub	  samples	  particularly	  where	  non-­‐modified	  protein	  appears,	  as	  in	  many	  assays	  no	  background	  is	  observed	  in	  the	  untagged	  Ub	  samples.	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Samples	   of	   Mes1,	   a	   yeast	   protein	   implicated	   in	   cell	   cycle	   progression,	   were	   kindly	  donated	  by	  Hiro	  Yamano	  (Kimata	  et	  al.,	  2008,	  Yamano	  et	  al.,	  2004)	  for	  testing	  in	  the	  
Xenopus	   laevis	   extract	   systems	   to	   see	   if	   a	   protein	   unrelated	   to	   bHLH	   transcription	  factors	  could	  be	  non-­‐canonically	  ubiquitylated.	  	  Mes1	  ubiquitylation	  is	  not	  altered	  by	  addition	   of	   reducing	   agents;	   however	   when	   all	   lysines	   are	   mutated	   to	   arginines,	  unmodified	   protein	   is	   released	   as	   demonstrated	   by	   the	   appearance	   of	   a	   band	   of	  protein	   of	   lower	   molecular	   weight.	   	   Therefore	   this	   protein	   exhibits	   a	   differing	  behaviour	   to	   xNgn2	   and	   mMyoD	   illustrating	   that	   Xenopus	   extract	   systems	   do	   not	  force	  non-­‐canonical	  ubiquitylation	  on	  all	  proteins.	  	  Comparison	  between	  species	   identifies	  2	  conserved	  cysteine	  residues	   in	  Ngn2	   from	  various	   species	   (Figure	   4.9)	   and	   mutants	   of	   these	   cysteines	   were	   analysed	   in	  degradation	   assays	   in	   interphase	   activated	   egg	   extract	   (Figure	   4.10).	   	   Cysteine	  mutation	   in	   this	  context	  does	   lead	  to	  subtle	  half-­‐life	  changes	  but	   in	   these	  particular	  extracts,	   the	   half-­‐life	   of	   xNgn2	   and	   xNgn2KO	  were	   unusually	   long	   and	   so	   I	   cannot	  state	  with	  confidence	  that	  these	  cysteines	  truly	  have	  an	  effect.	   	  Also	  it	  may	  be	  more	  relevant	   to	   investigate	   these	  mutants	   in	   a	   different	   extract	   system	   such	   as	  mitotic	  activated	  egg	  extract,	  which	  in	  Figure	  4.12	  shows	  that	  cysteines	  alone	  can	  affect	  Ub-­‐mediated	  destruction	  of	  xNgn2.	  	  Blocking	   cysteine	   residues	  by	   alkylation	  with	  NEM	  was	   investigated	   in	  degradation	  assays	  to	  see	  if	  there	  was	  an	  effect	  on	  xNgn2	  stability	  (Figure	  4.11).	  	  The	  hypothesis	  was	  that	  xNgn2	  and	  Ac2xNgn2KO	  stability	  may	  be	  affected	  as	  cysteines	  are	  present.	  	  Ac2xNgn2KOCO	   should	   show	   no	   difference	   compared	   with	   the	   control	   as	   there	  should	  be	  no	  groups	  available	  for	  alkylation	  of	  a	  soft	  electrophile	  such	  as	  NEM.	  	  This	  did	  not	  appear	  to	  be	  the	  case	  for	  xNgn2	  and	  xNgn2CO	  although	  from	  Figure	  4.11,	  B	  we	   see	   a	   greater	   difference	   between	   controls	   and	   NEM-­‐treated	   samples	   where	  cysteine	   is	   available	   and	   all	   canonical	   sites	   of	   ubiquitylation	   are	   unavailable	   in	  Ac2xNgn2KO.	  	  It	  could	  be	  that	  cysteines	  only	  become	  important	  when	  canonical	  sites	  are	   unavailable	   for	   ubiquitylation.	   	   However	   NEM	   is	   a	   potent	   alkylating	   agent	   and	  whilst	  steps	  were	  taken	  to	  purify	  the	  IVT	  radiolabelled	  protein	  from	  the	  NEM	  before	  adding	   to	   extract,	   it	   is	   not	   certain	   whether	   NEM	   could	   have	   had	   effects	   on	   the	  ubiquitylation	  process	  in	  the	  extract	  other	  than	  those	  predicted.	  	  This	  seems	  to	  be	  the	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case	  for	  the	  results	  for	  xNgn2CO,	  where	  NEM	  treatment	  stabilises	  the	  protein	  (albeit	  not	  significantly)	  but	  should	  not	  actually	  be	  alkylating	  it.	  	  In	  mitosis,	  xNgn2	  proteins	  had	  half-­‐lives	  of	  15.8	  +/-­‐	  2.1	  mins,	  35.6	  +/-­‐	  2.7	  mins	  and	  38.3	  +/-­‐	  5.4	  mins	   for	  xNgn2,	   xNgn2KO	  and	  xNgn2CO	  respectively	   (Figure	  4.12).	   	   In	  interphase,	  xNgn2	  proteins	  had	  half-­‐lives	  of	  30.5	  +/-­‐	  2.5	  mins,	  36.3	  +/-­‐	  2.9	  mins	  and	  33.0	   +/-­‐	   2.0	   mins	   for	   xNgn2,	   xNgn2KO	   and	   xNgn2CO	   respectively	   (Figure	   4.10).	  	  	  xNgn2	   is	   degraded	  more	   quickly	   in	   mitosis	   than	   in	   interphase	   and	   so	   the	   relative	  stabilisation	  of	  mutating	  cysteines	  or	  lysines	  is	  much	  greater	  in	  mitosis.	   	  As	  removal	  of	  cysteines	  is	  as	  stabilising	  as	  removal	  of	  lysines,	  it	  suggests	  a	  powerful	  role	  for	  non-­‐canonical	  ubiquitylation	  in	  targeting	  xNgn2	  for	  degradation	  in	  mitosis.	  	  	  Similar	   results	   were	   observed	   in	   neurula	   extract	   (Figure	   4.13)	   where	   conversely	  xNgn2	  exhibits	  a	  slightly	  longer	  half-­‐life	  than	  in	  interphase	  (Figure	  4.13,	  C),	  therefore	  cysteines	   are	   as	   efficient	   at	   driving	  Ub-­‐mediated	  proteolysis	   as	   lysines	   in	   neurulae.	  	  Furthermore	   whilst	   Ac2xNgn2KO,	   the	   form	   of	   xNgn2	   lacking	   all	   canonical	   amine-­‐based	   sites	   of	   ubiquitylation,	   exhibits	   a	   long	   half-­‐life	   in	   degradation	   assays	   (Figure	  4.14,	   C),	   further	   mutation	   to	   remove	   all	   cysteine	   residues	   and	   replace	   them	   with	  alanines	   stabilises	   the	   protein	   yet	   further	   (Figure	   4.14).	   	   All	   this	   evidence	   suggests	  that	   cysteines	   have	   an	   important	   role	   to	   play	   in	   regulating	   stability	   and	   the	  ubiquitylation	   assay	   in	   Figure	   4.15	   illustrates	   that	   not	   only	   is	   Ac2xNgn2KO	   still	  ubiquitylated,	   but	   Ac2xNgn2KOCO	   is	   also.	   	   This	   implicates	   serines,	   threonines	   and	  possibly	  even	  tyrosines	  in	  the	  Ub-­‐mediated	  proteolysis	  of	  xNgn2.	  	  Having	   highlighted	   differences	   in	   various	   Xenopus	   laevis	   extracts	   in	   the	   cysteine	  dependence	   of	   xNgn2	   stability	   I	   went	   on	   to	   compare	   the	   contribution	   of	   non-­‐canonical	  ubiquitylation	  to	  degradation	  in	  mammalian	  P19	  cells.	  	  The	   results	   from	   Figure	   4.16	   show	   clearly	   that	   xNgn2	   can	   be	   degraded	   by	   the	   Ub	  proteasome	   system	   in	  mammals	  but	  work	  has	   shown	   that	   xNgn2	   cannot	  drive	  P19	  neuronal	  differentiation,	  whereas	  mNgn2	  can	  (Christelle	  Fiore-­‐Heriche,	  unpublished	  data).	   	   However	   P19	   cells	   are	   still	   adequate	   for	   investigation	   of	   mechanisms	  regulating	  xNgn2	  ubiquitylation	  and	  degradation.	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Due	   to	   the	   lack	   of	   a	   suitable	   xNgn2	   antibody,	   HA-­‐tagging	   is	   an	   undesirable	   yet	  necessary	  modification	  to	  the	  protein,	  which	  may	  affect	  its	  degradation.	  	  Such	  issues	  are	  minimised	  by	  placing	  the	  tag	  on	  the	  C-­‐terminus	  –	  tagging	  the	  N-­‐terminus,	  which	  provides	  a	  site	  of	  ubiquitylation,	  should	  be	  avoided	  –	  but	  there	  may	  still	  be	  effects	  on	  the	  C-­‐terminus	  such	  as	  affecting	  folding	  properties.	  	  Also	  tissue	  culture	  information	  is	  arguably	  still	  an	   in	  vitro	  system.	   	  However	  it	  shows	  consistency	  with	  Xenopus	  laevis,	  which	  is	  very	  encouraging.	  	  xNgn2	  is	  proteasomally	  degraded	  in	  P19	  cells,	  as	  is	  Ac2xNgn2KO.	  	  Therefore	  xNgn2	  is	  degraded	   by	   Ub-­‐mediated	   proteolysis,	   and	   despite	   mutating	   all	   amine-­‐based	  ubiquitylation	   sites,	   Ac2xNgn2KO	   is	   stabilised	   on	   the	   addition	   of	   the	   proteasome	  inhibitor	   MG132	   and	   so	   this	   suggests	   non-­‐canonical	   ubiquitylation	   can	   target	   the	  protein	   for	  degradation.	   	  Figure	  4.17	   illustrates	   that	  xNgn2	  stability	   is	   regulated	  by	  canonical	   ubiquitylation	   sites	   in	   P19	   cells	   in	   an	   identical	  manner	   to	  Xenopus	   laevis	  extract	   systems	   and	   Figure	   4.18	   demonstrates	   that	   in	   an	   environment	   capable	   of	  neuronal	   differentiation	   that	   the	   P19	   cell	   line	   provides,	   xNgn2CO	   is	   stabilised	  compared	   to	   xNgn2,	   demonstrating	   again	   that	   in	   a	   physiological	   setting	   cysteines	  alone	  are	  sufficient	  to	  target	  xNgn2	  for	  proteasomal	  degradation.	  	  The	  results	  of	  the	  IP-­‐re-­‐IP	  experiment	  in	  Figure	  4.19	  are	  inconclusive	  but	  do	  suggest	  that	   Ac2xNgn2KOCO	   can	   still	   be	   ubiquitylated.	   	   This	   experiment	   might	   be	   best	  repeated	   with	   no	   heating	   of	   the	   non-­‐reducing	   agent	   samples	   as	   boiling	   will	   still	  liberate	  xNgn2	  from	  labile	  bonds	  to	  polyubiquitin	  chains.	  	  	  	  Having	  established	  that	  cysteine	  ubiquitylation	  can	  target	  for	  destruction,	  why	  should	  this	   be	   the	   case?	   	   As	   illustrated	   in	   Figure	   4.20,	   thioester	   linkages	   to	   cysteine	   are	  actually	  the	  weakest	  bond	  a	  protein	  could	  form	  with	  Ub	  (Clayden	  et	  al.,	  2000).	  	  Ester	  linkages	  with	  hydroxyls	  have	  an	  intermediate	  stability	  and	  isopeptide	  or	  amide	  bonds	  with	  amine	  groups	  form	  the	  most	  stable	  linkages.	  	  Whilst	  an	  unstable	  link	  is	  perhaps	  useful	  in	  a	  highly	  dynamic	  signalling	  system,	  are	  cysteines	  not	  simply	  too	  weak	  to	  be	  relevant	  as	  a	  nucleophile	  for	  ubiquitylation?	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In	   terms	   of	   thermodynamics,	   cysteines	   indeed	   would	   be	   a	   poor	   choice	   for	   stable	  ubiquitylation.	   	   However,	   the	   biochemical	   environment	   of	   the	   cell	   rarely	   ventures	  into	   the	   realm	   of	   stable	   thermodynamic	   equilibrium;	   rather,	   such	   biochemical	  reactions	   are	   governed	  by	   the	   kinetics	   of	   reactions	   and	   Figure	   4.21	   illustrates	  why	  cysteines	  may	  play	  a	  significant	  role	  particularly	  in	  modification	  for	  signalling.	  	  Ub	  is	  shuttled	  along	  the	  ubiquitylation	  cascade	  from	  an	  Ub-­‐activating	  enzyme,	  or	  E1,	  to	  an	  Ub-­‐conjugating	  enzyme,	  or	  E2,	  and	   in	   the	  case	  of	  HECT	  domains,	  onto	  an	  E3	   ligase,	  and	   in	   all	   these	   cases,	   Ub	   is	   conjugated	   to	   a	   cysteine	   residue	   on	   the	   enzyme.	  	  Therefore	  a	  weak	  thioester	  linkage	  is	  always	  attacked	  by	  a	  nucleophilic	  group	  when	  ubiquitylating	  a	   substrate	  protein.	   	  As	   this	   thioester	   link	   consists	  of	  diffuse	  orbitals	  particularly	  from	  the	  large	  sulfur	  atom,	  and	  there	  is	  not	  a	  large	  polarisation	  of	  charge,	  this	   is	   classed	   as	   a	   soft	   electrophile	   (Clayden	   et	   al.,	   2000).	   	   Soft	   electrophiles	   react	  preferentially	  with	  nucleophiles	  which	  are	  also	  soft,	  that	  is	  with	  diffuse	  large	  orbitals	  and	  high	  energy	  highest	  occupied	  molecular	  orbitals	  (HOMOs)	  that	  overlap	  well	  with	  the	   lowest	  unoccupied	  molecular	  orbital	   (LUMOs)	  of	   the	   thioester	   linkage	  (which	   is	  the	   carbonyl	  π*	  MO).	   	   In	   this	   respect,	   sulfur	   thiols	  will	  undergo	   the	   fastest	   reaction	  with	  a	  thioester	  carbonyl,	  followed	  by	  hydroxyls,	  followed	  by	  amines,	  which	  become	  harder,	  more	  charge-­‐dominated	  nucleophiles.	   	   So	  whilst	   the	   link	  may	  be	   labile,	   it	   is	  formed	   more	   quickly	   than	   the	   more	   stable	   isopeptide	   bond	   and	   could	   potentially	  provide	  a	  greater	  range	  for	  dynamic	  signalling	  behaviour	  in	  ubiquitylation.	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Figure 4.20: Extent of orbital overlap in linkages to ubiquitin. 
In an ester-like linkage between the amino acid residue and the C-terminus of ubiquitin, the extent 
of orbital overlap relates to the size, symmetry and energy of the orbitals involved, how closely 
these properties match, and whether the bond is polarised.  Hence amide bonds involving nitrogen 
are the strongest; and thioester linkages using sulfur are weakest. 
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Figure 4.21: Kinetics of protein-ubiquitin covalent bond formation. 
As a soft, high-energy nucleophile, the lone pair of electrons on sulfur actually form a better overlap 
with the lowest unoccupied molecular orbital (LUMO) of the E2-ubiquitin linkage, which is a soft 
electrophile, than the hard nucleophile presented by the nitrogen lone pair. 	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CHAPTER	  5	  
Phosphorylation	  and	  Stability	  of	  xNgn2	  
	  
	  
INTRODUCTION	  	  Transcription	   factor	   activity	   is	   tightly	   regulated	   and	   control	   can	  be	   achieved	   at	   the	  level	  of	  PTM,	  such	  as	  phosphorylation	  (Tootle	  and	  Rebay,	  2005).	  	  Work	  on	  the	  cyclin	  dependent	  kinase	  inhibitor	  (cdki)	  Xic1,	  which	  stabilises	  xNgn2	  (Vernon	  et	  al.,	  2003),	  has	  led	  to	  interest	  in	  the	  phosphorylation	  status	  of	  xNgn2	  and	  the	  effect	  that	  this	  has	  on	   activity	   and	   stability.	   	   There	   is	   a	   clear	   link	   between	   the	   signalling	   roles	   of	  phosphorylation	   and	   ubiquitylation	   for	   proteasomal	   degradation	   (Hunter,	   2007).	  	  The	  stability	  of	  many	  bHLH	  proteins	  such	  as	  MyoD	  is	  regulated	  by	  phosphorylation	  events	  (Tintignac	  et	  al.,	  2000,	  Kitzmann	  et	  al.,	  1999).	  	  Phosphorylation	  may	  or	  may	  not	  have	  a	  role	  in	  proteasomal	  degradation.	  	  Targeting	  of	   substrates	   for	   degradation	   by	   the	   SCF	   complex	   (Skp-­‐Cullin-­‐F-­‐box)	   requires	  phosphorylation	   of	   conditional	   ‘phosphodegron’	   sites	   (Mayer,	   2005,	  Willems	   et	   al.,	  2004).	   	   This	   phosphorylation	   is	   required	   for	   the	   production	   of	   substrate-­‐E3	   ligase	  interactions	  (Mayer,	  2005).	   	  The	  stability	  of	   the	  related	  bHLH	  protein	  MyoD	  against	  degradation	   can	   be	   regulated	   by	   phosphorylation	   events	   on	   cdk	   consensus	   sites	  (Song	   et	   al.,	   1998)	   and	   cell	   cycle	   regulating	   proteins	   such	   as	   p27	   are	   regulated	   by	  phosphorylation	   with	   respect	   to	   ubiquitylation	   (Montagnoli	   et	   al.,	   1999).	   	   xNgn2	  contains	  a	  number	  of	  putative	  cdk	  consensus	  sites	  for	  phosphorylation	  as	  ‘SP’	  or	  ‘TP’	  sites	   (phosphorylation	   possibly	   occurring	   on	   the	   serine	   or	   threonine	   in	   each	   case),	  which	  may	   serve	   as	   interaction	   domains	  with	  WD40	   domains	   present	   in	  many	   E3	  ligases	  (Yaffe	  and	  Elia,	  2001).	  	  	  	  Jonathan	  Vosper	  identified	  a	  Casein	  Kinase	  II	  (CK2)	  consensus	  site	  at	  T118	  in	  xNgn2	  related	   to	   Mash1	   (Vinals	   et	   al.,	   2004)	   and	   mutation	   at	   T118	   to	   alanine	   in	   xNgn2	  disrupts	  phosphorylation	  events	   shown	   to	  be	   linked	   to	  xE12-­‐binding	   (Vosper	  et	  al.,	  2007).	   	   Therefore	   there	   may	   be	   a	   role	   for	   phosphorylation	   in	   stability	   with	   the	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heterodimeric	  binding	  partner	  of	  xNgn2,	  namely	  xE12.	  	  Indeed	  E47	  phosphorylation	  affects	   association	   with	   MyoD	   (Lluis	   et	   al.,	   2005)	   so	   phosphorylation	   has	   an	  important	  role	   to	  play	   in	   the	  activity	  of	  xNgn2	  and	  a	  mechanism	  for	   the	  role	  of	   this	  modification	  is	  unknown.	  	  xNgn2	   is	  phosphorylated	   in	   a	  manner	   affecting	   its	   function	   (Hand	  et	   al.,	   2005)	   so	   I	  wanted	  to	  establish	  whether	  phosphorylation	  on	  cdk	  consensus	  sites	  had	  any	  effect	  on	   xNgn2	   stability.	   	   This	   is	   an	   especially	   interesting	   question	   as	   removal	   of	   all	  putative	   SP	   consensus	   sites	   in	   xNgn2	   results	   in	   a	   hyperactive	   form	   of	   xNgn2	   in	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Figure 5.1: Cyclin dependent kinase (cdk) consensus serines and threonine in xNgn2. 
Cyclin dependent kinases (cdks) are proline-directed kinases which phosphorylate serines or 
threonines followed by prolines , shown schematically. The sites are modelled onto a structure of a 
proneural bHLH heterodimer complexed to DNA. The disordered N-terminal domain is bordered in 
blue; the bHLH domain in red; and the disordered C-terminal domain in green. 
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Figure 5.2: xNgn2 and 9S-AxNgn2 stability in Xenopus laevis extracts. 
Xenopus laevis interphase activated egg extracts, mitotic activated egg extracts and neurula 
embryo extracts were supplemented with 35S-labelled xNgn2 or 9S-AxNgn2 and incubated at 21 
°C.  Samples were taken at the timepoints indicated and subjected to 15 % SDS-PAGE.  Gels were 
analysed by autoradiography (A) and quantitative phosphorimaging analysis, calculating the half-
life for degradation in each extract (B).  (C) Half-lives were calculated using first-order rate kinetics, 
and errors calculated using the Standard Error of the Mean (SEM). 
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Figure 5.3: xNgn2 and 9S-AxNgn2 treated with the cdk inhibitor roscovitine and the 
dephosphorylating protein λ-phosphatase. 
Xenopus laevis interphase activated egg extracts, mitotic activated egg extracts and neurula 
embryo extracts were supplemented with 35S-labelled xNgn2 or 9S-AxNgn2 and incubated with 
either the blanket cdk inhibitor roscovitine or λ-phosphatase.  Samples were subjected to 15 % 
SDS-PAGE.  Gels were analysed by autoradiography. 
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extract,	   roscovitine	   treatment	   results	   in	   faster	  migration	   of	   xNgn2	   than	   the	  DMSO-­‐incubated	  control,	  but	  9S-­‐AxNgn2	  gel	  migration	  is	  not	  affected	  (Figure	  5.3).	  	  Likewise	  
λ-­‐phosphatase	   treated	  xNgn2	  migrates	  more	  rapidly	   than	   the	  buffer-­‐only	  sample	   in	  mitotic	  and	  neurula	  extracts.	  	  Again,	  9S-­‐AxNgn2	  shows	  no	  alteration	  in	  its	  migration	  pattern.	   	   Therefore,	   the	   alteration	   in	  migration	   of	   xNgn2	   but	   not	   9S-­‐AxNgn2	   on	  λ-­‐phosphatase	  treatment	  demonstrates	  that	  xNgn2	  is	  phosphorylated	  in	  mitotic,	  and	  to	  a	   lesser	   extent	   neurula,	   extract	   in	   a	   manner	   that	   alters	   its	   migration	   in	   gel	  electrophoresis,	  whereas	  9S-­‐AxNgn2	  is	  not.	   	  Phosphorylation	  cannot	  be	  observed	  by	  gel	   electrophoresis	   in	   interphase	   extract.	   	   Roscovitine	   treatment	   shows	   that	   this	  migration-­‐altering	  phosphorylation	  of	  xNgn2	  is	  due	  to	  cyclin	  dependent	  kinases.	  	  Much	   of	   the	   work	   carried	   out	   on	   Ngn2	   activity	   is	   divided	   between	   xNgn2	   in	   vivo	  activity	   in	   Xenopus	   laevis	   embryos	   (Hindley,	   2011)	   and	   mNgn2	   activity	   in	   Mus	  
musculus	  P19	  embryonal	   carcinoma	  cells	   (Ali	   et	   al.,	   2011).	   	  Having	   investigated	   the	  degradation	  of	  xNgn2	  in	  P19	  cells	  (Figures	  4.16-­‐19)	  I	  decided	  to	  investigate	  whether	  the	  mouse	  protein,	  mNgn2	  -­‐	  which	  differs	  in	  distribution	  of	  SP	  sites	  from	  xNgn2	  -­‐	  and	  9S-­‐AmNgn2	  would	  exhibit	  similar	  degradation	  properties	  to	  xNgn2	  and	  9S-­‐AxNgn2	  in	  
Xenopus	   laevis	   extract	   systems.	   	   Therefore	   35S-­‐radiolabelled	   IVT	   xNgn2	   and	  mNgn2	  and	   their	   9S-­‐A	   mutants	   were	   incubated	   in	   Xenopus	   laevis	   interphase	   and	   mitotic	  activated	  egg	  and	  neurula	  embryo	  extracts	  for	  degradation	  assays	  (Figure	  5.4).	  	  Whilst	   both	   xNgn2	   and	   mNgn2	   exhibit	   shifts	   in	   gel	   migration	   on	   incubation	   with	  mitotic	  extract	  (Figure	  5.4,	  A),	  their	  behaviour	  in	  terms	  of	  degradation	  pattern	  is	  very	  different.	   	  mNgn2	   is	  actually	   stabilised	   in	  mitotic	  and	  neurula	  extracts	  compared	   to	  interphase,	  with	  half-­‐lives	  for	  degradation	  of	  31.1	  +/-­‐	  5.1	  mins	  and	  68.0	  +/-­‐	  12.6	  mins	  compared	  to	  just	  21.3	  +/-­‐	  4.8	  mins	  in	  interphase.	  	  Also,	  9S-­‐AmNgn2	  has	  a	  half-­‐life	  in	  interphase	  of	  28.3	  +/-­‐	  0.7	  mins	  which	  is	  significantly	  more	  than	  mNgn2	  with	  a	  half-­‐life	  of	  21.3	  +/-­‐	  4.8	  mins,	  whereas	  xNgn2	  and	  9S-­‐AxNgn2	  exhibit	  similar	  stabilities	  in	  interphase	   extract	   with	   half-­‐lives	   of	   25.4	   +/-­‐	   9.1	   mins	   and	   25.1	   +/-­‐	   3.2	   mins	  respectively.	   	  Therefore	  mNgn2	  stability	   in	  relation	  to	  phosphorylation	  does	  not	  act	  as	  a	  good	  comparison	  with	  xNgn2	  in	  Xenopus	  laevis	  extract	  systems.	  
	  138	  
 
Figure 5.4: xNgn2 and mNgn2 and their 9S-A mutants are degraded in Xenopus laevis 
extracts. 
Xenopus laevis interphase activated egg extracts, mitotic activated egg extracts and neurula 
embryo extracts were supplemented with 35S-labelled xNgn2, 9S-AxNgn2, mNgn2 or 9S-AmNgn2 
and incubated at 21 °C.  Samples were taken at the timepoints indicated and subjected to 15 % 
SDS-PAGE.  Gels were analysed by autoradiography (A) and quantitative phosphorimaging 
analysis, calculating the average stabilisation relative to wild-type xNgn2 within each extract (B).  
(C) Half-lives were calculated using first-order rate kinetics, and errors calculated using the 
Standard Error of the Mean (SEM).  Experiments in interphase and neurula extracts were carried 
out in duplicate. 
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Mutation	  of	  ‘TP’	  sites	  does	  not	  affect	  stability	  	  As	  well	   as	  9	   ‘SP’	   sites,	   xNgn2	  also	  has	  a	   ‘TP’	   site	  at	  T149	   in	   the	  C-­‐terminal	  domain.	  	  Site-­‐directed	   mutagenesis	   by	   Kate	   Wilson	   produced	   xNgn2	   and	   9S-­‐AxNgn2	   forms	  with	   this	   threonine	  mutated	   to	  alanine,	  namely	  T149AxNgn2	  and	  9S-­‐AT149AxNgn2	  (Figure	   5.5).	   	   SP	   and	   TP	   mutants	   were	   also	   made	   in	   backgrounds	   of	   lysineless	  xNgn2KO	   and	   the	   N-­‐terminal	   acetylation	   mutant	   Ac2xNgn2KO	   which	   also	   lacks	  lysines.	  	  Mutations	  of	  T118	  (the	  casein	  kinase	  II	  site)	  to	  alanine	  were	  also	  made.	  	  To	  investigate	  any	  effect	  on	  stability	  of	  the	  TP	  site,	  degradation	  assays	  were	  carried	  out	  using	   35S-­‐radiolabelled	   IVT	   proteins.	   	   Stability	   was	   assessed	   in	   Xenopus	   laevis	  interphase	   activated	   egg	   and	   neurula	   embryo	   extracts	   (Figure	   5.6).	   	   A	   full	   list	   and	  description	  of	  all	  xNgn2	  mutants	  can	  be	  found	  in	  the	  Abbreviations	  section.	  	  xNgn2,	  9S-­‐AxNgn2,	  9S-­‐AT149AxNgn2	  and	  9S-­‐AT(118,149)AxNgn2	  have	  half-­‐lives	   in	  interphase	  of	  35.0	  +/-­‐	  0.5	  mins,	  28.0	  +/-­‐	  0.7	  mins,	  56.0	  +/-­‐	  35	  mins	  and	  31.5	  +/-­‐	  1.5	  mins	  respectively.	   	   In	  neurula,	  they	  have	  half-­‐lives	  of	  39.5	  +/-­‐	  5.1	  mins,	  34.2	  +/-­‐	  7.4	  mins,	  30.0	  +/-­‐	  2.6	  and	  34.3	  +/-­‐	  6.0	  mins	  respectively.	  	  xNgn2KO,	   9S-­‐AxNgn2KO,	   9S-­‐AT149AxNgn2KO	   and	   9S-­‐AT(118,149)AxNgn2KO	   have	  half-­‐lives	   in	   interphase	  of	  63.8	  +/-­‐	  9.8	  mins,	  76.3	  +/-­‐	  12.3	  mins,	  44.8	  +/-­‐	  22.3	  mins	  and	  59.8	  +/-­‐	  17.3	  mins	  respectively.	   	   In	  neurula,	   they	  have	  half-­‐lives	  of	  44.5	  +/-­‐	  8.4	  mins,	  46.3	  +/-­‐	  3.7	  mins,	  57.9	  +/-­‐	  6.5	  mins	  and	  50.1	  +/-­‐	  5.3	  mins	  respectively.	  	  Ac2xNgn2KO	  and	  9S-­‐AxNgn2KO	  have	  half-­‐lives	  in	  interphase	  of	  173	  +/-­‐	  42	  mins	  and	  91.5	  +/-­‐	  66.5	  mins	  respectively.	  	  In	  neurula,	  they	  have	  half-­‐lives	  of	  79.2	  +/-­‐	  13.1	  and	  82.2	  +/-­‐	  7.9	  mins	  respectively.	  	  Therefore,	  the	  effect	  of	  mutating	  putative	  serine	  and	  threonine	  phosphorylation	  sites	  has	   very	   little	   effect	   on	   the	   stability	   of	   proteins	   which	   have	   all	   lysines	   and	   the	   N-­‐terminus	  available	  for	  ubiquitylation;	  or	  just	  the	  N-­‐terminus	  available;	  or	  no	  amino-­‐based	   nucleophilic	   sites	   at	   all.	   	   The	   presence	   of	   ubiquitylation	   sites	   themselves	   is	  more	  important	  than	  the	  availability	  of	  phosphosites	  in	  regulating	  xNgn2	  stability	  in	  interphase	  and	  neurula.	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Figure 5.5: xNgn2 mutants lacking SP and TP sites. 
Cyclin dependent kinases (cdks) are proline-directed kinases which phosphorylate serines or 
threonines followed by prolines.  There are 9 such serines and one threonine in xNgn2 and various 
mutants described in the text were made which are shown schematically. 
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Figure 5.6: Stability of xNgn2 SP/TP mutants in Xenopus interphase and neurula extracts.  
Xenopus laevis interphase extracts and neurula extracts were supplemented with 35S-labelled 
xNgn2 or xNgn2 phosphorylation mutants.  Samples taken at 0, 15, 30, 45, 60, 90, 120 mins were 
subjected to 15 % SDS-PAGE.  Gels were analysed by quantitative phosphorimaging analysis, 
calculating the average stabilisation relative to wild-type xNgn2 within interphase (A) and neurula 
extracts (B).  (C) Half-lives calculated using first-order rate kinetics, and errors calculated SEM. 
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Incubation	   in	   Xenopus	   laevis	   mitotic	   activated	   egg	   extract	   is	   shown	   to	   result	   in	  extensive	  phosphorylation	  of	  xNgn2	  (Figures	  5.2	  and	  5.3)	  and	  so	  TP	  mutations	  were	  investigated	  by	  degradation	  assays	  in	  mitotic	  extract,	  as	  well	  as	  mutants	  of	  SP	  sites	  in	  xNgn2	   mutating	   only	   the	   SP	   sites	   in	   the	   N-­‐terminal	   domain	   (NT-­‐S-­‐AxNgn2)	   or	   C-­‐terminal	   domain	   (CT-­‐S-­‐AxNgn2)	   (Figure	   5.5).	   35S-­‐radiolabelled	   IVT	   proteins	   were	  added	  to	  Xenopus	  laevis	  mitotic	  activated	  egg	  extract	  and	  incubated	  at	  21	  °C.	  	  Aliquots	  of	   the	   reaction	   were	   removed	   at	   increasing	   timepoints,	   quenched	   in	   SDS-­‐LB	   and	  samples	  were	  separated	  by	  15	  %	  SDS-­‐PAGE	  to	  allow	  measurement	  of	  protein	  levels	  over	  time	  and	  calculation	  of	  the	  half-­‐life	  for	  degradation	  using	  first-­‐order	  rate	  kinetics	  (Figure	  5.7).	  	  xNgn2	  has	  a	  half-­‐life	  of	  33.0	  +/-­‐	  2.1	  mins	  whilst	  9S-­‐AxNgn2	  is	  more	  stable	  with	  a	  half-­‐life	  of	  55.9	  +/-­‐	  10.0	  mins	  (Figure	  5.7,	  B).	  	  Additional	  mutation	  of	  the	  TP	  site	  threonine	  to	  alanine	  to	  give	  AP	  gives	  a	  half-­‐life	  of	  44.1	  +/	  3.4	  mins	  and	  therefore	  does	  not	  affect	  the	  stability	  of	  xNgn2	  any	  more	  than	  mutation	  of	  the	  SP	  sites.	  	  	  	  The	  N-­‐terminal	  SP	  mutants,	  NT-­‐S-­‐AxNgn2	  and	  NT-­‐S-­‐AT149AxNgn2,	  have	  half-­‐lives	  of	  28.5	  +/-­‐	  2.8	  mins	  and	  30.5	  +/-­‐	  4.9	  mins	   respectively	   that	  do	  not	  differ	   significantly	  from	   xNgn2.	   	   The	   C-­‐terminal	   mutants,	   CT-­‐S-­‐AxNgn2	   and	   CT-­‐S-­‐AT149AxNgn2,	   are	  degraded	  with	  half-­‐lives	  of	  74.4	  +/-­‐	  20.3	  mins	  and	  42.2	  +/-­‐	  11.9	  mins	   respectively.	  	  Therefore	  the	  C-­‐terminal	  SP	  sites,	  when	  mutated	  to	  alanines,	  confer	  a	  similar	  stability	  on	  xNgn2	  as	  mutation	  of	  all	  the	  SP	  sites.	  	  	  	  This	   data	   complements	   experiments	   showing	   that	   phosphorylation	   observed	   by	  retardation	   of	   xNgn2	   on	   gel	   electrophoresis	   is	   lost	   when	   C-­‐terminal	   SP	   sites	   are	  mutated	   to	   alanines	   (Ali	   et	   al.,	   2011).	   	   This	   would	   suggest	   that	   C-­‐terminal	  phosphorylation	  is	  important	  in	  regulating	  xNgn2	  stability	  in	  mitosis.	  	  
No	   individual	   SP	   site	   affects	   stability	   but	   combinations	   of	   sites	   in	   different	  
domains	  of	  xNgn2	  can	  affect	  stability	  	  Figure	  5.7	   suggests	   that	   phosphorylation	   of	   xNgn2	  differs	   in	   various	   regions	   of	   the	  protein.	  	  Mutants	  of	  xNgn2	  were	  created	  using	  site-­‐directed	  mutagenesis	  by	  Helen	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Figure 5.7: Stability of xNgn2 SP/TP mutants in Xenopus mitotic extract. 
Xenopus laevis mitotic activated egg extracts were supplemented with 35S-labelled xNgn2 or 
xNgn2 mutants lacking putative phosphorylation sites and incubated at 21 °C.  Samples were 
taken at 0, 15, 30, 45, 60, 75, 90 and 120 mins and subjected to 15 % SDS-PAGE.  Gels were 
analysed by quantitative phosphorimaging analysis, calculating the average stabilisation relative to 
wild-type xNgn2 within mitotic extract (A).  (B) Half-lives were calculated using first-order rate 
kinetics, and errors calculated using the Standard Error of the Mean (SEM). 
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Wise	   to	   mutate	   each	   SP	   site	   to	   an	   alanine	   additively,	   beginning	   with	   the	   most	   C-­‐terminal	  SP,	  S184,	  and	  mutating	  each	  SP	  serine	  in	  turn	  until	  all	  serines	  are	  mutated	  to	  9S-­‐AxNgn2	   (Figure	  5.8).	   	   To	   investigate	   the	   stability	   of	   these	  mutants	   I	   began	  with	  degradation	  assays	  in	  interphase	  and	  neurula	  extract.	  	  35S-­‐radiolabelled	  IVT	  proteins	  were	   added	   to	  Xenopus	   laevis	   interphase	   activated	   egg	   and	  neurula	   embryo	   extract	  and	   incubated	   at	   21	   °C.	   	   Aliquots	   of	   the	   reaction	   were	   removed	   at	   increasing	  timepoints,	  quenched	   in	  SDS-­‐LB	  and	  samples	  were	  separated	  by	  15	  %	  SDS-­‐PAGE	  to	  allow	   measurement	   of	   protein	   levels	   over	   time	   and	   calculation	   of	   the	   half-­‐life	   for	  degradation	  using	  first-­‐order	  rate	  kinetics	  (Figure	  5.9).	  	  xNgn2	  is	  degraded	  with	  a	  half-­‐life	  of	  22.0	  +/-­‐	  2.2	  mins	  in	  interphase	  extract	  and	  49.1	  +/-­‐	  12.8	  mins	  in	  neurula	  extract	  (Figure	  5.9,	  C).	  	  The	  serial	  SP	  mutants	  exhibit	  similar	  half-­‐lives	  in	  interphase,	  and	  lower	  values	  in	  neurula	  which	  are	  however	  similar	  to	  one	  another.	   	   xNgn2	   demonstrated	   a	   half-­‐life	   longer	   than	   usually	   observed	   in	   neurula	  therefore	   these	   values	   were	   taken	   as	   not	   differing	   significantly	   from	   wild	   type	  stability.	   	   Therefore	   in	   interphase	   and	   neurula	   extracts,	   where	   protein	  phosphorylation	   (as	   observed	   by	   chanes	   in	   gel	   migration)	   is	   low,	   there	   does	   not	  appear	  to	  be	  a	  change	  in	  stability	  as	  SP	  sites	  are	  progressively	  removed.	  	  As	  the	  most	  extensive	  phosphorylation	  of	  xNgn2	  occurs	  in	  mitotic	  extract,	  the	  assays	  in	   Figure	   5.9	  were	   repeated	   in	  Xenopus	   laevis	  mitotic	   activated	   egg	   extract	   (Figure	  5.10).	  	  	  	  xNgn2	  is	  degraded	  with	  a	  half-­‐life	  of	  18.5	  +/-­‐	  0.9	  mins.	   	  On	  mutation	  of	  the	  most	  C-­‐terminal	  SP	  site,	  xS-­‐A1	  has	  a	  half-­‐life	  for	  degradation	  of	  37.5	  +/-­‐	  8.7	  mins.	  	  The	  half-­‐life	  increases	  for	  additional	  mutation	  of	  SP	  sites	  to	  AP	  until	  xS-­‐A4,	  with	  a	  half-­‐life	  of	  51.9	   +/-­‐	   0.6	  mins.	   	   The	   half-­‐life	   then	   decreases	   upon	   additive	  mutation	   of	   SP	   sites	  towards	   the	   N-­‐terminus,	   reaching	   25.5	   +/-­‐	   2.3	   mins	   at	   9S-­‐AxNgn2	   which	   is	  significantly	  but	  slightly	  more	  stable	  than	  xNgn2.	  	  	  	  That	  the	  stability	  should	  increase	  to	  a	  maximum	  with	  successive	  SP	  mutations	  to	  AP	  from	  the	  C-­‐terminus	  at	  xS-­‐A4	  is	  significant;	  at	  this	  point,	  all	  putative	  C-­‐terminal	  serine	  phosphorylation	  sites	  are	  lost.	  	  This	  would	  suggest	  that	  phosphorylation	  at	  the	  C-­‐	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Figure 5.8: Serial SP mutants of xNgn2. 
Cyclin dependent kinases (cdks) are proline-directed kinases which phosphorylate serines or 
threonines followed by prolines.  There are 9 such serines in xNgn2 and mutants were constructed 
sequentially mutating serines to alanines beginning with the most C-terminal SP site, as shown. 
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 Figure 5.9: Stability of serial SP mutants of xNgn2 in interphase and neurula extracts. 
Xenopus interphase extracts and duplicate neurula extracts were supplemented with 35S-labelled 
xNgn2 or serial SP xNgn2 mutants.  Samples taken at 0, 15, 30, 45, 60, 90 and 120 mins were 
subjected to 15 % SDS-PAGE and analysed by quantitative phosphorimaging analysis, calculating 
the average stabilisation relative to wild-type xNgn2 within interphase (A) and neurula extracts (B).  




Figure 5.10: Stability of serial SP mutants of xNgn2 in mitotic extract. 
Xenopus laevis mitotic activated egg extracts were supplemented with 35S-labelled xNgn2 or serial 
SP xNgn2 mutants and incubated at 21 °C.  Samples were taken at 0, 15, 30, 45, 60, 75, 90 and 
120 mins and subjected to 15 % SDS-PAGE.  Gels were analysed by quantitative 
phosphorimaging analysis, calculating the average stabilisation relative to wild-type xNgn2 within 
mitotic extract (A).  (B) Half-lives were calculated using first-order rate kinetics, and errors 
calculated using the Standard Error of the Mean (SEM).  Results are from a duplicate set of 
experiments. 
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terminus	   is	   destabilising,	   but	   phosphorylation	   at	   the	   N-­‐terminus	   then	   promotes	  stability.	  	  The	  activity	  of	  these	  mutants	  has	  been	  investigated	  in	  vivo	  in	  Xenopus	  laevis	  embryos	   by	   in	   situ	   hybridisation	   (Ali	   et	   al.,	   2011)	   and	   activity	   increases	   gradually	  along	  the	  series,	  suggesting	  that	  activity	  may	  not	  perfectly	  reflect	  protein	  stability.	  	  To	  investigate	  whether	  individual	  serines	  are	  important	  in	  phosphorylation	  of	  xNgn2,	  Christopher	  Hindley	  and	  Ali	  Jones	  performed	  site-­‐directed	  mutagenesis	  of	  9S-­‐AxNgn2	  to	   reintroduce	   individual	  SP	  site	   serines,	   e.g.	  8S-­‐AxNgn2S19	  denotes	   reintroduction	  of	   SP	   serine	   19	   (all	   mutants	   are	   listed	   in	   the	   Abbreviations).	   35S-­‐radiolabelled	   IVT	  proteins	  of	  xNgn2,	  9S-­‐AxNgn2	  and	  single	  SP	  sites	  reintroduced	  into	  9S-­‐AxNgn2	  were	  added	  to	  Xenopus	  laevis	  mitotic	  activated	  egg	  extract	  and	  incubated	  at	  21	  °C.	  	  Aliquots	  of	   the	   reaction	   were	   removed	   at	   increasing	   timepoints,	   quenched	   in	   SDS-­‐LB	   and	  samples	  were	  separated	  by	  15	  %	  SDS-­‐PAGE	  to	  allow	  measurement	  of	  protein	  levels	  over	  time	  and	  calculation	  of	  the	  half-­‐life	  for	  degradation	  using	  first-­‐order	  rate	  kinetics	  (Figure	  5.11).	  	  xNgn2	   has	   a	   half-­‐life	   for	   degradation	   of	   30.1	   +/-­‐	   2.3	   mins	   whereas	   9S-­‐AxNgn2	  exhibits	  a	  half-­‐life	  of	  43.6	  +/-­‐	  7.2	  mins	  (Figure	  5.11,	  B).	  	  All	  phosphomutants	  of	  xNgn2	  with	  a	  single	  SP	  site	  reintroduced	  are	  degraded	  at	  the	  same	  rate	  as	  9S-­‐AxNgn2,	  with	  the	  exception	  of	  8S-­‐AxNgn2S181,	  which	  has	  a	  half-­‐life	  of	  37.0	  +/-­‐	  5.6	  mins	  and	  8S-­‐AxNgn2S184	  with	  a	  half-­‐life	  of	  36.7	  +/-­‐	  3.9	  mins	  (Figure	  5.11,	  B).	  	  8S-­‐AxNgn2S184	  is	  also	   the	   only	   mutant	   not	   significantly	   stabilised	   when	   half-­‐lives	   are	   normalised	   to	  xNgn2	  within	  each	  experiment	  (Figure	  5.11,	  A).	  	  The	  trend	  observed	  in	  Figure	  5.11,	  A	  shows	   a	   decrease	   in	   stabilisation	  when	  mutating	   alanines	   back	   to	   serines	   in	   the	   C-­‐terminus,	   for	   S172,	   S181	   and	   significantly	   S184.	   	   This	   data	   hints	   again	   at	   the	  importance	  of	  the	  most	  C-­‐terminal	  SP	  sites	  as	  demonstrated	  in	  Figure	  5.10.	  	  Serines	  181	  and	  184	  in	  fact	  constitute	  a	  GSK3-­‐β	  consensus	  site	  (Kennelly	  and	  Krebs,	  1991)	   and	   Christopher	   Hindley	   and	   Ali	   Jones	   constructed	   a	   SP	   site	   knock-­‐out	   (7S-­‐AxNgn2)	  and	  a	  SP	  site	  knock-­‐in	  (2S-­‐AxNgn2)	  of	   these	  sites	  (see	  Figure	  5.12,	  A	   for	  a	  schematic).	   	   These	   mutants	   were	   also	   subjected	   to	   degradation	   assays	   in	   mitotic	  extract.	   35S-­‐radiolabelled	   IVT	   proteins	   of	   xNgn2,	   9S-­‐AxNgn2,	   7S-­‐AxNgn2	   and	   2S-­‐AxNgn2	  were	  added	  to	  Xenopus	  laevis	  mitotic	  activated	  egg	  extract	  and	  incubated	  at	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Figure 5.11: Stability of single SP site knock-in mutants of xNgn2 in mitotic extract. 
Xenopus laevis mitotic activated egg extracts were supplemented with 35S-labelled xNgn2 or 
xNgn2 mutants containing single SP sites and incubated at 21 °C.  Samples were taken at the 
timepoints indicated and subjected to 15 % SDS-PAGE.  Gels were analysed by quantitative 
phosphorimaging analysis, calculating the average stabilisation relative to wild-type xNgn2 within 
mitotic extract (A).  (B) Half-lives were calculated using first-order rate kinetics, and errors 
calculated using the Standard Error of the Mean (SEM).  n= 6. 
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21	  °C.	   	  Aliquots	  of	  the	  reaction	  were	  removed	  at	  increasing	  timepoints,	  quenched	  in	  SDS-­‐LB	   and	   samples	  were	   separated	   by	   15	  %	   SDS-­‐PAGE	   to	   allow	  measurement	   of	  protein	   levels	   over	   time	   and	   calculation	   of	   the	   half-­‐life	   for	   degradation	   using	   first-­‐order	  rate	  kinetics	  (Figure	  5.12).	  	  9S-­‐AxNgn2	  has	  a	  half-­‐life	  of	  26.9	  +/-­‐	  2.9	  mins	  compared	  to	  xNgn2	  with	  a	  half-­‐life	  of	  23.2	  +/-­‐	  2.8	  mins	  (Figure	  5.12,	  C).	  	  	  	  7S-­‐AxNgn2	   exhibits	   a	   stability	   of	   24.8	   +/-­‐	   0.4	   mins	   similar	   to	   wild	   type	   xNgn2.	  	  Therefore	  mutation	  of	  all	  SP	  serines	  except	  the	  GSK3-­‐β	  consensus	  site	  has	  no	  effect	  on	  stability	  of	  xNgn2.	  	  	  	  2S-­‐AxNgn2	  is	  in	  fact	  identical	  to	  xS-­‐A2	  (compare	  Figures	  5.8	  and	  5.12,	  A),	  the	  half-­‐life	  of	   which	   was	   found	   to	   be	   47.4	   +/-­‐	   6.4	   mins	   (Figure	   5.10,	   B)	   and	   2S-­‐AxNgn2	   is	  degraded	  with	  a	  half-­‐life	  of	  43.5	  +/-­‐	  5.8	  mins	  (Figure	  5.12,	  C).	  	  Therefore	  mutation	  of	  the	  GSK3-­‐β	  consensus	  site	  stabilises	  xNgn2	  significantly.	   	  This	  does	  not	  prove	  a	  role	  for	  GSK3-­‐β	  phosphorylation	  of	  xNgn2	  but	  highlights	  an	  important	  region	  of	  xNgn2	  in	  the	  C-­‐terminus	  with	  respect	  to	  phosphorylation	  potential.	  	  




Figure 5.12: GSK3-β  consensus site mutant stability in Xenopus mitotic extract. 
(A) xNgn2 mutants with only the GSK3-β consensus site present or with the GSK3-β consensus 
site absent were made as shown schematically.  (B) Xenopus laevis mitotic activated egg extracts 
were supplemented with 35S-labelled xNgn2 or xNgn2 GSK3-β site mutants and incubated at 21 
°C.  Samples were taken at the timepoints indicated and subjected to 15 % SDS-PAGE.  Gels were 
analysed by quantitative phosphorimaging analysis, calculating the average stabilisation relative to 
wild-type xNgn2 within mitotic extract.  (C) Half-lives were calculated using first-order rate kinetics, 
and errors calculated using the Standard Error of the Mean (SEM). 
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allow	   measurement	   of	   protein	   levels	   over	   time	   and	   calculation	   of	   the	   half-­‐life	   for	  degradation	  using	  first-­‐order	  rate	  kinetics	  (Figure	  5.13).	  	  Where	  xNgn2	  is	  degraded	  with	  a	  half-­‐life	  of	  30.2	  +/-­‐	  2.3	  mins,	  and	  9S-­‐AxNgn2	  with	  a	  half-­‐life	  of	  43.6	  +/-­‐	  7.2	  mins,	  9S-­‐ExNgn2	   is	  degraded	  with	  a	  half-­‐life	  of	  53.0	  +/-­‐	  4.9	  mins	  in	  mitotic	  extract	  (Figure	  5.13,	  C).	   	  Therefore	  the	  phosphomimetic	  is	  stabilised	  more	   than	   the	   wild	   type	   or	   phosphomutant	   proteins.	   	   This	   suggests	   that	   the	  phosphomimetic	   cannot	   accurately	   reflect	   the	   phosphorylation	   effects	   of	   xNgn2	   as	  wild	  type	  xNgn2	  is	  phosphorylated	  in	  mitotic	  extract	  and	  previous	  data	  (Figure	  5.10)	  shows	  that	  blocking	  this	  phosphorylation	  in	  9S-­‐AxNgn2	  is	  stabilising.	  	  
Phosphorylation	  affects	  stability	  in	  the	  presence	  of	  xE12	  	  Phosphorylation	  of	  bHLH	  proteins,	  affecting	  their	  heterodimerisation	  with	  E2A	  gene	  products,	  has	  been	  identified	  in	  Mash1	  (Vinals	  et	  al.,	  2004)	  and	  xE12	  has	  been	  shown	  to	  stabilise	  xNgn2	  (Vosper	  et	  al.,	  2007).	  	  Therefore	  I	  wished	  to	  investigate	  the	  effect	  of	  xE12	   on	   stability	   of	   xNgn2	   and	   9S-­‐AxNgn2.	   	   Using	   Xenopus	   laevis	   interphase	   and	  mitotic	  activated	  egg	  and	  neurula	  embryo	  extracts,	  35S-­‐radiolabelled	  IVT	  xNgn2	  or	  9S-­‐AxNgn2	  were	  combined	  with	  an	  equal	  volume	  of	  non-­‐radiolabelled	  IVT	  xE12	  (or	  GFP	  as	  a	  control	  for	  addition	  of	  IVT	  protein)	  and	  incubated	  in	  extract	  at	  21	  °C.	  	  Aliquots	  of	  the	   reaction	   were	   removed	   at	   increasing	   timepoints,	   quenched	   in	   SDS-­‐LB	   and	  samples	  were	  separated	  by	  15	  %	  SDS-­‐PAGE	  to	  allow	  measurement	  of	  protein	  levels	  over	  time	  and	  calculation	  of	  the	  half-­‐life	  for	  degradation	  using	  first-­‐order	  rate	  kinetics	  (Figure	  5.14).	  	  xNgn2	  is	  stabilised	  2.5-­‐	  to	  3-­‐fold	  by	  xE12	  in	  all	  extracts	  (Figure	  5.14,	  B).	  	  In	  interphase	  extract,	  xNgn2	  is	  degraded	  with	  a	  half-­‐life	  of	  23.6	  +/-­‐	  2.3	  mins	  and	  in	  the	  presence	  of	  xE12,	  it	  has	  a	  half-­‐life	  for	  degradation	  of	  69.9	  +/-­‐	  8.7	  mins	  (Figure	  5.14,	  C).	  	  Similarly,	  in	  interphase,	  9S-­‐AxNgn2	  is	  degraded	  with	  a	  half-­‐life	  of	  25.4	  +/-­‐	  1.0	  mins	  and	  in	  the	  presence	  of	  xE12,	  the	  half-­‐life	  for	  degradation	  of	  this	  protein	  is	  70.1	  +/-­‐	  23.0	  mins.	  	  A	  similar	  pattern	  is	  observed	  in	  neurula	  extract	  (Figure	  5.14,	  B	  and	  C).	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Figure 5.13: Phosphomimetic xNgn2 stability in mitotic extract. 
(A) A xNgn2 mutant with all SP serines mutated to aspartic acids was made as shown 
schematically.  (B) Xenopus laevis mitotic activated egg extracts were supplemented with 35S-
labelled xNgn2, 9S-AxNgn2 or 9S-ExNgn2 and incubated at 21 °C.  Samples were taken at the 
timepoints indicated and subjected to 15 % SDS-PAGE.  Gels were analysed by quantitative 
phosphorimaging analysis, calculating the average stabilisation relative to wild-type xNgn2 within 
mitotic extract.  (C) Half-lives were calculated using first-order rate kinetics, and errors calculated 




Figure 5.14: xNgn2 and 9S-AxNgn2 stability in Xenopus extracts with xE12. 
Xenopus laevis interphase activated egg extracts, mitotic activated egg extracts and neurula 
embryo extracts were supplemented with 35S-labelled xNgn2 or 9S-AxNgn2 each with either non-
labelled IVT GFP or xE12 and incubated at 21 °C.  Samples were taken at the timepoints indicated 
and subjected to 15 % SDS-PAGE.  Gels were analysed by autoradiography (examples for 
interphase and mitotic extracts shown (A)) and quantitative phosphorimaging analysis, calculating 
the average stabilisation relative to wild-type xNgn2 within each extract (A).  (B) Half-lives were 
calculated using first-order rate kinetics, and errors calculated using the Standard Error of the 
Mean (SEM). 
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However,	  in	  mitotic	  extract,	  whilst	  xNgn2	  is	  stabilised	  2.5-­‐fold	  by	  xE12,	  9S-­‐AxNgn2	  is	  stabilised	  4-­‐fold	  (Figure	  5.14,	  B)	  and	  the	  half-­‐life	  of	  xNgn2	  in	  mitosis	  in	  the	  presence	  of	  xE12	  is	  61.7	  +/-­‐	  10.3	  mins	  whereas	  the	  corresponding	  value	  of	  9S-­‐AxNgn2	  is	  97.4	  +/-­‐	  5.5	  mins	  (Figure	  5.14,	  C).	  	  Therefore	  xE12	  stabilises	  the	  phosphomutant	  of	  xNgn2	  more	  than	  wild	  type	  xNgn2	  in	  mitosis.	  	  xE12	  also	  promotes	  phosphorylation	  of	  xNgn2	  in	   interphase	   where	   such	   phosphorylation	   is	   not	   usually	   observed,	   as	   seen	   by	   a	  retardation	  of	  gel-­‐migration	  over	  time	  of	  xNgn2	  in	  the	  presence	  of	  xE12,	  identical	  to	  the	  phosphorylation	  shift	  observed	  in	  mitotic	  extract	  (Figure	  5.14,	  A).	  	  
Ubiquitylation	   of	   xNgn2	   and	   9S-­AxNgn2	   suggests	   a	   difference	   in	   xNgn2	  
behaviour	  dependent	  on	  phosphorylation	  	  Phosphorylation	   would	   appear	   to	   be	   destabilising	   xNgn2.	   	   However	   it	   is	   unclear	  whether	   this	   destabilisation	   occurs	   at	   the	   point	   of	   ubiquitylation	   of	   xNgn2,	   or	  whether	  it	  is	  independent	  of	  the	  ubiquitylation	  process,	  for	  example	  perhaps	  instead	  assisting	  in	  unfolding	  xNgn2	  at	  the	  proteasome.	  	  To	  fully	  assess	  the	  crosstalk	  between	  ubiquitylation	   and	   phosphorylation	   in	   xNgn2,	   in	   vitro	   and	   in	   vivo	   experiments	   in	  
Xenopus	   laevis	  were	  carried	  out	  using	  xNgn2	  mutants	  N-­‐terminally	   fused	  to	  a	  single	  ubiquitin	   moiety,	   with	   a	   non-­‐cleavable	   linker,	   as	   constructed	   by	   Alison	   Jones.	  	  Proteins	  so	  tagged	  are	  degraded	  by	  the	  ubiquitin	  fusion/degradation	  pathway	  (UFD)	  (Johnson	  et	  al.,	  1995).	  	  The	  stability	  of	  Ub-­‐xNgn2	  and	  Ub-­‐9S-­‐AxNgn2	  was	  investigated	  by	  degradation	  assay	  in	  mitotic	  extract,	  where	  xNgn2	  is	  maximally	  phosphorylated,	  in	  the	  presence	  or	  absence	  of	  xE12.	  35S-­‐radiolabelled	  IVT	  xNgn2,	  9S-­‐AxNgn2,	  Ub-­‐xNgn2	  or	   Ub-­‐9S-­‐AxNgn2	   were	   combined	   with	   an	   equal	   volume	   of	   non-­‐radiolabelled	   IVT	  xE12,	  or	  GFP	  as	  a	  control	  for	  addition	  of	  IVT	  protein,	  and	  incubated	  in	  Xenopus	  laevis	  mitotic	   activated	   egg	   extract	   at	   21	   °C.	   Aliquots	   of	   the	   reaction	   were	   removed	   at	  increasing	   timepoints,	  quenched	   in	  SDS	   loading	  buffer	  and	  samples	  were	   separated	  by	  15	  %	  SDS-­‐PAGE	  to	  allow	  measurement	  of	  protein	  levels	  over	  time	  and	  calculation	  of	  the	  half-­‐life	  for	  degradation	  using	  first-­‐order	  rate	  kinetics	  (Figure	  5.15).	  	  Fusion	  of	  xNgn2	  to	  ubiquitin	  destabilises	  xNgn2	  from	  19.1	  +/-­‐	  3.4	  mins	  to	  9.1	  +/-­‐	  0.7	  mins	  (Figure	  5.15,	  C).	  	  Whilst	  9S-­‐AxNgn2	  is	  stabilised	  by	  xE12	  to	  a	  greater	  extent	  than	  xNgn2	  as	  shown	  in	  Figure	  5.14	  (Figure	  5.15,	  B),	  Ub-­‐xNgn2	  and	  Ub-­‐9S-­‐AxNgn2	  are	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Figure 5.15: Ubiquitylated xNgn2 and 9S-AxNgn2 stability in Xenopus mitotic extract with 
xE12. 
Xenopus laevis mitotic activated egg extracts were supplemented with 35S-labelled xNgn2, 9S-
AxNgn2, Ub-xNgn2 or Ub-9S-AxNgn2 each with either non-labelled IVT GFP or xE12 and 
incubated at 21 °C.  Samples were taken at the timepoints indicated and subjected to 15 % SDS-
PAGE.  Gels were analysed by autoradiography (A) and quantitative phosphorimaging analysis, 
calculating the average stabilisation relative to wild-type xNgn2 within each extract (B).  (C) Half-
lives were calculated using first-order rate kinetics, and errors calculated using the Standard Error 
of the Mean (SEM).   
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both	   stabilised	  by	   xE12	   to	   a	   similar	   extent	   (Figure	  5.15,	   B).	   	   The	  half-­‐life	   of	   xNgn2	  increases	  from	  9.1	  +/-­‐	  0.7	  mins	  to	  13.3	  +/-­‐	  1.2	  mins	  in	  the	  presence	  of	  xE12,	  and	  that	  of	  Ub-­‐9S-­‐AxNgn2	  increases	  from	  7.2	  +/-­‐	  1.2	  mins	  to	  11.6	  +/-­‐	  2.5	  mins	  in	  xE12	  (Figure	  5.15,	   C).	   	   This	   would	   suggest	   that	   phosphorylation	   can	   assist	   with	   proteasomal	  degradation;	  when	  SP	  sites	  are	  absent,	  xE12	  has	  a	  greater	  stabilising	  effect	  than	  with	  wild	  type	  xNgn2.	  	  However	  when	  xNgn2	  is	  already	  tagged	  with	  ubiquitin,	  there	  is	  no	  difference	  in	  stabilisation	  whether	  or	  not	  SP	  sites	  are	  available.	   	  There	   is	  a	  dramatic	  effect	  on	  stability	   in	  vitro	   in	  Xenopus	   laevis	  extract	  when	  xNgn2	  proteins	   with	   varying	   phosphorylation	   potential	   are	   ubiquitin-­‐tagged.	   	   I	   wished	   to	  investigate	  further	  in	  vivo	  how	  this	  stability	  might	  affect	  protein	  half-­‐life	  and	  so	  20	  pg	  GFP,	  xNgn2,	  9S-­‐AxNgn2,	  Ub-­‐xNgn2	  and	  Ub-­‐9S-­‐AxNgn2	  mRNA	  were	  injected	  into	  1	  cell	  of	  Stage	  2	  Xenopus	  laevis	  IVF	  embryos.	  	  mRNA	  was	  coinjected	  with	  β-­‐galactosidase	  so	  that	   fixed	   embryos	   could	   be	   treated	  with	   X-­‐gal	   to	   stain	   the	   injected	   side.	   	   Primary	  neurons	  were	  stained	  by	  in	  situ	  hybridisation	  (ISH)	  for	  neural	  β-­‐tubulin	  and	  embryos	  scored	  for	  ectopic	  neurogenesis	  relative	  to	  the	  uninjected	  side	  of	  the	  embryo	  (Figure	  5.16).	  	  xNgn2	   upregulates	   neurogenesis,	   whilst	   Ub-­‐xNgn2	   is	   completely	   inactive	   (Figure	  5.16,	   A	   and	  B).	   	   9S-­‐AxNgn2	   is	   hyperactive	   relative	   to	  wild	   type	   xNgn2	   as	   has	   been	  seen	   previously	   (Hindley,	   2011),	   however	   Ub-­‐9S-­‐AxNgn2,	   whilst	   promoting	   less	  ectopic	   neurogenesis	   than	  9S-­‐AxNgn2,	   is	   still	   active	   and	   to	   a	   similar	   extent	   as	  wild	  type	   xNgn2	   (Figure	   5.16,	   A	   and	   B).	   	   Therefore	   despite	   its	   instability,	   9S-­‐AxNgn2	   is	  able	  to	  maintain	  a	  high	  level	  of	  activity.	  	  xNgn2	   is	   upstream	   of	   a	   cascade	   of	   bHLH	   transcription	   factors	   such	   as	   xNeuroD	   to	  promote	   neurogenesis;	   but	   it	   also	   activates	   Notch	   signalling	   by	   activating	   the	  transcription	  of	  the	  Delta	  ligand,	  to	  set	  up	  lateral	  inhibition,	  resulting	  in	  neurogenesis	  of	  primary	  neurons	  surrounded	  by	  undifferentiated	  neural	  precursors.	  	  To	  investigate	  whether	   phosphorylation	   and	   stability	   affect	   xNgn2	   activity	   at	   the	   chromatin	   level,	  quantitative	   PCR	   (qPCR)	   analysis	   of	   these	   proteins	   was	   undertaken.	   	   20	   pg	   GFP,	  xNgn2,	   9S-­‐AxNgn2,	  Ub-­‐xNgn2	   and	  Ub-­‐9S-­‐AxNgn2	  mRNA	  were	   injected	   into	   Stage	  1	  embryos	  which	  were	  lysed	  upon	  reaching	  stage	  15.	  	  RNA	  was	  extracted	  and	  used	  for	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Figure 5.16: In vivo activity of ubiquitylated forms of xNgn2 and 9S-AxNgn2 by ISH. 
(A) Xenopus embryos were injected in 1 of 2 cells with 20 pg of either xNgn2, UbxNgn2, 9S-A 
xNgn2 or Ub9S-AxNgn2 mRNA as well as 500 pg β-galactosidase mRNA, fixed at stage 15 and 
subject to in situ hybridization for neural β-tubulin expression with X-gal staining to show the 
injected side (n≥76) (injected side, left).  (B) Embryos were scored for the extent of ectopic 
neurogenesis observed using the scale defined in Figure 2.3. 
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the	   synthesis	   of	   cDNA	  which	  was	   then	   used	   by	   Fahad	   Ali	   for	   qPCR	   of	   NeuroD	   and	  Delta	  transcripts	  using	  specific	  primers	  for	  each,	  as	  well	  as	  for	  a	  set	  of	  housekeeping	  genes	  as	  a	  control	  for	  transcript	  levels.	  	  The	  fold	  increase	  of	  transcript	  for	  NeuroD	  and	  Delta	  was	  then	  plotted	  (Figure	  5.17,	  A	  and	  B	  respectively).	  	  xNgn2	   upregulates	   xNeuroD	   7.4	   +/-­‐	   2.8	   fold	   but	   Ub-­‐xNgn2	   gives	   no	   detectable	  upregulation	   of	   xNeuroD	   (Figure	   5.17,	   A).	   	   In	   contrast,	   9S-­‐AxNgn2	   upregulates	  xNeuroD	   29.3	   +/-­‐	   3.5	   whilst	   Ub-­‐9S-­‐AxNgn2	   retains	   considerable	   activity	   with	   a	  NeuroD	  upregulation	  of	  7.7	  +/-­‐	  1.4	  fold	  (Figure	  5.17A).	  	  	  	  Delta	  expression	  is	  upregulated	  by	  xNgn2	  to	  3.0	  +/-­‐	  1.0	  fold,	  and	  by	  9S-­‐AxNgn2	  to	  3.8	  +/-­‐	   0.8	   fold	   (Figure	   5.17,	   B).	   	   They	   therefore	   exhibit	   similar	   activity	   at	   the	   Delta	  promoter.	  	  Ubiquitin-­‐tagging	  reduces	  this	  activity	  for	  both	  proteins,	  to	  1.7	  +/-­‐	  0.3	  fold	  for	   Ub-­‐xNgn2	   and	   1.9	   +/-­‐	   0.6	   fold	   for	   Ub-­‐9S-­‐AxNgn2	   (Figure	   5.17,	   B).	   	   Therefore	  whilst	   both	   xNgn2	   and	   9S-­‐AxNgn2	   exert	   similar	   effects	   at	   the	   Delta	   promoter,	  activation	   of	   transcription	   of	   xNeuroD	   varies	   significantly	   between	   xNgn2	   and	   9S-­‐AxNgn2,	   and	   ubiquitylation	   of	   xNgn2	   can	   completely	   inactivate	   activation	   of	  transcription	   of	   xNeuroD	   whereas	   ubiquitylation	   of	   9S-­‐AxNgn2	   merely	   reduces	   it.	  	  This	   implies	   differences	   in	   the	   ability	   of	   xNgn2	   to	   initiate	   transcription	   at	   the	  promoters	  of	  Delta	  and	  xNeuroD.	  	  
DISCUSSION	  	  xNgn2	  contains	  a	  number	  of	  putative	  phosphorylation	  sites	   including	  serine	  proline	  motifs,	  which	   can	   be	   phosphorylated	   by	   proline-­‐directed	   kinases	   such	   as	   cdks	   and	  GSK3-­‐β.	   	   Mutation	   of	   all	   these	   serine	   proline	   sites	   to	   alanine	   prolines	   results	   in	   a	  hyperactive	   form	   of	   xNgn2	   (Ali	   et	   al.,	   2011).	   	   Predicting	   which	   SP	   sites	   may	   be	  phosphorylated	   is	   not	   trivial	   (Errico	   et	   al.,	   2010)	   therefore	  mutating	   all	   SP	   sites	   is	  necessary	   to	   begin	   investigating	   proline-­‐directed	   kinase	   phosphorylation	   of	   xNgn2.	  	  To	  investigate	  the	  role	  of	  these	  SP	  sites	  in	  xNgn2	  stability,	  I	  began	  with	  degradation	  assays	  comparing	  xNgn2	  and	  the	  phosphomutant	  9S-­‐AxNgn2	  in	  Xenopus	  laevis	  extract	  systems	   (Figure	   5.2).	   	   xNgn2	  was	  minimally	   phosphorylated	   in	   interphase	   egg	   and	  neurula	  embryo	  extracts	  but	  maximally	  phosphorylated	  in	  mitotic	  extracts	  as	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Figure 5.17: In vivo activity of ubiquitylated forms of xNgn2 and 9S-AxNgn2 by qPCR. 
qPCR analysis of NeuroD and Delta expression in Xenopus embryos. Embryos were injected at 
the 1 cell stage with 20 pg of either xNgn2, UbxNgn2, 9S-AxNgn2 or Ub9S-AxNgn2 mRNA and 
harvested at stage 15. Graphs show average fold increase in (A) NeuroD (B) Delta mRNA 
expression normalized to GFP. 
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assessed	   by	   gel	  migration	   (e.g.	   Figure	   5.2).	   	   Loss	   of	   phosphorylation	   sites	   led	   to	   a	  small	   but	   significant	   increase	   in	   stability	   in	  mitotic	   extracts.	   There	   is	   also	   less	   9S-­‐AxNgn2	  present	  to	  begin	  with	  in	  the	  extract	  due	  to	  differing	  translation	  efficiencies	  of	  xNgn2	  and	  9S-­‐AxNgn2	  in	  vitro.	  	  Treatment	   with	   roscovitine	   (Figure	   5.3)	   suggests	   that	   phosphorylation	   is	   indeed	  taking	  place	  and	   in	  a	  manner	   that	  can	  be	  blocked	  by	  using	  cyclin	  dependent	  kinase	  inhibitors.	   	   The	   major	   caveat	   in	   these	   experiments	   is	   that	   we	   are	   comparing	   the	  migration	  of	  bands	  under	  gel	  electrophoresis,	  which	  suggests	  a	  changing	  electrostatic	  environment	   consistent	   with	   phosphorylation,	   but	   which	   does	   not	   necessarily	  preclude	  either	  other	  post-­‐translational	  modifications,	  nor	  the	  possibility	  that	  a	  band	  that	   is	   not	   shifted,	   such	   as	   9S-­‐AxNgn2	   in	   Figure	   5.3,	   is	   not	   still	   phosphorylated.	  	  However	  the	  roscovitine	  experiments	  in	  combination	  with	  the	  cell	  cycle	  dependence	  in	   such	   a	   shift	   suggests	   that	   phosphorylation	   is	   the	   modification	   that	   we	   are	  observing.	  	  The	  differences	  in	  xNgn2	  and	  mNgn2	  stabilities	  observed	  in	  Figure	  5.4	  illustrate	  the	  caveats	  of	  comparing	  the	  two	  proteins,	  especially	  as	  the	  stability	  of	  a	  mouse	  protein	  is	  being	   assessed	   in	   a	   frog	   system.	   	   xNgn2	   SP	   sites	   are	   distributed	   with	   4	   in	   the	   C-­‐terminal	   domain	   and	   5	   in	   the	  N-­‐terminal	   domain	   and	  whilst	  mNgn2	   also	   has	   9	   SP	  sites,	  these	  are	  placed	  as	  2	  in	  the	  N-­‐terminal	  domain	  and	  7	  in	  the	  C-­‐terminal.	  	  Similar	  functional	   behaviour	   of	   mNgn2	   in	   P19	   cells	   has	   been	   observed	   (Fahad	   Ali,	  unpublished	  data)	  compared	  to	  xNgn2	   in	  Xenopus	   laevis	   systems	  but	  comparison	  of	  both	  within	  the	  same	  system	  will	  yield	  no	  particularly	  useful	  information.	  	  Figure	  5.4	  does	   show	   that	   differences	   occur	   between	   extracts	   from	   different	   cell	   cycle	   and	  developmental	  phases	   in	   stability	  of	  mNgn2	  protein	   and	   so	   suggest	   again	   cell	   cycle	  dependence	  of	  mNgn2	  degradation.	  	  The	   inclusion	   of	   the	   TP	   site	   in	   the	   analysis,	   such	   as	   in	   Figures	   5.6	   and	   5.7,	   allows	  complete	   discussion	   of	   all	   serine	   and	   threonine	   sites	   forming	   a	   proline-­‐directed	  kinase	  consensus	  site.	   	  No	  differences	   in	  activity	  have	  been	  found	  upon	  mutation	  of	  T149	   to	  an	  alanine	   (Hindley,	  2011)	  and	   this	   is	   also	   the	   case	   in	   terms	  of	   stability	  of	  xNgn2.	   	  That	  no	  visible	  shift	   in	  gel	  migration	  occurs	  in	  9S-­‐AxNgn2	  corresponding	  to	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possible	  phosphorylation	  may	  also	  suggest	  that	  TP	  site	  phosphorylation	  either	  does	  not	  occur	  or	  has	  no	  effect.	  	  Figure	  5.7	  begins	  to	  highlight	  the	  importance	  of	  two	  obvious	  factors	  in	  relation	  to	  SP	  sites;	   the	   location	  of	   such	   sites,	   and	  which	   sites	   –	   and	  how	  many	  –	   are	   required	   to	  affect	   xNgn2	   activity,	   and	   stability.	   	   Mutation	   of	   C-­‐terminal	   SP	   sites	   to	   AP	   alone	  stabilises	  xNgn2	  significantly	   (Figure	  5.7)	  whereas	  mutation	  of	   the	  N-­‐terminal	   sites	  does	  not	   seem	  to	   result	   in	   significant	   stabilisation.	   	  There	   is	  a	   strong	  C-­‐terminal	  SP	  site	  dependence	  on	  the	  ability	  of	  xNgn2	  and	  mNgn2	  to	  induce	  neurogenesis	  also	  (Ali	  et	  al.,	  2011).	  	  	  	  This	  point	  is	  further	  illustrated	  in	  degradation	  assays	  involving	  the	  mutants	  of	  xNgn2	  sequentially	  removing	  SP	  sites	  starting	  from	  the	  C-­‐terminus	  as	  depicted	  in	  Figure	  5.8.	  	  There	   is	  no	  difference	  in	  stability	  on	  mutating	  these	  sites	  sequentially	   in	   interphase	  activated	   egg	   or	   neurula	   embryo	   extracts	   (Figure	   5.9)	   but	   in	  mitotic	   activated	   egg	  extract	  (Figure	  5.10)	  there	  is	  a	  very	  clear	  stabilisation	  of	  xNgn2	  reaching	  a	  maximum	  at	  xS-­‐A4,	  where	  all	  C-­‐terminal	  SP	  sites	  are	  mutated	  to	  AP.	   	  This	  effect	  is	  presumably	  due	  to	  the	  loss	  of	  phosphorylation	  sites,	  suggesting	  that	  phosphorylation	  itself	  might	  destabilise	  xNgn2.	  	  However	  as	  the	  additive	  mutations	  continue,	  xNgn2	  is	  destabilised	  again	  until	  all	  SP	  sites	  are	  lost	  in	  9S-­‐AxNgn2,	  which	  is	  only	  slightly	  more	  stable	  than	  xNgn2	  in	  mitotic	  extract	  (Figure	  5.10).	  	  As	  the	  two	  differing	  trends	  of	  stabilisation	  and	  destabilisation	  occur	  at	  opposite	  ends	  of	  the	  protein	  strand,	  this	  suggests	  that	  while	  phosphorylation	  on	  the	  C-­‐terminus	  might	  destabilise	  xNgn2,	  phosphorylation	  on	  the	  N-­‐terminus	  acts	  to	  stabilise	  xNgn2.	   	  Whether	  this	  is	  due	  to	  phosphorylation	  effect	  is	  uncertain.	  	  It	  could	  also	  be	  a	  structural	  effect	  and	  perhaps	  these	  serines	  form	  part	  of	  a	  binding	  region	  to	  a	  stabilising	  factor	  or	  form	  crucial	  hydrogen	  bonding	  contacts	  that	  prevent	  the	  protein	  from	  being	  unfolded.	  	  Under	  these	  conditions	  the	  cause	  cannot	  be	  determined	   but	   this	   striking	   effect	   perhaps	   hints	   at	   other	   factors	   in	   xNgn2	  stabilisation.	  	  	  	  Similarly	  reintroducing	  single	  serines	  at	  SP	  sites	   into	  9S-­‐AxNgn2	   illustrates	   that	   the	  most	  C-­‐terminal	  SP	  sites	  are	  destabilising	  (Figure	  5.11)	  and	  that	  these	  sites	  also	  form	  a	   GSK3-­‐β	   consensus	   site	   with	   a	   striking	   effect	   on	   xNgn2	   stability	   as	   shown	   by	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knocking	   in	   or	   knocking	   out	   both	   serines	   and	   investigating	   the	   effect	   on	   stability	  (Figure	  5.12).	  	  Whether	  or	  not	  GSK3-­‐β	  is	  the	  factor	  responsible	  is	  unclear	  and	  further	  work	  would	  be	  needed	  to	  identify	  if	  this	  was	  the	  case	  but	  the	  most	  C-­‐terminal	  SP	  sites	  are	  certainly	  important	  in	  regulating	  xNgn2	  stability.	  	  The	  greater	  stability	  of	  the	  phosphomimetic	  9S-­‐ExNgn2,	  with	  all	  SP	  serines	  mutated	  to	  glutamic	  acids,	  compared	  to	  xNgn2	  or	  9S-­‐AxNgn2	  (Figure	  5.13)	  is	  unexpected	  but	  perhaps	   not	   surprising.	   	   Whilst	   mutation	   of	   serines	   to	   aspartic	   or	   glutamic	   acid	  residues	   may	   appear	   to	   mimic	   phosphorylation	   in	   terms	   of	   the	   electrostatic	  environment	   produced,	   in	   reality	   a	   phosphate	  moiety	   and	   a	   carboxylate	   group	   are	  very	  different	  chemically.	   	  9S-­‐ExNgn2,	   if	  behaving	  as	  a	   true	  phosphomimetic,	  might	  be	  expected	  to	  have	  a	  stability	  similar	  to	  wild	  type	  xNgn2.	   	  However	  that	   it	   is	  more	  stable	   perhaps	   suggests	   that	   it	   may	   not	   be	   an	   appropriate	   phosphomimetic	  	  (discussed	   in	  (Tarrant	  and	  Cole,	  2009,	  Dulhanty	  and	  Riordan,	  1994,	  Germann	  et	  al.,	  1996,	  Gomez-­‐del	  Arco	  et	  al.,	  2004,	  Huang	  and	  Erikson,	  1994,	  Sun	  et	  al.,	  2007).	  	  xE12	  stabilises	  9S-­‐AxNgn2	  more	  than	  xNgn2	  only	  in	  mitosis	  (Figure	  5.14)	  suggesting	  that	  SP	  sites	  and	  phosphorylation	  may	  regulate	   the	  structure	  of	  xNgn2	  as	  an	  active	  heterodimer,	  which	  is	  interesting	  as	  it	  has	  been	  suggested	  that	  xE12	  binding	  actually	  promotes	  phosphorylation	  of	  xNgn2	  (Hand	  et	  al.,	  2005,	  Vosper	  et	  al.,	  2007).	   	  Indeed	  this	  appears	   to	  be	   the	   case	  as	   the	  presence	  of	   xE12	   results	   in	  xNgn2	  shifting	   in	  gel	  mobility	   in	   interphase	   extract	   (Figure	   5.15,	   A).	   	   xE12	   can	   no	   longer	   be	   observed	  stabilising	  9S-­‐AxNgn2	  to	  a	  greater	  extent	  than	  it	  stabilises	  xNgn2	  once	  Ub	  is	  fused	  to	  the	   N-­‐terminus.	   	   This	   may	   suggest	   that	   ubiquitylation	   of	   xNgn2	   is	   promoted	   by	  phosphorylation;	  in	  the	  absence	  of	  SP	  sites,	  xE12	  can	  stabilise	  9S-­‐AxNgn2	  to	  a	  greater	  extent	   in	  mitosis	  and	  9S-­‐AxNgn2	  alone	   is	  more	  stable	  than	  xNgn2	  in	  mitotic	  extract	  (Figure	   5.2).	   	   However	   as	   Ub-­‐9S-­‐AxNgn2	   is	   already	   fused	   to	   ubiquitin,	   presence	   or	  absence	  of	  putative	  phosphorylation	  sites	  no	  longer	  appears	  to	  affect	  stability.	  	  What	  is	  most	  important	  about	  the	  similar	  stabilities	  of	  Ub-­‐xNgn2	  and	  Ub-­‐9S-­‐AxNgn2	  is	  that	  their	   in	   vivo	   activity	   as	   assessed	  by	   scoring	  of	   ectopic	  neurogenesis	   in	   ISH	  Xenopus	  
laevis	  embryos	  injected	  with	  their	  mRNA	  is	  significantly	  different	  (Figure	  5.16).	  	  The	  upregulation	  of	  neurogenesis	  caused	  by	  injection	  of	  xNgn2	  mRNA	  is	  completely	   lost	  when	  Ub	   is	   fused	   to	   the	  N-­‐terminus	  of	   xNgn2.	   	  When	  9S-­‐AxNgn2	   is	   injected,	   this	   is	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hyperactive	  and	  Ub-­‐9S-­‐AxNgn2	  is	  less	  active	  than	  9S-­‐AxNgn2	  but	  of	  a	  similar	  activity	  to	   xNgn2.	   	   Therefore	   stability	   does	   not	   apparently	   correlate	  with	   activity.	   	   Looking	  deeper	   into	   this	   activity	   by	   qPCR	   analysis	   of	   transcriptional	   targets	   of	   xNgn2	   -­‐	  xNeuroD	   promoting	   neurogenesis,	   and	   Delta	   setting	   up	   Notch	   signalling	   for	   lateral	  inhibition	  –	  highlights	  that	  the	  differing	  in	  vivo	  activity	  of	  these	  forms	  of	  xNgn2	  lies	  in	  their	  ability	   to	  differentially	  activate	   transcription	  of	  different	   targets	   (Figure	  5.17).	  	  xNgn2	   upregulates	   xNeuroD	   and	   Delta	   expression;	   Ub-­‐xNgn2	   shows	   reduced	   Delta	  expression	   but	   no	   increase	   in	   xNeuroD	   expression	   compared	   to	   a	   GFP-­‐injected	  control.	   	   9S-­‐AxNgn2	   upregulates	   Delta	   to	   a	   similar	   extent	   as	   xNgn2,	   and	   Ub-­‐9S-­‐AxNgn2	  shows	  a	   similar	   reduction	   in	  activating	   transcription	  of	  Delta	  as	  Ub-­‐xNgn2.	  	  However,	  activation	  of	  transcription	  of	  xNeuroD	  mirrors	  exactly	  the	  results	  of	  the	  ISH	  experiment	   in	   Figure	   5.16.	   	   9S-­‐AxNgn2	   significantly	   upregulates	   activation	   of	  xNeuroD	   transcription,	   and	  whilst	  Ub-­‐9S-­‐AxNgn2	   is	   reduced	   in	   this	   ability,	   it	   has	   a	  similar	  level	  of	  activity	  as	  wild	  type	  xNgn2	  (Figure	  5.17,	  A).	  	  What	  therefore	  differs	  between	  the	  transcription	  of	  xNeuroD	  and	  Delta	  is	  the	  mode	  of	  interaction	   with	   the	   promoter	   region	   of	   these	   downstream	   targets	   of	   xNgn2.	   	   A	  schematic	  of	  a	  possible	  model	  is	  illustrated	  in	  Figure	  5.18.	  	  In	  cycling	  cells	  where	  cdk	  levels	  are	  rising	  as	  the	  cell	  cycle	  progresses	   into	  mitosis,	  xNgn2	  will	  be	   increasingly	  phosphorylated.	   	   This	   does	   not	   affect	   the	   interaction	  with	   the	   Delta	   promoter	   and	  Notch	  signalling,	  and	  therefore	   lateral	   inhibition,	   is	  maintained	  and	  the	  cell	  remains	  in	   a	   precursor	   state.	   	   However	   as	   the	   cell	   cycle	   lengthens	   and	   xNgn2	   is	   less	  phosphorylated,	   its	   stability	   increases	   and	   occupancy	   of	   the	   xNeuroD	   promoter	  increases	  as	  xNgn2	   is	  bound	   for	   longer	  periods	  of	   time	  and	  may	  be	  able	   to	  activate	  transcription	   at	   sites	   where	   assembly	   of	   transcription	   complexes	   is	   slower.	   	   Such	  differences	  in	  chromatin	  remodelling	  leading	  to	  transcriptional	  dynamics	  and	  varying	  “on/off”	  cycles	  of	  transcriptional	  complexes	  have	  been	  described	  (Hager	  et	  al.,	  2009)	  and	   the	   extent	   of	   chromatin	   remodelling	   required	   may	   affect	   the	   “speed”	   of	   the	  promoter,	   through	   to	   factors	  such	  as	  stalling	  of	  RNA	  polymerase	   II	  at	   the	  promoter	  during	  elongation	  (Nechaev	  and	  Adelman,	  2008).	  	  	  Such	   a	   mechanism	   ties	   together	   cell	   cycle	   dependence	   of	   xNgn2	   and	   xNgn2	  phosphomutant	  stability	  and	  differing	   in	  vivo	  activity.	   	  However	  there	  are	  still	  many	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questions	  to	  answer	  regarding	  the	  phosphorylation	  of	  xNgn2;	  precisely	  which	  kinases	  are	  involved,	  which	  sites	  are	  modified	  and	  ultimately	  how	  phosphorylation	  may	  affect	  the	  structure	  of	  xNgn2,	  itself	  a	  highly	  disordered	  protein.	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Figure 5.18: Suggested mechanism for xNgn2 using ‘fast’ or ‘slow’ promoters. 
xNgn2 upregulates both Delta and xNeuroD transcription.  If Delta is a ‘faster’ promoter – perhaps 
requiring a less complex assembly for activation of transcription – then Notch signalling can 
dominate and a primary neuron can maintain neighbouring cells in a precursor state.  However, if 
xNeuroD at the ‘slower’ promoter is favoured by xNgn2 which is around longer, say by stabilisation, 
then xNeuroD is upregulated over Delta and lateral inhibition is lost. 
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CHAPTER	  6	  
Protein	  Folding	  and	  xNgn2	  Stability	  
	  
	  












Figure 6.1: C-terminal HA tags can stabilise xNgn2. 
Xenopus laevis interphase activated egg extracts were supplemented with 35S-labelled IVT xNgn2, 
mNgn2 or C-terminally HA-tagged or triply HA-tagged (3HA) forms and incubated at 21 °C.  
Samples were taken at 0, 15, 30, 45, 60, 75, 90 and 120 mins and subjected to 15 % SDS-PAGE.  
Gels were analysed by quantitative phosphorimaging analysis, calculating the average stabilisation 
relative to wild type xNgn2 (A).  (B) Half-lives were calculated using first-order rate kinetics, and 
errors calculated using the Standard Error of the Mean (SEM).  
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p300	  is	  unable	  to	  stabilise	  xNgn2	  	  xNgn2	   stability	   can	   be	   affected	   by	   binding	   of	   cofactors	   such	   as	   its	   heterodimeric	  binding	  partner	  xE12	  (Figures	  5.14	  and	  5.15).	  	  xNgn2	  also	  associates	  with	  p300/CBP	  to	   form	   an	   active	   transcriptional	   complex	   (Bertrand	   et	   al.,	   2002).	   	   Therefore	   it	   is	  possible	  that	  binding	  to	  p300,	  like	  binding	  xE12,	  could	  affect	  xNgn2	  stability.	  	  E1A12S	  protein	   binds	   to	   p300	   (Fax	   et	   al.,	   2000)	   and	   inhibits	   its	   transcriptional	   activity	  (Oswald	  et	  al.,	  2001).	  	  Therefore	  I	  sought	  to	  investigate	  xNgn2	  stability	  in	  extract	  with	  the	   functional	   N-­‐terminal	   domain	   p300N,	   and	   the	   p300	   inhibitor	   E1A12S.	   35S-­‐radiolabelled	  IVT	  xNgn2	  was	  incubated	  in	  Xenopus	  laevis	  interphase	  activated	  egg	  and	  neurula	   embryo	   extract	   with	   IVT	   non-­‐radiolabelled	   p300N,	   E1A12S,	   or	   both	   (with	  GFP	   as	   a	   control)	   at	   21	   °C.	   	   Aliquots	   of	   the	   reaction	   were	   removed	   at	   increasing	  timepoints,	  quenched	   in	  SDS-­‐LB	  and	  samples	  were	  separated	  by	  15	  %	  SDS-­‐PAGE	  to	  allow	   measurement	   of	   protein	   levels	   over	   time	   and	   calculation	   of	   the	   half-­‐life	   for	  degradation	  using	  first-­‐order	  rate	  kinetics	  (Figure	  6.2).	  	  In	  interphase,	  xNgn2	  is	  degraded	  with	  a	  half-­‐life	  of	  23.6	  +/-­‐	  2.3	  mins	  and	  addition	  of	  p300N	  and/or	  E1A12S	  has	  no	  effect	  on	  the	  stability	  of	  xNgn2	  (Figure	  6.2,	  A	  and	  C).	  	  In	  neurula	  extract,	  xNgn2	  is	  degraded	  with	  a	  half-­‐life	  of	  27.4	  +/-­‐	  4.5	  mins.	   	  Addition	  of	  p300N	  has	  no	  effect	  on	  the	  stability	  as	  xNgn2	  is	  degraded	  with	  a	  half-­‐life	  of	  31.4	  +/-­‐	  4.5	  mins	  on	  the	  addition	  of	  p300N.	  	  However	  E1A12S	  significantly	  stabilises	  xNgn2	  to	  a	   half-­‐life	   of	   38.9	   +/-­‐	   2.3	  mins,	   but	   on	   addition	   of	   both	   p300N	   and	   E1A12S	   xNgn2	  stability	  is	  returned	  to	  normal	  levels	  with	  a	  half-­‐life	  of	  25.7	  +/-­‐	  0.3	  mins	  (Figure	  6.2,	  B	  and	  C).	  	  	  	  Therefore	   any	   possible	   effect	   on	   xNgn2	   stability	   of	   p300	   is	   unclear.	   	   Preliminary	  results	  for	  xNeuroD	  in	  interphase	  (Figure	  6.2C)	  further	  complicate	  the	  role	  of	  p300,	  as	  on	  addition	  of	  p300N,	  xNeuroD	  increases	   in	  stability	   from	  degrading	  with	  a	  half-­‐life	  of	  154	  mins	  to	  198	  mins,	  which	  drops	  to	  100	  mins	  in	  E1A12S	  alone,	  and	  returns	  to	  near-­‐wild	  type	  levels	  in	  the	  presence	  of	  both	  p300N	  and	  E1A12S	  to	  138	  mins.	  	  The	  role	  of	  p300	  in	  bHLH	  protein	  stabilisation	  is	  therefore	  unclear.	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Figure 6.2: xNgn2 stability in the presence of the transcriptional coactivator p300. 
Xenopus laevis interphase activated egg extracts and neurula embryo extracts were supplemented 
with 35S-labelled xNgn2 and non-radiolabelled IVT p300N and/or E1A12S and incubated at 21 °C.  
Samples were taken at 0, 15, 30, 45, 60, 90 and 120 mins and subjected to 15 % SDS-PAGE.  
Gels were analysed by quantitative phosphorimaging analysis, calculating the average stabilisation 
relative to wild type xNgn2 in interphase (A) and neurula (B) extracts.  (C) Half-lives were 
calculated using first-order rate kinetics, and errors calculated using the Standard Error of the 
Mean (SEM).  Experiments in neurula extract were carried out in duplicate.  Preliminary 
experiments using xNeuroD carried out only once in interphase extract are also shown. 
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xNgn2	  stabilisation	  with	  the	  cdki	  Xic1	  	  The	  Xenopus	   cdki	  Xic1	  has	  a	  stabilising	  effect	  on	  xNgn2	  (Vernon	  et	  al.,	  2003,	  Roark,	  2010).	   	   The	   mechanism	   of	   this	   stabilisation	   is	   thought	   to	   be	   through	   binding	   to	  xNgn2,	   rather	   than	   by	   its	   activity	   as	   an	   inhibitor	   of	   cdks	   (Roark,	   2010).	   	   35S-­‐radiolabelled	   IVT	   xNgn2	   was	   incubated	   in	   Xenopus	   laevis	   interphase	   activated	   egg	  extracts	  with	  Xic1	  (MBP-­‐tagged,	  purified	  by	  Ryan	  Roark)	  or	  MBP	  alone	  as	  a	  control	  at	  21	  °C.	   	  Aliquots	  of	  the	  reaction	  were	  removed	  at	  increasing	  timepoints,	  quenched	  in	  SDS-­‐LB	   and	   samples	  were	   separated	   by	   15	  %	   SDS-­‐PAGE	   to	   allow	  measurement	   of	  protein	   levels	   over	   time	   and	   calculation	   of	   the	   half-­‐life	   for	   degradation	   using	   first-­‐order	  rate	  kinetics	  (Figure	  6.3).	  	  	  xNgn2	  alone	  is	  degraded	  in	  interphase	  extract	  with	  a	  half-­‐life	  of	  20.1	  +/-­‐	  2.1	  mins.	  	  On	  addition	  of	  MBP	  this	  half-­‐life	  increases	  to	  27.5	  +/-­‐	  2.0	  mins	  –	  this	  is	  most	  likely	  due	  to	  dilution	  effects	  by	  adding	  MBP	  protein	  in	  solution,	  and	  is	  consistent	  with	  values	  found	  by	  Ryan	  Roark	  (Roark,	  2010).	  	  On	  addition	  of	  Xic1,	  xNgn2	  is	  degraded	  with	  a	  half-­‐life	  of	   42.6	   +/-­‐	   1.8	   mins	   (Figure	   6.3,	   B).	   	   Therefore	   Xic1	   does	   stabilise	   xNgn2	   against	  proteasomal	  degradation.	  	  This	   stabilising	   effect	   of	   Xic1	   on	   xNgn2	   has	   been	   investigated	   (Roark,	   2010)	   but	   I	  wished	  to	  assess	  whether	  (like	  xE12)	  Xic1	  was	  able	  to	  prevent	  ubiquitylated	  xNgn2,	  Ub-­‐xNgn2,	  from	  being	  degraded.	  	  This	  form	  of	  xNgn2	  with	  a	  single	  Ub	  fused	  linearly	  to	   the	   N-­‐terminus	   acts	   as	   a	   pre-­‐ubiquitylated	   priming	   site	   bypassing	   the	   first	  ubiquitylation	   event	   and	   allowing	   rapid	   degradation	   of	   xNgn2	   (Figure	   5.15).	   	   35S-­‐radiolabelled	   IVT	   xNgn2	   or	   Ub-­‐xNgn2	  were	   incubated	   in	  Xenopus	   laevis	   interphase	  activated	  egg	  extracts	  with	  Xic1	  (MBP-­‐tagged,	  purified	  by	  Ryan	  Roark)	  or	  MBP	  alone	  as	  a	  control	  at	  21	  °C.	  	  Aliquots	  of	  the	  reaction	  were	  removed	  at	  increasing	  timepoints,	  quenched	   in	   SDS-­‐LB	   and	   samples	   were	   separated	   by	   15	   %	   SDS-­‐PAGE	   to	   allow	  measurement	   of	   protein	   levels	   over	   time	   and	   calculation	   of	   the	   half-­‐life	   for	  degradation	  using	  first-­‐order	  rate	  kinetics	  (Figure	  6.4).	  	  xNgn2	  in	  MBP	  is	  degraded	  with	  a	  half-­‐life	  of	  27.4	  +/-­‐	  2.1	  mins	  but	  after	  the	  addition	  of	  Xic1	  the	  half-­‐life	  increases	  to	  37.9	  +/-­‐	  5.8	  mins	  (Figure	  6.4,	  C).	  	  Therefore	  Xic1	  is	  able	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Figure 6.3: xNgn2 stability with the Xenopus cyclin dependent kinase inhibitor Xic1. 
Xenopus laevis interphase activated egg extracts were supplemented with 35S-labelled IVT xNgn2 
and either maltose binding protein (MBP) or Xenopus cyclin dependent kinase inhibitor Xic1 protein 
and incubated at 21 °C.  Samples were taken at 0, 5, 10, 20, 30, 40, 50 and 60 mins and subjected 
to 15 % SDS-PAGE.  Gels were analysed by quantitative phosphorimaging analysis, calculating 
the average stabilisation relative to wild type xNgn2 (A).  (B) Half-lives were calculated using first-




Figure 6.4: Ubiquitylated xNgn2 stability with the Xenopus cyclin dependent kinase inhibitor 
Xic1 in interphase. 
Xenopus laevis interphase activated egg extracts were supplemented with 35S-labelled IVT xNgn2 
or Ub-xNgn2 and either maltose binding protein (MBP) or Xenopus cyclin dependent kinase 
inhibitor Xic1 protein and incubated at 21 °C.  Samples were taken at the timepoints indicated and 
subjected to 15 % SDS-PAGE.  Gels were analysed by autoradiography (A) and quantitative 
phosphorimaging analysis, calculating the average stabilisation relative to wild type xNgn2 (B).  (C) 
Half-lives were calculated using first-order rate kinetics, and errors calculated using the Standard 
Error of the Mean (SEM).  
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to	  stabilise	  xNgn2	  in	  interphase	  extract.	  	  Ub-­‐xNgn2	  with	  MBP	  only	  is	  degraded	  with	  a	  half-­‐life	  of	  7.0	  +/-­‐	  0.4	  mins	  and	  similarly	  upon	  addition	  of	  Xic1	  Ub-­‐xNgn2	  is	  degraded	  with	  a	  half-­‐life	  of	  7.6	  +/-­‐	  0.8	  mins	  (Figure	  6.4,	  C).	  	  Therefore	  Xic1	  is	  unable	  to	  stabilise	  ubiquitylated	  xNgn2	  in	  interphase	  extract.	  	  Phosphorylation	   affects	   xNgn2	   stability,	   most	   notably	   in	   mitosis	   (see	   Chapter	   5).	  	  Therefore	   to	   see	   if	   Xic1	   regulates	   the	   stability	   of	   phosphorylated	   xNgn2,	   the	  experiments	   in	   Figure	   6.4	   were	   repeated	   in	   mitotic	   extract.	   	   35S-­‐radiolabelled	   IVT	  xNgn2	  or	  Ub-­‐xNgn2	  were	   incubated	   in	  Xenopus	   laevis	  mitotic	  activated	  egg	  extracts	  with	  Xic1	  (MBP-­‐tagged,	  purified	  by	  Ryan	  Roark)	  or	  MBP	  alone	  as	  a	  control	  at	  21	  °C.	  	  Aliquots	  of	  the	  reaction	  were	  removed	  at	  increasing	  timepoints,	  quenched	  in	  SDS-­‐LB	  and	   samples	  were	   separated	   by	   15	  %	   SDS-­‐PAGE	   to	   allow	  measurement	   of	   protein	  levels	  over	  time	  and	  calculation	  of	  the	  half-­‐life	  for	  degradation	  using	  first-­‐order	  rate	  kinetics	  (Figure	  6.5).	  	  Contrary	  to	  the	  results	  in	  Figure	  6.4,	  xNgn2	  is	  not	  stabilised	  by	  Xic1	  in	  mitosis	  –	  with	  MBP	  alone	  it	  is	  degraded	  with	  a	  half-­‐life	  of	  15.0	  +/-­‐	  0.9	  mins	  and	  with	  Xic1	  the	  half-­‐life	  remains	  at	  14.7	  +/-­‐	  1.8	  mins	  (Figure	  6.5,	  C).	  	  Ub-­‐xNgn2	  is	  degraded	  with	  a	  half-­‐life	  of	  7.5	  +/-­‐	  1.9	  mins	  in	  MBP	  alone	  but	  with	  Xic1	  the	  half-­‐life	  is	  increased	  beyond	  wild	  type	   xNgn2	   to	   21.6	   +/-­‐	   2.5	  mins	   (Figure	   6.5,	   C).	   	   Therefore	   Xic1	   does	   not	   stabilise	  xNgn2	  in	  mitosis	  but	  does	  stabilise	  ubiquitylated	  xNgn2.	  	  
xNgn2	  stability	  in	  DNA-­binding	  	  xNgn2	   binds	   xE12	   as	   a	   heterodimer	   and	   binds	   to	   the	   E-­‐box	  DNA	   consensus	   site	   of	  promoter	  regions	  of	  target	  genes	  (Bertrand	  et	  al.,	  2002).	  	  Therefore	  it	  is	  possible	  that	  DNA-­‐binding	   itself	  may	  have	  a	   role	   in	  affecting	  xNgn2	  stability.	   	  Ali	   Jones	  created	  a	  site-­‐directed	  mutant	  of	  xNgn2	  with	  arginine	  82	  mutated	   to	  alanine	  and	  arginine	  83	  mutated	   to	  glutamine	  –	   from	  RR	   to	  AQ	   -­‐	  which	  should	  be	  unable	   to	  bind	   to	  DNA	   in	  analogy	  to	  similar	  mutants	  in	  Ngn1	  (Gowan	  et	  al.,	  2001,	  Sun	  et	  al.,	  2001)	  and	  Mash1	  (Nakada	  et	  al.,	  2004).	  	  I	  investigated	  the	  stability	  of	  this	  mutant	  in	  interphase,	  mitotic	  and	   neurula	   extracts.	   	   35S-­‐radiolabelled	   IVT	   xNgn2	   or	   xNgn2AQ	  were	   incubated	   in	  




Figure 6.5: Ubiquitylated xNgn2 stability with the Xenopus cyclin dependent kinase inhibitor 
Xic1 in mitosis. 
Xenopus laevis mitotic activated egg extracts were supplemented with 35S-labelled IVT xNgn2 or 
Ub-xNgn2 and either maltose binding protein (MBP) or Xenopus cyclin dependent kinase inhibitor 
Xic1 protein and incubated at 21 °C.  Samples were taken at the timepoints indicated and 
subjected to 15 % SDS-PAGE.  Gels were analysed by autoradiography (A) and quantitative 
phosphorimaging analysis, calculating the average stabilisation relative to wild type xNgn2 (B).  (C) 
Half-lives were calculated using first-order rate kinetics, and errors calculated using the Standard 
Error of the Mean (SEM).   Experiments were carried out in duplicate. 
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Figure 6.6: Stability and phosphorylation state of xNgn2 DNA-binding mutant, xNgn2AQ. 
Xenopus laevis interphase and mitotic activated egg and neurula embryo extracts were 
supplemented with 35S-labelled IVT xNgn2 or xNgn2AQ and incubated at 21 °C.  Samples were 
taken at 0, 5, 10, 20, 30, 40, 50 and 60 mins and subjected to 15 % SDS-PAGE.  Gels were 
analysed by quantitative phosphorimaging analysis, calculating the average stabilisation relative to 
wild-type xNgn2 within each extract (A).  (B) Half-lives were calculated using first-order rate 
kinetics, and errors calculated using the Standard Error of the Mean (SEM).  (C) 35S-labelled IVT 
xNgn2 or xNgn2AQ were incubated in mitotic activated egg extract with MG132 at 21 °C.  Samples 
were taken at the timepoints indicated and subjected to 15 % SDS-PAGE. 
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The	  difference	  in	  xNgn2	  and	  xNgn2AQ	  stability	  in	  neurula	  embryo	  extract	  alone	  is	  not	  surprising,	   as	   this	   extract	   contains	   the	   same	   cytoplasmic	   volume	   per	   unit	   as	   egg	  extracts,	  but	  a	  much	  higher	  DNA	  content	  as	  cells	  are	  dividing	  but	  not	  yet	  growing	  in	  the	  early	  Xenopus	  embryo	  (Sive	  et	  al.,	  2000).	  	  To	  see	  if	  any	  further	  effect	  on	  stability	  occurs	  in	  the	  presence	  of	  a	  stabilising	  factor	  such	  as	  xE12,	  the	  heterodimeric	  binding	  partner	   in	   the	  DNA-­‐bound	   xNgn2	   complex,	   degradation	   assays	  were	   carried	   out	   in	  neurula	  extract.	  	  35S-­‐radiolabelled	  IVT	  xNgn2	  or	  xNgn2AQ	  were	  incubated	  in	  Xenopus	  
laevis	  neurula	  embryo	  extracts	  with	  IVT	  non-­‐radiolabelled	  xE12,	  or	  GFP	  as	  a	  protein	  control,	   at	   21	   °C.	   	   Aliquots	   of	   the	   reaction	  were	   removed	   at	   increasing	   timepoints,	  quenched	   in	   SDS-­‐LB	   and	   samples	   were	   separated	   by	   15	   %	   SDS-­‐PAGE	   to	   allow	  measurement	   of	   protein	   levels	   over	   time	   and	   calculation	   of	   the	   half-­‐life	   for	  degradation	  using	  first-­‐order	  rate	  kinetics	  (Figure	  6.7).	  	  In	  neurula	  extract	  there	  appears	  to	  be	  no	  difference	  in	  stability	  between	  xNgn2	  and	  xNgn2AQ,	  xNgn2	  being	  degraded	  with	  a	  half-­‐life	  of	  47.2	  +/-­‐	  8.6	  mins	  and	  xNgn2AQ	  being	  degraded	  with	  a	  half-­‐life	  of	  37.5	  +/-­‐	  2.5	  mins	  (Figure	  6.7,	  C).	   	  However	  whilst	  xNgn2	  is	  stabilised	  2-­‐fold	  by	  xE12	  to	  77.7	  +/-­‐	  11.0	  mins,	  xNgn2AQ	  is	  stabilised	  3-­‐fold	  to	   118	   +/-­‐	   39	   mins	   in	   xE12	   (Figure	   6.7,	   B	   and	   C).	   	   Therefore	   xNgn2AQ	   can	   be	  stabilised	  by	  xE12	  in	  neurula	  extract	  and	  to	  a	  greater	  extent	  than	  wild	  type	  xNgn2.	  	  
xNgn2	  stability	  and	  unfolding	  	  To	   investigate	  structural	  aspects	  of	  xNgn2	  degradation	   it	  would	  be	  useful	   to	  dissect	  out	  the	  two	  components	  of	  degradation,	  protein	  ubiquitylation	  and	  protein	  unfolding.	  	  To	  this	  end	  I	  attempted	  to	  combine	  the	  form	  of	  xNgn2	  with	  a	  single	  Ub	  linearly	  fused	  to	   the	   N-­‐terminus,	   Ub-­‐xNgn2,	   using	   extract	   increasingly	   diluted	   with	   XB	   for	  degradation	  assays.	  	  Diluting	  the	  extract	  would	  hopefully	  reduce	  molecular	  crowding,	  viscosity	   and	   proteasome	   concentration	   within	   the	   sample.	   	   This	   could	   limit	   the	  proteasome	   concentration	   and	   so	   reduce	   the	   stability	   of	   xNgn2	   to	   a	   function	   of	   its	  rate	   of	   folding	   or	   unfolding,	   independent	   of	   ubiquitylation	   rates.	   	   35S-­‐radiolabelled	  IVT	   xNgn2	   or	  Ub-­‐xNgn2	  were	   incubated	   in	  Xenopus	   laevis	   interphase	   activated	   egg	  extracts	  diluted	  with	  XB	  buffer	  to	  give	  90,	  75,	  50	  and	  25	  %	  extracts	  by	  volume	  at	  21	  
°C.	  	  Aliquots	  of	  the	  reaction	  were	  removed	  at	  increasing	  timepoints,	  quenched	  in	  SDS-­‐	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Figure 6.7: Stability of xNgn2 DNA-binding mutant, xNgn2AQ, with xE12 in neurula extract. 
Xenopus laevis interphase and mitotic activated egg and neurula embryo extracts were 
supplemented with 35S-labelled IVT xNgn2 or xNgn2AQ and incubated at 21 °C.  Samples were 
taken at the timepoints indicated and subjected to 15 % SDS-PAGE.  Gels were analysed by 
autoradiography (A) and quantitative phosphorimaging analysis, calculating the average 
stabilisation relative to wild-type xNgn2 (B).  (C) Half-lives were calculated using first-order rate 
kinetics, and errors calculated using the Standard Error of the Mean (SEM).  Experiments were 
carried out in duplicate. 	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  LB	  and	  samples	  were	  separated	  by	  15	  %	  SDS-­‐PAGE	  to	  allow	  measurement	  of	  protein	  levels	  over	  time	  and	  calculation	  of	  the	  half-­‐life	  for	  degradation	  using	  first-­‐order	  rate	  kinetics	  (Figure	  6.8).	  	  The	  results	  in	  Figure	  6.8	  show	  that	  dilution	  of	  extract	  to	  slow	  folding	  does	  not	  even	  appear	  to	  work	  for	  wild	  type	  xNgn2	  as	  across	  100,	  90,	  75,	  50	  and	  25	  %	  extracts	  by	  volume	  all	  half-­‐lives	  are	  within	  error.	  	  75	  %	  and	  25	  %	  extracts	  demonstrate	  half-­‐lives	  for	  degradation	  of	  Ub-­‐xNgn2	  of	  16.0	  +/-­‐	  5.5	  mins	  and	  12.4	  +/-­‐	  1.8	  mins	  respectively,	  but	   50	  %	   extract	   exhibits	   a	   half-­‐life	   for	   Ub-­‐xNgn2	   degradation	   of	   6.7	   +/-­‐	   0.5	  mins.	  	  Therefore	   unfolding	   of	   xNgn2	   in	   stability	   cannot	   be	   experimentally	   investigated	  simply	  by	  using	  diluted	  Xenopus	  extract.	  
	  




Figure 6.8: xNgn2 stability in diluted Xenopus extract. 
Xenopus laevis interphase activated egg extracts were diluted with XB buffer and supplemented 
with 35S-labelled xNgn2 or Ub-xNgn2 and incubated at 21 °C.  Samples were taken at 0, 5, 10, 20, 
30, 40, 50 and 60 mins for xNgn2, and 0, 2, 4, 6, 8, 10, 15 and 20 mins for Ub-xNgn2 and 
subjected to 15 % SDS-PAGE.  Gels were analysed by quantitative phosphorimaging analysis, 
calculating the average stabilisation relative to wild-type xNgn2 (A).  (B) Half-lives were calculated 






Figure 6.9: Stability of xNeuroD in interphase and mitosis. 
Xenopus laevis interphase and mitotic activated egg extracts were supplemented with 35S-labelled 
IVT xNgn2 or xNeuroD and incubated at 21 °C.  Samples were taken at 0, 15, 30, 45, 60, 75, 90 
and 120 mins and subjected to 15 % SDS-PAGE.  Gels were analysed by autoradiography (A) and 
quantitative phosphorimaging analysis, calculating the average stabilisation of each protein relative 
to interphase (B).  (C) Half-lives were calculated using first-order rate kinetics, and errors 
calculated using the Standard Error of the Mean (SEM).  Results are from a duplicate set of 
experiments. 
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Figure 6.10: Ubiquitylation of xNeuroD. 
A) ClustalW2 analysis of sequences from xNgn2 and xNeuroD.  The disordered N-terminal domain 
is bordered in blue; the bHLH domain in red; and the disordered C-terminal domain in green. 
B) Xenopus laevis interphase activated egg extracts were supplemented with 35S-labelled IVT 
xNgn2 or xNeuroD in the presence of MG132 and either His6-ubiquitin (His-Ub) or untagged 
ubiquitin (Reg-Ub) and incubated at 20 °C for 90 mins.  Samples were bound to Ni-NTA Agarose 
beads for 75 mins and subjected to 15 % SDS-PAGE in either reducing or non-reducing conditions.  
Gels were analysed by autoradiography.  Experiments were carried out in duplicate.  Lanes are 
numbered 1-8 as described in the text. 
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However	  the	  xNeuroD	  polyubiquitylation	  ladder	  in	  reducing	  conditions	  (Figure	  6.10,	  B,	  lane	  2)	  does	  not	  contain	  a	  band	  representing	  unmodified	  xNeuroD	  running	  at	  the	  level	   of	   IVT.	   	   xNeuroD	   is	   polyubiquitylated	   in	   both	   reducing	   (lane	   2)	   and	   non-­‐reducing	  (lane	  4)	  conditions.	  	  Therefore	  whilst	  wild	  type	  xNgn2	  and	  xNeuroD	  are	  both	  polyubiquitylated	  in	  Xenopus	  egg	   extract,	   xNgn2	  demonstrates	   reducing	   agent,	   high	  pH-­‐dependent	  ubiquitylation	  whilst	  xNeuroD	  does	  not.	  	  xNgn2	  and	   xNeuroD	  are	   similar	  proteins	  but	  with	  differing	  degradation	  properties.	  	  There	  may	  be	  particular	  regions	  of	  xNgn2	  that	  are	  destabilising	  or	  conversely	  regions	  of	  xNeuroD	  which	  stabilise	  the	  protein	  against	  proteasomal	  degradation,	  perhaps	  by	  affecting	   the	   availability	   of	   unfolding	   initiation	   sites	   which	   are	   required	   for	  degradation	  (Prakash	  et	  al.,	  2004).	  	  To	  compare	  and	  contrast	  these	  regions	  of	  xNgn2	  and	   xNeuroD	   fusion	   proteins	   were	   made	   to	   create	   “domain	   swaps”	   of	   xNgn2	   and	  xNeuroD.	   	  These	  were	   constructed	   to	  place	   the	  N-­‐terminus	  of	  one	  protein	  onto	   the	  bHLH	  and	  C-­‐terminal	  domains	  of	  another	  protein,	  and	  vice-­versa;	  likewise	  to	  place	  the	  N-­‐terminal	  and	  bHLH	  domains	  onto	  the	  C-­‐terminal	  domain	  of	  the	  other.	  	  For	  these	  the	  definition	  of	  where	  the	  N-­‐	  and	  C-­‐termini	  begin	  and	  end,	  and	  where	  the	  bHLH	  domain	  resides,	  was	   taken	   from	   a	   review	   of	   bHLH	   proteins	   (Bertrand	   et	   al.,	   2002).	   	   These	  ‘domain	  swap’	  chimeric	  proteins	  were	  made	  as	  outlined	  in	  Figure	  6.11,	  but	  their	  most	  important	  feature	  is	  at	  the	  junction	  of	  the	  two	  fusion	  proteins.	  	  The	  simpler	  strategy	  practically	  speaking	  would	  be	  to	  produce	  polymerase	  chain	  reaction	  (PCR)	  products	  that	   represent	   the	   two	  parts	   of	   the	   protein	   to	   be	   fused,	   and	   fuse	   them	   together	   by	  ligating	   them	  with	   a	   restriction	   site	   between	   them.	   	   However,	   in	   order	   to	   do	   so,	   2	  extra	  amino	  acids	  would	  need	  to	  be	  introduced	  to	  the	  protein	  sequence.	  	  Not	  wishing	  to	  introduce	  non-­‐native	  residues	  to	  an	  already	  non-­‐native	  fusion	  protein,	  the	  protein	  fusions	   were	   instead	   made	   entirely	   by	   PCR,	   using	   primers	   complementary	   to	  sequence	  in	  both	  proteins,	  so	  that	  one	  when	  the	  required	  domains	  of	  one	  protein	  had	  been	  produced	  by	  PCR,	  they	  would	  have	  one	  part	  at	  the	  point	  of	  fusion	  that	  could	  act	  as	   a	   primer	   for	   the	   other	   protein	   (a	   schematic	   of	   the	   chimeric	   proteins	   is	   given	   in	  Figure	  6.12,	  E).	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Figure 6.11: Strategy for xNgn2/xNeuroD domain swapping. 
(A) The ultimate goal of the domain swap cloning is to fuse different regions of xNgn2 and xNeuroD 
together, e.g. the N-terminal domain of xNeuroD to the bHLH and C-terminus of xNgn2 to create N-
Ngn/BC-NeuroD, but without introducing extra amino acid residues between the domains as would 
occur if linking domains together using restriction sites.  (B) 1) A reverse primer is made for the C-
terminus of xNgn2, with a XhoI restriction site at the 5’ end, and a forward primer begins from the 
basic domain of xNgn2, but with the end of the xNeuroD N-terminal domain sequence preceding it. 
2) These primers are used in PCR using xNgn2 as a vector.  3) PCR products are generated of the 
bHLH and C-terminal domains of xNgn2, with a small region complementary to the end of the 
xNeuroD N-terminal domain at the start.  4) The PCR product can then be used as a primer itself 
as it has a short complementary sequence to xNeuroD.  This can be used with a forward primer 
from the start of the N-terminus of xNeuroD, with a BamHI site at the 5’ end, in a PCR reaction 5) 
using xNeuroD as the template.  When the PCR product is denatured, it can reanneal to the vector 
through the complementary sequence and act as a reverse primer.  6) The final product has the N-
terminal domain of xNeuroD fused to the bHLH and C-terminal domains of xNgn2.  The PCR 
product is flanked by BamHI and XhoI sites, which can be used to digest and ligate into pCS2+ 
vector. 
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I	  produced	  35S-­‐radiolabelled	  IVT	  chimeric	  proteins	  in	  the	  presence	  or	  absence	  of	  the	  proteasome	   inhibitor	  MG132	  and	  separated	   the	  proteins	  by	  15	  %	  SDS-­‐PAGE	  before	  assessing	  by	  autoradiography	  (Figure	  6.12,	  A).	  	  The	  proteins	  are	  named	  according	  to	  which	   domains	   they	   contain:	   N	   for	   N-­‐terminal;	   B	   for	   bHLH;	   C	   for	   C-­‐terminal.	  	  Therefore	  N-­‐Ngn/BC-­‐NeuroD	  has	  the	  N-­‐terminal	  domain	  of	  xNgn2	  fused	  to	  the	  bHLH	  and	  C-­‐terminal	  domains	  of	  xNeuroD	  (see	  Figure	  6.12,	  E).	  	  Figure	  6.12,	  A	  shows	  that	  there	  is	  a	  difference	  in	  the	  size	  of	  the	  proteins.	  	  This	  is	  due	  to	  the	  C-­‐terminal	  domain,	  which	  in	  xNeuroD	  is	  far	  larger	  than	  xNgn2.	  	  Bands	  with	  the	  N-­‐terminal	   domain	   of	   xNeuroD	   run	   as	   a	   cleaner	   band	   than	   the	   smeared	   band	   of	  proteins	  with	  the	  N-­‐terminal	  domain	  of	  xNgn2.	  	  	  To	  assess	  the	  stability	  of	  the	  domain	  swap	  proteins	  against	  proteasomal	  degradation,	  35S-­‐radiolabelled	   IVT	   domain	   swap	   proteins,	   xNgn2	   or	   xNeuroD	  were	   incubated	   in	  
Xenopus	   laevis	   interphase	   activated	   egg	   extracts	   at	   21	   °C.	   	   Aliquots	   of	   the	   reaction	  were	   removed	   at	   increasing	   timepoints,	   quenched	   in	   SDS-­‐LB	   and	   samples	   were	  separated	  by	  15	  %	  SDS-­‐PAGE	  to	  allow	  measurement	  of	  protein	  levels	  over	  time	  and	  calculation	  of	  the	  half-­‐life	  for	  degradation	  using	  first-­‐order	  rate	  kinetics	  (Figure	  6.12,	  B,	  C	  and	  D).	  	  xNgn2	  is	  degraded	  with	  a	  half-­‐life	  of	  22.2	  +/-­‐	  3.1	  mins	  whilst	  xNeuroD	  is	  stable	  with	  a	  half-­‐life	  of	  degradation	  greater	  than	  the	  length	  of	  the	  240	  min	  timecourse	  and	  so	  not	  accurately	  determinable	  (Figure	  6.12,	  D).	  	  	  	  N-­‐Ngn/BC-­‐NeuroD	  is	  stabilised	  relative	  to	  xNgn2,	  with	  a	  half-­‐life	  of	  128	  +/-­‐	  7	  mins.	  	  However	  swapping	  the	  bHLH	  domains	  to	  give	  NB-­‐Ngn/C-­‐NeuroD	  decreases	  the	  half-­‐life	  of	  degradation	  to	  69.2	  +/-­‐	  11.1	  mins.	   	  This	  means	  that	  the	  bHLH	  and	  C-­‐terminal	  domains	  of	  xNeuroD	  are	  stabilising	  on	  the	  N-­‐terminal	  domain	  of	  xNgn2,	  but	  when	  the	  bHLH	  domain	  of	  xNeuroD	  is	  swapped	  with	  that	  of	  xNgn2,	  the	  protein	  is	  destabilised.	  	  Therefore	   the	   bHLH	   domain	   of	   xNgn2	   is	   less	   stable	   than	   that	   of	   xNeuroD	   in	   this	  setting,	  despite	  being	  73	  %	  identical.	  	  N-­‐NeuroD/BC-­‐Ngn	  and	  NB-­‐NeuroD/C-­‐Ngn	  have	  similar	   half-­‐lives	   for	   degradation	   of	   112	   +/-­‐	   20	   mins	   and	   126	   +/-­‐	   21	   mins	  respectively.	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Figure 6.12: xNgn2/xNeuroD domain swap stability in interphase. 
MG132-treated 35S-radiolabelled IVT chimeric proteins analysed by autoradiography (A). Xenopus 
interphase extracts were supplemented with 35S-labelled IVT xNgn2, xNeuroD or chimeric protein.  
Samples were taken at indicated timepoints, subjected to 15 % SDS-PAGE and analysed by 
autoradiography (B).  The average stabilisation relative to wild-type xNgn2 within interphase extract 
was calculated (C).  (D) Half-lives were calculated using first-order rate kinetics, and errors 
calculated using SEM.  n ≥ 3.  (E) Schematic of chimeric proteins. 
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Therefore,	  with	  respect	  to	  xNgn2,	  replacing	  any	  domain	  with	  one	  from	  xNeuroD	  can	  be	   stabilising;	   however	   the	   least	   stable	   combination	   is	   the	   N-­‐terminal	   and	   bHLH	  domain	  of	  xNgn2.	  	  As	  xNeuroD	  is	  even	  more	  stable	  in	  mitosis,	  these	  degradation	  assays	  were	  repeated	  in	  a	  mitotic	  setting	  to	  see	  if	  any	  further	  difference	  was	  observed.	  	  35S-­‐radiolabelled	  IVT	  domain	  swap	  proteins,	  xNgn2	  or	  xNeuroD	  were	   incubated	   in	  Xenopus	   laevis	  mitotic	  egg	  extracts	  at	  21	  °C.	  	  Aliquots	  of	  the	  reaction	  were	  removed	  at	  increasing	  timepoints,	  quenched	   in	   SDS-­‐LB	   and	   samples	   were	   separated	   by	   15	   %	   SDS-­‐PAGE	   to	   allow	  measurement	   of	   protein	   levels	   over	   time	   and	   calculation	   of	   the	   half-­‐life	   for	  degradation	  using	  first-­‐order	  rate	  kinetics	  (Figure	  6.13).	  	  xNgn2	  has	   a	   half-­‐life	   for	   degradation	  of	   23.2	  +/-­‐	   5.0	  mins	  whilst	   xNeuroD	   is	   stable	  with	  a	  half-­‐life	  of	  degradation	  greater	  than	  the	  length	  of	  the	  240	  min	  timecourse	  and	  so	  not	  accurately	  determinable	  (Figure	  6.13,	  C).	  	  	  	  N-­‐Ngn/BC-­‐NeuroD	  is	  also	  stable	  with	  a	  half-­‐life	  of	  degradation	  greater	  than	  the	  length	  of	   the	   240	   min	   timecourse	   and	   so	   not	   accurately	   determinable.	   	   Therefore	   the	   N-­‐terminal	   domain	   of	   xNgn2	   is	   not	   destabilising	   in	   mitosis.	   	   However	   changing	   the	  bHLH	  domain	  of	  xNeuroD	  for	  that	  of	  xNgn2	  in	  NB-­‐Ngn/C-­‐NeuroD	  reduces	  the	  half-­‐life	  for	  degradation	  down	  to	  75.5	  +/-­‐	  10.8	  mins.	  	  Therefore	  the	  bHLH	  domain	  of	  xNgn2	  is	  destabilising	  in	  mitosis	  as	  well	  as	  in	  interphase	  in	  this	  domain	  swap.	  	  N-­‐NeuroD/BC-­‐Ngn	  and	  NB-­‐NeuroD/C-­‐Ngn	  exhibit	  half-­‐lives	  for	  degradation	  of	  110	  +/-­‐	  57	  mins	  and	  146	   +/-­‐	   61	   mins	   respectively	   which	   do	   not	   differ	   significantly	   from	   NB-­‐Ngn/C-­‐NeuroD.	  	  Therefore	  the	  C-­‐terminal	  domain	  of	  xNgn2	  appears	  destabilising,	  which	  was	  not	  the	  case	  in	  interphase	  extract	  (Figure	  6.12,	  C).	  	  To	   look	   at	   the	   ubiquitylation	   of	   the	   domain	   swap	   proteins,	   I	   subjected	   xNgn2,	  xNeuroD	   and	   the	   domain	   swap	  proteins	   to	   ubiquitylation	   assays.	   	   35S-­‐radiolabelled	  IVT	   proteins	   were	   added	   to	   Xenopus	   laevis	   interphase	   activated	   egg	   extract	  supplemented	  with	  MG132	   to	  prevent	  proteasomal	  degradation,	  and	  either	  His6-­‐Ub	  (Sigma)	  or	  untagged	  Ub	   (Sigma).	  This	   reaction	  was	   incubated	  at	  20	  °C	   for	  90	  mins.	  	  Samples	  were	  then	  incubated	  with	  denaturing	  Vosper	  buffer	  (containing	  8.5	  M	  urea)	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Figure 6.13: xNgn2/xNeuroD domain swap stability in mitosis. 
Xenopus laevis mitotic egg extracts were supplemented with 35S-labelled IVT xNgn2, xNeuroD or 
domain swapped protein and incubated at 21 °C.  Samples were taken at the timepoints indicated 
and subjected to 15 % SDS-PAGE.  Gels were analysed by autoradiography (A) and quantitative 
phosphorimaging analysis, calculating the average stabilisation relative to wild-type xNgn2 within 
mitotic extract (B).  (C) Half-lives were calculated using first-order rate kinetics, and errors 
calculated using the Standard Error of the Mean (SEM).  n ≥ 2. 
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and	  nickel-­‐chelating	  agarose	  beads	  (Ni-­‐NTA,	  Invitrogen)	  to	  purify	  his-­‐tagged	  protein.	  These	  samples	  were	  eluted	  in	  reducing	  or	  non-­‐reducing	  loading	  buffer	  and	  separated	  by	  12	  %	  SDS-­‐PAGE	  (Figure	  6.14).	  	  Polyubiquitylation	   ladders	  are	  present	   in	  all	  xNgn2	  and	  xNeuroD	  chimeric	  proteins,	  illustrated	   in	   Figure	   6.14,	   B,	   where	   all	   chimeric	   proteins	   treated	   with	   His-­‐Ub	   and	  reducing	  conditions	  are	  run	  out	  on	  a	  single	  SDS-­‐PAGE	  gel.	  	  Pulling	   down	   his-­‐tagged	   proteins	   results	   in	   a	   polyubiquitylation	   ladder	   of	  radiolabelled	   xNgn2	   in	  both	   reducing	   and	  non-­‐reducing	   treatments	   (Figure	  6.14,	  A,	  lanes	  1	  and	  2).	  	  The	  band	  in	  lane	  1	  running	  at	  the	  same	  mass	  as	  the	  IVT	  radiolabelled	  protein	   sample	   is	   not	   present	   in	   lane	   2.	   	   Therefore	   under	   reducing	   conditions,	  unmodified	   xNgn2	   is	   liberated	   from	   polyubiquitin	   chains	   after	   pulldown	   on	   nickel	  beads.	  	  This	  has	  been	  discussed	  previously	  and	  is	  due	  to	  linkage	  of	  ubiquitin	  to	  xNgn2	  through	  labile	  covalent	  bonds,	  which	  are	  broken	  in	  reducing	  conditions.	  	  For	   chimeric	   proteins	   containing	   the	   C-­‐terminal	   domain	   of	   xNeuroD	   (N-­‐Ngn/BC-­‐NeuroD	   and	   NB-­‐Ngn/C-­‐NeuroD)	   the	   polyubiquitylation	   ladders	   in	   His-­‐Ub	   treated	  samples	  (Figure	  6.14,	  A,	  lanes	  5	  and	  6,	  9	  and	  10)	  show	  no	  obvious	  difference	  between	  reducing	  and	  non-­‐reducing	  treatments	  (comparing	  lane	  5	  with	  6,	  and	  lane	  9	  with	  10).	  	  Although	   bands	   at	   the	   mass	   of	   the	   major	   band	   in	   the	   IVT	   protein	   of	   NB-­‐Ngn/C-­‐NeuroD	  are	  present,	  this	  is	  most	  likely	  due	  to	  the	  large	  amount	  of	  protein	  in	  the	  IVT	  sample	   affecting	   the	   level	   at	   which	   the	   band	   appears	   on	   SDS-­‐PAGE.	   	   The	  polyubiquitylation	  ladders	  are	  smeared,	  like	  xNeuroD	  (lanes	  21	  and	  22),	  compared	  to	  the	   clean	   defined	   polyubiquitylation	   ladder	   of	   xNgn2	   (lanes	   1	   and	   2).	   	   Therefore	  whilst	   chimeric	   proteins	   containing	   the	   C-­‐terminal	   domain	   of	   xNeuroD	   are	   highly	  ubiquitylated,	   no	   reducing	   agent	   dependence	   is	   exhibited	   in	   this	   ubiquitylation	  suggesting	  non-­‐canonical	  ubiquitylation	  may	  not	  occur	  on	  the	  N-­‐terminal	  domain	  or	  bHLH	  domain	  of	  xNgn2.	  	  In	   contrast,	   the	   chimeric	   proteins	   containing	   the	   C-­‐terminal	   domain	   of	   xNgn2	   (N-­‐NeuroD/BC-­‐Ngn	  and	  NB-­‐NeuroD/C-­‐Ngn)	  exhibit	  a	  band	  at	  the	  level	  of	  the	  IVT	  sample	  in	  the	  reducing	  buffer-­‐treated	  lanes	  only	  (Figure	  6.14,	  lanes	  13	  and	  17).	  	  This	  is	  less	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Figure 6.14: Ubiquitylation of xNgn2/xNeuroD domain swap proteins. 
(A) Xenopus laevis interphase activated egg extracts were supplemented with 35S-labelled IVT 
xNgn2, xNeuroD or chimeric domain swap proteins (marked IVT) in the presence of MG132 and 
either His-Ub (lanes 1, 2, 5, 6, 9, 10, 13, 14, 17, 18, 21 and 22) or untagged Ub (lanes 3, 4, 7, 8, 
11, 12, 15, 16, 19, 20, 23 and 24) and incubated at 20 °C for 90 mins.  Samples were bound to Ni-
NTA Agarose beads for 75 mins and subjected to 12 % SDS-PAGE in either reducing (odd-
numbered lanes) or non-reducing conditions (even-numbered lanes).  Gels were analysed by 
autoradiography.  Experiments were carried out in duplicate.  Lanes are numbered as described in 
the text.  (B)  All proteins from (A) treated with His-Ub and reducing conditions were run out on 12 
% SDS-PAGE and analysed by autoradiography. 
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clear	   for	   N-­‐NeuroD/BC-­‐Ngn	   where	   there	   is	   a	   low	   level	   of	   IVT	   but	   in	   reducing	  conditions	  (lane	  13),	  a	  low	  band	  is	  clearly	  seen	  at	  36	  kDa	  that	  is	  not	  present	  in	  non-­‐reducing	   conditions	   (lane	   14).	   	   The	   polyubiquitylation	   ladders	   also	   resemble	   the	  clean	  ladders	  of	  xNgn2	  (lanes	  1	  and	  2)	  compared	  to	  the	  smeared	  ladder	  of	  xNeuroD	  (lanes	   21	   and	   22).	   	   The	   C-­‐terminal	   domain	   of	   xNgn2	   is	   therefore	   non-­‐canonically	  ubiquitylated.	   	  As	   the	  C-­‐terminus	  of	   xNgn2	  does	  not	   contain	  any	   lysines,	   this	   is	   the	  only	  possible	  mode	  of	  ubiquitylation	  in	  this	  region.	  	  Whilst	   ubiquitylation	   occurs	   in	   both	   xNgn2	   and	   xNeuroD,	   the	   nature	   of	   this	  ubiquitylation	   is	   different	   for	   these	   two	   structurally	   related	   but	   quite	   distinct	  proteins.	  
	  
DISCUSSION	  	  xNgn2	   is	   a	   highly	  unstable	  protein	   and	   its	   degradation	  by	   the	  proteasome	   in	   a	  Ub-­‐dependent	   manner	   is	   discussed	   in	   detail	   in	   Chapter	   3	   and	   4.	   	   The	   effects	   of	   cdk	  phosphorylation	  on	  ubiquitylation	  and	  stability	  are	  then	  covered	  in	  Chapter	  5.	   	  This	  chapter	   however	   has	   looked	   at	   the	   role	   of	   protein	   structure	   in	   controlling	  degradation.	  	  The	  stabilising	  effect	  of	  bulky	  tags	  such	  as	  GFP	  on	  the	  N-­‐	  and	  C-­‐terminus	  has	  been	  described	  (Vosper	  et	  al.,	  2009)	  but	  a	  much	  smaller	  HA	  tag	  is	  also	  stabilising	  when	  fused	  to	   the	  C-­‐terminus	   	  (Figure	  6.1).	   	  As	  a	  practical	  concern,	  no	  experiments	  have	  been	  carried	  out	  in	  Xenopus	  laevis	  extract	  using	  HA-­‐tagged	  xNgn2.	  	  xNgn2-­‐3HA	  –	  the	   triply	   C-­‐terminally	   HA-­‐tagged	   form	   of	   xNgn2	   –	   has	   been	   used	   only	   in	   P19	   cell	  experiments	  such	  as	  described	  in	  Chapter	  4.	  	  There	  being	  no	  suitable	  xNgn2	  antibody,	  HA-­‐tagging	  is	  necessary	  to	  assess	  protein	  degradation	  by	  Western	  blot.	   	   In	  this	  case	  all	   proteins	   are	   compared	   with	   other	   HA-­‐tagged	   proteins	   and	   so	   the	   HA	   tag	   is	  assumed	  to	  have	  an	  equal	  effect	  on	  all	  proteins.	   	  This	  seems	  to	  be	  the	  case	  from	  the	  experiments	   carried	   out	   in	   cell	   lines	   in	   Chapter	   4.	   	   mNgn2	   does	   not	   appear	   to	   be	  affected	   by	   HA-­‐tagging,	  which	   is	   encouraging	   evidence	   for	  work	   in	   P19	   cells	   using	  mNgn2.	   	   Again	   this	   hints	   at	   significant	   differences	   between	   xNgn2	   and	   mNgn2	  stability	  as	  suggested	  in	  Chapter	  5.	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xNgn2	   associates	   with	  many	   factors	   that	   confer	   a	   stabilising	   effect	   on	   the	   protein,	  such	  as	  xE12	  and	  Xic1	  (Vernon	  et	  al.,	  2003,	  Vosper	  et	  al.,	  2007).	  	  p300	  also	  binds	  the	  transcriptional	   complex	   of	   xNgn2	   and	   xE12	   and	   therefore	   may	   also	   affect	   xNgn2	  stability.	   	  Figure	  6.2	  suggests	   that	   there	   is	  no	  effect	  on	  xNgn2	  stability	  with	  p300N,	  the	   functional	   N-­‐terminal	   domain	   of	   p300,	   in	   these	   interactions.	   	   There	   is	   some	  suggestion	   that	   E1A12S	  may	   stabilise	   xNgn2	   somehow	   in	   neurula	   extract.	   	   Indeed	  neurula	  extract	  may	  be	  the	  more	  relevant	  setting	  for	  this	  experiment	  given	  its	  higher	  DNA	  content,	  perhaps	  providing	  the	  more	  relevant	  setting	  for	  assembly	  of	  the	  active	  complex.	   	  However,	  without	  xE12	  added	  to	  the	  mix,	  assessment	  of	  stability	   in	  these	  experiments	  would	  not	  be	  worthwhile.	   	  There	  may	  also	  be	  a	   limit	   to	   the	  number	  of	  IVT	  proteins	  combined	  in	  this	  fashion,	  where	  the	  concentration	  of	  protein	  involved	  is	  poorly	   quantified.	   	   The	   preliminary	   experiment	   with	   xNeuroD	   has	   only	   been	  undertaken	   once	   no	  meaningful	   conclusions	   can	   be	   drawn	   from	   it.	   	   Xic1	   stabilises	  xNgn2	  (Roark,	  2010,	  Vernon	  et	  al.,	  2003).	  	  Results	  in	  Figure	  6.3	  correspond	  to	  values	  for	  stability	  obtained	  by	  Ryan	  Roark	  (Roark,	  2010).	  	  Addition	  of	  MBP	  or	  MBP-­‐tagged	  Xic1	  adds	  a	  substantial	  volume	  of	  solution	  to	  the	  reaction	  mixture,	  and	  dilution	  may	  lead	  to	  the	  increased	  half-­‐life	  of	  xNgn2	  with	  MBP	  alone.	   	  If	  MBP	  alone	  is	  exerting	  an	  effect	   on	   stability,	   then	   using	   this	   control	   to	   compare	   the	   effect	   of	   Xic1-­‐MBP	   on	  stability	  is	  essential.	  	  	  	  N-­‐terminally	  ubiquitylated	  xNgn2	  is	  not	  stabilised	  by	  Xic1	  in	  interphase	  (Figure	  6.4)	  therefore	   if	   Xic1	   stabilises	   xNgn2	   by	   binding	   as	   suspected	   (Roark,	   2010),	   it	   could	  stabilise	   xNgn2	   by	   binding	   to	   some	   ubiquitylation	   site	   and	   so	   preventing	  modification.	  	  If	  a	  priming	  ubiquitylation	  event	  has	  already	  occurred,	  as	  in	  Ub-­‐xNgn2,	  then	  blocking	  any	  other	  site	  becomes	  redundant.	  	  	  	  Figure	   6.5	   also	   shows	   that	   xNgn2	   is	   not	   stabilised	   by	   Xic1	   in	  mitosis	  whereas	   Ub-­‐xNgn2	   is.	   	  xNgn2	   is	  phosphorylated	   in	  mitotic	  extract	  as	  discussed	   in	  Chapter	  5	  but	  Xic1	  stabilisation	  of	  xNgn2	  is	  not	  thought	  to	  be	  through	  its	  role	  as	  a	  cdki	  (Vernon	  et	  al.,	  2003).	  	   	  Action	  as	  a	  cdki	  seems	  the	  least	  likely	  means	  of	  stabilisation	  as	  both	  Ub-­‐xNgn2	   and	   Ub-­‐9S-­‐AxNgn2	   demonstrated	   similar	   stability	   in	   Chapter	   5	   and	   so	  preventing	  phosphorylation	  does	  not	  provide	  stability	  to	  N-­‐terminally	  ubiquitylated	  xNgn2.	   	   Ubiquitylation	   of	   xNgn2	   perhaps	   differs	   in	   interphase	   and	  mitosis,	   or	   how	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Xic1	  interacts	  with	  xNgn2	  may	  change,	  leading	  to	  a	  difference	  in	  the	  ability	  of	  Xic1	  to	  stabilise	  xNgn2.	   	  Ubiquitylation	  assays	  of	  xNgn2	  in	  interphase	  and	  mitosis	  with	  Xic1	  may	  be	  able	  to	  shed	  more	  light	  on	  this	  problem.	  	  To	  investigate	  whether	  DNA	  binding	  affects	  stability,	  we	  tested	  the	  xNgn2AQ	  mutant,	  which	   is	   no	   longer	   able	   to	   bind	   to	   the	   E-­‐box	   site	   in	   DNA	   (Nakada	   et	   al.,	   2004).	  	  xNgn2AQ	   is	   identical	   in	   stability	   to	  xNgn2	   in	   interphase	  and	  mitotic	  extracts,	  but	   is	  more	   stable	   in	   neurula	   extract	   (Figure	   6.6).	   	   Neurula	   extract	   is	   perhaps	   the	   most	  relevant	   extract	   to	   work	   with	   for	   DNA-­‐binding	   as	   it	   contains	   a	   higher	   DNA	  concentration	   than	  egg	   extracts.	   	   Fertilised	   eggs	  have	  only	   a	  diploid	   genome	  whilst	  neurula	   embryos	   contain	   thousands	   of	   cells	   each	  with	   a	   tetraploid	   genome	   and	   so	  have	  much	  more	  DNA.	  	  The	  result	  from	  Figure	  6.6	  suggests	  that	  when	  xNgn2	  is	  unable	  to	  bind	  DNA,	  it	  is	  more	  stable	  than	  xNgn2	  bound	  to	  DNA.	  	  It	  could	  be	  that	  binding	  to	  DNA	   reveals	   a	   ubiquitylation	   site	   not	   exposed	   in	   the	   xNgn2/xE12	   heterodimer;	  perhaps	   there	   is	   a	   structural	   distortion	   of	   the	   heterodimer	   on	   DNA	   binding	   that	  affects	   the	   folding	   stability	   of	   xNgn2;	   or	   recruitment	   of	   another	   factor	   at	   the	  transcription	   site	   could	   affect	   stability.	   	   It	   has	   been	   suggested	   that	   the	   Ngn1/E47	  heterodimer	   bound	   to	  DNA	   is	   a	   “fuzzy”	   complex	   (Aguado-­‐Llera	   et	   al.,	   2010)	  where	  Ngn1	   lacks	   the	   disordered	   N-­‐	   and	   C-­‐terminal	   domains.	   	   Figure	   6.7	   shows	   that	  xNgn2AQ	   is	  more	   stabilised	   by	   xE12	   than	   xNgn2,	   but	   the	   xNgn2AQ	  mutant	   shows	  similar	  stability	  to	  xNgn2	  in	  this	  experiment.	  	  Figure	  6.7	  was	  produced	  using	  neurula	  extract	   that	   had	   been	   snap-­‐frozen	   and	   stored	   at	   -­‐80	   °C	  before	   being	   defrosted	   and	  used	  in	  this	  experiment.	   	  The	  long	  half-­‐life	  for	  degradation	  of	  xNgn2	  alone	  (47.2	  +/-­‐	  8.6	  mins,	   Figure	   6.7,	   C)	   suggests	   a	   difference	   between	   fresh	   and	   previously	   frozen	  extracts.	  	  To	  date	  no	  controlled	  comparison	  of	  fresh	  and	  frozen	  Xenopus	  extracts	  has	  been	   carried	   out	   and	   so	   to	   compare	   results	   between	   the	   two	   is	   inadvisable.	   	   This	  experiment	  would	  be	  best	  carried	  out	  again	  in	  fresh	  neurula	  extract	  to	  compare	  with	  Figure	   6.6.	   	   It	   does	   suggest	   that	   xNgn2AQ	   may	   be	   more	   stabilised	   by	   xE12	   than	  xNgn2.	  	  Figure	   6.8	   shows	   that	   diluted	   extracts	   do	   not	   seem	   to	   be	   suitable	   for	   investigating	  unfolding	   of	   xNgn2	   independent	   of	   ubiquitylation.	   	   The	   simplest	   method	   will	  probably	  be	  fusion	  of	  xNgn2	  to	  tetra-­‐Ub,	  the	  minimal	  signal	  required	  for	  targeting	  to	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the	   proteasome	   without	   a	   requirement	   for	   further	   ubiquitylation	   (Thrower	   et	   al.,	  2000).	  	  Therefore	  no	  further	  ubiquitylation	  will	  be	  required	  and	  attempts	  to	  maintain	  xNgn2	   folding	   such	   as	   by	   addition	   of	   cofactors	   could	   then	   be	   attempted	   in	   extract	  systems.	  	  Comparison	  of	  xNgn2	  and	  xNeuroD	  is	  useful	  as	  whilst	  the	  two	  proteins	  are	  generally	  similar,	  particularly	  with	  73	  %	  homology	  in	  their	  bHLH	  domains,	  there	  are	  some	  key	  differences	   between	   the	   2	   proteins.	   	   Certain	   amino	   acids	  within	   the	   bHLH	   domain	  (particularly	   in	   the	   loop	  region),	  and	  parts	  of	   the	  N-­‐	  and	  C-­‐terminal	  domains	  differ.	  	  For	   example,	   xNeuroD	   has	   a	   large	   acidic	   region	   in	   its	   N-­‐terminus;	   and	   perhaps	  surprisingly	   xNeuroD	   has	   more	   lysine	   residues	   than	   xNgn2,	   and	   whilst	   being	  ubiquitylated	  is	  not	  degraded	  efficiently	  by	  the	  proteasome	  (Vosper,	  2008,	  Vosper	  et	  al.,	   2007).	   	   Figure	   6.9	   again	   shows	   that	   xNeuroD	   is	   more	   stable	   than	   xNgn2	   in	  interphase,	   but	   that	   it	   is	   stabilised	   even	   further	   in	  mitotic	   extract	   where	   xNgn2	   is	  actually	  destabilised.	   	  Figure	  6.10	  shows	  that	  xNeuroD	  is	  still	  ubiquitylated	  but	  that	  the	   reducing	   agent-­‐dependence	   of	   ubiquitylation	   exhibited	   in	   xNgn2	   (highlighting	  non-­‐canonical	   ubiquitylation)	   is	   not	   demonstrated	   for	   xNeuroD.	   	   xNeuroD	   is	  much	  more	  stable	  than	  xNgn2	  and	  it	  may	  be	  that	  non-­‐canonical	  ubiquitylation	  is	  necessary	  in	  xNgn2	  to	  ensure	  rapid	  degradation,	  whilst	  this	  is	  not	  required	  in	  xNeuroD.	  	  	  	  Swapping	   the	   domains	   of	   xNgn2	   and	   xNeuroD	   directly	   using	   overlapping	   PCR	  primers	  rather	   than	  using	  restriction	  sites	  at	   the	  points	  of	   fusion	   is	  a	  more	  difficult	  technique,	   but	   ultimately	   prevents	   the	   introduction	   of	   non-­‐native	   amino	   acids	   into	  the	  xNgn2/xNeuroD	  fusion	  protein	  sequence.	  	  In	  Figure	  6.12	  all	  fusion	  proteins	  show	  intermediate	   stability	   between	   xNgn2	   and	   xNeuroD.	   	   The	  most	   intriguing	   result	   is	  that	   N-­‐Ngn/BC-­‐NeuroD	   and	   NB-­‐Ngn/C-­‐NeuroD,	   which	   differ	   only	   in	   their	   bHLH	  domains	  and	  so	  might	  be	  expected	  to	  be	  almost	  identical,	  have	  significantly	  different	  stabilities	  suggesting	  that	  the	  bHLH	  domain	  of	  xNgn2	  can	  confer	  more	  instability	  than	  that	   of	   xNeuroD.	   	   However	   this	   is	   not	   repeated	   in	   the	   comparison	   between	   N-­‐NeuroD/BC-­‐Ngn	   and	   NB-­‐NeuroD/C-­‐Ngn,	   suggesting	   that	   the	   N-­‐terminal	   domain	   of	  xNgn2	   is	   required	   as	   a	   destabilising	   accomplice	   to	   the	   bHLH	   domain.	   	   In	   fact,	   one	  possible	   explanation	   is	   that	   the	  N-­‐terminal	   and	  bHLH	  domains	  of	   xNeuroD	  are	   less	  easily	  unfolded	  than	  the	  corresponding	  domains	  in	  xNgn2.	  	  Therefore	  the	  N-­‐terminus	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of	  xNgn2	  could	  act	  as	  an	  unfolding	  initiation	  site	  and	  induce	  unfolding	  in	  the	  weakly	  folded	  xNgn2	  bHLH	  domain.	   	  However	  the	  bHLH	  domain	  of	  xNeuroD,	  perhaps	  being	  more	  stably	  folded,	  could	  resist	  this;	  likewise,	  though	  the	  xNgn2	  bHLH	  domain	  is	  less	  stably	   folded	   than	   the	   xNeuroD	   counterpart,	   if	   the	   N-­‐terminal	   domain	   of	   xNeuroD	  does	  not	  act	  as	  an	  unfolding	  initiation	  site,	  then	  unfolding	  of	  the	  xNgn2	  bHLH	  domain	  may	  not	  occur.	  	  It	  could	  also	  be	  that	  the	  N-­‐terminal	  and	  bHLH	  domains	  differ	  in	  likely	  ubiquitylation	  sites	  compared	  to	  xNeuroD	  –	  crucially,	  all	  lysines	  in	  xNgn2	  occur	  in	  the	  N-­‐terminus	  and	  bHLH	  domains;	  there	  are	  none	  in	  the	  C-­‐terminal	  domain.	  	  Of	  course,	  it	  could	  be	  that	  both	  work	  in	  concert,	  and	  that	  the	  unfolding	  initiation	  site	  is	  required	  next	   to	  a	  ubiquitylation	  site	  as	   is	   required	   for	  proteasomal	  degradation	  (Prakash	  et	  al.,	  2004);	  if	  xNeuroD	  is	  more	  stable	  against	  unfolding,	  then	  this	  could	  explain	  why	  it	  is	   not	   degraded	   despite	   being	   ubiquitylated,	   there	   being	   no	   suitable	   unfolding	  initiation	  site	  present.	  	  Comparing	  the	  domain	  swap	  proteins	  in	  mitotic	  extract	  could	  hint	  at	  the	  importance	  of	   unfolding,	   ubiquitylation	   and	   phosphorylation	   all	   coming	   together	   to	   tightly	  regulate	  xNgn2	  stability.	  	  Like	  interphase	  extract,	  N-­‐Ngn/BC-­‐NeuroD	  and	  NB-­‐Ngn/C-­‐NeuroD	   differ	   only	   in	   their	   bHLH	   domains	   but	   the	   protein	   with	   the	   xNgn2	   bHLH	  domain	  is	  less	  stable	  than	  that	  with	  the	  xNeuroD	  bHLH	  domain.	  	  In	  fact,	  in	  mitosis,	  the	  xNeuroD	   bHLH	   domain-­‐containing	   protein	   is	   stable,	   like	   xNeuroD.	   	   Therefore	   in	  mitosis	   it	   would	   appear	   that	   replacing	   its	   N-­‐terminal	   domain	   with	   the	   N-­‐terminal	  domain	  of	  xNgn2	  is	  insufficient	  to	  destabilise	  xNeuroD.	  	  However	  in	  comparison	  with	  interphase,	  N-­‐NeuroD/BC-­‐Ngn	  and	  NB-­‐NeuroD/C-­‐Ngn	  are	  as	  unstable	  as	  NB-­‐Ngn/C-­‐NeuroD	  and	  what	  seems	  to	  be	  destabilising	  here	  is	  the	  C-­‐terminal	  domain	  of	  xNgn2.	  	  This	   is	   the	   very	   region	   that	   appears	   most	   important	   for	   phosphorylation	   and	  controlling	   stability	   in	   a	   phosphorylation	   dependent	   manner	   in	   mitotic	   extract	  (Chapter	   5	   and	   (Hindley,	   2011)).	   	   Therefore	   the	   arguments	   in	   interphase	   for	  unfolding	  and	  ubiquitylation	  still	  hold	  true	  in	  the	  mitotic	  case	  but	  in	  conjunction	  with	  phosphorylation.	   	   Ubiquitylation	   can	   only	   occur	   on	   lysines	   in	   the	   N-­‐terminal	   and	  bHLH	   domains	   and,	   in	   the	   wild	   type	   protein	   in	   interphase,	   canonical	   sites	   of	  ubiquitylation	  appear	  important,	  whereas	  non-­‐canonical	  residues,	  such	  as	  cysteines,	  serines	   and	   threonines	   (all	   of	   which	   are	   present	   in	   the	   C-­‐terminus)	   are	   not	   as	  important	  in	  targeting	  xNgn2	  for	  degradation	  in	  interphase	  –	  but	  they	  are	  in	  mitosis	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(Chapters	   3	   and	   4).	   	   Phosphorylation	   is	   shown	   to	   be	   most	   important	   on	   the	   C-­‐terminus.	   	   Therefore	   in	   mitosis	   xNgn2	   would	   appear	   to	   have	   many	   destabilising	  features.	  	  Ubiquitylation	   in	   the	   chimeric	   proteins	   shows	   variation	   (Figure	   6.14).	   	   Chimeric	  proteins	   containing	   the	   C-­‐terminal	   domain	   of	   xNeuroD	   show	   smeared	  polyubiquitylation	   ladders	   with	   no	   reducing	   agent-­‐dependent	   ubiquitylation,	   like	  xNeuroD.	   	   Proteins	   containing	   the	   xNgn2	   C-­‐terminal	   domain	   are	   ubiquitylated	   in	   a	  reducing	  agent-­‐dependent	  manner	  with	  a	  clear	  polyubiquitylation	  ladder	  displayed	  in	  ubiquitylation	  assays.	  	  The	  assays	  in	  Figure	  6.14	  could	  be	  repeated	  with	  less	  loading	  of	  IVT	  protein	  on	  SDS-­‐PAGE.	  	  The	  extent	  to	  which	  xNeuroD	  is	  ubiquitylated,	  and	  the	  smeary	  nature	  of	  the	  polyubiquitylation	  ladders	  to	  xNeuroD,	  make	  detailed	  analysis	  of	  the	  ubiquitylation	  assays	  of	  xNeuroD	  proteins	  difficult.	  	  Also,	  non-­‐reducing	  SDS-­‐LB	  often	  results	  in	  distorted	  bands	  on	  a	  gel	  and	  proteins	  running	  at	  different	  masses	  than	  in	   reducing	   SDS-­‐LB	   (e.g.,	   Figure	   6.14,	   A,	   lane	   18	   compared	   to	   lane	   17).	   	   However	  enough	   information	   can	   be	   obtained	   from	   these	   assays	   to	   show	   that	   there	   is	   a	  difference	  in	  the	  ubiquitylation	  of	  xNgn2	  and	  xNeuroD	  and	  apparently	  relating	  to	  the	  C-­‐terminal	  domains	  of	  these	  proteins.	  	  	  	  Therefore	   overall,	   alterations	   in	   the	   structure	   of	   xNgn2,	   by	   affecting	   folding	   or	  interaction	  with	  other	  factors,	  have	  an	  important	  role	  in	  affecting	  xNgn2	  degradation.	  	  
200	  
CHAPTER	  7	  
Nuclear	  Magnetic	  Resonance	  Spectroscopy	  of	  mNgn2	  
	  
	  
INTRODUCTION	  	  There	  is	  no	  direct	  structural	   information	  available	  for	  Ngn2	  but	  based	  on	  homology	  with	   other	   bHLH	   proteins	   it	   is	   supposed	   to	   consist	   of	   a	   structured	   bHLH	   domain	  flanked	  by	  disordered	  N-­‐	  and	  C-­‐termini	  (Bertrand	  et	  al.,	  2002).	  	  The	  closest	  structural	  data	  to	  Ngn2	  within	  the	  literature	  relate	  to	  the	  crystal	  structure	  of	  NeuroD	  in	  complex	  with	  E47	  bound	  to	  the	  consensus	  E-­‐box	  DNA	  sequence	  (Longo	  et	  al.,	  2008)	  and	  to	  the	  NMR	  structure	  of	  Ngn1	  bound	  to	  E47	  and	  the	  E-­‐box	  (Aguado-­‐Llera	  et	  al.,	  2010).	  	  Ngn2	  shares	  many	  similarities	  with	  intrinsically	  disordered	  (ID)	  proteins	  with	  regard	  to	   amino	   acid	   composition	   (Dunker	   et	   al.,	   2001),	   function	   (Ward	   et	   al.,	   2004)	   and	  stabilisation	  upon	  binding	  other	   cofactors	   (Wright	   and	  Dyson,	  2009)	   (Vosper	  et	   al.,	  2007).	   	   In	   addition	   the	   bHLH	   proteins	   show	   significant	   sequence	   homology	   in	   the	  bHLH	   domain	   only	   (Bertrand	   et	   al.,	   2002)	   and	   large	   sequence	   variability	   in	   the	  disordered	   regions	   as	   suggested	   in	   the	   evolutionary	   comparison	   of	   related	   ID	  proteins	   (Brown	   et	   al.,	   2002).	   	   It	   is	   a	   highly	   unstable	   protein	   (Vosper	   et	   al.,	   2007,	  Vosper	   et	   al.,	   2009,	   McDowell	   et	   al.,	   2010),	   which	   appears	   to	   be	   highly	  phosphorylated	   by	   cell	   cycle-­‐related	   kinases	   (Hindley,	   2011,	   Gsponer	   et	   al.,	   2008).	  	  The	  related	  protein	  Ngn1	  even	  forms	  a	  “fuzzy	  complex”	  (Tompa	  and	  Fuxreiter,	  2008)	  in	  NMR	  studies	  (Aguado-­‐Llera	  et	  al.,	  2010).	  	  	  It	  is	  possible	  that	  Ngn2	  carries	  out	  many	  of	  the	  functions	  of	  ID	  proteins	  (Dunker	  et	  al.,	  2002)	  especially	  in	  displaying	  sites	  for	  binding	  other	   factors	  such	  as	  LMO4	  (Asprer	  et	  al.,	  2011)	  xE12,	  p300/CBP,	  and	  DNA	  (Bertrand	  et	  al.,	  2002),	  which	  are	  associated	  with	  its	  stability	  (Vosper	  et	  al.,	  2009).	  	  Protein	  NMR	   gives	   information	   about	   protein	   structure	   at	   the	   atomic	   detail	   and	   in	  particular	   ID	   proteins	   or	   disordered	   regions	   can	   be	   studied	   (Verdegem,	   2009).	  	  Therefore	   I	   wished,	   in	   collaboration	   with	   the	   lab	   of	   Guy	   Lippens	   at	   Université	   de	  Sciences	   et	   Technologies	   Lille,	   to	   investigate	   the	   behaviour	   of	   	   Ngn2	   in	  NMR	  using	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mNgn2	  and	  xNgn2	  are	  predicted	  to	  be	  intrinsically	  disordered	  (ID)	  proteins	  








Figure 7.1: xNgn2 and mNgn2 are predicted to be disordered proteins 
(A) ClustalW2 sequence alignment of xNgn2 and mNgn2. The disordered N-terminal domain is 
bordered in blue; the bHLH domain in red; and the disordered C-terminal domain in green.  
PONDR-FIT disorder predictions of (B) xNgn2 and (C) mNgn2. 
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prediction.	   	   Disposition	   towards	   disorder	  was	   plotted	   for	   each	   residue.	   	   There	   is	   a	  high	  degree	  of	  disorder	  in	  the	  N-­‐	  and	  C-­‐terminal	  regions	  of	  xNgn2	  (Figure	  7.1,	  B)	  and	  mNgn2	  (Figure	  7.1,	  C)	  with	  a	  highly	  ordered	  segment	  in	  the	  middle	  of	  the	  sequence.	  	  The	  ordered	  region	  corresponds	  with	  the	  bHLH	  domain.	  	  Both	  xNgn2	  and	  mNgn2	  exhibit	  low	  sequence	  conservation	  in	  the	  N-­‐	  and	  C-­‐terminal	  domains	   (Figure	   7.1,	   A)	   but	   these	   regions	   are	   both	   highly	   disordered	   to	   a	   similar	  extent	   (Figure	   7.1,	   B	   and	   C).	   	   Further	   disorder	   predictions	   were	   carried	   out	   with	  mNgn2	   to	   compare	   the	   results	   from	   various	   disorder	   predictors.	   	   DISOPRED2	  (http://bioinf.cs.ucl.ac.uk/disopred/,	  (Ward	  et	  al.,	  2004))	  is	  a	  predictor	  that	  has	  been	  developed	   using	   standards	   for	   prediction	   identified	   in	   earlier	   experiments.	   	   The	  disorder	   prediction	   using	   DISOPRED2	   is	   plotted	   in	   Figure	   7.2,	   A.	   	   This	   plot	   shows	  highly	   disordered	  N-­‐	   and	   C-­‐termini	   flanking	   a	   folded	   region	   in	   agreement	  with	   the	  PONDR-­‐FIT	   prediction	   in	   Figure	   7.1,	   C.	   	   FoldIndex	  (http://bip.weizmann.ac.il/fldbin/findex,	   (Prilusky	   et	   al.,	   2005))	   uses	   the	  hydrophobicity	  and	  charge	  of	  the	  amino	  acid	  sequence	  to	  make	  a	  prediction	  and	  for	  mNgn2	  this	  is	  plotted	  in	  Figure	  7.2,	  B.	  	  Here	  again	  we	  see	  disordered	  regions	  at	  the	  N-­‐	  and	  C-­‐termini	  and	  a	   folded	  region	   in-­‐between.	   	  However,	  compared	  to	   the	  previous	  predictions	  (Figure	  7.1,	  C	  and	  Figure	  7.2,	  A),	  the	  folded	  region	  is	  shifted	  towards	  the	  N-­‐terminus	  and	  is	  much	  larger.	  	  This	  correlates	  with	  the	  distribution	  of	  hydrophobic	  and	  charged	  residues	  in	  mNgn2	  (Figure	  7.1,	  A).	  	  Therefore	  whilst	  Ngn2,	  and	  other	  bHLH	  proteins,	  may	  not	  be	  entirely	  disordered,	  the	  difficulties	  in	  protein	  purification	  and	  the	  disorder	  predictions	  for	  mNgn2	  described	  above	  suggest	  that	  intrinsically	  disordered	  regions	  are	  present.	  	  




Figure 7.2: mNgn2 protein disorder predictions. 
mNgn2 disorder predictions using (A) DISOPRED2 and (B) FoldIndex. 
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phosphorylation	  and	  activity	  (Ali	  et	  al.,	  2011)	  and	  allows	  use	  of	  mammalian	  cdks	  for	  
in	  vitro	  phosphorylation	  experiments.	  	  	  	  Purification	  of	  bHLH	  proteins	  is	  difficult	  and	  often	  results	  in	  production	  of	  insoluble	  products	   (Longo	   et	   al.,	   2008).	   	   In	   fact,	   purification	   of	   these	   proteins	   has	   proved	   so	  difficult	  that	  in	  one	  case,	  purification	  was	  abandoned	  and	  the	  bHLH	  domain	  of	  Ngn1	  was	   chemically	   synthesised	   (Aguado-­‐Llera	   et	   al.,	   2010).	   	   Purification	   of	   bHLH	  proteins	  directly	  has	  been	  achieved	  by	  cotransformation	  of	  the	  heterodimeric	  binding	  partners,	  such	  as	  MyoD	  with	  E47	  (Cottle	  et	  al.,	  2007).	  	  	  	  DNA	  constructs	  of	  mNgn2,	  codon	  optimised	  for	  bacterial	  expression,	  were	  produced	  by	   Genecust	   (Luxembourg)	   in	   pUC	   vectors.	   	   These	   were	   subcloned	   into	   pGEX	   (N-­‐terminal	  GST-­‐tagging	   vector,	   (Kaelin	   et	   al.,	   1992))	   and	  pET	   (N-­‐terminal	  His-­‐tagging	  vector,	   Novagen,	   (Studier	   et	   al.,	   1990))	   vectors.	   GST-­‐tagged	   and	  His-­‐tagged	  mNgn2	  proteins	  were	  bacterially	  expressed,	  with	  clear	  production	  of	  protein	  in	  bacteria	  after	  overnight	  induction	  (Figure	  7.3,	  A:	  lane	  2	  for	  His-­‐mNgn2	  and	  lane	  4	  for	  GST-­‐mNgn2).	  	  Upon	  cell	  lysis,	  however,	  there	  was	  a	  clear	  difference	  in	  the	  solubility	  of	  the	  proteins,	  for	  although	  GST-­‐mNgn2	  was	  present	   in	  both	  soluble	  (S)	  and	   insoluble	  (I)	   fractions	  (Fig	  7.3,	  A,	  lanes	  6	  and	  7	  respectively),	  His-­‐mNgn2	  was	  entirely	  insoluble	  (Fig	  7.3,	  A,	  lane	   10).	   	   Recovery	   of	   insoluble	   proteins	   using	   urea	   is	   undesirable	   for	   NMR	   but	   is	  possible	   using	   particular	   detergents	   (Tao	   et	   al.,	   2010).	   	   Whilst	   preliminary	  experiments	  trying	  to	  extract	  His-­‐mNgn2	  from	  the	  insoluble	  phase	  were	  promising,	  I	  decided	  to	  continue	  the	  NMR	  experiments	  with	  the	  GST-­‐tagged	  protein.	  	  Upon	  cleavage	  of	  the	  GST-­‐tag	  from	  mNgn2,	  mNgn2	  was	  liberated	  (Figure	  7.3,	  B,	  lane	  11,	   arrow)	  but	   there	  also	  appeared	  a	  higher	  band	   (Figure	  7.3,	  B,	   lane	  11,	   asterisk),	  which	  ran	  at	  a	  higher	  molecular	  mass	  than	  GST-­‐mNgn2	  (such	  as	  in	  Figure	  7.3,	  A,	  lane	  4).	   	   Upon	   in	   vitro	   kinase	   treatment	   with	   cyclinA/cdk2	   at	   30	   °C,	   the	   lower	   band	  disappeared	   and	   the	   higher	   band	   had	   shifted	   to	   a	   slightly	   higher	   molecular	   mass	  (Figure	   7.3,	   B,	   lane	   12).	   	   This	   band	   appears	   to	   be	   a	   dimeric	   form	  of	  mNgn2	   that	   is	  somehow	  resistant	  to	  the	  conditions	  of	  SDS-­‐PAGE.	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Figure 7.3: Protein purification of mNgn2. 
(A) Overexpression of His-mNgn2 and GST-mNgn2 demonstrated on SDS-PAGE.  Pre: pre-
induction; Post: post-induction; S: soluble cell lysis fraction; I: insoluble cell lysis fraction.  (B) 
mNgn2 protein (after GST-tag cleavage) Pre and Post in vitro kinase treatment with cyclinA/cdk2 
on SDS-PAGE. 
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CyclinA/cdk2	  phosphorylates	  mNgn2	  in	  vitro	  	  To	  investigate	  the	  structure	  of	  mNgn2,	  1H-­‐15N	  HSQC	  was	  performed	  using	  bacterially	  expressed,	  1H	  and	  15N-­‐labelled	  mNgn2	  at	  600	  MHz.	  	  The	  spectrum	  is	  shown	  in	  Figure	  7.4A	   (spectra	   prepared	   by	   Isabelle	   Landrieu).	   	   Each	   peak	   identifies	   an	   amino	   acid	  residue	   by	   virtue	   of	   the	   contact	   between	   the	   amide	   proton	   and	   its	   corresponding	  isotopically-­‐labelled	  nitrogen.	  	  However	  this	  means	  that	  prolines	  are	  not	  identified	  as	  they	   lack	  the	  amide	  backbone	  proton.	   	   In	  2D	  HSQC	  experiments	  such	  as	   this,	  whilst	  estimates	  of	  the	  type	  of	  amino	  acid	  residue	  at	  particular	  chemical	  shifts	  can	  be	  made,	  the	  amino	  acids	  cannot	  be	  assigned	  precisely	  and	  further	  experiments	  are	  required.	  	  The	  number	  of	  peaks	  present	  correspond	  to	  regions	  of	  intrinsic	  disorder,	  as	  ordered	  residues	   in	  structural	  regions	  are	  not	  seen	  under	   the	  conditions	  of	   this	  experiment.	  	  Only	   residues	   where	   the	   labelled	   nuclei	   are	   in	   dynamic	   regions	   are	   observed,	   as	  nuclei	  in	  structured	  regions	  relax	  too	  quickly	  for	  a	  signal	  to	  be	  observed.	  	  To	   investigate	  the	  effect	  of	  phosphorylation	  on	  this	  structure,	   I	  purified	  mNgn2	  and	  phosphorylated	  the	  protein	  in	  vitro	  with	  cyclinA/cdk2,	  which	  phosphorylates	  Ngn2	  in	  




Figure 7.4: 1H-15N HSQC spectrum of mNgn2 and cyclinA/cdk2-treated mNgn2. 
1H-15N HSQC experiments were carried out at 600 MHz on (A) mNgn2 (grey) and (B), (C) 
cyclinA/cdk2-treated mNgn2 (red) superimposed over the unphosphorylated mNgn2 spectrum.  
Spectra produced by Isabelle Landrieu and phosphorylated mNgn2 experiment run by Guy 
Lippens.  
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and	  were	  identified	  by	  Isabelle	  Landrieu	  using	  the	  13C	  chemical	  shifts	  as	  illustrated	  in	  Figure	  7.6.	  	  The	  Cα	  and	  Cβ	  of	  the	  amino	  acid	  residue	  in	  question	  can	  be	  identified	  by	  their	   chemical	   shift	   (Bienkiewicz	  and	  Lumb,	  1999,	  Wishart	  and	  Sykes,	  1994).	   	  With	  good	  resolution,	  the	  Cα	  and	  Cβ	  of	  the	  amino	  acid	  residue	  immediately	  N-­‐terminal	  to	  the	  residue	  under	  consideration	  (i.e.,	   residue	   i-­‐1	  compared	  to	  residue	   i)	  can	  also	  be	  seen.	  	  Therefore	  a	  sequence	  can	  be	  assembled	  from	  a	  3D	  NMR	  spectrum.	  	  	  	  Some	  particular	  details	   also	   assist	   in	   assignment.	   	   Phosphorylation	  has	   a	  particular	  effect	  on	  the	  shift	  of	  serines	  and	  threonines	  (Bienkiewicz	  and	  Lumb,	  1999).	  	  Glycines	  do	  not	  have	  a	  Cβ	  (as	  illustrated	  in	  Figure	  7.6,	  C).	  	  Individual	  peaks	  for	  prolines	  are	  not	  seen	   as	  mentioned	   above;	   however,	  when	   a	   proline	   is	   immediately	   C-­‐terminal	   to	   a	  residue	  (i.e.	  i+1),	  the	  normal	  13C	  chemical	  shift	  for	  a	  residue’s	  Cα	  is	  shifted	  by	  -­‐2	  ppm,	  and	   for	   Cβ	   by	   -­‐1	   ppm.	   	   This	   is	   illustrated	   for	   all	   residues	   in	   Figure	   7.6	   and	   the	  phosphorylated	   residues	   with	   their	   preceding	   and	   succeeding	   residues	   are	  highlighted	  in	  Figure	  7.5.	  	  Therefore	  mNgn2	   is	  phosphorylated	  on	  the	  two	  SP	  sites	  and	  one	  TP	  site.	   	  From	  the	  sequence	   information	   given	   by	   NMR	   we	   can	   identify	   these	   sites	   as	   the	   three	   cdk	  consensus	  sites	  (Errico	  et	  al.,	  2010)	  in	  the	  N-­‐terminus	  of	  mNgn2.	   	  Therefore	  we	  can	  infer	   that	   cyclinA/cdk2	   can	   phosphorylate	   all	   available	   N-­‐terminal	   SP	   sites	   and	  therefore,	   that	   the	  N-­‐terminal	  domain	  of	  mNgn2	   is	  disordered,	   as	   this	   is	   the	   region	  visible	  in	  NMR	  experiments	  used	  for	  observing	  ID	  proteins.	  	  





Figure 7.5: 1H-15N-13C HSQC spectrum of phosphorylated mNgn2. 
1H-15N-13C HSQC experiment with cyclinA/cdk2-treated mNgn2.  Phosphorylated SP and TP sites 
are labelled.  Experiment carried out and spectrum prepared by Isabelle Landrieu.   
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Figure 7.6: Assignment of phosphorylated residues in mNgn2. 
13C chemical shifts for Cα (CA) and Cβ (CB) nuclei of phosphorylated amino acid residues were 
assigned by Isabelle Landrieu.  i: residue corresponding to 2D HSQC peak; i-1: preceding residue 
(N-terminal to residue i). 
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FoldIndex	   output	   is	   one	   prediction	   included	   in	   the	   assessment	   performed	   by	   the	  PONDR-­‐FIT	  predictor	   (Xue	   et	   al.,	   2010)	   and	   so	   as	   these	  have	   two	  differing	   outputs	  clearly	  other	  predictors	   incorporating	  other	   factors	  may	  be	   required	   to	  produce	  an	  accurate	  assessment	  of	  disorder.	  	  The	   purification	   of	   bHLH	   proteins	   is	   difficult	   as	   illustrated	   in	   (Aguado-­‐Llera	   et	   al.,	  2010).	  	  The	  authors	  attempted	  to	  purify	  the	  bHLH	  domain	  of	  Ngn1	  using	  His-­‐tagged,	  GST-­‐tagged,	   maltose	   binding	   protein-­‐tagged,	   biotin-­‐tagged	   and	   thioredoxin-­‐tagged	  protein	  constructs	  in	  BL21,	  Rosetta,	  C41	  and	  BL21pLys	  cells	  with	  induction	  at	  several	  different	   temperatures	   and	   with	   varying	   concentrations	   of	   IPTG;	   only	   one	  combination	  appeared	  to	  work	  at	  all	  but	  it	  turned	  out	  to	  be	  partially	  degraded.	  	  The	  authors	  turned	  to	  chemical	  synthesis	  of	  the	  bHLH	  domain	  of	  Ngn1	  instead.	  	  That	  the	  purification	   of	   mNgn2	   proved	   to	   be	   difficult	   was	   not	   surprising	   as	   I	   have	   made	  previous	   attempts	   to	   purify	   xNgn2,	   both	   using	   bacterial	   expression	   (with	   some	  success)	  and	  baculovirus	  (with	  none).	   	  Solubility	  was	  greatly	  improved	  using	  a	  GST-­‐tag,	  and	  Sarkosyl-­‐based	  treatment	  (Tao	  et	  al.,	  2010)	  can	  result	  in	  liberating	  some	  His-­‐mNgn2	   from	   the	   insoluble	   fraction	  of	   cell	   lysis.	   	   The	   strange	  behaviour	   even	  of	   the	  GST-­‐tagged	  protein	  –	  which	  appears	  to	  dimerise	  and/or	  be	  partially	  degraded	  upon	  liberation	   from	   the	   GST	   tag	   –	   did	   not	   appear	   to	   affect	   the	   results	   of	   the	   NMR	  experiments.	  	  Whilst	  in	  vitro	  kinase	  treatment	  resulted	  in	  an	  apparent	  disappearance	  of	  any	  monomeric	  protein	  by	  Coomassie	  staining,	  the	  NMR	  results	  suggest	  that	  in	  fact	  protein	  is	  still	  present	  and	  effects	  on	  the	  structure	  are	  minimal.	   	  Dimerisation	  of	  the	  protein	  upon	  phosphorylation	   is	  not	  surprising	  as	  heterodimerisation	  with	  E12	  and	  phosphorylation	  have	  been	  linked	  in	  xNgn2	  before	  (Vosper	  et	  al.,	  2007).	  	  That	  the	  NMR	  results	  have	  given	  spectra	  allowing	  identification	  of	  phosphorylated	  SP	  and	  TP	  sites	   in	  the	  N-­‐terminus	   illustrates	  not	  only	  quite	  specific	  phosphorylation	  of	  consensus	   cdk	   sites	   in	   vitro	   but	   also	   that	   the	   N-­‐terminus	   is	   disordered.	   	   It	   is	   not	  possible	  to	  speculate	  on	  the	  phosphorylation	  of	  the	  C-­‐terminus	  because	  this	  region	  is	  not	  observed	  as	  a	  disordered	  region	  in	  the	  NMR	  experiment,	  but	  work	  by	  Christopher	  Hindley	   and	   Fahad	   Ali	   has	   highlighted	   the	   important	   role	   of	   C-­‐terminal	   SP	   sites	   in	  particular	   in	   xNgn2	   and	   mNgn2	   (Ali	   et	   al.,	   2011).	   	   Therefore	   it	   is	   interesting	   to	  observe	  phosphorylation	  occurring	  on	   the	  N-­‐terminus	   also.	   	   That	   the	  N-­‐terminus	   if	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  xNgn2	   is	  a	   transcription	   factor	   that	  regulates	  cell	  division	  and	  differentiation	   in	   the	  developing	  brain.	  	  The	  regulation	  of	  xNgn2	  activity	  through	  its	  stability	  is	  the	  focus	  of	  this	   thesis.	   	   I	   have	   investigated	   the	   roles	   of	   ubiquitylation	   and	   phosphorylation,	   as	  well	  as	  protein	  folding	  and	  structural	  stability	  of	  xNgn2.	  	  This	  work	  has	  been	  carried	  out	  using	  Xenopus	  laevis	  extract	  systems	  and	  Mus	  musculus	  P19	  embryonal	  carcinoma	  cell	  lines,	  with	  structural	  studies	  carried	  out	  by	  NMR	  using	  mNgn2.	  	  Firstly,	   I	  demonstrated	   that	   xNgn2	   is	  ubiquitylated	  on	  multiple	   lysine	   residues.	   	  No	  specific	   lysine	   is	   essential	   for	   ubiquitylation,	   including	   lysines	   conserved	   in	   the	  neurogenin	   sequence	   between	   species.	   	  Whilst	   mutation	   of	   all	   lysines	   to	   arginines	  renders	   xNgn2	  more	   stable	   in	   vitro,	   xNgn2KO	   is	   less	   able	   to	   bind	  DNA	   in	   vitro	   (as	  demonstrated	  by	  EMSA)	  and	  promote	  ectopic	  neurogenesis	  in	  vivo	  (as	  demonstrated	  by	   embryo	  microinjection).	   	   Furthermore,	   lysineless	   xNgn2	   is	   still	   degraded	   by	   the	  UPS.	  	  Other	  sites	  are	  present	  in	  proteins	  that	  can	  act	  as	  nucleophiles	  and	  pick	  up	  Ub	  from	  the	  E2	   enzymes.	   	   The	  N-­‐terminal	   amino	   group	   is	   amino-­‐based,	   identically	   to	   lysine	  residues,	   and	   is	   ubiquitylated	   to	   target	   xNgn2	   for	   proteasomal	   degradation	   as	  demonstrated	   by	   blocking	   the	   N-­‐terminus	   with	   cotranslational	   acetylation.	  	  Acetylated,	  lysineless	  xNgn2	  (Ac2xNgn2KO)	  is	  still	  proteasomally	  degraded.	  	  Through	  ubiquitylation	  assays	  manipulating	  the	  reducing	  environment	  of	  gel	   loading	  buffers,	  non-­‐canonical	  ubiquitylation	  through	  labile	  linkages	  is	  observed	  on	  cysteines,	  serines	  and	  threonines.	  	  Mutation	  of	  cysteines	  to	  alanines	  in	  xNgn2	  has	  a	  stabilising	  effect	  in	  mitotic	   and	   neurula	   extracts.	   	   Non-­‐canonical	   ubiquitylation	   is	   evident	   in	   wild	   type	  xNgn2.	  	  Work	  carried	  out	  in	  Xenopus	  extracts	  was	  replicated	  in	  P19	  cells,	  yielding	  the	  same	  results.	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xNgn2	  is	  also	  modified	  by	  phosphorylation	  .	   	  Investigation	  of	  cdk	  consensus	  SP	  sites	  shows	   that	  mutation	   of	   all	   SP	   serines	   to	   alanines	   affects	   xNgn2	  phosphorylation	   in	  mitosis.	  	  C-­‐terminal	  phosphorylation	  sites	  in	  particular	  affect	  stability	  of	  xNgn2.	  	  The	  stability	   of	   xNgn2	   in	   association	   with	   xE12	   is	   enhanced	   when	   all	   SP	   serines	   are	  mutated	  to	  alanines	  although	  stability	  of	  xNgn2	  and	  9S-­‐AxNgn2	  is	  similar	  in	  extract.	  	  When	  Ub	  is	  fused	  to	  the	  N-­‐terminus	  of	  xNgn2	  or	  9S-­‐AxNgn2,	  xE12	  confers	  the	  same	  stabilisation	   upon	   both	   proteins.	   	   However,	   9S-­‐AxNgn2	   is	   hyperactive	   in	   vivo	   at	  promoting	   ectopic	   neurogenesis	   compared	   to	   xNgn2	   and	   fusion	   of	   Ub	   to	   the	   N-­‐terminus	   reduces	   but	   does	   not	   abolish	   this	   activity,	   in	   particular	   at	   the	   xNeuroD	  promoter.	   	   Complete	   inactivity	   of	   both	   proteins	   at	   the	   Delta	   promoter	   upon	  ubiquitylation	  highlights	  the	  role	  of	  phosphorylation	  in	  regulating	  cell	  differentiation,	  for	   as	   the	   cell	   cycle	   lengthens,	   phosphorylation	   of	   xNgn2	  will	   reduce	   and	   xNeuroD	  transcription	  will	  be	  favoured	  over	  Delta,	  inducing	  neurogenesis	  and	  cell	  cycle	  exit.	  	  Numerous	   factors	   such	   as	   bulky	   tags,	   xE12,	   Xic1	   and	   DNA-­‐binding	   affect	   xNgn2	  stability.	  	  xNgn2	  is	  an	  unstructured	  protein	  and	  associated	  factors	  appear	  to	  regulate	  stability	   by	   binding	   to	   xNgn2	   and	   affecting	   structural	   properties	   to	   regulate	  proteasomal	   degradation.	   	   The	   downstream	   target	   of	   xNgn2,	   xNeuroD,	   whilst	  ubiquitylated	  is	  not	  degraded	  and	  domain	  swapping	  experiments	  between	  xNgn2	  and	  xNeuroD	  suggest	  that	  the	  N-­‐terminal	  domain	  of	  xNgn2	  is	  destabilising	  and	  that	  the	  C-­‐terminal	  domains	  of	  both	  proteins	  exhibit	  different	  ubiquitylation	  patterns,	  with	  non-­‐canonical	   ubiquitylation	   observed	   on	   xNgn2	   only.	   	   Therefore	   xNgn2	   can	   be	  ubiquitylated	  on	  many	  more	  possible	   sites	   to	  allow	  maintenance	  of	  a	   short	  half	   life	  and	   rapid	   degradation,	   whilst	   the	   N-­‐terminus	  may	   provide	   the	   unfolding	   initiation	  site	  required	  to	  feed	  into	  the	  26S	  proteasome	  and	  allow	  proteasomal	  degradation.	  	  The	   role	   of	   the	   N-­‐terminal	   domain	   in	   unfolding	   is	   shown	   in	   the	   NMR	   experiments	  proving	  that	  the	  N-­‐terminal	  domain	  of	  the	  mouse	  homologue,	  mNgn2,	  is	  disordered.	  	  This	   domain	   is	   also	   phosphorylated	   on	   cdk	   consensus	   SP	   and	   TP	   sites	   but	  phosphorylation	  does	  not	  affect	  the	  structure	  observed	  by	  NMR	  spectroscopy.	  	  	  	  xNgn2	  stability	   is	   therefore	   tightly	  regulated	  by	  many	   factors,	   regulating	   its	  activity	  and	  allowing	  precise	  control	  of	  cell	  fate.	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From (Bertrand et al., 2002): Schematic representation of the structure of a bHLH dimer that is 
complexed to DNA. The basic region fits in the main groove of the DNA, and many residues in this 
region make direct contact with the E-box sequence. The two α-helices of both partners together 
form a four-helix bundle. 
 
Structure of proneural bHLH/E2A/DNA complex, adapted from (Longo et al., 2008), 
PDB file 2QL2 
 
 
Structure of a proneural bHLH heterodimer complexed to DNA.  There is no structural information 
for the intrinsically disordered N- and C-terminal domains and so representative strands have been 
added to illustrate the full xNgn2 protein.  The disordered N-terminal domain is bordered in blue; 
the bHLH domain in red; and the disordered C-terminal domain in green. 
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Polyubiquitylation targets multiple proteins for degradation
by the proteasome. Typically, the first ubiquitin is linked to
lysine residues in the substrate for degradation via an isopeptide
bond, although rarely ubiquitin linkage to the N-terminal resi-
due has also been observed. We have recently shown that Neu-
rogenin (NGN), a basic helix-loop-helix transcription factor
that plays a central role in regulating neuronal differentiation, is
degraded by ubiquitin-mediated proteolysis. We have taken a
biochemical and mutagenesis approach to investigate sites of
ubiquitylation of NGN, initially using extracts of eggs from the
frog Xenopus laevis as a source of ubiquitylation and degrada-
tion components. NGN can be targeted for destruction by ubiq-
uitylation via lysines or the N terminus. However, we see that a
modified NGN, where canonical lysine ubiquitylation and
N-terminally linked ubiquitylation are prevented, is neverthe-
less ubiquitylated and degraded by the proteasome. We show
that polyubiquitin chains covalently attach to non-canonical
cysteine residues in NGN, and these non-canonical linkages
alone are capable of targeting NGN protein for destruction.
Importantly, canonical and non-canonical ubiquitylation
occurs simultaneously in the native protein and may differ in
importance for driving degradation in interphase and mitosis.
We conclude that native NGN is ubiquitylated on multiple
canonical and non-canonical sites by cellular ubiquitin ligases,
and all types of linkage can contribute to protein turnover.
The selective degradation of proteins by ubiquitin-mediated
proteolysis is a crucial regulator of diverse cellular processes in
eukaryotes. Ub4 is classically conjugated to the -amino group
of a substrate lysine by an isopeptide bond (1). This serves as an
anchor point to build a polyubiquitin chain that results in sub-
sequent targeting to the proteasome for destruction. In a small
number of proteins, Ub has been shown to be conjugated to the
N-terminal -amino group of a protein via a peptide linkage
used as an anchor site for assembly of a lysine-linked polyubiq-
uitin chain (2).
The conjugation of ubiquitin to substrate proceeds when a
nucleophilic substrate amino group attacks the labile E2-ubiq-
uitin thioester bond. Thismechanismdoes not exclude the pos-
sibility that ubiquitylation can occur on other substrate nucleo-
philic groups on amino acid side chains, such as the thiol groups
present on cysteines. The resultant thioester-anchored ubiq-
uitin chains would, however, be predicted to be less stable than
the isopeptide/peptide bonds formed between ubiquitin and
lysine/N-terminal amino groups (3, 4). Based on this, cysteine
residues have generally been considered to be unlikely targets
for ubiquitin modification (4).
However, there is recent evidence that ubiquitylation can
occur on substrate cysteine residues, albeit in a very limited
number of cases, largely regulating intracellular protein move-
ments and usually driven by viral E3 ligases (3, 5–7). Only one
substrate, the N-terminal fragment of the Bcl2-related protein
Bid, has been described thus far to undergo both non-canonical
ubiquitylation and proteasomal degradation by cellular E3
ligases (8), but mutational analyses failed to demonstrate a link
between removing the non-canonical ubiquitylated residues
and increased stability. In addition, the E2 UBC7 undergoes
auto-polyubiquitylation via cysteine and proteasomal degrada-
tion (7).
We have been studying the degradation of the proneural
transcription factor Neurogenin (NGN), which plays a pivotal
role in the neural versus glial decision during embryonic central
nervous system formation (9). To this end, we have exploited
the highly versatile Xenopus egg extract system. Centrifugal
extracts of Xenopus egg cytoplasm contain a large stockpile of
enzymes required for early stages of embryogenesis including
multiple components of the ubiquitin-proteasome system
(UPS) and have been used extensively to explore the biochem-
istry of ubiquitylation (10). Using Xenopus eggs and embryos
and mammalian cultured cells, we have demonstrated that
NGN is a very short-lived protein whose rapid turnover is con-
trolled by the UPS (11).
In this study, we demonstrate that NGN is one of the small
number of proteins that can be targeted for destruction by
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ubiquitylation on both the N terminus and the internal lysines,
and both contribute to its rapid degradation. Strikingly, we also
found that a mutant NGN protein, where Ub conjugation to
either lysines or the N terminus had been prevented, was still
degraded by the UPS. Under these circumstances, ubiquityla-
tion of NGN can occur on non-canonical cysteine sites. We
show that polyubiquitylation on both canonical and non-ca-
nonical residues also simultaneously occurs in the wild-type
native protein, and the relative contribution of these Ub link-
ages to speed of protein degradation may vary according to cell
cycle stage.Moreover, in the absence of other potential sites for
ubiquitylation, Ubs can also be added to serines and/or threoni-
nes, demonstrating the remarkable flexibility of the ubiquityla-
tion machinery.
EXPERIMENTAL PROCEDURES
Plasmids andConstructs—NGN (also known as X-NGNR1a)
and NeuroD constructs were described previously (11).
NGNKO, NGNCO, and NGNKOCO mutants were generated
using the QuikChange multisite-directed mutagenesis kit
(Stratagene). AC1, AC2, AC3 NGN, and NGN mutant con-
structswere generated by PCR and cloned into the pCS2 vector.
Ub and UbKO were amplified by PCR without the last two
glycine codons to prevent cleavage of the fusion by cytoplasmic
deubiquitinating enzymes (12) and fused in-frame to NGNKO
by a polar tetrapeptide linker (13).
In Vitro Translation—TNT SP6 quick coupled transcrip-
tion/translation system (Promega), in the presence of [35S]
methionine (Amersham Biosciences), was carried out accord-
ing to the manufacturer’s instructions.
Mitotic Extracts—Activated interphase egg extracts were
prepared as described previously (11) and were then supple-
mented with 5 g of recombinant non-degradable cyclin B
delta 90 per 100 l of extract. Extracts were incubated at room
temperature for 20 min to enable extracts to enter mitosis. The
effectiveness of this treatment in driving extracts into mitosis
was determined initially by examining the morphology of
sperm nuclei added to the extract.
Degradation Assays—Activated interphase and mitotic egg
extracts were prepared as described previously (11). Extracts
were supplemented with ubiquitin (from bovine erythrocytes,
Sigma) at a final concentration of 1.25 mg/ml. 35S-IVT protein
(protein generated by in vitro translation in the presence of
[35S]methionine) was added to the extract (8l of 35S-IVT pro-
tein per 36 l of extract) and incubated at 21 °C. Aliquots were
taken at various time points and mixed with 2 Laemmli sam-
ple buffer containing 100 mM -mercaptoethanol. Samples
were denatured for 3–5 min at 95 °C and separated by SDS-
PAGE (15% Tris-glycine). The half-life of the protein was cal-
culated by plotting the concentration of protein against time
and finding the first order rate constant for degradation.
Where appropriate, proteasome inhibitors were added to
extracts at the concentrations indicated, 5 min prior to the
addition of 35S-IVT protein. Mg132 and epoxomicin were
obtained commercially (BIOMOL) and used at the concentra-
tions indicated (200 and 100M, respectively, or addingDMSO
(1% (v/v)) in place of proteasome inhibitors in controls. Where
appropriate, extracts supplemented with a final concentration
of 10mg/mlmethylated ubiquitin (BIOMOL)were used in deg-
radation assays where indicated with ubiquitin from bovine
erythrocytes at a final concentration of 10 mg/ml as a control.
Ubiquitylation Assays—Ubiquitylation assays were per-
formed in accordance with the protocol described by Salic et al.
(10), with minor alterations. 5 l of 35S-IVT protein (or IVT
reaction with pCS2 vector as control) was added as indicated
to 23 l of activated interphase or mitotic egg extracts, supple-
mented with 200 M MG132 and either 2.5 mg/ml His-ubiq-
uitin (N-terminally hexahistidine tagged ubiquitin, Sigma) or
1.25mg/ml ubiquitin. Extract reactionswere incubated at 20 °C
for 1 h. Following incubation, the reactionswere diluted 10-fold
inHis buffer (100mMTris/HCl (pH7.4), 1% (v/v)Nonidet P-40,
8M urea, 20mM imidazole, 600mMNaCl and 10% (v/v) ethanol)
and supplemented with 15 l (5% (v/v)) of Ni2-nitrilotriac-
etate-agarose beads (Qiagen). Reactions were incubated for 90
min at room temperature, rotating at 12 rpm, and then washed
five times with His buffer prior to elution with 2 Laemmli
sample buffer supplemented with 100 mM -mercaptoethanol.
Sampleswere heat-treated for 5min at 95 °C prior to separation
on 15% Tris-glycine SDS-PAGE gels.
Reducing Treatments—Reducing ubiquitylation assays were
performed as described above except that at the elution step, sam-
ples were eluted with either reducing 2 Laemmli sample buffer
(2 Laemmli sample buffer (pH 10.5)  10% (v/v) -mercapto-
ethanol) or non-reducing 2 Laemmli sample buffer (2 Lae-
mmli sample buffer (pH 6.8) 10% (v/v) water), see Fig. 4, B and
C). Sample buffers also included 100 mM imidazole in the case of
Fig. 6A and were rocked at room temperature for 20 min after
sample buffer addition but before SDS-PAGE.
Blocking N-terminal Acetylation—The blocking of N-termi-
nal acetylation in reticulocyte lysates was based on procedures
described previously (14, 15). Briefly, 120l of quick coupled in
vitro transcription/translation system (Promega) was supple-
mented with 1 mM oxaloacetic acid (Sigma) and 50 units/ml of
citrate synthase (fromporcine heart, Sigma), incubated at 25 °C
for 7min, and then supplementedwith desulfoCoA lithium salt
(Sigma) to give a final concentration of 1 mM after the addition
of plasmid DNA and [35S]methionine. Reactions were incu-
bated for 2 h at 30 °C. Oxaloacetate and desulfo CoA were
removed using Zeba microspin columns (Pierce). A control
reactionwas included towhich citrate synthase onlywas added.
ATP Depletion—8 l of in vitro translated 35S-methione-
labeledproteinwas combinedwith40l of high speed interphase-
activated egg extract, cleared of ribosomes by spinning at
107,400 g for 40min, supplemented with 200g/ml cyclohexi-
mide, 10g/ml leupeptin, pepstatin, and chymostatin, 1.5 mg/ml
ubiquitin, and 2 l of Energy Regeneration mix (20 l of 100 mM
EGTA; 20l of 1MMgCl2; 150l of 1Mphosphocreatine (Sigma);
200 l of 100 mM adenosine 5-triphosphate (GE Healthcare)) or
0.8 l of 1600 units/ml hexokinase with 0.8 l of 1 M glucose.
Samples were used as in a normal degradation assay, described
above.
RESULTS
NGN Can Be Ubiquitylated on Both Lysines and the N
Terminus—We have previously demonstrated that NGN is
turned over extremely rapidly inXenopus eggs and embryos via
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the UPS, whereas a related proneural protein NeuroD is stable
(11). In an attempt to generate a stabilized form of NGN, its 8
lysine residues were mutated to arginines to produce a lysine-
less protein (NGNKO). Arginine cannot be ubiquitylated but
preserves the basic character of the lysine residues they replace
(16). Both NGNKO and wild-type protein (NGN) were in vitro
translated (IVT) in rabbit reticulocyte lysates in the presence of
[35S]methionine and added to Xenopus egg extracts, and the
half-life was determined after SDS-PAGE analysis at increasing
time points in a standard degradation assay. NGNKO had
approximately double the half-life of the wild-type protein
(46.6  3.3 min versus 22.5  1.2 min, Fig. 1) but was still
degraded. We investigated whether NGN could join the small
number of proteins thus far identified as being ubiquitylated on
the N terminus.
Bulky N-terminal tags, such as six consecutive Myc tags, are
thought to impede the accessibility of the -amino group to the
ubiquitylation machinery and so prevent N-terminal ubiquity-
lation (17). However, adding bulky tags (Myc tags or green flu-
orescent protein) to both the N termini and the C termini of
NGN resulted in its stabilization (supplemental Fig. 1A and
data not shown). Although this observation may have impor-
tant implications for the use of tags on short-lived transcription
factors, it led us to seek other ways to prevent N-terminal
ubiquitylation.
Blocking the N Terminus by Promoting N-terminal Acetyla-
tion—A free, unmodified -amino group of the substrate pro-
tein is required for N-terminal ubiquitylation. N-terminal
cotranslational acetylation of the -amino group is a common
protein modification in eukaryotes, occurring in up to 80% of
cytosolic proteins (18). The presence of an acetyl group at theN
terminus prevents the attachment of ubiquitin (19), and this
modification is thought to be irreversible (18). Primary
sequence requirements for N-terminal acetylation in
eukaryotes have been identified (18) and can be used to predict
whether a protein with a given N-terminal sequence will be
cotranslationally acetylated (20). We used an online prediction
tool (TermiNator, available from the CNRS) to determine the
likelihood that NGN is cotranslationally acetylated. This anal-
ysis revealed that NGN is highly likely to be expressed with a
free, unmodified N terminus (supplemental Fig. 1B). We then
devised two alterations to the N terminus of NGN (MVLLK to
FIGURE 1.Neurogenin is degraded by both a lysine-dependent pathway and anN-terminal-dependent pathway.Degradation assays in interphase egg
extract were performed using [35S]methionine-radiolabeled NGN, NGNKO, Ac2NGNKO, Ac2NGN, and NeuroD, as indicated, and analyzed by autoradiography
(left panels) and quantitative phosphorimaging analysis (right graphs). Half-lives for degradation were calculated using first order kinetics (bottom table).
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MSESK and to MAESK, forming Ac1NGN and Ac2NGN,
respectively) to promote its cotranslational acetylation (18).
Additionally, a mutant was made in which the penultimate res-
idue of NGN was replaced with proline (MVLLK to MPLLK,
forming Ac3NGN), which completely blocks its N-terminal
acetylation and therefore represents an appropriate control for
our experiments (18).
Using our degradation assay, we compared the stability of
Ac1NGN, Ac2NGN, and Ac3NGN with the wild-type protein.
As we would predict whether N-terminal ubiquitylation con-
tributes to NGN destruction, Ac1NGN and Ac2NGN had
enhanced stability when compared with wild-type NGN
(33.7  1.7 min and 37.7  1.7 min versus 22.5  1.2 min).
Ac3NGN had a half-life similar to the wild-type NGN protein
(26.1 0.6 min versus 22.5 1.2 min).
To see whether ubiquitylation on lysines and the N terminus
target for destruction additively or redundantly, we con-
structedNGNKOmutants where theN terminus was addition-
ally modified to block ubiquitylation to produce Ac1NGNKO
and Ac2NGNKO. The half-life of Ac1NGNKO and
Ac2NGNKO was substantially increased (103.4 3.9 min and
110.2  8.6 min, respectively) when compared with NGN
(22.5  1.2 min), NGNKO (46.6  3.3 min), and Ac2NGN
(37.7  1.7 min) (Fig. 1). Thus, ubiquitylation on internal
lysines and the N terminus both contribute to the rapid degra-
dation of NGN protein.
To confirm that these sequence alterations block degrada-
tion by promoting cotranslational acetylation, we examined the
degradation of NGN, Ac3NGNKO, and Ac2NGNKO where
cotranslational acetylation had been enzymatically inhibited.
Methods for inhibiting translational acetylation in reticulocyte
lysates have been previously described (14, 15). These involve
enzymatic depletion of free acetyl CoA in reticulocyte lysates
using citrate synthase and oxaloacetate followed by in vitro
translation in the presence of a dead end analogue of acetyl CoA
to competitively inhibit acetyl CoA-dependent N-terminal
acetyltransferases. When Ac2NGNKO is in vitro translated
under these conditions (Fig. 2), a marked destabilization in egg
extract is observed (half-life of 42.5  5.9 min after blocking
acetylation when compared with 91.4  10.1 min in the con-
trol). In contrast, NGNKO and Ac3NGNKO were found to be
refractory to this treatment (Fig. 2), consistent with the non-
acetylated status of the N termini of these proteins under nor-
mal in vitro translation conditions.
NGN Is Stabilized by Truncation at the N Terminus—It has
been shown that several of the substrates of N-terminal ubiq-
uitylation can be stabilized by the deletion of 5–30 amino acids
from the N terminus. We took this approach with NGN as a
further line of evidence for N-terminal ubiquitylation. We
observed that an N-terminally truncated form of NGNKO
where the first 20 amino acids had been removed (NGNKO
1–20) was also degraded more slowly than NGNKO (63.4 
4.4 min versus 45.3  4 min, (supplemental Fig. 2A), again
indicative of N-terminal ubiquitylation.
To mimic N-terminal ubiquitylation, we generated non-
cleavable fusions of Ub and UbKO to NGNKO and examined
the degradation kinetics. Consistent with N-terminal ubiquity-
lation contributing to NGN turnover, UbNGNKO was
degraded faster than wild-type NGN (half-life of 10.5  1 min
versus 22.5  1.2 min, respectively). In contrast, when we
blocked N-terminal polyubiquitylation using an N-terminal
fusion of ubiquitin where lysines had been mutated to argin-
ines, this UbKONGNKO form of NGNwas considerably stabi-
lized when compared with both wild-type NGN and NGNKO
(half-lives of 110.8 10.7min versus 22.5 1.2min and 46.6
3.3 min, respectively, and see supplemental Fig. 2B). This fur-
ther indicates that N-terminal ubiquitylation contributes to
NGN instability. However, we were intrigued to see that, like
Ac2NGNKO, slow degradation of UbKONGNKO was still
observed.
In summary, the evidence presented above shows that NGN
is ubiquitylated on the N terminus and on internal lysines, and
both contribute to the instability of the protein. However, it is
clear that, even when these two canonical modes of ubiquityla-
tion are prevented, NGN is still subject to slow proteolysis. We
have explored this further.
NGN Is Ubiquitylated on Cysteines—Despite the apparent
absence of canonical ubiquitylation sites, Ac2NGNKO is still
degraded in Xenopus egg extracts. Mg132 addition to the
extract resulted in stabilization of Ac2NGNKO, as did the addi-
tion of a different proteasomal inhibitor epoxomicin (Fig. 3A; at
180 min on average, 32% of the Ac2NGNKO protein remained
after the addition of DMSO when compared with 74 and 84%
after the addition of MG132 and epoxomicin, respectively),
indicating degradation by the proteasome. Furthermore, deple-
tion of ATP by the addition of glucose and hexokinase, which
would inactivate ATP-dependent proteasomal-mediated deg-
radation, also resulted in stabilization of both wild-type NGN
and Ac2NGNKO (Fig. 3B).
To determine whether degradation of Ac2NGNKO requires
polyubiquitylation, we addedmethyl-Ub, a formofUb that can-
not support chain formation (21), to the extract. As expected,
methylatedUb competes with an endogenous pool of freeUb in
the extract resulting in stabilization ofAc2NGNKO (Fig. 3C); at
180 min, an average of 34% of the Ac2NGNKO protein still
remained after the addition of Ub when compared with 76%
after the addition of methylated Ub. To confirm that ubiquity-
lation was occurring even in the absence of canonical ubiquity-
lation sites, we performed an assay to detect ubiquitylated
forms of NGN directly.
IVT [35S]methionine-labeled NGN and mutants thereof
were incubated in egg extract in the presence of Mg132 to pre-
vent protein degradation by the 26 S proteasome and allow
ubiquitylation to be observed. Proteins covalently bound to
His-Ub (with untagged Ub as a control) were then pulled down
using Ni2-nitrilotriacetate-agarose, in the presence of 8 M
urea. Proteins covalently attached to His-Ub were separated by
SDS-PAGE and subjected to autoradiography (Fig. 4A). After
His-Ub pull down, as expected, multiple slower migrating
forms ofNGNandAc2NGNwere visible as a ladder specifically
in the presence of His-Ub, consistent with multiply ubiquity-
lated forms of the protein (Fig. 4A), presumably linked to
lysines. A similar ladder was seen using NGNKO, where ubiq-
uitylation on theN terminus is possible.However, Ac2NGNKO
(Fig. 4A), which does not have canonical Ub sites, was also pre-
cipitated usingHis-Ub, although the ladder at highermolecular
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weights tended to be somewhat reduced. Significantly, in addi-
tion to this faint ladder of polyubiquitylated forms, a band was
observed running below 36 kDa, the size at which unmodified
NGN protein migrates on SDS-PAGE. Moreover, this band
appears more prominent in NGNKO mutants, although it is
clearly detectable even in the wild-type NGN sample. We rea-
soned that unconjugated NGN protein would be released from
Ub chains if attachment were via linkages labile to the condi-
tions used in SDS-PAGE, which involve sample preparation at
high temperature and include reducing agents, conditions that
would break thioester bonds.
To test whetherNGN can be conjugated toUb via such labile
linkages, we performed a standard ubiquitylation assay but sep-
arated bound proteins by SDS-PAGE either without reducing
agents (non-reducing (Fig. 4B (Non red)) or with reducing
agents at high pH (reducing (red) conditions), based upon con-
ditions that have previously been used to disrupt labile Ub thio-
ester linkages to cysteines (3) (Fig. 4B). NGN showed a ladder of
FIGURE 2. Stability of acetylation mutants of NGN is affected by acetylation-blocking. Degradation assays in interphase egg extract were performed on
NGN constructs, as indicated, in vitro translated either in the absence (Control) or in the presence of citrate synthase, oxaloacetate, and desulfo CoA (Acetyl
block). Assays were analyzed by autoradiography (left panels) and quantitative phosphorimaging analysis (right graphs).
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polyubiquitylated species in both reducing and non-reducing
conditions (Fig. 4B), indicating that most Ubs are indeed con-
jugated to lysine, an isopeptide linkage insensitive to these con-
ditions. However, in reducing conditions, we saw a prominent
band at the size corresponding to unmodified NGN that is
barely present with non-reducing sample preparation (Fig. 4B,
marked with *), indicating that a proportion of ubiquitylated
wild-type NGN is conjugated through labile linkages.
In contrast to wild-type NGN, forms of NGN lacking ly-
sines and precipitated by His-Ub (NGNKO, Ac2NGNKO,
Ac3NGNKO) appeared strikingly different when separated by
SDS-PAGE in non-reducing and reducing conditions (Fig. 4C).
In non-reducing conditions, a ladder of polyubiquitylated spe-
cies is present, but this is substantially diminished under reduc-
ing conditions, and this coincides with the appearance of a
strong band of unconjugatedNGN. This is consistent with sub-
stantial ubiquitylation of NGNKO via linkages that are labile to
reducing conditions, which would include thioester linkages
between Ub and cysteine.
To investigate this further, we generated an NGN mutant
where all 7 cysteines had been mutated to alanine (NGNCO).
Importantly, this mutant version of NGN, NGNCO, as well as
the other mutant forms of NGN assayed above, are all able to
bind to DNA and to activate an NGN reporter construct after
expression inXenopus embryos (Fig. 5). Functionality indicates
largely intact structures of the mutant forms. We did note that
FIGURE 3. N-terminally blocked NGN lacking lysines is still degraded in a ubiquitin-dependent manner in egg extracts. A, degradation assays in
interphase egg extract of [35S]methionine-radiolabeledAc2NGNKOwere performed in the presence of the proteasome inhibitorMg132 (200M), epoxomicin
(100 M) or DMSO alone and analyzed by autoradiography and quantitative phosphorimaging analysis. B, degradation assays in interphase egg extract of
[35S]methionine-radiolabeledNGNorAc2NGNKOwereperformed in thepresence (ER) or absence (glucose/hexokinase) ofATP,whereER represents Energy
Regeneration mix. C, degradation assays of Ac2NGNKO was performed in the presence of ubiquitin or methylated ubiquitin (MeUb).
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NGNCOmutants do run as a tighter band than NGN on SDS-
PAGE (Fig. 6). To determine whether the presence of cysteine
residues contributes to NGN instability, we tested the half-life
ofNGNCO in interphase, whichwas similar to that ofwild-type
NGN (24.2  1.9 min versus 22.5  1.2 min). We constructed
forms ofNGNwith other potential ubiquitylation sitesmutated
(see above) in a background where cysteines were also mutated
(Ac2NGNCO, NGNKOCO, and Ac2NGNKOCO). Half-life
analyses (Fig. 6, A and B) show that mutation of cysteines
results in slower degradation of all these modified forms of
NGN. In particular, in interphase, when the N-terminal ubiq-
uitylation pathway is blocked, ubiquitylation on lysines cannot
fully compensate for the loss of cysteines; Ac2NGNCO is
degraded more slowly than Ac2NGN, although lysines are
intact in both (Fig. 6B). However, although ubiquitylation on
canonical residues and on cysteines can both target for degra-
dation in interphase, redundancy between ubiquitylation path-
ways exists under these conditions as cysteines are not abso-
lutely required for rapid degradation (Fig. 6A).
NGN protein has a short half-life in interphase extracts, but
the control of degradation of proteins can often vary between
interphase and mitosis (22). Hence,
we investigated the half-life of NGN
in egg extracts that had been ren-
dered mitotic by the addition of a
non-degradable form of cyclin B
(23) (Fig. 6C). Strikingly, in mitosis,
NGN is degraded evenmore rapidly
than in interphase, with a half-life of
15.8  2.1 min. We then compared
the contribution of lysines and cys-
teines with the degradation of
NGN in mitosis. NGNKO had an
increased half-life of 35.6 2.7 min
in mitotic extracts. Importantly and
in contrast to interphase, NGNCO
was also significantly stabilized
when compared with wild-type
NGN, with a half-life, 38.3  5.4
min, almost three times that of the
wild-type protein. These results
indicate that ubiquitylation on cys-
teine and lysine both contribute to
the very rapid rate of degradation
seen in mitosis. N-terminal ubiqui-
tylation can also contribute to deg-
radation in mitosis; Ac2NGNKO
had a half-life of 82.0  47.8 min
when comparedwith 35.6 2.7min
for NGNKO.
We then determined whether
NGN lacking both canonical and
cysteine ubiquitylation sites was
fully stable, investigating the degra-
dation of Ac2NGNKOCO, where
the N terminus was blocked by
acetylation and both lysines and
cysteines were mutated to arginines
and alanines, respectively. When compared with NGNKO, we
observed that Ac2NGNKOCO was dramatically stabilized,
with a half-life of greater than 180 min, and appeared more
stable than Ac2NGNKO, yet we still observed very slow degra-
dation (Fig. 7). Moreover, the stability of Ac2NGNKOCO was
further enhanced by the presence of Mg132 (Fig. 7B) and
epoxomicin (Fig. 7B). Under these condition, ubiquitins may
still form ester linkages to serines and/or threonines, which
have been predicted to be broken by high pH alone (4, 24). To
investigate these potential linkages further, we performed ubiq-
uitylation assays using wild-type NGN, NGNCO, and
Ac2NGNKOCO either in the absence or in the presence of
reducing agents or at high pH (Fig. 7C).
NGN Can Be Ubiquitylated on Serines and/or Threonines—
To determine whether Ub was linked to Ac2NGNKOCO via
ester bonds, we performed ubiquitylation assays and separated
samples by SDS-PAGE either in the presence of reducing
agents (with sample heating) or at high pH (Fig. 7C). In the
absence of reducing agents, His-Ub precipitation of polyubiq-
uitylated NGN, as expected, showed a multitude of higher
molecular weight forms, corresponding to polyubiquitylated
FIGURE 4. N-terminally blocked NGN lacking lysines is still ubiquitylated in egg extracts. A, ubiquitylation
assayswere performedusingNGN, Ac2NGN,NGNKO, Ac2NGNKO, andAc3NGNKO in thepresenceofHis-ubiquitin
or ubiquitin. B, ubiquitylation assays were performedwith NGN. Reactions were eluted either under non-reducing
(Non red) or under reducing/pH 10 conditions (red). C, ubiquitylation assays were performed using NGNKO,
Ac2NGNKO, and Ac3NGNKO. Reactions were eluted either under non-reducing or under reducing/pH 10 condi-
tions. Note that NGN and NGN mutant samples were from the same experiment with identical conditions and
exposures. Non-modified NGN ismarked by *.
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NGNprotein. UnconjugatedNGNwas visible particularly after
the addition of dithiothreitol, indicating that a population of
wild-type NGN is linked to Ub via thioester linkages, as
described above. A polyubiquitylated ladder of NGNCO was
also visible, where presumably most Ubs are linked to lysines
via isopeptide bonds. Interestingly, when ubiquitylated
NGNCO was run after sample treatment at high temperature
and pH, conditions that would break ester bonds, free NGNCO
is released, indicating that in the absence of cysteines, ubiqui-
tylation can occur on serines and/or threonines instead.We did
note that when NGNCO samples were run in the presence of
reducing agents, we still observed higher forms of NGNCO,
although some release of free NGNCO did occur. This is most
likely due to breaking of highly labile ester linkages on sample
heating as cysteine residues are not available for thioester bond
formation.
In contrast to NGN and NGNCO, His-Ub pull down of
Ac2NGNKOCO showed reduced very high molecular mass
forms of the proteins, but instead, we saw a prominent short
ladder of NGN conjugates between 30 and 60 kDa.When sam-
ples were run in the presence of reducing agents, we still
observed higher forms of wild-type NGN, although again some
release of free Ac2NGNKOCO did occur, most likely due to
breaking of labile ester linkages on sample heating. However,
raising the sample pH as well as heating, which results in effi-
cient alkaline hydrolysis of ester bonds, led to substantial col-
lapse of slower migrating forms of NGN, releasing almost
entirely unconjugatedAc2NGNKOCO. Thus, in the absence of
a free N terminus, lysines, and cysteines, Ubs can still conjugate
via ester linkages to serines and/or threonines (Fig. 7C), and
these linkages alone can result in very slow turnover of the
protein (Fig. 7).Wewould note that high pH treatment alone of
ubiquitylated wild-type NGN did not release substantial free
NGN protein, indicating that Ser/Thr ubiquitylation of NGN
does not usually occur to a great extent.
DISCUSSION
For the first time, we demonstrate here that ubiquitylation of
an intact and active cellular protein occurs at three distinct
types of site: Ub conjugation to theN terminus, Ub conjugation
to lysines, and Ub conjugation via non-canonical linkages to
cysteines. In addition, in the absence of other available sites,
ubiquitylation can be redirected to serines and/or threonine
residues. Ubiquitylation on cysteine residues has been theoret-
ically postulated for many years, yet it has only been very
recently shown to occur in a cellular setting, almost exclusively
to regulate intracellular movement. We show here that it can
occur and act in parallel with canonical ubiquitylation to target
a protein for destruction. Moreover, non-canonical ubiquityla-
tion via cysteines may play a greater role in NGN turnover in
mitosis, where degradation rate is faster than in interphase,
indicating that different Ub acceptors may change in promi-
nence under different cellular conditions. Although different
modes of ubiquitylation may individually contribute to small
differences in protein stability, nevertheless, this may lead to a
significant difference in the steady state level of the protein (25).
Several studies (3, 5, 6, 8) have reported very unusual non-
canonical ubiquitylation including on cysteines, but none have
demonstrated this modification directly by mass spectroscopy.
It has been proposed that one explanation is the small amount
of ubiquitylated molecules available for purification (3). In
addition, thioester and ester bonds are very labile and may not
withstand sample preparation.We have also encountered tech-
nical problems purifying sufficient NGN monomeric protein
for mass spectroscopy analysis. Hence, for these reasons, we
have instead used biochemical methods to demonstrate non-
canonical ubiquitylation.
Non-canonical ubiquitylation does occur on the wild-type
NGNprotein, butwedid observe that these non-canonical link-
ages assumedmore experimental prominence in the absence of
lysines; we would note that very few proteins have had ubiqui-
FIGURE5.MutantNGNprotein showswild-typeDNAbinding.A, NGNcon-
structs, as indicated, were translated in vitro and incubated with 32P-labeled
E-box DNA probe in the presence or absence of the heterodimeric binding
partner, E12. In the absence of E12, neither wild-type nor mutant NGN pro-
teins are able to bind the probe. In the presence of E12, all NGN derivatives
showwild-type binding to the probe. The experiment has been performed in
triplicate; slight variations in binding efficiency seen here were not consis-
tently observed. B, mutant NGN constructs activate a reporter gene at wild-
type levels in vivo. Xenopus laevis embryos were injected with 50 pg of NGN
mRNA as indicated, together with 200 pg of Beta2 reporter Firefly luciferase
construct (FFL), as a direct downstream target of NGN, and 6 pg of constitu-
tively expressed Renilla luciferase (RL), as an internal control. There is no sig-
nificant difference between activation of the reporter gene bywild-typeNGN
or by mutant NGN constructs. Values obtained are from independent dupli-
cate experiments (each sample in triplicate) and showmean S.E.GFP, green
fluorescent protein.
Canonical and Non-canonical Ubiquitylation of Neurogenin
JUNE 5, 2009•VOLUME 284•NUMBER 23 JOURNAL OF BIOLOGICAL CHEMISTRY 15465
 at Cam











Supplemental Material can be found at:
FIGURE 6. NGN lacking canonical ubiquitylation sites is still ubiquitylated and degraded in a proteasomal-dependent manner. Degradation
assays in interphase egg extract of [35S]methionine-radiolabeled constructs of NGN were performed using NGNCO, Ac2NGNKO, and Ac2NGNKOCO (A)
or Ac2NGN and Ac2NGNCO (B). Assays were analyzed by autoradiography and quantitative phosphorimaging analysis. C, degradation assays in mitotic
egg extract were performed using NGN, NGNKO, NGNCO, and Ac2NGNKO and analyzed by autoradiography and quantitative phosphorimaging
analysis.
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tylation analyzed after all lysine residues have been mutated.
Cysteine ubiquitylation may be more important under these
circumstances or where native lysines are not available for
ubiquitylation due to other modifications such as acetylation.
However, it is quite possible that non-canonical ubiquitylation
may occur more widely than has previously been supposed, but
these modifications could have been overlooked by current
experimental approaches, particularly as assay and analysis
conditions very commonly including sample preparation
involving high temperature and reducing agents, conditions
that will break these non-canonical linkages.
If simultaneous canonical and non-canonical ubiquitylation
occurs on other proteins and site prominence varies at different
cell cycle phases, this would sub-
stantially increase the complexity of
the UPS system and require reanal-
ysis of, for instance, some proteins
thought to be targeted to the protea-
some in the absence of ubiquityla-
tion (for a review, see Ref.26). Possi-
ble candidates for non-canonical
ubiquitylation include other basic
helix-loop-helix proteins such as
MyoD, which shows different
modes of canonical ubiquitylation
to NGN (27, 28). In addition, natu-
rally lysineless proteins such as
p14ARF (29, 30) may also undergo
ubiquitylation on non-canonical
sites such as cysteine to target for
proteasomal degradation.
Non-canonical ubiquitylation of
NGN does lead to Ub chains of suf-
ficient length and with the correct
linkage to target for destruction.
The ability to ubiquitylate onmulti-
ple canonical and non-canonical
sites demonstrates remarkable flex-
ibility of the ubiquitylation appara-
tus. Ubiquitin ligases for NGN have
yet to be identified and, at present, it
is not clear whether the same
enzymes that catalyze ubiquityla-
tion of lysines can also target the N
terminus and/or cysteine residues
and indeed also serines and threoni-
nes in the absence of other available
ubiquitylation sites. There clearly is
much flexibility in the machinery
that ubiquitylates NGN; we have
seen that no single lysine in NGN is
indispensable for canonical ubiqui-
tylation (supplemental Fig. 3). Thus,
how specificity of these ubiquityla-
tion reactions is controlled remains
to be established.
Another important point to note
is that, in our system, ubiquitylation
on canonical and non-canonical sites can be brought about
entirely by cellular ubiquitin ligases found in the Xenopus egg
extract. We have preliminary data that ubiquitylation on non-
canonical residuesmay also occur inmammalian cells (data not
shown), indicating that non-canonical ubiquitylation is a more
widespread phenomenon. In summary, our analyses demon-
strate that both canonical and non-canonical ubiquitylation
brought about by the cellular ubiquitylation machinery occur
simultaneously, and both can drive proteasomal degradation.
We postulate that such regulation of a single protein by multi-
ple canonical and non-canonical ubiquitylation events may be
found to be more widespread on closer study of other proteins
and systems and that the importance of these two modes of
FIGURE 7. NGN lacking canonical ubiquitylation sites and non-canonical cysteines is still ubiquitylated
and degraded by the proteasome.Degradation assays in interphase egg extract of [35S]methionine-radiola-
beled constructs of NGN were performed using Ac2NGNKO (A) and Ac2NGNKOCO (B) in the presence or
absence of proteasome inhibitors Mg132 and epoxomicin. Assays were analyzed by autoradiography and
quantitative phosphorimaging analysis. C, ubiquitylation assays were performed in interphase extract using
NGN, NGNCO, and Ac2NGNKOCO in the presence of His-Ub or Ub, and samples prepared for SDS-PAGE under
non-reducing conditions (Non red), reducing conditions (red), or high pH (pH10) conditions (with samples
heated to 95 °C for 5 min prior to loading in all cases).
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ubiquitylation may differ for the same protein under differing
cellular conditions.
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a b s t r a c t
Poly-ubiquitin chains targeting proteins for 26S proteasomal degradation are classically anchored on
internal lysines of substrates via iso-peptide linkages. However recently, linkage of ubiquitin moieties
to non-canonical nucleophilic residues, such as cysteines, serines and threonines, has been demonstrated
in a small number of cases.
Non-canonical ubiquitylation of the proneural protein Ngn2 has previously been seen in Xenopus egg
extract, but it was not clear whether such highly unusual modes of ubiquitylation were restricted to
the environment of egg cytoplasm. Here we show that Ngn2 is, indeed, ubiquitylated on non-canonical
sites in extracts from neurula stage Xenopus embryos, when Ngn2 is usually active. Moreover, in the
P19 mammalian embryonal carcinoma cell line capable of differentiating into neurons, xNgn2 is ubiqui-
tylated on both canonical and non-canonical sites. We see that mutation of cysteines alone results stabi-
lisation of the protein in P19 cells, indicating that non-canonical ubiquitylation on these residues
normally contributes to the fast turnover of xNgn2 in mammalian cells.
! 2010 Elsevier Inc. All rights reserved.
Introduction
The levels of individual proteins must be tightly controlled to
generate a highly dynamic cellular environment adapted to re-
spond to changing environmental and developmental cues. Large
numbers of proteins are targeted by the ubiquitin–proteasome sys-
tem, resulting in their rapid and responsive regulation [1,2]. The
small protein ubiquitin (Ub), when covalently fused to its sub-
strate, plays a context dependent role in signalling the destination
of a protein, for instance localising the protein to the nucleus, or
dispatching the protein to cellular compartments such as the lyso-
zome [3]. Poly-ubiquitin chains are built up on a substrate protein
via covalent linkages, typically to lysine48 of the first Ub moiety,
and this is sufficient to deliver the substrate to the 26S proteasome
where unfolding and cleavage into peptides, and subsequent deg-
radation, occurs [4].
The sites on the substrate protein to which the first Ub is at-
tached, providing an anchor point for subsequent Ub chain elonga-
tion, have been well-studied in many proteins, and typically occurs
on substrate lysines via an iso-peptide linkage. In a small number
of proteins, often those lacking lysines, ubiquitylation has been
shown to occur on the N-terminal alpha-amino group via a peptide
linkage [5,6]. It is chemically possible for other nucleophilic amino
acid side chains to covalently link to Ub. While formerly consid-
ered unlikely as these bonds would be considerably weaker than
the canonical iso-peptide and peptide bonds described above, such
ubiquitylation events via cysteine (and even serines and threo-
nines) have recently been shown to occur on both viral and cellular
proteins, although such examples remain very rare [7–12].
Amongst classes of proteins that may be targeted for proteaso-
mal destruction, transcription factors in particular have short half-
lives and their ubiquitin-mediated degradation has been proposed
to play a key role in their function at the promoter [13]. For instance
Xenopus Neurogenin 2 (xNgn2) [14], a basic helix–loop–helix
(bHLH) proneural protein that plays a key role in neuronal differen-
tiation in the developing central nervous system [15], is very rapidly
degraded by the UPS. We have previously shown that xNgn2 is
targeted for destruction by ubiquitylation on both lysines and the
N-terminus [16]. Moreover, in Xenopus eggs, xNgn2 is ubiquitylated
on cysteines and this can be sufficient to drive protein degradation
[17]. However, these studies were performed in extracts of unferti-
lised Xenopus eggs where xNgn2 would not normally be expressed.
Wehave shown that xNgn2 is ubiquitylated inmammalian cells, but
have not investigated whether non-canonical ubiquitylation of
xNgn2 is occurring [17].
Here we show that xNgn2 is, indeed, ubiquitylated on cysteines
in Xenopus embryos at neurula stage where it would be transcrip-
tionally active. Moreover, using P19 embryonal carcinoma cells
that can respond to bHLH overexpression by undergoing neuronal
differentiation [18], we see that xNgn2 is ubiquitylated on the
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N-terminus, lysine residues and cysteine residues. Multiple sites of
ubiquitylation result in the very rapid degradation that we observe
for xNgn2, which is likely important for its role as a regulator of the
transition between stem/progenitor and neuronal identity during
development of the nervous system.
Materials and methods
Plasmid constructs
Constructs were made by site-directed mutagenesis (Strata-
gene) and cloned into pCS2+ as described previously [16,17].
Tagged constructs were made by sub-cloning into pCS2+ contain-
ing a triple HA tag.
Xenopus laevis neurula embryo extract
Female wild-type Xenopus laevis were primed using Pregnant
Mare Serum Gonadotropin and ovulation induced using Human
Chorionic Gonadotropin. Eggs were fertilised in vitro. Neurula stage
embryos [19] were lysed in XB (extract buffer: 100 mM KCl; 1 mM
MgCl2; 0.1 mM CaCl2; 50 mM sucrose; 10 mM HEPES pH 7.7) with
10 lg ml!1 Cytochalasin B in a microcentrifuge at 4 "C to isolate
cytoplasmic extract.
Ubiquitylation assays
Extract was supplemented with 10 lg ml!1 LPC (10 lg ml!1
leupeptin, 10 lg ml!1 pepstatin, 10 lg ml!1 chymostatin; Sigma);
20 lg ml!1 cycloheximide (Sigma); ER (energy regeneration mix:
20 ll 100 mM EGTA; 20 ll 1 M MgCl2; 150 ll 1 M phosphocreatine
(Sigma); 200 ll 100 mM adenosine 50triphosphate (GE Health-
care); 1 lMMg132 (Biomol); 3.75 mg ml!1 His-tagged ubiquitin
(Sigma). For each condition 5 ll in-vitro translated 35S-methio-
nine-radiolabelled protein (SP6 TNT# Master Mix (Promega),
35S-methionine (Perkin Elmer)) was added. Samples were incu-
bated at 20 "C for 90 min then supplemented with VOSPER buffer
(8 M urea, 0.1 M Tris pH 7.4, 20 mM imidazole, 6 mM NaCl, 1%
Nonidet P40 (Sigma), 10 lg ml!1 LPC) and Ni–NTA™ agarose beads
(Qiagen) and rotated for 75 min at room temperature. Samples
were washed in VOSPER buffer and eluted in either reducing buffer
(Laemmli buffer pH 10; 100 ll b-mercaptoethanol; 100 mM imid-
azole) or non-reducing buffer (Laemmli buffer; 100 ll H2O;
100 mM imidazole). Samples were rocked at room temperature
for 20 min and separated using SDS–PAGE.
Xenopus laevis degradation assays
Degradation assays were performed as described previously
[17] using neurula embryo extract.
P19 cell degradation assays
P19 cells were grown as described previously [20]. Prior to
transfection cells on plates were incubated in antibiotic-free
a-MEM for 2 h at 37 "C. DNA (5 lg) (encoding triply-HA-tagged
protein) was transfected with lipofectamine (Invitrogen) and OPTI-
MEM (Invitrogen) overnight at 37 "C. Protein synthesis was
blocked using 100 lg ml!1 cycloheximide (with 50 lMMg132
(BioMol) or an equivalent volume of DMSO if investigating protea-
some inhibition). Cells were lysed in lysis buffer (50 mM Tris/HCl
pH 7.5; 150 mM NaCl; 1% IgePal (Sigma); protease inhibitors (Sig-
ma); 1 lM pepstatin) and subjected to Western blot analysis using
20 lg total protein. Proteins were detected using an HRP-coupled
anti-HA antibody (Roche) or anti-tubulin antibody (Sigma) fol-
lowed by anti-mouse secondary antibody (GE Healthcare). Immu-
nodetection was performed using ECL Plus™ Western Blotting
Reagent (GE Healthcare). Protein levels were quantified using Im-
ageJ software (http://rsb.info.nih.gov/ij/) [21] and half-lives calcu-
lated using first-order kinetics. The half-life for each mutant was
normalised to the wild-type in each experiment. The average ratio
compared to wild-type stability from the triplicate data set was
then calculated.
P19 immunoprecipitation assays
HA-tagged or untagged xNgn2 constructs were cotransfected
with FLAG-Ubiquitin in P19 cells overnight using Lipofect-
amine2000™ (Invitrogen). Cells were incubated in 50 lM MG132
for 1 h and lysed in lysis buffer (50 mM Tris/HCl pH 7.5; 150 mM
NaCl; 1% (v/v) IgePal (Sigma); complete proteasome inhibitor cock-
tail (Roche); 1 lMpepstatin). xNgn2 was immunoprecipitated in IP
buffer (50 mM Tris/HCl pH 7.5; 150 mM NaCl, 0.1% (v/v) NP40,
complete proteasome inhibitor cocktail (Roche), 1 lM pepstatin)
using an anti-HA antibody (Roche) and HA-matrix. Ubiquitylated
proteins were immunoprecipitated using an anti-FLAG antibody
(M2 clone, Sigma) and Protein-A Sepharose (GE Healthcare). For
IP pull down 400 lg of protein was diluted in 1 ml of IP buffer
for each condition and further incubated with primary antibody
overnight. The next day samples were subjected to Western blot
analysis and proteins were detected using an HRP-coupled anti-
HA antibody (Roche) or anti-FLAG antibody (Sigma) followed by
a-mouse secondary antibody (GE Healthcare).
Results
Xenopus Ngn2 (xNgn2) is degraded very rapidly in Xenopus egg
extracts [16], which contain all components of the UPS system.
Moreover, this ubiquitylation can occur on multiple sites including
the N-terminus, lysines and cysteine residues and all can target the
protein for destruction [17]. However, xNgn2 is normally first ex-
pressed post-gastrulation [14], raising the question as to whether
degradation in egg extracts is via physiologically relevant mecha-
nisms. To address this, we wanted to determine whether xNgn2
was also ubiquitylated on canonical and non-canonical sites in em-
bryos at neural plate stage 15 [19], when the endogenous protein is
most active. We investigated ubiquitylation of wild-type xNgn2, of
Ac2xNGNKO where N-terminal sequence of xNgn2 had been mu-
tated to one that will direct co-translational acetylation, prevent-
ing N-terminal ubiquitylation, and where all lysines have been
mutated to arginines [17], and of Ac2xNgn2KOCO where addition-
ally cysteine residues, potential sites of non-canonical ubiquityla-
tion, were also mutated to alanine.
Several hundred Xenopus eggs were fertilised in vitro then al-
lowed to develop until neurula stage 15 [19]. Cytoplasmic extracts
were prepared and incubated with in-vitro translated 35S-methio-
nine-radiolabelled xNgn2 protein (either xNgn2, Ac2xNgn2KO, or
Ac2xNgn2KOCO), proteasome inhibitor MG132, and His-tagged
ubiquitin. Ubiquitylation was allowed to occur for 90 min then
ubiquitylated proteins were isolated on Ni–NTA beads. After 8 M
urea washes to remove non-covalently bound proteins, proteins
were eluted into SDS–PAGE loading buffer either under hydroly-
sing, reducing conditions (Red/pH10: 1.3 mM b-ME, pH10), or
non-reducing, non-hydrolysing conditions (Non-red: no b-ME,
pH7.5). After SDS–PAGE separation, ubiquitylated conjugates of
the different xNgn2 mutants were compared by autoradiography
(Fig. 1A).
xNgn2 normally runs on SDS–PAGE at around 36 kDa. However,
each additional 7 kDa Ub moiety should result in slowed migration
on SDS–PAGE; multiple ubiquitylation events will produce a ladder
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of gel-retarded forms (e.g., Fig. 1A, lane 1). Wild-type xNgn2 shows
a prominent ladder of ubiquitylated forms running above the posi-
tion of unconjugated xNgn2 under Non-red conditions (Fig. 1A,
lane 2). Under reducing conditions, this ladder is still visible,
indicating that much ubiquitylation is occurring via stable peptide
and iso-peptide linkages. However, we now see the appearance of
an unconjugated xNgn2 band, indicating that some Ubs are bound
to xNgn2 via bonds that can be broken under these conditions
(Fig. 1A, lane 1; unconjugated xNgn2 marked with an arrow). Such
bonds would include thioester linkages between xNgn2 and Ub, as
has been observed in Xenopus egg extracts [17]. To confirm that, in
the absence of canonical ubiquitylation sites, ubiquitylation occurs
via labile linkages, we looked at ubiquitylation of Ac2xNgn2KO in
embryo extracts. Similar to our observations in eggs [17], despite
lacking canonical Ub sites, Ac2xNgn2KO is extensively ubiquitylat-
ed in Non-red conditions (Fig. 1A, lane 4). However, after incuba-
tion in Red/pH10 conditions, poly-ubiquitylated forms largely
collapse and the majority of the protein runs as the unconjugated
form (Fig. 1A, lane 3), indicating that, in the absence of canonical
ubiquitylation sites, extensive Ub conjugation can still occur via la-
bile linkages potentially to cysteine, serine or threonine residues.
To determine whether non-canonical ubiquitylation could still
occur in the absence of cysteines (as observed in egg cytoplasm
[17]), we investigated the behaviour of ubiquitylated Ac2xNgn2-
KOCO under Red/Ph10 and Non-red conditions. This form of xNgn2
can still be ubiquitylated, although we saw release of free
Ac2xNgn2KOCO protein from these weak linkages even in Non-
red conditions, possibly due to sample heating (Fig. 1A, lane 6).
However, considerably more free protein was liberated after Red/
Ph10 treatment (Fig. 1A, lane 5), further indicating ubiquitylation
via ester linkages to serines and/or threonines.
To examine whether non-canonical ubiquitylation could affect
the stability of xNgn2, we carried out degradation assays in cyto-
plasmic extract from neurula stageX. laevis embryos. In-vitro trans-
lated protein was incubated with extract at 21 "C and aliquots
were removed at increasing times into SDS–PAGE loading buffer.
After SDS–PAGE separation the level of xNgn2 protein at each
timepoint was quantified by autoradiography (Fig. 1B). xNgn2
exhibits a half-life of 42.8 ± 2.4 min whereas Ac2xNgn2KO is stabi-
lised, half-life 112.21 ± 7.29 min. Ac2xNgn2KOCO has a half-life
greater than the range of the timecourse. Therefore loss of non-
canonical sites of ubiquitylation can further stabilise xNgn2 in
the absence of canonical ubiquitylation sites.
Thus, xNgn2protein canbe extensively andmultiplyubiquitylat-
ed on both canonical and non-canonical sites in Xenopus embryos to
target xNgn2 for degradation. This was similar to observations in
Xenopus eggs, indicating that non-canonical ubiquitylation is not re-
stricted to egg cytoplasm.Nevertheless, it is possible that this highly
unusual non-canonical ubiquitylation of xNgn2 is a consequence of
specialised mechanisms present in Xenopus not found in mamma-
lian cells. As manipulating Ngn2 activity in mammalian stem and
progenitor cells has become a focus for groups keen to potentiate
generation of neurons for transplantation, it is important to fully
characterise mechanisms of post-translational control of xNgn2
protein. We wished to determine whether xNgn2 is also subject to
non-canonical ubiquitylation in mammalian cells and whether this
contributes to its rapid rate of destruction.
We have chosen to investigate ubiquitylation and degradation
of xNgn2, and mutants thereof, in mammalian P19 embryonal car-
cinoma cells, which are capable of differentiating into neurons in
response to retinoic acid or proneural protein expression [18].
These cells offer a cellular environment resembling many aspects
of differentiating neurons during development.
We have previously demonstrated that xNgn2 can be rapidly
degraded in P19 cells by the UPS system [16]. To determine
whether destruction was solely due to ubiquitylation on canonical
sites, i.e., lysines and the N-terminus, we conducted degradation
assays for xNgn2, xNgn2KO, Ac2xNgn2 and Ac2xNgn2KO. P19 cells,
transfected with plasmids encoding HA-tagged xNgn2 or deriva-
tives thereof, were incubated for approx. 24 h before cyclohexi-
Fig. 1. Non-canonical ubiquitylation targets xNgn2 for degradation. (A) IVT 35S
xNgn2, Ac2xNgn2KO, and Ac2xNgn2KOCO were incubated in neurula Xenopus
embryo extracts in the presence of His-ubiquitin (His-Ub) and MG132. Proteins
covalently linked to His-ubiquitin were purified by affinity chromatography with
Ni–NTA agarose under denaturing conditions. Reactions were either eluted using
pH 6.8 SDS–PAGE buffer, which should not promote the hydrolysis of thioester and
ester bonds (Non-red) or with pH 10 SDS–PAGE buffer containing 1.3 mM
b-mercaptoethanol to promote hydrolysis of thioester bonds (Red). Experiments
were then subjected to SDS–PAGE and quantitative phosphorimaging analysis. (B)
IVT samples were incubated in neurula Xenopus embryo extracts at 21 "C. Aliquots
of the reaction were added to SDS–PAGE loading buffer and separated by SDS–
PAGE. Protein levels at each timepoint were quantified by autoradiography and the
half-life of the protein calculated using first-order rate kinetics.
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mide addition preventing further protein synthesis. Samples were
then removed at intervals. Cell lysates were separated by SDS–
PAGE and subjected to Western blotting to detect HA-tagged pro-
teins (using tubulin as a loading control). The half-life of each sam-
ple was normalised to wild-type xNgn2 (Fig 2A).
xNgn2KOwas stabilised by 2.6-fold ±0.4 and Ac2xNgn2was sta-
bilised by 3.2-fold ±1.4 compared to the wild-type protein, respec-
tively. The mutant lacking all sites of canonical ubiquitylation,
Ac2xNgn2KO, showed considerably greater stability, 23.2-fold
±4.6 more stable that xNgn2. Degradation of xNgn2 in mammalian
cells is driven by ubiquitylation on both lysines and the N-terminus,
as in Xenopus egg extracts, indicating mechanistic conservation be-
tween the systems. However, we also saw that, even when all
canonical ubiquitylation sites weremutated, xNgn2 still underwent
slow proteolysis, raising the possibility that ubiquitylation on non-
canonical sites was also occurring. To investigate further, we looked
to seewhether degradation of Ac2xNgn2KO could be further slowed
by proteasome inhibition.
P19 cells were transfected with plasmids encoding HA-tagged
xNgn2 or Ac2xNgn2KO, incubated for approx. 24 h then cyclohex-
imide added with or without MG132 and samples removed for
Western blot analysis. As expected, addition of MG132 led to con-
siderable stabilisation of xNgn2 (Fig. 2B). We also saw that MG132
enhanced the stability of Ac2xNgn2KO, indicating that, in the
absence of canonical ubiquitylation sites, xNgn2 is subject to
non-canonical ubiquitylation. To confirm this, we undertook
immunoprecipitation experiments to demonstrate that Ac2xNgn2-
KO is still ubiquitylated.
Ac2xNgn2KO is still degraded by the proteasome, but proteins
have been identified which do not require prior ubiquitylation
for this to occur [22]. To demonstrate that Ac2xNgn2KO is, indeed,
ubiquitylated, we transfected P19 cells with HA-tagged xNgn2 or
Ac2xNgn2KO with or without FLAG-tagged Ub. After 24 h, we lysed
the cells and undertook immunoprecipitation of either FLAG-Ub or
HA-xNgn2 or Ac2xNgn2KO, as labelled (Fig. 3). After SDS–PAGE
separation, we probed the FLAG-Ub immunoprecipitates by Wes-
tern blotting to detect the HA epitope on xNgn2/Ac2xNgn2KO,
and probed the HA-xNgn2/Ac2xNgn2KO immunoprecipitates to
detect FLAG-Ub. All samples were expressing similar levels of
xNgn2/Ac2xNgn2KO (see loading control).
When HA-tagged xNgn2 or Ac2xNgn2KO were immunoprecipi-
tated and probed for presence of FLAG-Ub, high molecular weight
forms corresponding to poly-Ub xNgn2 were observed. When
FLAG-tagged Ub was immunoprecipitated, then subsequently
blotted for HA-xNgn2, we saw a prominent ladder of poly-ubiqui-
tylated forms of xNgn2 stretching up the gel. In contrast, Ub
Fig. 2. xNgn2 is stabilised by mutation of canonical sites of ubiquitylation in a proteasome-dependent manner in P19 cells. (A) P19 cells were transfected with triply C-
terminally HA-tagged xNgn2, xNgn2KO, Ac2xNgn2 or Ac2xNgn2KO. Cells were lysed at the timepoints indicated after cycloheximide addition to inhibit protein translation
and proteins detected by Western blot analysis using anti-HA antibody. Proteins were detected by chemiluminescence and quantified using ImageJ software. (B) Degradation
assays were carried out with xNgn2 or Ac2xNgn2KO in the presence or absence of the proteasome inhibitor MG132.
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immunoprecipitates containing Ac2xNgn2KO did not result in high
molecular weight Ub-Ac2xNgn2KO conjugates, a result that would
be expected if Ub chains had been released under reducing gel con-
ditions. Consistent with this, a prominent band of unconjugated
Ac2xNgn2KO was present. We noted that there was also a clear
band of unconjugated xNgn2 under these conditions, which would
suggest that a subset of xNgn2 is also conjugated to poly-Ub chains
via labile linkages. Thus, our evidence indicates that xNgn2 is ubiq-
uitylated on both canonical and non-canonical residues in both
Xenopus and mammalian cells. We then wished to determine
whether ubiquitylation on cysteines contributed to the rapid deg-
radation of xNgn2.
To determine the effect of cysteine ubiquitylation on the half-
life of xNgn2, we used a mutant form of xNgn2 where all 7 cysteine
residues were mutated to alanines (xNgn2CO). xNgn2CO is still lar-
gely structurally intact as it is still able to site-specifically bind to
DNA with its heterodimeric E protein partner [17]. xNgn2 and
xNgn2CO were transfected into P19 cells, and after approx. 24 h,
cycloheximide was added and cell samples removed at increasing
times. Extracted proteins were separated by SDS–PAGE and
Western blotted to detect xNgn2/xNgn2CO protein (Fig. 4).
We noted that even at the time of cycloheximide addition, t = 0,
xNgn2CO had accumulated to a higher level than the wild-type
protein, indicating that mutation of cysteines did stabilise xNgn2
in mammalian cells. This was confirmed when we quantitatively
analysed the amount of protein present at increasing times; we
saw that xNgn2CO was 3.5 ± 0.9 times more stable than xNgn2. Ta-
ken together our results demonstrate that xNgn2 lacking canonical
ubiquitylation sites can still be degraded by the UPS system and
that ubiquitylation occurs on cysteine residues. Moreover, in the
absence of cysteines, ubiquitylation on canonical sites is not suffi-
cient to drive the very rapid degradation of the wild-type protein,
demonstrating that non-canonical ubiquitylation contributes to ra-
pid destruction in mammalian cells as well as in Xenopus.
Discussion
Modification of proteins by ubiquitylation controls a multitude
of molecular systems, yet we are still learning new information
about the basic biochemistry of the process. Originally, ubiquityla-
tion was thought to occur exclusively on lysines, before ubiquity-
lation on the N-terminus of selected proteins was identified [6].
More recently, ubiquitylation on non-canonical sites has been
demonstrated in a handful of proteins [9,11,12].
Our recent work showed that cellular E3 ligases could target the
proneural transcription factor xNgn2 for degradation by ubiquity-
lation on the N-terminus, lysines or cysteines, resulting in a very
short protein half-life [17]. However, these biochemical studies
were conducted using extracts from Xenopus frog eggs at a devel-
opmental stage when xNgn2 would not normally be expressed.
Here, we set out to investigate whether xNgn2 undergoes this
highly unusual non-canonical ubiquitylation in both neurula
Xenopus embryos, when the protein would be active, and in mam-
malian P19 cells which are capable of differentiating into neurons.
We see that both N-terminal and lysine ubiquitylation contrib-
ute to degradation of xNgn2 in Xenopus embryos and P19 cells;
Fig. 3. Immunoprecipitation indicates Ac2xNgn2KO is still ubiquitylated. HA-tagged xNgn2 or HA-tagged Ac2xNgn2KO were transfected alone, or with FLAG-tagged
ubiquitin, into P19 cells. Cells were lysed and immunoprecipitation carried out to pull down either FLAG-associated proteins, using Protein-A Sepharose beads, or HA-
associated proteins using Protein-G Sepharose beads. Samples were subjected to Western blotting using a-HA or a-FLAG antibody.
Fig. 4. Mutation of cysteines alone stabilises xNgn2. P19 cells were transfected
with HA-tagged xNgn2 or xNgn2CO and treated with or without MG132. Cells were
lysed at the timepoints indicated after cycloheximide addition and analysed by
Western blot using a-HA antibody. Proteins were detected by chemiluminescence
and quantified using ImageJ software.
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mutation of these acceptor sites alone leads to a more than 10-fold
increase in half-life of the protein. However, these mutant xNgn2
constructs are still ubiquitylated and degraded by the proteasome
in both these systems, strengthening the possibility of ubiquityla-
tion on non-canonical sites targeting the protein for destruction.
Indeed, we see that mutation of cysteine residues alone in xNgn2
results in a 2-fold increase in xNgn2 half-life in P19 cells, strongly
indicating that ubiquitylation on cysteines contributes to rapid
degradation in mammalian cells. Moreover, when proteins are
ubiquitylated with His-Ub and pulled down with Nickel affinity re-
sin, free xNgn2 protein is released on treatment with reducing
agents in both P19 cells and neurula stage embryos, demonstrating
ubiquitylation via labile linkages.
Why would xNgn2 be ubiquitylated on so many sites? xNgn2 is
a highly unstable transcription factor whose activity is required to
oscillate to maintain ‘‘stem-ness” in neural progenitor cells of the
developing brain [13]. Such dynamic behaviour may require the
multiple sites of ubiquitylation that we observe. Most of the lysine
residues are found around and within the bHLH domain of xNgn2
required for binding to the heterodimeric partner protein xE12 and
to its cognate DNA sequence. Binding of xE12 to xNgn2 increases
protein half-life [16], and which could potentially occur through
slowing unfolding of the ubiquitylated protein by the proteasome.
Recent work has demonstrated that ubiquitylationmust occur near
a region of structural instability to allow proteasomal unfolding
[23]. Cysteine residues, in contrast to lysines, are found fairly
evenly distributed in the N- and C-terminae of xNgn2, and so
may aid in ubiquitylation-mediated unfolding of the transcription
factor when it is bound to E proteins and DNA.
Non-canonical ubiquitylation is gradually being observed in
more and more proteins [12,24] and offers an alternative or com-
plimentary method for targeting proteins for ubiquitin-mediated
processes. The labile nature of the covalent attachment of ubiquitin
chains, and the reducing conditions often used routinely for bio-
chemical analysis, makes non-canonical ubiquitylation more diffi-
cult to identify. However, it is becoming increasing probable that
these modifications will play a widespread role in dynamic protein
control.
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Regulation of cell fate determination by
Skp1-Cullin1-F-box (SCF) E3 ubiquitin ligases
CHRISTOPHER J. HINDLEY1, GARY S. MCDOWELL1, HELEN WISE1,2 and ANNA PHILPOTT*
Department of Oncology, University of Cambridge, Hutchison/Medical Research Council (MRC) Research
Centre, Addenbrooke’s Hospital, Cambridge, U.K.
ABSTRACT  The developing embryo is patterned by a complex set of signals and interactions
resulting in changes in cell division, cell fate determination and differentiation. An increasing body
of evidence points to the role of the ubiquitin proteasome system (UPS) and ubiquitin-mediated
protein degradation as a major mechanism of protein regulation, crucial for control of develop-
mental processes. The specific and irreversible signal generated by protein degradation can
function as an integrator of cell signaling events, coupled with other post-translational protein
modifications, but also as a master switch for differentiation in its own right. The UPS also displays
more subtle mechanisms of regulating signaling than decreasing protein levels, such as pro-
teolytic processing and altering subcellular localization. In particular, the SCF E3 ligase family
plays pivotal roles in regulating diverse developmental events in varied species. This review will
focus on the role played by SCF E3 ligases in cell fate determination and differentiation.
KEY WORDS: differentiation, SCF, signaling, ubiquitylation, UPS
Introduction
During embryogenesis, individual cells must respond to signal-
ing within the developing embryo and elicit the appropriate re-
sponse. Such responses involve changes in the level and/or
activity of proteins and must be dynamic. Within the field of
developmental biology, most emphasis has traditionally been
placed on regulation of protein levels by control of transcription.
However, it is becoming clear that many proteins are subject to
regulated degradation and that this plays a critical regulatory role
during embryogenesis. Regulated protein degradation has three
key features: irreversibility, responsiveness and selectivity.
Regulated proteolysis of up to 90% of short-lived proteins is
achieved by the ubiquitin proteasome system (UPS) (Ciechanover
et al., 1984). Ubiquitin-mediated degradation is initiated by the
covalent attachment of ubiquitin (Ub), a 76-amino acid protein,
onto a substrate (Ciechanover et al., 1980a; Ciechanover et al.,
1980b; Hershko et al., 1980; Wilkinson et al., 1980). Subsequent
rounds of ubiquitylation attach additional Ubs to the first to build
up a chain; chains of at least 4 Ubs then facilitate the recognition
and destruction of the substrate by the 26S proteasome (reviewed
in Pickart and Cohen, 2004; Wolf and Hilt, 2004).
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Abbreviations used in this paper: APC/C, anaphase promoting complex/
cyclosome; Arm, armadillo; bHLH, basic helix-loop-helix; -TRCP, -
transducin repeat containing protein; Ci, Cubitus interruptus; CKI, cyclin
dependent kinase inhibitor; Dlg, discs large; dpp, decapentaplegic; Fbw, F-
box protein containing WD40 repeats; Fbx, F-box protein; GCM, glial cells
missing; GSK3, glycogen synthase kinase 3; HECT, homologous to E6-
associated protein C-terminus; Hh, hedgehog; IKK, IB kinase; MAFbx,
muscle atrophy F-box; NT, neural -tubulin; NC, neural crest; NF-B,
nuclear factor-B; PKA, protein kinase A; Ppa, partner of paired; Ptc,
patched; REST, RE1-silencing transcription factor; RING, really interesting
new gene; SCF, Skp1-cullin1-F-box complex; Smo, smoothened; Ub, ubiquitin;
UPS, ubiquitin proteasome system.
 The addition of Ub onto substrate proteins is catalysed by a
multi-enzyme cascade (Fig. 1). Firstly, Ub is activated using
energy from ATP hydrolysis, resulting in the fusion of AMP to the
C-terminal carboxyl group. The active site cysteine of an E1 (Ub
activating) enzyme can then form a thioester bond with activated
Ub. Ub is then passed to the active site cysteine of an E2 (Ub
conjugating) enzyme. The last enzyme in the cascade, an E3 (Ub
ligase), facilitates the attachment of Ub onto the substrate protein
from the E2 enzyme (Hershko et al., 1983; Pickart and Rose,
1985). Successive Ub moieties can be added to the first by a
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sequential enzyme cascade. Alternatively, entire polyUb chains
may be attached to the substrate protein by the action of an E4
enzyme, such as p300, which has been demonstrated to add
chains of polyUb to p53 at sites previously monoubiquitylated by
Mdm2 (Grossman et al., 2003; reviewed in Hoppe, 2005). In
humans, only 2 E1 enzymes and approximately 100 E2 enzymes
have been characterised. By contrast, it is estimated that there
may be as many as 1000 E3 ligases (reviewed in Hicke et al.,
2005) further divided into 3 classes: Homologous to E6-Associ-
ated Protein C-Terminus (HECT), Really Interesting New Gene
(RING) and U-box.
Probably the most diverse family is that of the RING E3 ligases;
there are almost 400 proteins with RING domains in the human
genome, compared to around 38 with HECT domains (Semple,
2003). RING E3 ligases are characterised by the presence of a
RING motif (consensus CX2CX9-39CX1-3HX2-3[C/H]X2CX4-48CX2C).
Based on bioinformatic data, RING E3 ligases can be further
divided into single subunit and modular classes. Single subunit
RING E3 ligases bind to both E2 enzymes and substrates. In the
case of modular RING E3 ligases, the RING protein functions as
part of a multi protein complex and substrates are recruited by a
separate subunit (reviewed in Deshaies and Joazeiro, 2009).
Skp2 is the F-box component. The SMART database (http://
smart.embl-heidelberg.de/) gives an estimated 56 F-box proteins
in humans, 77 in mice and 30-50 in Xenopus laevis, compared to
the 600-700 found in the large gene networks of Arabidopsis and
rice (Gagne et al., 2002; Jain et al., 2007; Kuroda et al., 2002). In
the crystal structure of SCFSkp2 (Schulman et al., 2000; Zheng et
al., 2002), which is, to date, the only structure of a complete SCF
complex described, Cullin1 forms a rigid, bi-lobed structure which
acts as a ‘molecular scaffold’ on which to assemble the SCF
complex. The C-terminal globular domain recruits Roc1, which in
turn recruits the E2 enzyme. The Cullin1 N-terminal domain
recruits Skp1, which then binds to the F-box protein substrate
recognition subunit via interactions between the C-terminus of
Skp1 and the F-box domain.
Structural studies are also providing insight into further mecha-
nisms of SCF activity. Many F-box proteins interact with their
cognate substrates only after the substrates have been post-
translationally modified, adding an extra level of regulation. Al-
though the most widely reported prior modification is phosphory-
lation, substrates have also been reported to require acetylation,
glycosylation or nitration (Guinez et al., 2008; Hwang et al., 2010).
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Fig.1. Schematic of Ub mediated protein degra-
dation. Ub is first covalently linked to an E1 (Ub-
activating) enzyme using energy from ATP hydroly-
sis before being shuttled to an E2 (Ub-conjugating)
enzyme. Ub is then either conjugated directly to a
HECT E3 ligase before transfer to the substrate or
the E2-Ub is recruited via a RING E3 ligase into a
complex containing the substrate. Note that all Ub
conjugation from E1 to E3 is via thioester linkage to
a cysteine sidechain sulfur. Further attachment of
Ub to internal lysines on the original substrate Ub is
achieved either by repetition of the above scheme
or the action of an E4 enzyme, which transfers
polyUb chains to monoubiquitylated substrate
ubiquitin. A chain of four or more K48-linked polyUb
targets the substrate to the 26S proteasome where
it is unfolded and degraded in an ATP-dependent
manner into small peptides with concurrent
deubiquitylation to recycle Ub.
Examples include the Anaphase Promoting
Complex/Cyclosome (APC/C) and Cullin-
based RING E3 ligases. Cullin-based E3
ligases (reviewed in Petroski and Deshaies,
2005) use the RING protein Roc1 (also known
as Rbx1 and Hrt1) to recruit E2 enzymes
(Chen et al., 2000; Furukawa et al., 2002;
Ohta et al., 1999).
This review will concentrate on the role in
development of the most well characterised
sub-group of Cullin-based RING E3 ligases,
the Skp1-Cullin1-F-box (SCF) E3 ligase com-
plexes. Within the SCF complex, Cullin1 binds
to Roc1, Skp1 and a variable F-box protein
(Lyapina et al., 1998; Wu et al., 2000), and it
is this latter component that confers the SCF
complex designation, e.g. SCFSkp2, where
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is triggered only following phosphorylation at multiple sites (Ye et
al., 2004). Binding partners increase or inhibit the activity of SCF
complexes and in particular binding or covalent modification of
the C-terminal winged helix bundle domain of the Cullin subunit
plays an important role in regulating SCF activity (Duda et al.,
2008; Liu et al., 2002). Versatility in substrate specificity for the
SCF E3 ligases is provided by the recognition subunit F-box
proteins, which bind distinct substrates. Structural analysis of
SCF complexes and their cognate substrates is beginning to
reveal a wide range of mechanisms for substrate recognition. For
example, the atypical F-box protein Fbx4 contains a GTPase
domain which is crucial for the binding of a globular domain of its
TRF1 substrate (Zeng et al., 2010). By contrast, the Arabidopsis
F-box protein TIR1 requires only the presence of the plant
hormone auxin in order to bind to its cognate substrates, the Aux/
IAA proteins (Kepinski and Leyser, 2004). Structural studies have
revealed that TIR1 is itself the sensor of auxin and that the binding
of auxin to TIR1 is necessary to complete the docking site for Aux/
IAA proteins (Tan et al., 2007). Thus, although the F-box motif
provides a consistent recognition motif for binding to the SCF
scaffold, the mechanism of substrate recognition by the F-box
protein varies.
A number of F-box proteins have exhibited roles in develop-
ment through regulation of substrate levels (see Table 1). This
review will focus on the role that F-box proteins play in cell fate
determination and signaling during embryogenesis and organo-
genesis. Although many F-box proteins are also involved in the
degradation of cell cycle components (Skaar et al., 2009a; Skaar
et al., 2009b), this aspect of F-box protein activity has been
previously described in detail (reviewed in Ang and Harper, 2004;
Skaar and Pagano, 2009) and this role in development will not be
considered here.
F-box proteins and signaling: patterning in the early
embryo
Several F-box proteins have key roles in major signaling
pathways involved in patterning of the embryo, for instance -
Transducin Repeat Containing Protein (-TRCP), which plays
pleiotropic roles in regulation of cell signaling. Indeed, -TRCP is
one of the best studied of this class of E3 ubiquitin ligases
because of its multiple important substrates. Xenopus  has 2 F-
box -TRCP genes, -TRCP1 and -TRCP2 (also known as
FBXW1 and FBXW11 respectively). 4 transcripts of -TRCP are
expressed in Xenopus, which differ in the presence or absence of
amino acid sequences at the N- or C-termini (Ballarino et al.,
2004; Ballarino et al., 2002). Similarly, 2 distinct genes exist in
humans with multiple isoforms expressed (Fuchs et al., 1999;
Suzuki et al., 1999). Recent evidence suggests that different
isoforms of -TRCP play different roles in development, with
differing tissue-specific expression in mouse, while assays in
Xenopus demonstrate differential isoform activity (Seo et al.,
2009).
-TRCP recognises substrates via binding to seven WD40
repeats present in its C-terminus and phosphorylation of sub-
strates is a prerequisite for binding (for example, Winston et al.,
1999). Most -TRCP substrates identified to date have a specific
phosphodegron (DpSGXpS, where  is a hydrophobic amino
acid, and p denotes phosphorylation), a motif which, when phos-
phorylated, allows targeting of the substrate for degradation
(reviewed in Ang and Wade Harper, 2005; Jin et al., 2003;
Winston et al., 1999). In addition, lysines that are 9-13 amino
acids N-terminal to this phosphodegron are preferentially
ubiquitylated. This is due to structural constraints associated with
optimal presentation of the substrate to the E2 enzyme (Wu et al.,
Tissue/cell type F-box component Substrate Function Ref 
Extraembryonic Fbw2 GCM1 GCM1 required for development of extraembryonic tissue in mammals Schreiber et al., 2000 
Early embryo β-TRCP β-Catenin Regulation of β-Catenin stability and transcriptional activity Latres et al., 1999; Kitagawa et al., 1999; 
Hart et al., 1999 
  Cactus Regulation of Dorsal transcriptional activity and dorsal-ventral patterning in Drosophila Belvin et al., 1995; 
Maniatis, 1999 
  Ci Regulation of Ci transcriptional activity Jia et al., 2005; 
Wang and Li, 2006 
 Fbw7 Notch  Phosphorylation-dependent degradation of Notch-ICD and regulation of transcription  Gupta-Rossi et al., 2001; 
Wu et al., 2001 
Epithelia β-TRCP hDLG Dlg inhibits epithelial differentiation in Drosophila, interaction with β-TRCP seen only with hDLG so 
far 
Mantovani and Banks, 2003;  
Woods et al., 1996 
  
IκB NF-κB signalling implicated in proliferation and differentiation of basal layer of epidermis Hu et al., 1999,  
Takeda et al., 1999 
  
TAp63γ Possible role in epidermal differentiation via regulation of transcriptional activity Gallegos et al., 2008 
Haematopoietic Fbw7  c-Myc Abnormal thymocyte development due to aberrant c-myc regulation; regulates haematopoietic stem 
cell gene expression signature 
Onoyama et al., 2007, 
Reavie et al., 2010  
  Notch  Negative regulation of Notch signalling in haematopoietic, vascular and cardiac development in mice  Tetzlaff et al., 2004 
Muscle MAFbx MyoD Promotes MyoD polyubiquitylation and degradation in vitro and in vivo Lagirand-Cantaloube et al., 2009,  
Tintignac et al., 2005 
  myogenin Promotes myogenin polyubiquitylation and degradation Jogo et al., 2009 
Neural β-TRCP REST Degradation of transcriptional repressor, promoting neuronal differentiation Chong et al., 1995, 
Westbrook et al., 2008 
 Fbw2 gcm Degradation of gcm allows cell cycle exit and differentiation of glial progenitors in Drosophila Ho et al., 2009,  
Hosoya et al., 1995 
 Skp2  Xic1 Regulation of primary neuronal differentiation in Xenopus Boix-Perales et al., 2007 
Neural crest Ppa Slug Regulation of Slug stability during neural crest development Vernon et al., 2006 
 Fbw7 Unknown Fbw7 necessary for development of neural crest Almeida et al., 2010 
TABLE 1
SUMMARY OF F BOX PROTEINS INVOLVED IN CELL FATE DETERMINATION
Known SCF substrates per tissue and cell type for each F-box protein are summarized along with their roles.
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2003). The phosphodegron is a highly effi-
cient binding motif that can act as a transfer-
able destruction signal (Wulczyn et al., 1998).
A role for -TRCP was first identified from
studies with the Drosophila orthologue, Slimb
(Jiang and Struhl, 1998). Loss of function of
Slimb resulted in the accumulation of the
transcription factors Armadillo/-catenin (Arm)
and Cubitus interruptus (Ci), components of
the Wnt and Hedgehog (Hh) signaling path-
ways, respectively. It was proposed that Slimb
negatively regulates these pathways through
proteolysis of Arm and Ci. Since then, SCF-
TRCP complexes have been demonstrated to
degrade a large number of substrates, many
of which have roles during development (re-
viewed in Fuchs et al., 2004).
Wnt signaling
 The transcription factor -catenin medi-
ates signaling via the canonical Wnt pathway,
which regulates multiple developmental pro-
cesses, for instance dorsal-ventral axis for-
mation in Xenopus. -catenin has an asym-
metric localisation in the early Xenopus em-
bryo, concentrated on the future dorsal side of
the embryo, allowing the expression of dor-
sal-specific genes. Elevations in dorsal -
catenin levels are attributed to activation of
Wnt signaling (Larabell et al., 1997); -catenin
is degraded by Ub-mediated proteolysis, and
removal of glycogen synthase kinase 3
GSK3 phosphorylation sites or activation
of Wnt signaling stabilises the protein (Aberle
et al., 1997). This has led to a model whereby,
in the absence of Wnt signaling, -catenin is
degraded in a manner dependent upon phos-
phorylation at GSK3 sites (Fig. 2), but in
response to Wnt signaling, -catenin is
stabilised and can promote gene expression.
-TRCP has been characterised as a nega-
tive regulator of Wnt signaling; overexpression
of -TRCP reduces formation of Wnt8-in-
duced secondary axes in Xenopus, and inhi-
bition of SCF-TRCP using a dominant negative
F-box deleted (F-box) mutant results in for-
mation of secondary axes (Lagna et al., 1999;
inhibition of SCF-TRCP mediated degradation. GSK3 targets
human Snail for phosphorylation at serines between amino acids
92-120 and this is required for nuclear export, -TRCP binding
and proteasomal degradation (Yook et al., 2005; Zhou et al.,
2004).
Hh signaling
The Hh signaling pathway is involved in a range of patterning
processes during development, many of which have been identi-
fied using Drosophila as a model system (reviewed in Ingham and
McMahon, 2001; Ingham and Placzek, 2006). In the absence of










































Fig. 2. Regulation of Wnt signaling by Ub mediated protein degradation. The Wnt pathway
is shown in the presence and absence of Wnt, leading to activation and inhibition, respectively,
of -catenin transcriptional activity. In the absence of Wnt, -catenin is phosphorylated by GSK3
and targeted for degradation by SCF-TRCP. When Wnt is present, binding by the Fzd receptor
leads to the complex containing GSK3 being bound at the membrane and unavailable to
phosphorylate -catenin. -catenin is therefore not degraded and enters the nucleus to form a
transcriptionally active complex with TCF, displacing the repressor, Groucho. APC, adenomatous
polyposis coli; Fzd, frizzled; GSK3, glycogen synthase kinase 3; LRP, low density lipoprotein
receptor related protein; TCF, T cell factor. P is used to denote phosphorylation.
Marikawa and Elinson, 1998). The latter effect is inhibited by co-
overexpression of mediators of the Wnt pathway (Marikawa and
Elinson, 1998). Subsequently, SCF-TRCP was demonstrated to
be the E3 ligase for -catenin (Fuchs et al., 1999; Hart et al., 1999;
Latres et al., 1999).
A distinct role has been identified for SCF -TRCP in neural crest
formation. Neural crest (NC) development depends on the activity
of the Snail family of transcription factors, which trigger the
epithelial to mesenchymal transition, via repression of E-cadherin
that results in the migration of NC cells from the neural tube
throughout the embryo. Work in several cell lines has demon-
strated that Wnt signaling leads to stabilisation of Snail through
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inhibited by a multipass transmembrane receptor for Hh, Patched
(Ptc). Binding of secreted Hh proteins to Ptc alleviates inhibition
of Smo and results in the activation of signaling within the cell. The
transcription factor Ci (the Gli family in mammals) is the major
mediator of Hh signaling in cells. In the absence of Hh signaling,
Ci is a transcriptional repressor for genes such as Decapentaplegic
(dpp). However, when Hh signaling is activated, dpp expression
is de-repressed. The duality of Ci activity is achieved by pro-
teolytic processing; full length Ci (Ci155) is a transcriptional
activator and a C-terminally truncated form (Ci75) is a repressor.
It appears that processing of Ci to repressor forms is mediated by
the SCFSlimb complex, the Drosophila homologue of SCF-TRCP.
Recruitment of SCFSlimb to Ci requires phosphorylation of Ci
protein at multiple residues in the C-terminus by Protein Kinase A
(PKA) and GSK3. This facilitates further phosphorylation by
Casein Kinase I A and E, followed by SCFSlimb recruitment (Jia et
al., 2005; Smelkinson et al., 2007). SCFSlimb-mediated process-
ing of Ci is unusual, as ubiquitylation triggers partial proteolysis
rather than full destruction (Fig. 3). SCFSlimb activity must be
inhibited following Hh pathway activation; this allows accumula-
1986). It is a member of the Rel family of transcription factors, of
which there are three genes in Drosophila: Dorsal, Dif and Relish
(Dushay et al., 1996; Ip et al., 1993; Steward, 1987). Also
important in mounting an effective immune response, the devel-
opmental role played by NF-B was elucidated through genetic
analysis of signaling by its Drosophila homologue, Dorsal (re-
viewed in Karin and Ben-Neriah, 2000). Ablation of Dorsal activity
resulted in embryos lacking ventral structures, which require
nuclear localisation of Dorsal at the ventral side of the embryo.
Dorsal is usually bound in the cytoplasm by its inhibitor, Cactus,
a homologue of mammalian IB (Geisler et al., 1992), such that
its nuclear localisation signal is obscured and entry to the nucleus
does not occur (Henkel et al., 1992; Wu and Anderson, 1998).
Ventral activation of the IL-1 receptor homologue, Toll (Hashimoto
et al., 1988), leads to phosphorylation and degradation of Cactus,
allowing Dorsal to dimerise and enter the nucleus as an active
complex (Belvin et al., 1995).
The SCF complex responsible for targeting IB for degradation
is, once again, SCF-TRCP, which ubiquitylates IB at lysines 21
and 22 (Maniatis, 1999) after modification of IB by phosphoryla-
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Fig. 3. Regulation of Hh signaling by Ub medi-
ated protein processing. The Hh pathway is
shown in the presence and absence of Hh, leading
to activation and inhibition, respectively, of Ci
transcriptional activity. In the absence of Hh, Ci is
phosphorylated by PKA, active in the presence of
inhibited Smo, and polyubiquitylated by SCF-
TRCP. This targets Ci for partial proteolysis by the
26S proteasome, leading to the formation of a
transcriptional repressor form. When Hh is present,
the binding of Hh to Ptc alleviates repression of
Smo and inhibits activation of PKA and phospho-
rylation of Ci. Ci therefore enters the nucleus in a
transcriptionally active form that has not been
proteolysed. Note the similarities between the
Wnt and Hh pathways: signaling at the external
surface of the membrane inhibits intracellular
signaling and phosphorylation of a transcription
factor, which in turn inhibits targeting by SCF-TRCP
tion of the Ci activator form (Ci155) rather
than its repressor form (Ci75). The situation
in mammals is more complex. There are 3
Gli proteins, homologues of Ci, Gli1, Gli2
and Gli3. Mouse Gli3 is efficiently processed
to a repressive form (Pan et al., 2006), most
likely by SCF-TRCP (Wang and Li, 2006),
whilst Gli2 is important for transcriptional
activation. In mouse, Gli2 is inefficiently pro-
cessed to the repressive form and instead
can be degraded fully by the SCF-TRCP com-
plex (Bhatia et al., 2006; Pan et al., 2006).
NF-B signaling
Nuclear factor-B (NF-B) was first iden-
tified as a transcription factor involved in
expression of the immunoglobulin  light
chain gene in B cells (Sen and Baltimore,
to the 26S proteasome. Ci, Cubitus interruptus (Act and Rep are used to denote activator and repressor forms, respectively); dpp, decapentaplegic;
Hh, Hedgehog; PKA, protein kinase A; Ptc, Patched; Smo, Smoothened. P is used to denote phosphorylation.
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tion (Alkalay et al., 1995). Inhibition of the 26S proteasome also
inhibits NF-B signaling, suggesting that the post-translational
modifications that occur to IB are insufficient to cause dissocia-
tion from NF-B (Lin et al., 1995). Intriguingly, a role for NF-B
signaling in dorsal-ventral patterning in vertebrates has not been
established and NF-B1-null mice do not display any gross
developmental abnormalities (reviewed in Attar et al., 1997).
However, NF-B signaling does seem to play a role in the
formation of the epidermis, as knockout of a kinase responsible
for phosphorylation of IB, IB kinase  (IKK), leads to severe
deformity and death of neonates 4 hours post-partum due to
thickening of the epidermis (see below).
The examples given above highlight several common features
of signaling regulated by SCF-TRCP. Most notably, they illustrate
how the UPS can produce a rapid response to signaling events.
For instance, in the absence of Wnt signaling, -catenin is
degraded by SCF-TRCP, while activation of Wnt signaling rapidly
stabilises the protein through inhibition of GSK3. This allows a
much faster response than if -catenin needed to be synthesised
de novo. Similarly, the response allowed by the switching of Ci
from a repressor to an activator form, following inhibition of
SCFSlimb by Hh signaling, is more rapid than that allowed by
changes in expression of repressor and activator genes. It is also
noteworthy that, in all these cases, signaling begins with kinases
and, for instance, targeting of the substrate to SCF-TRCP is
mediated by phosphorylation of a phosphodegron motif. Integra-
tion of the UPS and phosphorylation cascades allows a fine-
tuning of the system by combining reversible and irreversible
aspects of regulation.
-TRCP and epidermal development
The epidermis consists of a stratified epithelium that is made
up of keratinocytes. Mitotically active keratinocytes reside in the
inner basal layer and continuously renew the surface of the
epidermis by detaching from the basement membrane and mi-
grating to the outer, terminally differentiated, layer. The transcrip-
tion factor p63, a member of the p53 family, is crucial for the
differentiation of keratinocytes and p63-null mice lack epidermis,
epidermal structures and squamous epithelia (Mills et al., 1999;
Yang et al., 1999). The gross manifestation of the lack of epider-
mis is the truncation of the limbs and severe craniofacial abnor-
malities.
There are 6 isoforms of p63 resulting from differential promoter
usage, producing the full N-terminal TAp63 and the N-terminally
truncated Np63, and alternative splicing at the 3’ end of the
transcripts, to produce the ,  and  isoforms of both TAp63 and
Np63. Both TAp63 and Np63 are transcriptionally active,
although only TAp63 contains the transactivation domain (re-
viewed in Candi et al., 2008). In mature epidermis, Np63
appears to be the major isoform expressed in proliferating
keratinocytes in the basal layer, but not present in suprabasal
layers, although several isoforms are claimed to be required for
normal stratification in the embryo (Gu et al., 2006; Koster and
Roop, 2004). It has been reported that there is an interaction
between endogenous SCF-TRCP and TAp63 in a human
keratinocyte cell line, HaCaT (Gallegos et al., 2008). Unexpect-
edly, the interaction with SCF-TRCP increases the half life of p63
and ubiquitylation of TAp63 appears to increase its transcrip-
tional activity by around 50%, as assessed by RT-PCR. Although
it is likely that SCF-TRCP has a role in epidermal development in
vivo there are, as yet, no data to confirm this.
In contrast to its role in promoting the stability and activity of
p63, SCF-TRCP also interacts with hDLG, the human homologue
of Drosophila discs large (Dlg). Mutations in Dlg result in invasive
growth of epithelial cells in Drosophila (Woods et al., 1996) and
hDLG is recruited to the plasma membrane by E-cadherin cell-cell
adhesion, where it organises junction structures and the actin
cytoskeleton (Ide et al., 1999; Reuver and Garner, 1998). Interac-
tion with SCF-TRCP promotes the ubiquitylation and degradation
of hDLG (Mantovani and Banks, 2003). The interaction appears
to be promoted by phosphorylation of the SH3 domain of hDLG
(Mantovani et al., 2001), although the physiological relevance of
this interaction remains unclear.
As well as the central role played by p63 in epidermal formation
and stratification, it appears that NF-B signaling may also play a
role in the differentiation of epidermal cells. The inhibitory binding
partner of NF-B, IB, is targeted for degradation following
phosphorylation by IKK, (reviewed in Karin and Ben-Neriah,
2000). The IKK-null mouse appears to phenocopy the p63-null
mouse, as at a superficial level the neonates lack limbs and show
aberrant craniofacial development (Hu et al., 1999; Takeda et al.,
1999). Closer inspection of the IKK mutants shows that skeletal
organisation is approximately wild type, but the epidermis is 5-  to
10-fold thicker and so limbs cannot emerge out of the thickened
skin. The epidermis is composed of a single layer and it would
appear that the loss of NF-B signaling leads to gross
overproliferation of the basal layer.
 Intriguingly, in Drosophila one of the target genes of Dorsal is
twist, ablation of which is associated with craniofacial abnormali-
ties (Howard et al., 1997). Further, IKK is a direct and indirect
target of TAp63, both by direct binding to a p53-like consensus
sequence on the IKK promoter and by upregulation of the
transactivators Ets-1 and GATA-3 (Candi et al., 2006; Gu et al.,
2004; Sil et al., 2004). IKK interacts with Np63 and promotes
its Ub mediated degradation (Chatterjee et al., 2010), suggesting
that NF-B and p63 share multiple components which regulate
their activities, the most prominent being the SCF-TRCP E3 ligase.
However, the exact level of crosstalk between these two tran-
scription factors remains to be firmly established.
Other developmental signaling pathways
SCF-TRCP is not the only SCF complex to play a role in major
signaling pathways. Mammalian FBW7 was initially identified as
an F-box protein in a yeast screen for effectors of the cell cycle and
termed cdc4 (Nurse et al., 1976). The Caenorhabditis elegans
homologue, SEL-10, was found through mutational analysis to be
responsible for the degradation of the Notch intracellular domain,
the effector of Notch signaling, and thus termination of the Notch
signal (Gupta-Rossi et al., 2001; Wu et al., 2001). In C. elegans,
mutation of SEL-10 resulted in aberrant vulval development, a
process dependent upon Notch signaling (Hubbard et al., 1997).
In mice, knockout of FBW7 results in embryonic lethality at E10.5
through a combination of aberrant haematopoietic and vascular
development and heart maturation defects (Tetzlaff et al., 2004).
Defects in neural tube closure and development of all brain
regions were also observed at E9.5. Intriguingly FBW7+/- mice
appear grossly phenotypically normal up to 1 year of age and,
despite reports of mutation of FBW7  in T-ALL cell lines and
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patient samples (O’Neil et al., 2007), did not display an increased
incidence of tumorigenesis (Tetzlaff et al., 2004).
 However, a role for FBW7 as a tumour suppressor has been
observed in the absence of p53 activity (Mao et al., 2004). Most
recently, conditional inactivation of FBW7 in murine T cells was
found to increase the number of double-positive thymocytes but
not single-positive thymocytes, due to increased apoptosis of
double-positive thymocytes (Onoyama et al., 2007). This is sug-
gestive of a developmental block in thymocyte maturation and is
supported by an increased incidence of thymic lymphoma in Lck-
Cre/FBW7F/F mice resulting from clonal expansion of progenitors
bearing an immature, double-positive phenotype. These abnor-
malities in thymocyte development were also observed in CD4-
Cre/FBW7 F/ F/RBP-JF/ F mice but not in CD4-Cre/FBW7F/ F/c-
MycF/ F mice, leading the authors to conclude that abnormal
thymocyte development arises due to disregulation of c-Myc and
not Notch signaling (Onoyama et al., 2007). More recently, FBW7
has been found to play a more general role in haematopoiesis, as
regulation of the level of c-Myc was found to be sufficient to direct
the gene expression signature of haematopoietic stem cells.
Intriguingly, adult and embryonic haematopoietic stem cells dis-
played different responses to c-Myc levels at the level of gene
expression (Reavie et al., 2010).
Skp2, -TRCP, FBW2 and neural differentiation
SCFSkp2 is an SCF complex containing the leucine rich repeat
F-box protein Skp2 (also known as FBXL1). SCFSkp2 has been
shown to ubiquitinate a number of cell cycle substrates, including
c-Myc (Kim et al., 2003; von der Lehr et al., 2003), Cyclin E
(Nakayama et al., 2000), the cyclin dependent kinase inhibitors
(CKI) p27Kip1 (Carrano et al., 1999), p57Kip2 (Kamura et al., 2003)
and the Xenopus CKI Xic1 (Lin et al., 2006), and has been
implicated in development of many cancers (Bashir et al., 2004;
Kitagawa et al., 2008; Signoretti et al., 2002). However, in addition
to a central role in proteolysis of cell cycle regulators, SCFSkp2 may
have additional functions in differentiation and development.
Recent work has highlighted a role for Skp2 during neural
development in Xenopus. Primary neurogenesis in this species
results in differentiation of neurons that mediate the early move-
ments of the embryo. This process is driven by a cascade of
proneural basic Helix-Loop-Helix (bHLH) transcription factors,
resulting in the expression of markers of terminal neuronal differ-
entiation, such as neural -tubulin (NT) (reviewed in Lee, 1997).
Depletion of Skp2 protein using translation-blocking anti-sense
morpholinos promotes primary neurogenesis, as assessed by
expression of NT, by a mechanism independent of changes in
the cell cycle. Conversely, overexpression of Skp2 inhibits forma-
tion of primary neurons and this inhibition occurs at an early point
in the bHLH cascade (Boix-Perales et al., 2007). Skp2-mediated
inhibition of this process is likely to occur via ubiquitylation of
substrates by the SCFSkp2 complex, as overexpression of a F-
box form of Skp2, which can no longer bind to Skp1 and therefore
the rest of the SCF complex, has no effect on formation of primary
neurons (Boix-Perales et al., 2007). As the CKI Xic1 is required for
differentiation of primary neurons in Xenopus (Vernon et al.,
2003), degradation of Xic1 in neural precursors may be the major
mechanism by which SCFSkp2 regulates this process. It is interest-
ing to note in this regard that the CKI p57Kip2 has been reported
to associate with several proteins involved in differentiation, such
as MyoD (reviewed in Besson et al., 2008; Reynaud et al., 2000).
However, unlike the degradation of the CKI p27Kip1 by SCFSkp2 in
mammals, Xic1 degradation in Xenopus by SCFSkp2 does not
require prior phosphorylation of its CKI target (Lin et al., 2006).
The stability of Skp2 itself is regulated by the UPS in mammals,
and the E3 ligase responsible is the APC/C coupled to the
substrate recognition subunit, Cdh1 (Bashir et al., 2004; Wei et
al., 2004). Degradation of Skp2 by APC/CCdh1 is also important for
myogenesis, as depletion of Cdh1 by siRNA in the mouse skeletal
muscle cell line, C2C12, reduces cellular elongation and myo-
genic fusion (Li et al., 2007). It was found that the attachment of
Ub to and degradation of Skp2 was greatly reduced in Cdh1-
depleted cells when compared to control C2C12 cells. The
authors speculated that the increase in Skp2 levels in Cdh1-
depleted cells would lead to reduced levels of p21 and p27, cell
cycle regulators which are crucial for muscle differentiation (Vernon
and Philpott, 2003; Zhang et al., 1999). However, it was also
suggested that the myogenic transcription factor myf5 is a target
for APC/CCdh1 (Li et al., 2007).
Although a key determinant in neural differentiation, SCFSkp2 is
not the only E3 ligase to have been implicated in this process.
Recently it has been shown that the master repressor of neuronal
gene expression, RE1 silencing transcription factor (REST), is a
substrate for SCF-TRCP-mediated degradation (Chong et al.,
1995; Schoenherr and Anderson, 1995; Westbrook et al., 2008).
However, the functional relevance of this interaction to neural
development is not clear, as the in vivo data presented are mostly
obtained from epithelial cells or cell lines of non-neural origin.
Nevertheless, data from neural stem and progenitor cells seem
to suggest that endogenous REST stability is regulated by
SCF- TRCP during early neural differentiation (Westbrook et al.,
2008).
FBW2, another F-box protein, currently has only one known
substrate, glial cells missing homologue 1 (GCM1), an interaction
observed in a placental cell line (Chiang et al., 2008). In Droso-
phila, glial cells missing (gcm) was first identified as a glial fate
switch gene which, when overexpressed, caused an increase in
the number of glial cells but not total number of cells in the nervous
system (Hosoya et al., 1995; Jones et al., 1995). More recent work
suggests that gcm degradation allows cell cycle exit and differen-
tiation of glial progenitors in Drosophila (Ho et al., 2009). Rapid
degradation of gcm allows the daughter cells of the thoracic
neuroglioblast, NB6-4T, which expresses gcm at low levels, to
adopt differing cell fates following asymmetric segregation of gcm
transcript. Recently, a role for gcm in the differentiation of the
Drosophila haemocyte lineage has also been reported (Jacques
et al., 2009). Intriguingly, although the mammalian homologues
GCM1 and GCM2 share high sequence homology in the DNA
binding domain and conservation of domain structure (Akiyama et
al., 1996; Altshuller et al., 1996; Kim et al., 1998), there appears
to be no functional conservation between Drosophila and mam-
mals (Basyuk et al., 1999; Kanemura et al., 1999).
GCM1 is mainly expressed in the placenta, with lower levels of
expression in the thymus, whilst GCM2 is expressed in the
developing mouse parathyroid gland (Basyuk et al., 1999; Kim et
al., 1998). In the placenta, GCM1 is absolutely required for
expression of the fusogenic protein syncytin and knockout leads
to embryonic lethality at E9.5-10 due to aberrant labyrinth forma-
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tion (Anson-Cartwright et al., 2000; Schreiber et al., 2000). In
contrast to the extraembryonic tissue, there appear to be no
embryonic abnormalities associated with GCM1 knockout. Al-
though little is known about the role of degradation in the regula-
tion of GCM1, it is noteworthy that both Drosophila and mamma-
lian homologues have a conserved role for the UPS despite a
complete lack of conservation of developmental function.
Ppa, Fbw7 and neural crest development
The transcription factor Slug is required for NC development in
Xenopus (for example, LaBonne and Bronner-Fraser, 2000), and
the degradation of Slug by the F-box protein Partner of Paired
(Ppa, also known as FBXL14 in vertebrates) has been reported in
Xenopus (Vernon and LaBonne, 2006). Using overexpression
and knock-down techniques, it was demonstrated that SCFPpa -
mediated degradation of Slug was important for patterning the
neural plate border; overexpression of Ppa expanded the neural
plate, at the expense of the NC, whereas by contrast,
overexpression of a Ppa-refractory Slug mutant expanded the NC
and led to premature migration of NC cells in the spinal cord. It is
interesting to note that two key regulators of NC development,
Slug and Snail, are degraded by SCF E3 ligases (SCFPpa and
SCF-TRCP respectively, see above).
A further role for F-box proteins in the development of the NC
has been recently described in Xenopus, where the function of
Fbw7 was perturbed by expression of an Fbw7F-box mutant
(Almeida et al., 2010). Loss of Fbw7 activity led to reduced
expression of both Slug and Snail, as well as c-Myc, and the loss
of NC-derived tissues, such as melanocytes. The activity of Fbw7
appeared to be required specifically for development of NC, as
expression of early markers in other tissues was unperturbed
when Fbw7 activity was inhibited. Thus it appears that several
stages of NC development are regulated by SCF complexes.
MAFbx and myogenesis
Muscle Atrophy F-box (MAFbx), also known as Atrogin-1 and
FBXO32, was first identified as an E3 ligase that could target
MyoD, the master regulator of myogenesis, for Ub-mediated
proteolysis (Davis et al., 1987; Lassar et al., 1991) and is a
muscle-specific gene upregulated during muscle atrophy (Bodine
et al., 2001; Gomes et al., 2001). In C2C12 cells, MAFbx expres-
sion increased during ex vivo differentiation (Tintignac et al.,
2005).
MAFbx was first characterised following a yeast two-hybrid
screen using Skp1 binding proteins as prey and MyoD as bait
(Tintignac et al., 2005), establishing that the two proteins inter-
acted via an LXXLL motif on MyoD. This suggests that, unusually
for an F-box protein, MAFbx recognises MyoD independently of
MyoD phosphorylation state. Overexpression of MAFbx reduced
the half-life of MyoD and also increased the ubiquitylation of
MyoD. Conversely, inhibition of MAFbx using a dominant nega-
tive F-box construct (MAFbxF) increased the half-life of MyoD.
As well as the considerable evidence for MyoD degradation by
MAFbx in vitro, a recent report has also demonstrated increased
polyubiquitylation of MyoD following transfection of MAFbx, but
not MAFbxF, into C2C12 cells (Lagirand-Cantaloube et al.,
2009). A direct interaction between SCFMAFbx and myogenin, a
bHLH transcription factor downstream of MyoD, has been demon-
strated and SCFMAFbx was seen to promote polyubiquitylation and
degradation of myogenin in vivo (Jogo et al., 2009).
Conclusions
The UPS is well known for its housekeeping role in protein
turnover but it is becoming increasingly clear that it also plays a
crucial role in dynamic processes involved in development, where
ubiquitylation can result in either protein destruction, proteolytic
processing or change in sub-cellular localization. Single SCF E3
ligase complexes may have multiple targets, exemplified by
SCF-TRCP, which potentially results in co-ordination of develop-
mental signaling pathways, while single targets can be ubiquitylated
by more than one E3 ligase complex. The selectivity, irreversibility
and responsiveness of SCF complexes make them excellent
candidates for developmental regulation, while substrate
ubiquitylation is also often regulated by further post-translational
substrate modification such as phosphorylation, which can fine-
tune cellular responses.
Such complexity, illustrated well by the multiple roles of
SCF-TRCP, often makes it difficult to define the role of individual E3
ligases in distinct developmental events. However, the use of
multiple model systems and analysis of individual substrates can
both facilitate this reductionist approach to identifying the role of
distinct SCF complexes, and allow us to explore the role of
multiple ubiquitylation pathways in regulating complex develop-
mental events. There is clearly a lot to learn.
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INTRODUCTION
During development of the central nervous system, cell cycle
lengthening accompanies the transition from stem cell-like to
neurogenic divisions, and this is subsequently followed by
differentiation (Lange and Calegari, 2010; Miyata et al., 2010).
However, recent experiments show that lengthening (but not
necessarily arresting) the cell cycle alone by perturbation of the
core cell cycle machinery is sufficient to trigger neuronal
differentiation, whereas shortening the cell cycle inhibits
neurogenesis (Lange et al., 2009). These findings indicate that cell
cycle length is itself a regulator of the balance between progenitor
maintenance and differentiation, although the mechanism for this
regulation is unknown.
The proneural basic helix-loop-helix (bHLH) transcription
factor Neurogenin 2 (Ngn2, or Neurog2) is required for
development of cranial and spinal sensory ganglia, as well as for
the ventral spinal cord (Bertrand et al., 2002). Moreover, in the
embryonic cortex, Ngn2 is required for neuronal commitment
and inhibition of the astrocytic fate of progenitors, as well as for
the specification of glutamatergic neurotransmitter identity and
the migration of cortical neurons (Bertrand et al., 2002). Ngn2
has been shown to transcriptionally upregulate multiple direct
targets. Among these, one crucial Ngn2 target is the bHLH
transcription factor NeuroD, which plays a central role in driving
neuronal differentiation.
Although transcriptional regulation of Ngn2 itself is complex,
evidence has emerged of additional Ngn2 control by post-
translational modification. A limited exploration of the role of
phosphorylation in Ngn2 activity has been undertaken (Hand et al.,
2005; Vosper et al., 2007; Ma et al., 2008). For example,
phosphorylation of tyrosine 241 in Ngn2 is important for the
migration and dendritic morphology of cortical neurons (Hand et
al., 2005) and phosphorylation on two specific C-terminal serines,
which are GSK3 consensus sites, appears to have no effect on
neurogenesis per se in the spinal cord but does regulate
motoneuron specification in this tissue (Ma et al., 2008).
Ngn2 protein level is regulated by ubiquitin-mediated
proteolysis, and the rate of proteolysis is sensitive to cell cycle
stage; Xenopus Ngn2 [xNgn2, also known as XNgnR1 (Nieber et
al., 2009)], the frog homologue of mammalian Ngn2 (Ma et al.,
1996; Nieber et al., 2009), has a shorter half-life in mitosis than in
interphase (Vosper et al., 2009). Accumulation of cyclin-dependent
kinase inhibitors (cdkis), which occurs upon cell cycle lengthening
and exit, promotes neurogenesis mediated by Ngn2 (Vernon et al.,
2003). Surprisingly, this particular effect of cdkis is independent of
their ability to inhibit cdk kinase activity, but instead results from
an independent role for cdkis in stabilising the Ngn2 protein
(Vernon et al., 2003; Nguyen et al., 2006). In addition, it is also
possible that Ngn2 protein undergoes other post-translational
modifications, including phosphorylation, that might be used to
coordinate its activity with cell cycle progression.
Cyclin A/cdk2 overexpression inhibits primary neurogenesis in
Xenopus embryos. Moreover, ectopic neurogenesis in embryos
driven by Ngn2 mRNA injection is still inhibited by cdk activation
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SUMMARY
During development of the central nervous system, the transition from progenitor maintenance to differentiation is directly
triggered by a lengthening of the cell cycle that occurs as development progresses. However, the mechanistic basis of this
regulation is unknown. The proneural transcription factor Neurogenin 2 (Ngn2) acts as a master regulator of neuronal
differentiation. Here, we demonstrate that Ngn2 is phosphorylated on multiple serine-proline sites in response to rising cyclin-
dependent kinase (cdk) levels. This multi-site phosphorylation results in quantitative inhibition of the ability of Ngn2 to induce
neurogenesis in vivo and in vitro. Mechanistically, multi-site phosphorylation inhibits binding of Ngn2 to E box DNA, and
inhibition of DNA binding depends on the number of phosphorylation sites available, quantitatively controlling promoter
occupancy in a rheostat-like manner. Neuronal differentiation driven by a mutant of Ngn2 that cannot be phosphorylated by cdks
is no longer inhibited by elevated cdk kinase levels. Additionally, phosphomutant Ngn2-driven neuronal differentiation shows a
reduced requirement for the presence of cdk inhibitors. From these results, we propose a model whereby multi-site cdk-
dependent phosphorylation of Ngn2 interprets cdk levels to control neuronal differentiation in response to cell cycle lengthening
during development.
KEY WORDS: Cell cycle, Neuronal differentiation, Ngn2, Phosphorylation, Xenopus
Cell cycle-regulated multi-site phosphorylation of
Neurogenin 2 coordinates cell cycling with differentiation
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(Richard-Parpaillon et al., 2004), indicating that cell cycle control
does not occur at the level of Ngn2 transcription. Instead, cell
cycle-dependent post-translational regulation of Ngn2 protein has
the potential to directly regulate the ability of Ngn2 to drive
neuronal differentiation. Here, we demonstrate how multi-site post-
translational modification of Ngn2 is used as a sensor of cdk kinase
levels to balance progenitor maintenance and differentiation, in
coordination with cell cycle length.
MATERIALS AND METHODS
Xenopus laevis extracts and embryos
Acquisition of Xenopus laevis eggs and embryos, preparation and injection
of synthetic mRNA and DNA morpholinos, staging of embryos, in situ
hybridisation and egg extract preparation have been described previously
(Vernon et al., 2003; Vosper et al., 2007; Vosper et al., 2009).
In vitro translated (IVT) protein synthesis and assay
Degradation assays were performed as described previously (Vosper et al.,
2007; Vosper et al., 2009). Phosphorylation assays in Xenopus extract were
performed as for degradation assays, except that extract was supplemented
with 0.2 mM MG132 (Biomol) and samples were incubated for 45 minutes
unless otherwise indicated. Where indicated, extracts were supplemented
with the GSK3 inhibitor (2Z,3E)-6-bromoindirubin-3-oxime (BIO)
(Sigma) at 100 nM or with roscovitine (VWR) at 50 mM. Where indicated,
following the 45 minute incubation in extract, 400 units l-phosphatase
(NEB) were incubated with the sample at 30°C for 30 minutes.
Cell culture, transfection, immunocytochemistry and western
blotting
Mouse P19 cells were cultured in -MEM (Gibco) with 7.5% newborn calf
serum and 2.5% fetal bovine serum (HyClone), 1% Glutamax (Gibco), and
100 units/ml penicillin/100 g/ml streptomycin (Sigma). Cells were
transfected with Lipofectamine 2000 (Invitrogen), and extracts western
blotted with anti-HA-peroxidase (3F10; Roche) or anti-c-Myc (9E10;
Santa-Cruz). Where indicated, cells were treated with either 5-25 m
roscovitine or 400 units l-phosphatase. P19 cells plated on poly-D-lysine
and laminin (Sigma) and fixed in 4% formaldehyde for 15 minutes were
stained with anti-TuJ1 (neuronal class III -Tubulin; 1:200; Covance) and
chicken anti-green fluorescent protein (GFP; 1:500; Invitrogen).
Somatic cell extract preparation for Ngn2 phosphorylation assay
Somatic cell extracts were prepared as described previously (Deibler and
Kirschner, 2010).
Quantitative real-time PCR (qPCR)
cDNA was generated from either P19 cells or stage 15 Xenopus embryos
and 50 ng used per qPCR reaction in a Light-Cycler 480 PCR system with
SYBR Green mix (Roche). -actin, Gapdh and EF1 were used as
housekeeping genes. Thermal cycling conditions: 95°C for 5 minutes, then
45 cycles of 95°C for 10 seconds, 60°C for 10 seconds and 72°C for 10
seconds. For primer sequences, see Table S1 in the supplementary material.
Electrophoretic mobility shift assay (EMSA)
Non-radiolabelled IVT protein was prepared and incubated in XB buffer
or Xenopus egg extract as for phosphorylation assays before EMSA
analysis as previously described (Vosper et al., 2009), using the annealed,
end-labelled oligonucleotide pair (5-TCTAACTGGCGACAGATGGG -
CCACTTTCTT-3 and complement).
Chromatin Immunoprecipitation assay (ChIP)
DNA-protein complexes from P19 cells transfected with either HA-tagged
wild-type mNgn2 or 9S-A mNgn2 for 24 hours and normalised for
mNgn2/9S-A mNgn2 expression (see Results) were cross-linked with 1%
formaldehyde. Five micrograms of rat monoclonal anti-HA antibody
(Roche) or anti-IgG (Abcam) (as a control) were used per ChIP reaction
and quantified using SYBR Green mix. The signal over background
normalisation method was used to quantify immunoprecipitated DNA. For
primer sequences, see Table S1 in the supplementary material.
Statistical analysis
Data were subjected to statistical analysis using a two-tailed Student’s t-
test (P≤0.05). The standard error of the mean (s.e.m.) was calculated from
at least three independent experiments. Immunostaining, western blotting
and in situ hybridisation experiments were performed in three independent
experiments and representative results are shown.
RESULTS
Neurogenin 2 phosphorylation is regulated during
the cell cycle
Ngn2 phosphorylation has previously been demonstrated on
tyrosine and GSK3 consensus sites (Hand et al., 2005; Vosper et
al., 2007; Ma et al., 2008), but cell cycle-dependent
phosphorylation has not been investigated. We have previously
observed that Ngn2 protein can be phosphorylated in Xenopus egg
extract, which provides a complex biochemical environment that
contains stockpiles of many of the kinases and phosphatases
required for cell cycle transitions and early embryonic
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Fig. 1. Ngn2 undergoes cell cycle-regulated
phosphorylation. (A)In vitro translated (IVT)
[35S]methionine-labelled xNgn2 and 9S-A xNgn2
were incubated in interphase (I) and mitotic (M)
Xenopus egg extracts before SDS-PAGE and
autoradiography. In M extracts, phosphorylated
xNgn2 runs at the level of the 36 kDa molecular
weight marker (indicated). (B)Western blot
analysis of HA-tagged mNgn2 and mutants
thereof, transfected into mouse P19 cells with and
without l-phosphatase treatment. (C)Western
blot analysis of myc-mNgn2 from E16.5 mouse












development, and results in slowed migration of Ngn2 in SDS-
PAGE (Vosper et al., 2007). We hypothesised that this
phosphorylation might be regulated by the cell cycle.
We compared SDS-PAGE migration of in vitro translated (IVT)
[35S]methionine-labelled Xenopus Ngn2 (xNgn2) in interphase egg
extract (I) or in extract driven into mitosis (M) by addition of non-
degradable cyclin B D90 (King et al., 1996). IVT xNgn2 runs at
~28 kDa by SDS-PAGE, and its migration is slowed slightly after
incubation in I extract (Fig. 1A), and more dramatically after
incubation in M extract, resulting in the appearance of one or more
forms of Ngn2 running up to 8 kDa ‘larger’ (Fig. 1A, see Fig. S2
in the supplementary material). Retardation was reversed by
incubation with l-phosphatase (data not shown).
Although predictions of consensus sequences that contribute to
kinase recognition are imprecise (Errico et al., 2010), several
prominent kinases potentially present in the egg extract, such as
cdks, MAP kinases and GSK3, preferentially phosphorylate on
serine or threonine residues followed by a proline (SP or TP sites)
(Ubersax and Ferrell, 2007). xNgn2 contains nine SP and one TP
site. To prevent phosphorylation on SP sites, a mutant form of
xNgn2, 9S-A xNgn2, in which all SP sites are mutated to alanine-
proline (S-A mutant) was generated. 9S-A xNgn2 ran similarly to
the IVT protein after incubation in I or M extracts (Fig. 1A),
indicating that the phosphorylation seen for the wild-type protein
does not occur on 9S-A xNgn2. We did not detect significant
phosphorylation of the TP site by SDS-PAGE migration (data not
shown), and did not consider modification of this site further.
Mouse Ngn2 (mNgn2) can drive neuronal differentiation of
mouse embryonal carcinoma P19 cells when overexpressed (Farah
et al., 2000), and also contains nine SP sites. However, only the
position of the two most C-terminal GSK3 consensus sites, which
have previously been shown to be phosphorylated in spinal cord
(Ma et al., 2008), is conserved with xNgn2. After transfection into
P19 cells, at least two phosphoforms of mNgn2 were seen, as
evidenced by migration in SDS-PAGE and phosphatase treatment,
whereas 9S-A mNgn2 ran as a single, faster migrating band (Fig.
1B). Further analysis of Ngn2 mutants in which SP sites in the N-
and C-termini have been separately mutated shows that xNgn2 and
mNgn2 are both phosphorylated on multiple sites in both the N-
and C-terminal domains (Fig. 1B, see Fig. S2 in the supplementary
material). Analysis of phosphorylation of 2S-A Ngn2 (which lacks
the potential GSK3 sites) and 7S-A Ngn2 (in which only the two
potential GSK3 SP sites are present in an otherwise S-A
background) indicates that phosphorylation does not predominantly
occur on these GSK3 SP sites (Fig. 1B).
To determine the phosphorylation status of Ngn2 expressed from
its endogenous locus, we investigated the migration of a myc-
tagged form of mNgn2 in embryonic brain from a mouse line in
which myc-mNgn2 is inserted in the place of endogenous mNgn2
(Hand et al., 2005). Western blotting demonstrated that mNgn2 is
phosphorylated in the developing mouse brain (Fig. 1C).
Ngn2 is phosphorylated on multiple sites by
cyclin-dependent kinases
Cdks drive cell cycle progression and are known to target SP (and
TP) sites (Errico et al., 2010). We postulated that Ngn2 might be a
direct cdk substrate. Addition of roscovitine, a chemical cdk
inhibitor with marked specificity for cdks alone (Bain et al., 2007),
results in a dose-dependent reduction of the slower migrating form
of mNgn2 expressed in P19 cells (Fig. 2A). Roscovitine also
reversed the reduction in mobility seen when xNgn2 was incubated
in neurula stage Xenopus embryo extracts (see Fig. S3 in the
supplementary material).
To quantitatively analyse the sensitivity of Ngn2 to increasing
cdk activity, we turned to an in vitro human HeLa cell extract
system that exhibits quantitative cyclin dose-dependent effects on
substrate phosphorylation (Deibler and Kirschner, 2010), as
evidenced by slowed migration in SDS-PAGE, and recapitulates
cell cycle-relevant transitions. From entry into S phase through
prometaphase, cyclin A concentration increases in the cell, and this
can be reproduced by increasing the dose of cyclin in the cell
extract (Deibler and Kirschner, 2010). mNgn2 is highly sensitive
to cyclin A-dependent kinase, and phosphorylation is evident when
only 12.5 nM cyclin A is added (Fig. 2B). As the cyclin A
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Fig. 2. Ngn2 is phosphorylated by cyclin-dependent kinases. (A)Western blot analysis of HA-tagged mNgn2 and 9S-A mNgn2 24 hours after
transfection into mouse P19 cells with and without treatment with the cdk inhibitor roscovitine. -Tubulin provides a loading control. (B)SDS-PAGE
analysis of IVT mNgn2 in human HeLa cell extract in response to increasing doses of recombinant cyclin A (top) or cyclin B (bottom). Arrows indicate
different phosphoforms of mNgn2. (C) SDS-PAGE analysis of the kinetics of phosphorylation of IVT mNgn2 when added to HeLa extracts containing











concentration rises, at least two or three increasingly retarded
mNgn2 forms appear (Fig. 2B), indicating that mNgn2 is
phosphorylated on multiple sites. That slower migrating
phosphoforms require higher cyclin A concentrations demonstrates
that there is no single threshold at which multiple sites are
phosphorylated, but rather that the extent of phosphorylation is
sensitive to the level of kinase activity. Above 100 nM cyclin A,
when cyclin A-dependent kinase levels are saturating, the fastest
migrating mNgn2 band is lost, indicating that all Ngn2 is
essentially phosphorylated. These results demonstrate that mNgn2,
together with Wee1, is one of the most sensitive substrates of cyclin
A-dependent kinase currently known (Deibler and Kirschner,
2010), although in contrast to Wee1, as cyclin A levels rise mNgn2
becomes further phosphorylated on additional sites.
The addition of cyclin B to these G2 phase HeLa extracts leads
to triphasic cdk kinase activation: a first phase in which cdk kinase
activity increases in proportion to cyclin B up to ~100 nM,
followed by a plateau of kinase activity between 125-400 nM, and
finally a further increase to saturation above 400 nM (Deibler and
Kirschner, 2010). mNgn2 is also highly sensitive to cyclin B-
dependent kinase (Fig. 2B), showing phosphorylation at the lowest
concentration of cyclin B assayed, 31 nM, with maximal
phosphorylation at additional sites achieved around the plateau
stage from 125 nM cyclin B upwards, indicating dose-dependent
sensitivity to cdk kinase levels.
Ngn2 phosphorylation is rapid. After addition of cyclins A or B,
histone H1 kinase levels become maximal after a 16-minute lag
required for cdk kinase activation. When mNgn2 was added to
these extracts, initial phosphorylation at some sites occurred within
20 minutes (Fig. 2C), but additional phosphorylations took longer,
indicating that some sites are phosphorylated before others and that
phosphorylation continues over a considerable period. We see
greater phosphorylation in these mitosis-like extracts than in P19
lysates from asynchronous P19 cells representing all cell cycle
stages, where interphase will predominate (Fig. 1).
Immunodepletion of specific cdks from HeLa extracts indicates
that Ngn2 is a substrate of both cdk1 and cdk2 (see Fig. S4 in the
supplementary material).
Phosphorylation of Ngn2 reduces its ability to
induce neuronal differentiation
Ngn2 can be phosphorylated on multiple sites by cdks. What is the
effect of phosphorylation on Ngn2 activity in the developing
embryo? To distinguish effects of post-translational modification
from fluctuating levels of Ngn2 transcripts, which vary from cell
to cell and as development progresses (Ma et al., 1996; Bertrand et
al., 2002; Shimojo et al., 2008), we chose to express xNgn2 from
microinjected mRNA in order to allow us to control the level of
xNgn2 expression in vivo in Xenopus embryos that are at the
correct developmental stage to provide the physiological response
of primary neuron differentiation (Ma et al., 1996).
Injection of 5 pg xNgn2 mRNA results in a small increase in
neurogenesis within the neural plate in individual embryos, but
little ectopic neurogenesis outside the neural plate, indicating a
similar level of expression to endogenous xNgn2 mRNA. Injection
of 5 pg 9S-A xNgn2 mRNA, by contrast, induces both a significant
increase in neurogenesis in the neural plate and is sufficient to
change the fate of epidermis to differentiated neurons (Fig. 3A)
(Ma et al., 1996). At 20 pg mRNA, xNgn2 was still only able to
induce a modest increase in neurogenesis, although now neurons
were present outside the neural plate, whereas the same amount of
9S-A xNgn2 mRNA induced very extensive neurogenesis (Fig. 3A).
Quantitation of neural -tubulin levels in these neural plate stage
embryos by qPCR demonstrates that 9S-A xNgn2 is ~7-fold more
active than wild-type xNgn2 when expressed at near physiological
levels in Xenopus embryos (Fig. 3B).
Testing of seven mutants, in which individual SP sites had been
reintroduced into a phosphomutant xNgn2 background,
demonstrated a similar level of activity of each to 9S-A xNgn2 (see
Fig. S5 in the supplementary material), indicating that no
individual SP site is responsible for substantially limiting Ngn2
activity, but instead that phosphorylation at a combination of sites
might be required to limit the ability of Ngn2 to induce
neurogenesis.
Mutation of SP sites also promotes Ngn2-driven neurogenesis in
P19 cells. Significantly more extensive neurogenesis was seen in
P19 cells expressing 9S-A mNgn2 than in cells expressing wild-
type mNgn2, as measured by TuJ1 staining (Fig. 3C) and
confirmed by qPCR analysis (Fig. 3D). Analysis of mutants
indicated that potential phosphorylation on the GSK3 sites might
contribute to phosphoregulation of Ngn2 activity to a small extent,
but that phosphorylation of other sites accounts for the majority of
the inhibition of Ngn2-dependent neuronal differentiation (see Fig.
S6 in the supplementary material).
Mechanism of regulation of Ngn2 activity by
phosphorylation
The transcriptional activation of promoters of genes promoting
differentiation may require many cycles of productive transcription
factor binding and greater promoter occupancy to bring about
progressive chromatin modification, ultimately resulting in an
active transcribable state (Koyano-Nakagawa et al., 1999; Hager et
al., 2009; Michel, 2009). Ngn2 must bind and activate the
promoters of key target genes, such as NeuroD, to drive neuronal
differentiation. Hence, we reasoned that phosphorylation might
affect Ngn2 half-life or its ability to stably bind to promoter DNA,
either of which could affect the duration and/or productivity of the
interaction between Ngn2 and target promoters driving
differentiation.
We first investigated whether phosphorylation status affects
Ngn2 protein stability. Ngn2 has a short half-life of ~20 minutes in
Xenopus and P19 cells, which is enhanced by binding to its
heterodimeric E protein partner (Vosper et al., 2007). We
determined whether phosphorylation directly affects Ngn2 half-life
by incubating IVT xNgn2 or 9S-A xNgn2 in I and M extract. The
half-life of 9S-A xNgn2 was similar to that of xNgn2 in both I and
M (Fig. 4A) and in neurula stage Xenopus embryo extracts (data
not shown). Addition of E12 protein stabilised xNgn2 and 9S-A
xNgn2 in both I and M extracts (Fig. 4A). However, in M extract,
where cdk-dependent phosphorylation is maximal, E12 stabilised
9S-A xNgn2 to a greater extent than it stabilised the wild-type
protein. Hence, the phosphorylation status of Ngn2 affects its
ability to be stabilised by E protein binding; un(der)phosphorylated,
and therefore more stable, Ngn2-E protein complexes might be
expected to show greater promoter occupancy than the
phosphorylated form of the protein.
To test this we investigated whether phosphorylation affects
Ngn2 binding to the NeuroD (Neurod1) and Delta (Dll1)
promoters, which are direct downstream targets of Ngn2, by
chromatin immunoprecipitation (ChIP) in P19 cells, 24 hours post-
transfection. As described above, phosphorylation status affects the
stabilisation of Ngn2 by E proteins (Fig. 4A). To distinguish
differences in chromatin affinity from potential differences in
mNgn2 and 9S-A mNgn2 protein levels, we quantitated the











expression of wild-type mNgn2 versus 9S-A mNgn2 by western
blot, allowing normalisation of the amount of Ngn2 protein prior
to chromatin immunoprecipitation. After normalisation, 9S-A
mNgn2 was more than 2-fold enriched compared with wild-type
mNgn2 on each promoter, but promoter-specific differences in
mNgn2 versus 9S-A mNgn2 binding were not observed (Fig. 4B).
To test directly whether phosphorylation of Ngn2 affects its
ability to associate with DNA, we investigated the binding of
xNgn2-E12 complexes to their cognate E box-binding motif in an
electrophoretic mobility shift assay (EMSA) in I and M extracts.
Wild-type xNgn2 and 9S-A xNgn2 had similar DNA-binding
activity in I extract, where xNgn2 phosphorylation is low, but 9S-
A xNgn2-E12 bound DNA with considerably greater affinity than
the wild-type protein in M extracts, where Ngn2 phosphorylation
is maximal (Fig. 4C).
Multi-site phosphorylation of Ngn2 acts
quantitatively to control DNA binding
Promoter activation requires productive transcription factor binding
cycles, which in turn depend on the strength and/or duration of
promoter occupancy by that transcription factor. Phosphorylation
of Ngn2 occurs on multiple sites, which together can regulate DNA
and promoter binding. We investigated whether specific SP sites
are responsible for Ngn2 phosphoregulation or whether regulation
is attained by the additive effect of individual phosphorylation
events, each one quantitatively having a small effect on promoter
occupancy by Ngn2, the number of sites phosphorylated being
quantitatively dependent on the cdk kinase level (Fig. 2). We tested
whether the mutation of an increasing number of phosphorylation
sites had an additive effect on Ngn2 DNA binding and its ability to
induce neuronal differentiation.
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Fig. 3. Mutation of phosphorylation sites promotes Ngn2 activity. (A)Xenopus embryos were injected (left side) in one of two cells with
either 5 or 20 pg mRNA as indicated, fixed at stage 15 and subject to in situ hybridisation for neural -tubulin. The number of embryos scored was
39-90 per condition. (B)qPCR analysis of neural -tubulin in stage 15 Xenopus embryos injected at the one-cell stage with 20 pg xNgn2 or 9S-A
xNgn2 mRNA. Average fold increase in neural -tubulin mRNA expression is shown normalised to GFP-injected control (mean ± s.e.m.; *, P£0.05).
(C)Mouse P19 cells transfected with mNgn2 or 9S-A mNgn2 with GFP were fixed 24 hours after transfection and stained for expression of neuron-
specific III-tubulin (TuJ1) (red), quantitating TuJ1+ among GFP+ cells (mean ± s.e.m.). (D)qPCR analysis of III-tubulin in P19 cells 24 hours following
transfection with mNgn2 and 9S-A mNgn2. Average fold increase in mRNA expression is shown normalised to housekeeping gene expression
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Fig. 4. Phosphomutant Ngn2 binds more efficiently than wild-type Ngn2 protein to DNA and is stabilised more by E12. (A)IVT
[35S]methionine-labelled xNgn2 or 9S-A xNgn2 were incubated in I or M Xenopus egg extracts in the presence of unlabelled IVT GFP or E12.
Samples were removed every 10 minutes, separated by SDS-PAGE and the amount of Ngn2 protein determined by phosphorimaging, calculating
the half-life of Ngn2 protein degradation using first-order rate kinetics. Half-lives were normalised to that of xNgn2 with GFP in each experiment
and the average ratios of stability relative to xNgn2 with GFP for three experiments were plotted (mean ± s.e.m.). (B)Chromatin
immunoprecipitation (ChIP) analysis of cell extracts containing normalised amounts of HA-tagged mNgn2 and 9S-A mNgn2, assessing binding to
the promoters of Neurod1, delta-like 1 (Dll1) and Neurod4 in mouse P19 cells, 24 hours following transfection (IgG control for non-specific
background binding). ***, P£0.005. (C)Electrophoretic mobility shift assay (EMSA) showing E box binding of normalised IVT xNgn2 or 9S-A xNgn2










A panel of S-A mutant versions of mNgn2 was constructed in
which the mutation of SP sites was undertaken additively from the
N-terminus (i.e. mS-A1 has the most N-terminal SP site mutated to
AP, mS-A2 has the first two N-terminal sites mutated, and so on;
see Fig. S1 in the supplementary material), and their DNA binding
tested by EMSA. As previously seen with xNgn2 and 9S-A xNgn2
(Fig. 4C), there was little difference in the DNA binding of any of
our additive mNgn2 phosphomutants in I extract (see Fig. S7 in the
supplementary material). However, in M extract, the E box binding
increases progressively as phosphorylation sites are lost (Fig. 5A).
To determine whether the number of SP sites available for
phosphorylation is more important than the location of those
sites, we investigated a series of xNgn2 phosphomutants in
which SP sites were additively mutated, but this time from the
C-terminus (see Fig. S1 in the supplementary material). Again,
we saw that the availability of SP sites quantitatively regulates
DNA binding in M; as each SP site was additionally mutated,
DNA-binding activity progressively increased (Fig. 5A). Thus,
phosphorylation of multiple SP sites can act quantitatively, in a
rheostat-like manner, to control E box binding by mNgn2 and
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Fig. 5. Phosphorylation on multiple serine-proline (SP) sites has an additive effect on Ngn2 DNA binding. (A)EMSA analyses in Xenopus
M extracts showing E box binding of normalised IVTs of xNgn2 or mNgn2 and additive phosphorylation site mutants of xNgn2 or mNgn2 as
labelled. Graphs show quantitation of E box binding of phosphorylation site mutants by phosphorimaging, normalised to DNA binding of xNgn2 or
mNgn2 as appropriate (see Fig. S1 in the supplementary material). (B)qPCR analysis of neural III-tubulin in P19 cells. P19 cells were transiently
transfected with mNgn2 and additive phosphorylation site mutants thereof for 24 hours. Average fold increase (± s.e.m.) in III-tubulin mRNA











xNgn2, even though the context and location of only the two
most C-terminal SP sites are conserved between these two
species.
We next investigated whether the ability of Ngn2 to induce
neuronal differentiation of P19 cells is quantitatively dependent on
the number of phosphorylation sites available. Using our mNgn2
phosphomutant series (see Fig. S1 in the supplementary material),
we saw a fairly gradual increase in III-tubulin expression as
additional SP sites were mutated (Fig. 5B), demonstrating that the
propensity of Ngn2 to drive neuronal differentiation depends, at
least semi-quantitatively, on the number of phosphorylation sites
available. However, mutation of the final three (most C-terminal)
SP sites had the biggest effect.
Cell cycle regulators control neuronal
differentiation by post-translational regulation of
Ngn2 protein
Enhancing cdk activity inhibits neurogenesis in vivo (Richard-
Parpaillon et al., 2004; Lange et al., 2009). The results presented
above led us to hypothesise that its inhibitory activity is via post-
translational modification of the Ngn2 protein, and so
phosphomutant Ngn2 would not be susceptible to inhibition by
cyclin A/cdk2 overexpression. To test this, we chose to inject levels
of xNgn2 mRNA that induce limited ectopic neurogenesis, largely
within the neural plate, to mimic in vivo expression levels.
As previously reported, injection of cyclin A/cdk2 mRNA
promotes cell cycling within the ectoderm and inhibits endogenous
neurogenesis (Richard-Parpaillon et al., 2004). Cyclin A/cdk2
overexpression also inhibited neurogenesis in the presence of
ectopic xNgn2 mRNA, indicating that inhibition occurs at the level
of post-translational modification of xNgn2 or, potentially, of a
downstream target (Fig. 6A,B). 9S-A xNgn2 induced substantially
greater ectopic neurogenesis in both the neural plate and epidermis
than the wild-type protein, as expected. Strikingly, this extensive
ectopic neurogenesis induced by 9S-A xNgn2 overexpression was
unaffected by cyclin A/cdk2 overexpression (Fig. 6A,B). This
demonstrates that enhanced cyclin/cdk kinase activity, which
promotes more rapid cell cycling (Richard-Parpaillon et al., 2004),
also directly inhibits the neurogenesis-inducing ability of xNgn2
protein in vivo by post-translational modification.
Cdk inhibitors (cdkis) accumulate as the cell cycle lengthens
and their expression is associated with both a drop in cdk kinase
levels and neuronal differentiation (e.g. Cremisi et al., 2003;
Vernon et al., 2003; Nguyen et al., 2006). We have previously
shown that cdkis have an additional role in neurogenesis
independent of, but complementary to, their role in inhibiting
cyclin/cdk kinase activity: the Xenopus Cip/Kip family cdk
inhibitor, Xic1, is required for neuronal differentiation in the
developing embryo, where it functions to stabilise xNgn2 protein
independently of its ability to inhibit overall cdk kinase activity.
Similarly, p27Kip1 stabilises Ngn2 in the mouse cortex (Nguyen
et al., 2006).
Because of their more stable association with promoter DNA,
we hypothesised that 9S-A xNgn2-E protein complexes might be
less dependent on the presence of Xic1 to enhance Ngn2 protein
stability and hence drive neuronal differentiation in vivo than the
wild-type protein. To test this, we investigated the ability of xNgn2
and 9S-A xNgn2 to induce neurogenesis in the presence of a Xic1
morpholino (Xic1 Mo), which has previously been shown to
abolish Xic1 protein expression and inhibit Ngn2-dependent
neuronal differentiation (Vernon et al., 2003). As expected, Xic1
Mo injection significantly reduced endogenous neurogenesis, as
assayed by in situ hybridisation, whereas the control morpholino
(Con Mo) had little effect (Fig. 7A,B) (Vernon et al., 2003). The
low doses of xNgn2 mRNA chosen to achieve near-physiological
levels of expression induced modest but clear ectopic neurogenesis
both within and outside the neural plate in the presence of Con Mo.
Both the ectopic and endogenous neurogenesis seen in xNgn2-
injected embryos were largely abolished by co-injection of Xic1
Mo, confirming that wild-type xNgn2 requires Xic1 for full activity
(Fig. 7A,B) (Vernon et al., 2003).
As expected, extensive neurogenesis was induced by 9S-A
xNgn2 mRNA plus Con Mo both within and outside the neural
plate. However, in contrast to xNgn2, 9S-A xNgn2 could induce
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Fig. 6. 9S-A xNgn2 is resistant to cyclin A2/cdk2-mediated suppression of neurogenesis in vivo. (A)Xenopus embryos were injected (left
side) in one of two cells with 20 pg xNgn2 or 9S-A xNgn2 mRNA, together with 500 pg cyclin A2 and cdk2 mRNA, assaying for expression of
neural -tubulin at stage 15 by in situ hybridisation. (B)Semi-quantitative analysis of in situ hybridisation data. The number of embryos scored was
48-86 per condition. Neurogenesis was enhanced (+3, +2, +1), the same as (0) or reduced (–1, –2, –3) compared with the uninjected side (see Fig.










substantial neurogenesis even in the presence of Xic1 Mo (Fig.
7A,B). Thus, 9S-A xNgn2 has a reduced requirement for Xic1
compared with the wild-type protein, consistent with the enhanced
stability of un(der)phosphorylated Ngn2.
DISCUSSION
Ngn2 acts as a master regulatory transcription factor that controls
the balance between progenitor maintenance and differentiation in
response to increasing cell cycle length as development progresses.
We show that this is achieved by multi-site phosphorylation of
Ngn2, which is quantitatively sensitive to cdk levels and
quantitatively regulates the stability of Ngn2 binding to promoters
of key downstream transcriptional targets, resulting in the
regulation of neuronal differentiation.
Transcription factors undergo dynamic binding cycles on
promoters. Increased dwell time on promoters is associated with
more active transcription; for example, a slower exchange rate of
the glucocorticoid receptor at promoters would promote the
assembly of additional components required for chromatin
remodelling and transcriptional activation (Stavreva et al., 2004;
Hager et al., 2009). The requirement for stable association of Ngn2
with the target promoter to drive differentiation leads directly to a
mechanism whereby post-translational modification of Ngn2 in
response to the cellular environment, and the cdk kinase level in
particular, can influence the propensity to differentiate.
Cdk-dependent inhibitory phosphorylation of Ngn2
complements another level of cell cycle-dependent post-
translational regulation of Ngn2. We have previously shown that
the cdkis p27Xic1 in Xenopus and p27Kip1 (Cdkn1b) in mouse are
required for transcriptional activity of Ngn2 (Nguyen et al., 2006;
Vernon et al., 2003). Acting independently of (but complementary
to) their ability to inhibit cyclins and cdks, these cdkis inhibit
ubiquitin-mediated proteolysis of Ngn2 protein, thus facilitating
neuronal differentiation. In addition to this stabilising effect,
accumulation of cdkis in neural precursors with lengthening cell
cycles will also directly inhibit cdk activity, reducing the inhibitory
phosphorylation of Ngn2 and so enhancing its transcriptional
activity on differentiation targets. However, it should be noted that
these cdkis themselves have not been shown to be direct
transcriptional targets of Ngn2 (Seo et al., 2007).
From our biochemical in vitro assays, coupled with
overexpression experiments in both cultured P19 cells and
Xenopus embryos, we propose the following model (Fig. 8). In
cycling cells, cdk levels rise rapidly on transition through late
G1 and S phase into G2 and mitosis, promoting increasing
phosphorylation of Ngn2 by cdk2 and cdk1, and resulting in
reduced promoter occupancy, which is insufficient to activate the
Ngn2-responsive promoters of genes required for neuronal
differentiation, such as NeuroD. By contrast, cell cycle
lengthening results in a longer time spent in G1, where cdk
levels are low and cdk inhibitors accumulate. This favours
un(der)phosphorylated, more stable Ngn2, which binds E box
DNA more tightly. This greater promoter occupancy would be
permissive for transcription of Ngn2 targets driving neuronal
differentiation. Moreover, the graded response of neural -
tubulin to Ngn2 phosphorylation on additive sites allows cdk
levels to be interpreted in a rheostat-like manner (Deshaies and
Ferrell, 2001; Pufall et al., 2005). Here, we have concentrated on
cdk-dependent phosphorylation of Ngn2. However, multi-site
phosphorylation could be used as a mechanism to integrate a
range of signals that culminate in proline-directed kinase activity.
The promoter of the NeuroD gene is known to respond slowly
to Ngn2 expression and to require extensive chromatin
modification for activation (Koyano-Nakagawa et al., 1999), which
fits with our model in which stable promoter association is required
to drive neuronal differentiation. Ngn2 has many direct
downstream targets with potentially differing requirements for
epigenetic modification, and hence for recruitment of chromatin
modifiers, before activation (Koyano-Nakagawa et al., 1999; Seo
et al., 2007). Different promoters might therefore respond
4275RESEARCH ARTICLECdks regulate Ngn2 activity
Fig. 7. 9S-A xNgn2 does not require the cdk inhibitor Xic1 for activity. (A)Xenopus embryos were injected (left side) in one of four cells
(dorsally targeted) with 20 pg mRNA as indicated, together with 20 ng of either control (a,c,e) or Xic1 (b,d,f) morpholino, fixed at stage 15 and
subject to in situ hybridisation for neural -tubulin expression. (B)Semi-quantitative analysis of in situ hybridisation data. The number of embryos
scored was 43-59 per condition. Neurogenesis was enhanced (+3, +2, +1), the same as (0) or reduced (–1, –2, –3) compared with the uninjected












differently to changes in Ngn2 phosphorylation status, affecting the
frequency/duration of promoter occupancy, and we are currently
exploring this possibility.
Our analyses indicate the importance of the number of SP sites
modified, rather than their precise location, for regulation of protein
function (Fig. 5). Native Ngn2 might be largely unstructured, like
the related protein Ngn1 (Aguado-Llera et al., 2010), and hence
might have limited structural constraints for phosphorylation on SP
sites. Several classes of transcription factors have been identified
in which unstructured N- and C-terminal extensions from the
known DNA-binding domains contribute to DNA-binding affinity
(Crane-Robinson et al., 2006), which would in turn affect the
frequency and duration of DNA-protein binding cycles (Michel,
2009). Our data demonstrate that phosphorylation of residues in
both the N- and C-termini quantitatively reduce Ngn2 DNA-
binding activity.
In summary, we have shown here that Ngn2 is directly
phosphorylated at multiple sites by cdk kinases and that this
directly controls its ability to drive neuronal differentiation. Hence,
we have uncovered a molecular mechanism whereby cell cycle
lengthening can directly trigger neuronal differentiation.
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UbxNgn2:  Ubiquitin fused to N-terminus of xNgn2 
 
N-Ngn/BC-NeuroD:  N-terminal domain of xNgn2 fused to bHLH and C-terminal domains 
of xNeuroD 
N-NeuroD/BC-Ngn:  N-terminal domain of xNeuroD fused to bHLH and C-terminal 
domains of xNgn2  
NB-Ngn/C-NeuroD:  N-terminal and bHLH domains of xNgn2 fused to C-terminal domain 
of xNeuroD 
NB-NeuroD/C-Ngn:  N-terminal and bHLH domains of xNeuroD fused to C-terminal 
domain of xNgn2 
 
NgnNDNgn:  N- and C-terminal domains of xNgn2 fused to bHLH domain of xNeuroD 
NDNgnND:  N- and C-terminal domains of xNeuroD fused to bHLH domain of xNgn2 
 
NTNeuroD:  N-terminal domain of xNeuroD 
ΔNTNeuroD:  bHLH and C-terminal domains of xNeuroD 
ΔbHLHNeuroD:  N-terminal domain of xNeuroD fused directly to C-terminal domain 
CTNeuroD:  C-terminal domain of xNeuroD 
ΔCTNeuroD:  N-terminal and bHLH domains of xNeuroD 
UD-NeuroD/NeuroD-UD:  Unfolded residues 1–95 of cytochrome b2 fused to N- or C-
terminus of xNeuroD, respectively 
 
NTSPxNgn2:  xNgn2 with all N-terminal SP site serines mutated to alanines 
NTSPTPxNgn2: xNgn2 with all N-terminal SP/TP sites mutated to alanines 
CTSPxNgn2:  xNgn2 with all C-terminal SP site serines mutated to alanines 
N-SP/BC-NeuroD:  N-terminal domain of 9S-AxNgn2 fused to bHLH and C-terminal 
domains of xNeuroD 
NB-SP/C-NeuroD:  N-terminal and bHLH domains of 9S-AxNgn2 fused to C-terminal 
domain of xNeuroD 
NB-NeuroD/C-SP:  N-terminal and bHLH domains of xNeuroD fused to C-terminal 




Figure A1: Ubiquitylation timecourse for xNgn2 and UbxNgn2 in the presence or absence of 
Xic1. 
35S-radiolabelled in vitro translated (IVT) xNgn2 or UbxNgn2 were incubated in previously frozen 
Xenopus laevis interphase activated egg extract, supplemented with the proteasome inhibitor 
MG132.  Samples were treated with His6-ubiquitin (His-Ubiquitin) or untagged ubiquitin (Regular 
Ubiquitin).  Samples were further treated with maltose binding protein (MBP)-fused Xic1 (+ Xic1-
MBP) or MBP alone (+ MBP).  The reactions were incubated at 20ºC for 0, 5 or 10 minutes, before 
dilution in Vosper buffer and incubation with Ni-NTA (Qiagen) beads at room temperature for 75 
minutes.  SDS-LB was added and samples boiled before running on SDS-PAGE with untreated in 
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Figure A2: xNgn2/xNeuroD domain swap stability in interphase. 
Xenopus interphase extracts were supplemented with 35S-labelled IVT xNgn2, xNeuroD or chimeric 
protein.  Samples were taken at indicated timepoints, subjected to 15 % SDS-PAGE and analysed 
by autoradiography (A).  The average stabilisation relative to wild-type xNgn2 within interphase 
extract was calculated (B).  (C) Half-lives were calculated using first-order rate kinetics, and errors 






































































































Figure A3: xNgn2/xNeuroD domain swap stability in mitosis. 
Xenopus laevis mitotic egg extracts were supplemented with 35S-labelled IVT xNgn2, xNeuroD or 
domain swapped protein and incubated at 21 °C.  Samples were taken at the timepoints indicated 
and subjected to 15 % SDS-PAGE.  Gels were analysed by autoradiography (A) and quantitative 
phosphorimaging analysis, calculating the average stabilisation relative to wild-type xNgn2 within 
mitotic extract (B).  (C) Half-lives were calculated using first-order rate kinetics, and errors 








































































































Figure A4: xNgn2/xNeuroD SP domain swap stability in mitosis. 
Xenopus laevis mitotic egg extracts were supplemented with 35S-labelled IVT xNgn2, xNeuroD or 
SP domain swapped protein and incubated at 21 °C.  Samples were taken at the timepoints 
indicated and subjected to 15 % SDS-PAGE.  Gels were analysed by autoradiography (A) and 
quantitative phosphorimaging analysis, calculating the average stabilisation relative to wild-type 
xNgn2 within mitotic extract (B).  (C) Half-lives were calculated using first-order rate kinetics, and 






































































































Figure A5: xNeuroD domain deletions affect protein stability in interphase. 
(A) IVT radiolabelled proteins for domain deletions of xNgn2 and xNeuroD. Xenopus laevis 
interphase egg extracts were supplemented with 35S-labelled IVT xNeuroD domain deleted 
proteins and incubated at 21 °C.  Samples were taken at timepoints indicated and subjected to 15 
% SDS-PAGE.  Gels were analysed by autoradiography (B) and quantitative phosphorimaging 






















































































Figure A6: Unstructured domains do not affect xNeuroD stability in interphase. 
Xenopus laevis interphase egg extracts were supplemented with 35S-labelled IVT xNeuroD proteins 
fused to unstructured regions and incubated at 21 °C.  Samples were taken at timepoints indicated 
and subjected to 15 % SDS-PAGE.  Gels were analysed by autoradiography (A) and quantitative 
phosphorimaging analysis, calculating the half-life (B, C) using the standard error of the mean 
(SEM).  n = 3   
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